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FOREWORD 
 
 
In September 2003 the European Parliament and the Council of the European Union adopted 
the Regulation No. 1831/2003 on additives for use in animal nutrition. The purpose of this 
regulation is to establish a Community procedure for authorising the placing on the market and 
use of feed additives and to lay down rules for the supervision and labelling of feed additives 
and premixtures in order to provide the basis for the assurance of a high level of protection of 
human health, animal health and welfare, environment, and “users and consumers” interests in 
relation to feed additives, whilst ensuring the effective functioning of the internal market. 
Any person seeking an authorisation for a feed additive or for a new use should submit an 
application to the European Commission and the European Food Safety Authority (EFSA), as 
provided by Article 7 of Regulation No. 1831/2003 at least one year before the expiry date of 
the previous authorisation for additives with a limited authorisation period, and within a 
maximum of seven years after the 18th October 2004, date of entry into force of this Regulation 
for additives authorised without a time limit or pursuant Directive 82/471/EEC. 
The guidelines for the applicants to prepare the dossier for the authorisation of additives in 
animal nutrition are provided according to Directive 2001/79/EC, until specific guidelines 
following Regulation No. 1831/2003 will be established by the Panel on Additives and Products 
of Substances used in Animal Feed (FEEDAP) of the European Food Safety Authority (EFSA).  
Under the current regulation detailed guidelines for some family of products are completely 
missing, that it is the case of the plants/herbs, plant/herb extracts and their naturally or 
synthetically produced components. For this reason it is one of the priorities of the FEEDAP 
Panel to implement guidelines/guidance for these types of compounds. 
It has been observed that plant/herbs and their extracts are increasingly being used (and 
informally marketed) not only as sensory additives, but also for other purposes not covered by 
the legislation, notably better growth or feed conversion, improved meat quality, and for 
prophylactic purposes. There are strong indications that such use will further increase as 
replacement additives for the antibiotic growth promoters whose use will be prohibited by the 
end of 2005.  
Nowadays, a compiled list of these compounds or extracts does not exists although the 
European Federation of Animal Feed Additive Manufacturers (FEFANA) notes that some 280 
plant extracts and a further 1700 chemically defined compounds have been used within 
Member States as sensory additives in animal feeds. 
The results of this study will be used by EFSA, in consultation with the European Commission, 
Member States and other stakeholders, to provide input for the development of 
guidance/guidelines documents for the authorisation of plants/herbs, plant/herb extracts and 
their naturally or synthetically produced components for use in animal nutrition. 
 
       Claudia Roncancio Peña 
       FEEDAP Panel 
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ASSESSMENT OF PLANTS/HERBS, PLANT/HERB EXTRACTS AND THEIR NATURALLY OR 
SYNTHETICALLY PRODUCED COMPONENTS AS “ADDITIVES” FOR USE IN ANIMAL NUTRITION 
 
CFT/EFSA/FEEDAP/2005/01 
 
 
INTRODUCTION 
The last two decades have seen a substantial increase in use of herbs/botanicals and their 
products not only as herbal medicinal products and for food supplements, but also in the field of 
animal nutrition. The use of herbal feed additives, which include essential oils and (exotic) 
herbal mixtures, is extensively promoted by the producers, but the scientific background 
underpinning their use often is limited. Consequently an adequate knowledge of quality control 
(content of active substance(s) stability), efficacy and safety is often lacking. A critical 
examination of bioactive plant products has to cover analytical aspects, absorption, 
bioavailability and molecular functionality in addition to feeding experiments and technology 
development. Finally, quality assurance management (analytical methods) is considered an 
absolute prerequisite. 
Presently herbs/botanicals are used by the feed industry only as sensory additives, functional 
group “flavouring compounds”. These are defined by Annex I of Regulation (EC) No 1831/2003 
as “substances the inclusion of which in feedingstuffs increases smell or palatability”.  This 
regulation foresees the evaluation of all herbal products and their derived extracts currently on 
the market and notified to the European Commission.  This is to be completed by 2010. 
BACKGROUND 
The challenge that food suppliers face is to accept the consequences of consumers’ demands 
and aspirations and to become more proactive in developing scientific approaches to meet 
these demands. In this context, sustainable farming must be guided by the following principles: 
- animal friendly - scientifically proven to respect the welfare of livestock and to enhance 
their physiological condition through nutrition 
- consumer friendly – 100% natural, traceable, no risk of pathogenic cross-resistance, 
non-GM products, no harmful effects on humans 
- environmentally friendly – products that actively reduce the environmental impact of 
intensive livestock production through the reduction of both atmospheric emissions and 
non-organic effluents. 
In-feed antibiotics have been used for growth promotion and prophylaxis against enteric 
pathogens for the last 50 years. However, recognition that the continuing use of antibiotics for 
growth promotion contributed to a growing resistance among human pathogens  has resulted in 
these additives have been withdrawn stepwise since 1994. This withdrawal was completed in 
2006 and the use of antibiotics for growth promotion is now prohibited in the EU member 
states.  
Proposed alternatives to in-feed antibiotics are extremely diverse and include organic acids, pre- 
and pro-biotics, enzymes and especially herbs and herbal products/botanicals. For most of the 
ever-evolving area of feed additives, the flavour and appetizing substances based on 
plants/plant extracts represent a real alternative both for the European feed industry and the 
livestock production. Although the understanding of their modes of action is a prerequisite for 
their optimal application and use, in terms of efficacy, at the moment, a full understanding of 
these aspects in animals is not achieved yet. For example, phytocompounds act along the 
animal’s digestive tract to improve appetite, bacterial modulation, and are able to induce a 
number of very positive benefits on well being (Kamel, 2001). The antimicrobial properties of 
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plant extracts and herbs can be dose-dependently bacteriostatic and/or bactericidal. In addition, 
several investigations have been performed concerning the changes in digestive physiology and 
digestion at weaning (Zabielski et al., 1999), the microbiology of the gut (Jensen, 1998) and the 
implementation of test models in poultry (Hess, 2002). 
Herbs and herbal products/botanicals represent a large array of nutraceuticals, which are 
defined as “any non-toxic feed component that has scientifically proven health benefits 
including disease prevention or treatment” (Boothe, 1997). Many classes of plant products have 
been shown to have antimicrobial activity including phenolics, quinones, flavones, tannins, 
coumarins, several compounds of essential oils (mono- and sesquiterpenes, phenylpropanoids) 
and isothiocyanates. One perceived advantage is that many of these plant products occur in 
complex mixtures and not only as single compounds, hence resistance is less likely to become a 
problem than with conventional synthetic compounds.  An often investigated group is 
represented by essential oils, especially those containing the phenolic compounds thymol and 
carvacrol. A review made by Gollnisch et al. (2001) has shown, however, that the main 
parameter studied is the weight gain and less attention has been given to the influence of these 
compounds on the microflora and particularly the pathogenous microflora and their elimination. 
The distribution of multi-resistant strains is however decisive for the health status of the animal 
population.  
Another interesting group of secondary plant products are tannins which can confer benefits on 
animal production and animal health (Caygill and Mueller-Harvey, 1999). The assessment of 
tannins is however complicated and the data available are partly contradictory due to the fact 
that this class of compounds comprise many different molecules, some of which have 
detrimental toxic effects.  
Because of the need to asses the safety of all herbal and related products seen under 
Regulation (EC) No 1831/2003 and because of the potential for herbs and herbal 
products/botanicals to contribute as zootechnical additives in animal nutrition, the European 
Food Safety Authority (EFSA) identified the need to collect further information on the efficacy 
and safety of these products. The immediate aim is to use this data to develop guidelines for 
their evaluation, following the Regulation (EC) No 1831/2003. A secondary objective is to 
assess the scientific evidence for effects in livestock other than that driven by their sensory 
properties in anticipation of herbal-based additives seeking authorisation for use for purposes 
other than flavouring of feed. 
 
In a first step, a background document has been prepared dealing with the most crucial points 
of botanicals and botanical preparations identified for being used in animal nutrition. For a 
selected group of herbs/botanicals model monographs have been elaborated compiling the 
most recent information on the following issues (Table 1). 
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Table 1.  Structure and areas of the monographs 
 
No Chapter Section 
1 Introduction a  Background experience with the plant 
  b  Historical use of the plant 
2 Description of the plant a  Systematic 
  b  Occurrence 
  c  Plant description 
  d  Used plant parts and products 
3 Phyto-chemical constituents a  Chemistry 
  b  Variation / Diversity 
  c  Analysis 
  d  Specifications, Standardisation  
4 Pharmacology a  In vitro 
  b  Human studies 
  c  Animal studies: ADME 
5 Antimicrobial  effects  
6 Efficacy / Quality of the animal product  
7 Toxicology / Safety  
 
 
 
 
The reasons for selecting particular plants/herbs (Table 2) were specific but the final selection 
was made to illustrate  the diversity of the notified sensory additives, taking into account 
particularly: 
- indigenous (European) vs. exotic species (some of them introduced since long as 
culinary herbs or herbal teas; some of them rather ‘new’); 
- plants with clear taxonomic identification vs. genera with a number of closely related 
species showing a high chemical variation; 
- cultivated plants as well as plants collected from the wild; 
- plants commonly/frequently used as dietary (food) supplements (herbal teas) vs. very 
specifically used species; 
- herbs containing typical flavouring agents (e.g. essential oils or bitter substances) vs. 
such of unclear ‘sensory’ properties; 
- species of different pharmacological/toxicological profile. 
Inevitably the monographs vary in size and completeness reflecting the availability of published 
data: some species are well known and documented due to their traditional human (medicinal) 
use; some other, used since ancient times as food, food additives or fodder crops, are generally 
recognized as safe, but in some case needing a revised risk assessment due to recent data. 
Finally, there are relatively ‘new’ (exotic) species coming from traditional use in other parts of 
the world which partly still lacking relevant data. 
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Table. 2:  Selected Group of Plants used as Sensory Additives in Animal Feeds 
(according to Annex I to Part III . 2 of the Contract)  
 
 
 
Number English Name Latin Name 
Page 
number 
  1 Yarrow, Milfoil Achillea millefolium L.     9 
  2 Onion Allium cepa L.   18 
  3 Leek Allium porrum L.   18 
  4 Garlic Allium sativum L.   18 
  5 Aloe Aloe vera L., A. barbadensis, A. capensis   43 
  6 Tragant Astragalus gummifer Labill.   53 
  7 Borage Borago officinalis L.   61 
  8 Marigold, Goldbloom Calendula officinalis L.   74 
  9 Common celandine Chelidonium majus L. 140 
10 Oregano, Spanish (see also 37) Coridothymus capitatus, Thymus capitatus 182 
11 Echinacea Echinacea sp.   88 
12 Eucalyptus Eucalyptus globulus Labill.   97 
13 Fennel, bitter Foeniculum vulgare Mill. ssp. vulgare  107 
14 Wintergreen Gaultheria procumbens L. 116 
15 Gentian Gentiana lutea L. 123 
16 Lavender Lavandula angustifolia Mill. 133 
17 Lavandin Lavandula hybrida (L. angustifolia x L. latifolia) 133 
18 Lavandin Lavandula hybrida (L.officinalis x L. latifolia) 133 
19 Spike lavender Lavandula latifolia L. 133 
20 Lavender Lavandula officinalis Chaich. 133 
21 Macleaya, Plume poppy Macleaya cordata ( Willd.) R. Br. 140 
22 Camomile, German  Matricaria recutita (L.)Rauschert 155 
23 Japanese mint Mentha arvensis L. 170 
24 Pennyroyal Mentha pulegium L. 170 
25 Spearmint Mentha spicata L. var. crispa 170 
26 Peppermint Mentha x piperita L. 170 
27 Oregano Origanum dictamnus L. 182 
28 Marjoram 
Origanum majorana L. (Majorana hortensis 
Moench) 
182 
29 Oregano Origanum vulgare L. spp. 182 
30 Parsley Petroselinum crispum Mill. 194 
31 Parsley Petroselinum sativum Hoffm. 194 
32 Anise, Aniseed Pimpinella anisum L. 201 
33 Black currant Ribes nigrum L. 210 
34 Rosemary Rosmarinus officinalis L. 218 
35 Sage Salvia officinalis L. 230 
36 Milk thistle Silybum marianum L.  237 
37 Thyme Thymus capitatus. Hoffm. & Link 250 
38 Thyme Thymus vulgaris L. 250 
39 Thyme Spanish Thymus zygis L.  250 
40 Cats claw Uncaria tomentosa Roxb. 259 
41 Stinging nettle Urtica dioica L., Urtica urens L. 269 
42 Valerian root Valeriana officinalis L. 277 
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ACHILLEA MILLEFOLIUM 
  
Achillea millefolium L.  
 
1. INTRODUCTION 
Achillea millefolium L. has a long history of use as traditional herb medicine even in veterinary 
medicine (Ludwig, 1996; Moder, 1997; Hirtl, 2000). Preparations in the form of infusions, 
decoctions or fresh juices have been applied against anorexia, stomach cramps, flatulence, 
gastritis, enteritis, internal and external bleeding (coughing blood, nosebleed, hemorrhoidal and 
menstrual bleeding, bloody urine), wounds, sores, skin rash as well as dog and snake bites. Its 
name is derived from Achilles, a mythical Greek character, who carried it with his army to heal 
the wounds of his fellow soldiers. This medicinal utilisation is also reflected in some of its 
common name: Woundwort, nosebleed, blood wort, sanguinary, herb militaris, and knight’s 
milfoil [Chandler et al., 1982]. 
 
2. DESCRIPTION OF THE PLANT 
The perennial herb grows to a height up to 30-60 cm. Due to the numerous small hairs covering 
it, the plant appears grey-green. The stem is angular with lanceolate, dissected leaves ranging 
from 3-20 cm in length and 1-6 cm in width. The dissection is giving the leaves a feathery 
appearance. The flowers are arranged in flattened, terminal, loose heads or cymes and are most 
often white, although pink, magenta, and red also occur. Yarrow is flowering throughout the 
whole summer from May to October. The odour is highly aromatic and somewhat resembling 
chamomile [Chandler et al., 1982]. 
 
2.1 SYSTEMATICS 
Achillea millefolium L. belongs to the genus Achillea with more than 120 species, divided into 5 
sections: Sectio Millefolium (ADANS.) W.D.J. KOCH, Sectio Ptamica (MILL.) W.D.J. KOCH, Sectio 
Achillea, Sectio Babounya (DC.) O. HOFFM. and Sectio Arthrolepis (BOISS.) BOISS..  
Solely plants of the Achillea millefolium group belonging to the Sectio Millefolium (ADANS.) 
W.D.J. KOCH are used as medicinal plant. This group consists of several species difficult to 
distinguish which again are polymorphic, e.g. A. asplenifolia VENT. and A. setacea WALDST. et 
KIT. (diploid), A. collina BECKER ex REICHENB. (tetraploid), A. millefolium L. sensu stricto and A. 
distans WALDST. et KIT. (hexaploid), and A. pannonica SCHEELE (octaploid). Due to the 
existence of several chemotypes the content and chemistry of the essential oil is highly complex 
[Mokute et al., 2003; Hofmann et al., 1992]. For pharmaceutical preparations at least 2% of 
essential oil with 0.02% proazulene are demanded (Ph. Eur.). Therefore, hexaploid and octaploid 
species considered as azulene-free should be avoided [Chandler et al., 1982].  
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2.2 OCCURRENCE 
Yarrow is a common herb found in fields and urban waste places throughout the temperate and 
boreal zones of the northern hemisphere and, to a lesser extent, of the southern hemisphere 
[Tutin et al. 1976; Ohwi, 1965; Hultén, 1968; Holm et al., 1979; Fernald, 1950; Angier, 1978]. 
Achillea millefolium L. sensu stricto (A. millefolium L. s.str.) is the most widespread variety, 
found sparsely in southern Europe, abundantly throughout central and northern Europe, and has 
been widely introduced into North America. There Achillea lanulosa NUTT., a tetraploid species, 
is distributed. Achillea borealis BONG. is popular on the west coast from California to Alaska, 
and in the Arctic and Subarctic [Mulligan and Bassett, 1959]. In India it grows up to an altitude 
of 1.050-3.600 m in the temperate Himalaya [Agnihotri et al., 2005]. 
 
2.3 PLANT PARTS AND PRODUCTS 
The plant parts used are the fresh or dried aerial parts or the whole fresh plant including the 
rhizomes of Achillea millefolium L.. The best quality crude drug is harvested from tetraploid 
(sub)species at time of full flowering and beginning of maximum development, where plants 
from native habitat show higher azulene content than from cultivated fields. Therefore, the drug 
in the European market is usually collected in the south of Europe and only few originates from 
cultivated plants. Thus, mixtures of the A. millefolium group with related species occur [Marchart 
and Kopp, 2003]. Furthermore, flower materials are best since stem content lowers azulene 
yield. The largest amount of proazulene has been found in buds or inflorescences at the 
beginning of flowering. After harvesting, shade drying at ordinary temperatures proved to be 
suitable, with azulene contents approximately 20% less than from the fresh plant. Alternatively, 
infrared drying can be used, however losses of 50% have to be accepted [Kucera, 1956]. The 
plants are processed to teas, juices, extracts (1:1 with 25% ethanol) and tinctures (1:5 with 45% 
ethanol) [Hänsel et al., 1992]. 
 
 
3. INGREDIENTS/CONSTITUENTS:  
Yarrow contains a large number of therapeutically interesting active compounds. For the most 
medicinal effects the volatile components in the essential oil, including the sesquiterpene 
lactones, seem to be relevant. The oil content and composition are influenced by environmental 
conditions [Kowal and Pic, 1980; Verzar-Petri and Shalaby, 1977], the age of the plant 
[Ruminska, 1970], the part of the plant used [Racz-Kotilla and Racz, 1969; Yaskonis, 1971], 
and the season of harvest [Kowal and Pic, 1980; Racz-Kotilla and Racz, 1969; Verzar-Petri and 
Shalaby, 1977; Yaskonis, 1971]. Thus, the oil content changes during ontogenesis from 0.13% 
in the vegetative stage to 0.34% in the stage of full bloom. At the same time increasing 
amounts of monoterpenes in relation to the sesquiterpenes, and a decrease of azulene could be 
observed [Rohloff et al., 2000; Figueiredo et al. 1992a; Popescu and Katz, 1978; Popescu and 
Winand, 1977; Racz-Kotilla and Racz, 1969].  
In numerous studies over 100 compounds of the essential oil isolated from the aerial parts of A. 
millefolium and roots have been identified [Figueiredo et al., 1992a; 1992b; Hofmann et al., 
1992; Laurenco et al., 1999]. Relating to the chromosome number, azulene-containing 
(tetraploid) and azulene-free (hexaploid and octaploid) plants and difference in the proportion of 
mono- and sesquiterpenes exist. The major compounds of an oil obtained from the tetraploid 
species A. collina with a comparatively low proportion of only 34 % monoterpenes were 
chamazulene (25%), β-pinene (23%), caryophyllene (10%), and α-pinene (5%). The artefact 
chamazulene is formed from precursor compounds like achillicin (8 α-acetoxy-10-epi-artabsin), 
a sesquiterpene lactone, by the elimination of water and acetic acid and following 
decarboxylation during steam distillation. The structures of achillicin and chamazulene are given 
in Figure 3.1.. Further proazulenes are the sesquiterpene lactones 8 α-angelicoyloxy-10-epi-
artabsin, 8 α-tigloxy-10-epi-artabsin, rupicolin A and rupicolin B [Kastner et al., 1991; Kastner et 
al., 1992; Zitterl-Eglseer et al., 1991]. In contrast, the oil of hexaploid A. millefolium contained 
80% monoterpenes and no chamazulene. The main components of this oil were camphor 
(18%), sabinene (12%), 1,8-cineole (10%), α-pinene (9%), and isoartemisia ketone (9%) 
Achillea 
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[Hofmann et al. 1992]. The differences in the chemical compositions of the volatile oils 
emphasise the high importance of chromosome numbers. 
 
 
 
 
 
 
 
 
 
 Achillicin       Chamazulene 
Fig. 3.1: Structure of achillicin and chamazulene 
 
The aerial parts of Achillea ssp. contain a range of flavonoid glycosides responsible for the 
spasmolytic activity of yarrow. Apart from the aglycones apigenin and luteolin, mainly their 7-O-
glycosides could be identified. In addition, quercetin, rutin, isorhamnetin, and the methoxylated 
aglyca artemetin, casticin were found. The highest amounts of flavonoids (0.028%-0.186%) 
were present during anthesis [Falk et al., 1975; Guedin et al., 1993; Ivancheva et al., 2000; 
Ivancheva et al., 2002; Glasl et al., 2002]. Furthermore, the occurrence of C-glycosylflavones 
based either on apigenin or luteolin in the genus Achillea is described [Valant-Vetschera, 1982; 
1985]. However, within the A. millefolium complex, only the three taxa A. setacea, A. cusipedata 
and A. asiatica produced vitexin, isovitexin, swertisin, orientin, isoorientin, swertiajaponon and 
di-C-glycosylapigenins. Therefore, the C-glycosylflavones have been shown to be of 
chemotaxonomic importance for the difficult differentiation between species of the genus 
Achillea. Especially A. nobilis showing morphological similarities can be distinguished from the 
most species of the Achillea millefolium group by its flavonoid pattern [Valant, 1978; Valant-
Vetschera, 1982; 1984; 1985; 1987; 1994; Kastner et al., 1995; Marchart and Kopp, 2003]. 
Other constituents reported include phenolic acids, triterpene, sterols, and a range of alkamides 
in the subterranean parts [Ulubelen et al., 1990; Greger and Hofer, 1989]. 
 
3.1 CHEMICAL ANALYSIS 
The constituents of the essential oil were analysed by GC and GC-MS after steam distillation of 
the dried plant [Mockute and Judzentiene, 2003; Agnihotri et al., 2005, Dokhani et al., 2005]. 
Sesquiterpene lactones were identified from a dichloromethane extracts of flower heads of 
Achillea pannonica SCHEELE by GC-MS, GC-IR and NMR [Werner et al., 2003]. 
Characterisation of guajanolides, e.g. desacetylmatricarin, leucodin, achillin and their 8 alpha-
angeloxy-derivatives, were performed by TLC on silica gel and HPLC using isocratic and gradient 
systems with different methanol-water mixtures as mobile phases [Glasl et al., 2003]. 
Flavonoids were separated and quantified using capillary electrophoresis after extraction of the 
dried material with methanol water (40:60, v/v) [Marchart and Kopp, 2003]. Furthermore, 
flavonoid glycosides and free aglycones from flower heads and leaf exudates were investigated 
[Valant-Vetschera and Wollenweber, 1988; Gherase et al., 2004]. 
 
3.2 STANDARDISATION, STABILITY 
According to DAB 10 drugs containing at least 0.2% of volatile oil and not less than 0.02% 
azulene are required. Determination of the volatile oil content after steam distillation is 
conducted volumetrically (ÖAB 90) or photometrically at 610 nm (ÖAB 90, DAC 86), 
respectively. A test method for pro-azulenes was developed by Verzar-Petri and Hanh (1977). 
After extraction of the powdered drug with chloroform and addition of 4-dimethyl-
aminobenzaldehyde reagent, the solution was extracted with petrolether. Drugs containing pro-
azulenes show a distinctly blue colour of the lower phase.  
Saberi (1990) developed a procedure for the qualitative estimate of the chamazulene content. 
For this, 100 mg of flowers were moistened with a few drops of 1% sulphuric acid, followed by 
CH3
O CH3
O
O
CH3
O
CH3 OH
CH3
CH3
CH3
CO2, H2O 
CH3COOH 
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sublimation at 150°C in vacuo. Material poor in azulene furnishes a reddish rather than an 
intense blue to blue-green sublimate. Additionally, capillary gas chromatography of the 
sublimate allowed quantification.  
The identity of the volatile oil is proved by TLC, using caryophyllene and guaiazulene as 
reference compounds, as described by the DAC 1986. 
Studies regarding the stability of Achillea millefolium drugs are scarce. Kucera (1956) observed 
a loss of 20% of azulene compared to the fresh plant after shade drying, which increased to 
50% using infrared drying. Data concerning the stability of pharmaceutical preparations of 
yarrow were not available.  
 
 
4. PHARMACOLOGY 
The internal and external use of yarrow is very similar to that of Matricaria flos. Fresh plant juice, 
infusions and other galenic preparations are applied for their antiphlogistic, spasmolytic, 
stomachic, carminative, and cholagogue effects. The main applications are in gastrointestinal 
complaints, e.g. inflammation, diarrhoea, flatulence and cramps. In addition, it is also employed 
as a bitter aromatic to stimulate the appetite and the secretion of bile. Externally, yarrow is used 
in the form of poultices, lotions, and baths, but mostly in the form of preparation with alcohol, 
e.g. percolates, fluid extracts, for inflammation of the skin and mucous membranes, as well as 
for healing wounds. In folk medicine, the drug is often employed as a haemostyptic, e.g. in 
bleeding from haemorrhoids, and in problems of menstruation [Chandler et al., 1981; De La 
Puerta and Herrera, 1995].  
 
4.1 ANIMAL STUDIES  
Anti-inflammatory activity was found for 11,13-dehydrodeacetylmatricarin and rupicolin B in an 
aqueous extract of the aerial parts of Achillea setacea in the croton oil ear test. An inhibition of 
oedema development for 11,13-dehydrodeacetylmatricarin of 45.5% and for rupicolin B of 14.3 
% was observed [Zitterl-Eglseer et al., 1991]. Sosa et al. (2001) investigated the anti-
inflammatory activity of the sesquiterpene 1,4-dihydroxy-germacra-5E-10(14) [DHGD] isolated 
from Achillea pannonica SCHEELE. As references, hydrocortisone and the non steroidal anti-
inflammatory drug (NSAID) indomethacin were used. DHCD inhibited ear odema in a dose-
dependent manner (61%) and was more effective than NSAID (43%). For comparision, the 
reduction by hydrocortision was 68%.  
A protein-carbohydrate complex isolated from the aqueous extract of Achillea millefolium 
flowers and subcutaneously applied to mice (40 mg/kg) exhibited systemic and antiphlogistic 
activity [Goldberg et al., 1969].  
In mice and rats with alloxan diabetes yarrow showed marked hypoglycaemic and glycogen 
sparing properties [Molokovskii et al., 1989].  
Tozyo et al. 1994 isolated and characterised three sesquiterpenoids form Achillea millefolium, 
achimillic acids A, B and C, which were found to be active against mouse p-388 leukemia cells 
in vivo. A pronounced cytotoxic effect against HeLa cancer cells (IC50 = 25.92 ± 4.96µg/ml), and 
lower cytotoxicity against K562 leukemia cells (IC50 = 48.59 ± 18.31 µg/ml) were observed for a 
combined chloroform and ethylacetate herb extract of Achillea alexandri-regis. In contrast, the 
methanol extract was found to be a moderately cytotoxic in vitro agent against HeLa and K562 
cells [Kundakovic et al., 2005].  
 
4.2 HUMAN STUDIES  
In a double-blind placebo controlled clinical trial the antihyperlipidemic and antihypertensive 
effects of a hydroalcoholic extract of Achillea wilhelmsii C. KOCH were investigated. The results 
showed a significant decrease in triglycerides, total cholesterol and LDL-cholesterol after 4 
months, and a significantly increased HDL-cholesterol after 6 months treatment, respectively 
[Asgary et al., 2000]. Sibel and Canan (2005) studied the protective effects of an infusion 
prepared from 15 Achillea species against hydrogen peroxide induced oxidative damage in 
human erythrocytes and leucocytes. The results indicated that infusions of all Achillea species 
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investigated are a potential source of natural antioxidants for treatment and prevention of 
diseases in which lipidperoxidase is involved.  
The efficacy of a herbal medicine containing an Achillea millefolium extract on liver cirrhosis 
was probed in a randomized, double-blind, placebo-controlled study. After 6 months significantly 
better child-pugh score, decreased ascites, decreased serum alanine and aspartate 
aminotransferase activities compared to the placebo were observed. The hepatoprotective 
effect in cirrhotic patients was attributed to the diuretic, anti-inflammatory, anti-oxidative, and 
immunomodulating properties of the herbs [Huseini et al., 2005]. 
 
4.3 ADME (ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION) 
At the date of write no information available. 
 
 
5. MICROBIOLOGY 
In a disk diffusion assay the extract of aerial parts of yarrow (hexane:ether:methanol, 1:1:1) 
possessed a broad spectrum of antimicrobial activity against Staphylococcus aureus, 
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella enteritis, 
Aspergillus niger and Candida albicans [Stojanovic et al., 2005]. The essential oil of Achillea 
millefolium ssp. millefolium AFAN. showed antimicrobial activity against Streptococcus 
pneumoniae, Clostridium perfringens, Candida albicans, Mycobacterium smegmatis, 
Acinetobacter lwoffi and Candida krusei [Candan et al., 2003]. Against respiratory tract 
pathogens like Klebsiella pneumoniae and penicillin-susceptible and penicillin-resistant 
Streptococcus pneumoniae the essential oil of Achillea clavennae showed maximum 
antibacterial activity. The oil also exhibited strong activity against Gram-negative Haemophilus 
influenzae and Pseudomonas aeruginosa, whereas Gram-positive Streptococcus pyogenes was 
the most resistant [Skocibusic et al., 2004].  
Furthermore, a water extract of Achillea millefolium possessed strong activity against 
Plasmodium falciparum and Babesia gibsoni, inducing malaria and anemia in dogs, respectively 
[Murnigsih et al., 2005].  
 
6. EFFICACY 
The digestive and appetising properties of Yarrow attributed to bitter substances and essential 
oils are used in different animal species (ruminant, horse, pig, dog, cat, chicken) (Reichling et 
al., 2005). Special prescriptions are available for calves suffering from diet-related 
gastroenteritis (Gachnian and Assenov, 1990; Rabinovich, 1981).  
 
 
7. TOXICOLOGY 
To evaluate the possible toxicitiy of aqueous extracts from leaves of Achillea millefolium on 
reproductive endpoints in Wistar rats, adult male rats were treated daily with yarrow extract 
(0.3, 0.6, 1.2 g/kg/day) administrated orally during 90 days. Over the treatment period, no 
clinical signs of toxicity or estrogenic/antiestrogenic activity were detected. Furthermore, the 
body weight gain was similar in all groups [Dalsenter et al., 2004].  
Applications of Millefolii herba are allowed for administration to food-producing animals in the 
EU [VO (EWG) Nr. 2377/90]. No experiences are available about the application of Calendulae 
flos to pregnant and lactating animals [Reichling et al., 2005]. 
Rarely allergic reactions (pruritus, exanthem) and in long term applications gastritis could be 
observed [Danilenko and Rodionov, 1982; Manolov, 1987; Jurenitsch, 2003]. 
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7.1 SAFETY 
Dosage/Administration 
According to the German Commission E monographs: Unless otherwise prescribed an average 
daily dosage of 4.5 g of yarrow, 3 teaspoonfuls of juice pressed from the fresh plant or 3 g of 
yarrow flowers and equivalent preparations, respectively, for internal use. For external use, e.g. 
hip baths, 100 g of yarrow to 20 L of water are recommended. 
 
 
Side effects 
Yarrow may cause contact dermatitis with itching, inflammatory reactions, and the formation of 
vesicles. The guaianolide peroxides α-peroxyachifolide is believed to be responsible for the 
allergic contact dermatitis [Hausen et al., 1991].  
 
Interactios with other drugs 
None known. 
__________________________________________________________________________________
KS 
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ALLIUM SP. 
  
Allium sativum L. (garlic)  
 
  
Allium cepa L. (onion)  
 
 
 
 
Allium porrum L. (leek)   
 
1. INTRODUCTION 
Among Allium species Allium sativum L., Allium cepa L. and Allium porrum L. have been 
cultivated since ancient times as vegetables and characteristic pungent flavouring agents for 
food but also for their pharmaceutical properties. The use of garlic, onion and leek is well 
documented by the Egyptians, Greeks and Romans. In the Middle ages Constantinus Africanus, 
Hildegard von Bingen, Albertus Magnus and many others mentioned the plants in their 
medicinal books [Sendl, 1995].  
However, scientific investigations started only 200 years ago. One of the earliest studies was 
performed in 1844 by the German chemist Wertheim, who obtained some strongly smelling 
substances named as allyl derivatives (from Allium) and sulphurlallyl derivatives [Wertheim, 
1844]. During the 19th and the 20th century scientific work on garlic extraction and identification 
of many constituents has been performed. In recent years most investigations aimed at 
standardisation of the active principles in pharmaceutical preparations. Further research work is 
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still needed to elucidate and quantify the active principles including pharmacokinetics and 
metabolism [Sendl, 1995].  
 
2. DESCRIPTION OF THE PLANTS 
Allium sativum L. 
Garlic is a bulbous perennial plant. A wild species of garlic is probably A. longicuspis REGEL, 
which grows wild in southwestern Asia. The bulb, which is commonly used for food flavouring, 
has 5-8 cm in diameter and is composed of several single bulblets (6-20) also known as cloves. 
The bulb varies slightly in shape, colour and flavour depending on variety and growing 
conditions. The foliage comprises a central stem up to 100 cm with erected flat or keeled 
leaves. The white, pink or purple flowers are arranged at the top of the stem. 
 
Allium cepa L. 
The onion bulb commonly used as a vegetable or seasoning in foods has been cultivated for 
over 4000 years and has never been found as wild species. Allium cepa is classified in two 
infraspecific groups (Hanlet, 1990): The common ′onion′ group constitutes the vast majority of 
modern highly adapted cultivars. One characteristic feature of this group is large, single bulbs. 
The second group, called ′Aggregatum′, contains rapidly dividing varieties forming laterals and 
as a consequence thereof bulb clusters. The shallot and the multiplier onion belong to this 
group. Their propagation is typically vegetative and flowers are infertile to members of the 
′common′ onion-group, which is indicative of a shared species. Allium cepa is a biennial crop 
that forms a large bulb in the first year of growth. The bulb is composed of fleshy enlarged leaf 
bases. The outermost layers do not swell but become thin, dry, and discoloured, forming a 
covering, which is generally removed prior to use. The bulbs vary in colour (white, yellow, red) 
and pungency from mild to very strong. After vernalisation by winter cold, rapid re-growth of 
foliage in spring is followed by the production of several tubular flower stalks (60-120 cm), each 
producing a single spherical umbel of around 200 flowers.  
 
Allium porrum L. 
Leek is a vegetable valuable in the fall and winter. Cultivated forms are known as the garden 
leek and the Egyptian leek, which is grown for its leaves in Egypt and elsewhere in the Middle 
East. It is supposed to go back to A. ampeloprasum L. originating from the Mediterranean 
region. Wild leek (A. tricoccum AIT.), grown in America, is a plant with a cluster of ovoid bulbs 
and large oblong elliptical leaves. 
Rather than forming a tight bulb such as onion, leek develops a long cylinder of bundled leaf 
sheaths up to 0.9 m. They are milder than onions and are grown mainly for their long, thick, 
tender white, yellow and greenish stems.  
 
2.1 SYSTEMATICS 
According to more recent taxonomic concepts, Allium and its close relatives are recognized as 
distinct family termed Alliaceae. The derivation of the botanical name is still uncertain and the 
classification has been discussed for a long time. The genus Allium comprises more than 500 
species, but garlic, onion, leek and chives constitute the major Allium foods consumed by 
humans [Dahlgren et al., 1985; Sendl, 1995]. Rich in species, the genus is divided into three 
subgenera Amerallium TRAUB, Nectaroscordum (LINDL.) TRAUB and Allium L., 18 sections and 
several subsections.  
 
2.2 OCCURRENCE 
Garlic 
Garlic used in Europe comes from Spain, Hungary, Czech Republic, Slovakia, Italy and France. 
Large amounts are cultivated in China, India, Egypt and Japan. In America the main producers of 
garlic are Mexico, Argentina and the United States, especially California. 
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It requires fertile, sandy, clay soil. The climate should be warm, sunny, not to windy or rainy. 
Garlic is vegetatively propagated because of its sterility which precludes plant breeding in order 
to obtain higher amounts of constituents [Sendl, 1999]. 
 
Onion and leek 
Their origin is believed to be located in central Asia as the highest diversity of Allium species can 
be found in the irano-turanian floristic region (Hanelt, 1990). Onions and leek are native to 
Eurasia, and now grow all over the world, especially in moderate climates.  
For common dry bulb production a crop culture can be established either from seeds, sets or 
transplants. Onions are classified according to day length they require to induce bulbing. As a 
result of the long history of cultivation and modern methods of selection and breeding, onions, 
technically long-day plants (>14 h day length), have been adapted to intermediate (12-14 h) and 
short (10-12 h) day length. The choice of cultivars depends first on the photoperiodical 
conditions in the growing area and on the desired method of planting, since suitability for set 
production is not given for every variety. The planting methods and the impact of the type of 
preceding crop within a crop rotation have shown to be significant factors affecting quality traits 
of onions [Resemann et al., 2004a] 
Leek is often sold as small seedlings in flats which are started early in greenhouses, to be set 
out as the weather permits. Once established in the garden, leeks are hardy. Many varieties can 
be left in the ground during the winter to be harvested as needed.  
 
2.3 PLANT PARTS AND PRODUCTS  
Allium plants attracted interest as spice, herb and vegetable, but also for pharmaceutical. With 
the objective of seasoning garlic, onion and leek are freshly harvested or dried and used for 
consumption. The plants are also utilized for the production of volatile oils, juices, extracts in 
liquid and dried forms and macerates [Koch, 1988a].  
 
Raw Allium 
Raw Allium species possess the natural flavour and provide textural and water-retaining 
properties when incorporated into food products, although the major constituent of the plants is 
water. However, the unpretentious production conditions and inadequate instructions of the 
farmers may cause considerable hygienic problems. As a consequence, high microbial loads are 
found in the raw material. Bacterial contamination poses a tremendous risk, which has been 
tragically borne out in the U.S. where sautéed onions in hot sandwiches were responsible for a 
large outbreak of botulism [Solomon and Kautter, 1986]. 
 
Dehydrated Allium  
Onions for dehydration are generally white or yellow varieties, grown for strong pungency and 
high solid contents. The root bases of the bulbs are washed thoroughly. The tops and the outer 
contaminated layers are removed. The peeled onions and garlic, respectively, are sliced or 
chopped and dehydrated in hot air tunnels. Since the microbial load is not entirely eliminated, 
additional decontamination treatments are required. Finally, the onion or garlic slices may be 
ground, powdered or granulated [Fenwick and Hanley, 1990a]. 12 different types of dehydrated 
onion products have been known [Farell, 1985]. 
 
Allium oil 
The garlic oil comprising 0.1-0.2% of the fresh weight of garlic is obtained by steam distillation 
of the minced raw material. One gram of the reddish-brown liquid is equivalent in flavouring 
terms to 900 g of fresh garlic or 200 g dehydrated powder. The pungency of the product makes 
it difficult to use directly, and it is therefore diluted in vegetable oil or encapsulated [Fenwick 
and Hanley, 1990a]. 
The onion oil is derived from distillation of the fresh raw material standing for a period of hours 
prior to distillation. In contrast to garlic, the dark amber liquid is obtained in low yields (< 0.1%) 
depending on source, sulphur fertilisation and processing conditions [Fenwick and Hanley, 
1990a; Resemann et al., 2004a]. 
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Leek oil results from the distillation of freshly crushed whole leeks ranging from 0.005% to 0.2% 
of fresh weight depending on the maturity and physiological character of the plants [Fenwick 
and Hanley, 1985].  
 
Allium juice 
After inspection and washing, the raw material is disintegrated by means of a grinding mill 
affording a medium structured mash. The mash is pumped into a stirred buffer tank, where the 
macerate typically rests between 15 to 60 minutes to complete enzymatic reactions. Juice 
extraction is accomplished by pressing or decantation. Before entering the preheater the juice is 
adjusted to the desired pH. After being preheated the juice is sterilised for a few seconds 
[Resemann, 2004]. Addition of pectinolytic enzyme preparations, acetic acid and NaCl diminish 
the viscosity and avoid discoloration, respectively, which derives from non enzymatic Maillard 
reactions between sugars and amino acids [Fenwick and Hanley, 1990a; Koch, 1988a].  
Allium extracts 
Allium extracts are obtained by extraction of the raw material with aqueous alcohols. The 
addition of methanol and ethanol, respectively, inactivates enzyme systems such as alliinase 
and peroxidase isoenzymes. Sometimes the liquid extracts are thoroughly evaporated, spray 
dried or lyophilised [Duziuban, 1979]. 
 
Allium macerates 
The raw material is minced and blended with vegetable oils dissolving the lipophilic agents.  
 
3. INGREDIENTS/CONSTITUENTS 
The proximate composition of garlic, onions and leek is shown in Table 1, but can vary 
considerably dependent on individual varieties [Ketiku, 1976; ]. 
 
Table 1  Proximate composition (%) and energy values (cal 100 g-1) of garlic, onions and leek 
[Fenwick and Hanley, 1990b] 
 Moisture Protein Fat Carbohydrate Ash Energy 
Garlic  61.3 6.2 0.2 30.8 1.5 137 
Leaves, stems 86.4 2.6 0.5 9.5 1.0 44 
Shoots 77.7 1.2 0.3 20.1 0.7 76 
Flowers 88.4 1.4 0.2 9.4 0.6 39 
Onion  89.1 1.5 0.1 8.7 0.6 38 
Immature bulbs/tops 91.6 1.6 0.4 5.8 0.6 28 
Green onion 86.8 0.8 tr. 8.5  35 
Bulb + top 89.4 1.5 0.2 8.2 0.7 36 
Bulb + white top 87.6 1.1 0.2 10.5 0.6 45 
White top 91.8 1.6 0.4 5.5 0.7 34 
Leek 85.4 2.2 0.3 6.0 0.9 52 
Flowers 83.1 5.5 0.5 10.5 0.4 55 
 
Besides the compounds listed in Table 1, Allium species also contain numerous trace elements, 
vitamins, amino acids, anthocyanins (red onions: cyanidin and peonidin glycoside), flavonols 
(mainly quercetin glycosides), phenolics (e.g. ferulic acid, protocatechuic acid and 
phloroglucinol), sterols and saponins.  
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Plants of the genus Allium represent a natural, rich source of organosulphur compounds with 
different amounts in the three species described. The most important classes are the amino 
acids cysteine and methionine, the γ-glutamyl peptides and especially the S-substituted cysteine 
sulphoxides. 
 
γ-Glutamyl-S-alkylcysteines, alliin and other S-alk(en)yl-L-cysteine-sulphoxides: 
 
Allium plants selectively contain two or three kinds of S-alk(en)yl-L-cysteine sulphoxides 
(′ACSOs′) and γ-glutamyl-S-alkylcysteines (Figure 1A,B) with varying amounts and proportions, 
corresponding to their flavours. 
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Figure 1 Structures of S-allyl-L-cysteine-(+)-sulphoxide (alliin) (A) and γ - glutamyl-S-methyl-
cysteine (B) 
 
Overall, the primary sulphur-containing constituents ranging from 0.5% to 1.3% on a fresh 
weight basis containing alliin (Figure 1) as the major component [Kubec et al., 1999]. Alliin 
concentrations can increase during storage as a result of the transformation of γ–glutamyl-
cysteines [Milner, 2001]. Alliin itself is odourless and the characteristic odour arises from allicin 
and lipophilic sulphur compounds formed when the bulb is crushed or damaged. In the intact 
cells the sulphoxides as flavour precursor are compartmentalised in the cytoplasm and the 
hydrolytic enzyme alliinase in the vacuole. Disruption of cell tissue results in the release of 
alliinase, which rapidly hydrolyses the sulphoxides to volatile sulphides. The intermediate 
sulphenic acid is very reactive and gives rise to a large number of volatile sulphur-containing 
products [Sendl, 1995].  
Additionally, other cysteines and cysteine sulphoxides such as (+)-S-methyl-L-cysteine 
sulphoxides, (+)-S-(trans-1-propenyl)-L-cysteine sulphoxide, γ–glutamyl-S-allylcysteines were 
found in smaller concentrations [Fenwick and Hanley, 1985]. In contrast to garlic, onions and 
leek mainly contain S-propenyl, S-propyl- and S-methylcysteine sulphoxides ranging from 0.2-
0.5% on fresh weight [Sun and Pike, 1998] and smaller amounts of γ–glutamyl-S-alk(en)yl-L-
cysteines.  
Freeman and Whenham (1975) divided the Allium species into three groups: A. sativum and A. 
ursinum containing mainly ACSOs, A. cepa and A. schoenoprasum including (+)-S-(trans-1-
propenyl)-L-cysteine sulphoxide as major component, and finally A. flavum and A. siculum being 
dominated by derivatives of S-methyl-L-cysteine.  
 
The lachrymatory factor (LF) 
The sulphenic acid exhibits a unique flavour development in that it gives rise to the lachrymatory 
factor [Virtanen and Spare, 1961]. Based on works of Wilkens (1964), Brodnitz and Pascale 
(1971) and Block et al. (1979, 1980) the responsible compound was finally identified as 
thiopropanal S-oxide possessing a E:Z ratio of 5:95. In a recent study, Imai et al. (2002) gave 
evidence for this isomerisation to be catalysed by the action of the enzyme LF-synthetase. 
Thiopropanal S-oxide is highly volatile and responsible for the tear producing effect and the 
pungent, biting flavour perception of particularly cut onion. 
 
CH3
S
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Figure 2 Structure of (Z)-thiopropanal S-oxide (LF) 
 
 
Allicin and other thiosulphinates: 
Allicin (Figure 3), the odoriferous substance of Allium species, is the predominant thiosulphinate 
in garlic generated by the action of the enzyme alliinase as mentioned above. 
CH2
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Figure 3 Structure of diallyl-thiosulphinate (allicin) 
 
Symmetrically or asymmetrically substituted thiosulphinates, responsible for the characteristic 
smell of freshly prepared Allium extracts, are formed by the condensation of sulphenic acids. 
The amounts of thiosulphinates vary in the different Allium species as can be seen from Table 3. 
 
Table 3  Thiosulphinates and related compounds from extracts of Allium species determined 
by HPLC (mol% based on total thiosulphinates) [Block et al., 1992, 1993] 
Compound Garlic  Yellow Onion Leek 
AllS(O)SAll 89 - - 
AllS(O)SCH=CHMe-(Z,E) 5.3 - - 
AllSS(O)CH=CHMe-(E) 1.6 - - 
n-PrSS(O)Propenyl-(E)  10 12 8 
n-PrS(O)SPropenyl-(Z,E) 17 10 15 
n-PrS(O)SPr-n 14 13 25 
MeSS(O)Propenyl-(E) 24 24 12 
AllS(O)SMe - - - 
MeS(O)SPropenyl-(Z,E) 33 25 27 
MeSS(O)Pr 1 1 5 
MeS(O)SPr 1 1 -5 
AllSS(O)Me - - - 
MeS(O)SMe 1 14 3 
Abbreviations  All: Allyl-; Me: Methyl-; Pr: Propyl- 
 
Ajoene/Cepaenes 
Ajoene (Figure 4), an oily liquid in garlic extracts, was found to be a very potent inhibitor of 
thrombocyte aggregation. The cis- and trans-isomers of ajoene are major secondary degradation 
products of allicin which are formed under certain conditions via allylsulphenic acid. Besides 
ajoene, methyl and dimethyl homologues of ajoene have been proposed, since the 
corresponding cysteine sulphoxides and thiosulphinates have been found in garlic [Sendl, 
1995]. 
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Figure 4 Structure of 4,5,9-trithiododeca-1,6,11-triene-9-oxide (ajoene) 
 
Condensation of the LF with sulphenic acids leads to a new class of biologically active 
compounds named cepaenes (Bayer et al., 1989a; Kawakishi and Morimitsu, 1988). Cepaenes 
are reported to impart a “fruity, fresh onion, sulphur, green, melon-like” flavour [Block et al., 
1997] to the sensory perception of freshly cut onion. 
 
 
Vinyldithiins/Zwiebelanes 
2-Vinyl-4H-1,3-dithiin and 3-vinyl-4H-1,2-dithiin (Figure 5) first described by Brodnitz et al. (1971) 
are cyclic compounds which are also degradation products of allicin. Commercially available oily 
extracts of garlic contain mainly vinyldithiins [Sendl, 1995].  
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Figure 5 Structures of 2-Vinyl-4H-1,3-dithiin (A), 3-vinyl-4H-1,2-dithiin (B) and 2,3-dimethyl-
5,6-dithiabicyclo[2.1.1]hexan-5-oxide (C) 
 
In freshly prepared chloroform extract of onions two bicyclic sulphur compounds called 
zwiebelanes were found [Bayer et al., 1989b]. Their structures were elucidated as cis- and trans-
2,3-dimethyl-5,6-dithiabicyclo[2.1.1]hexan-5-oxides. Besides onion, which contains about 14% 
zwiebelanes based on total thiosulphinates, about 7.5% were also found in leek [Block et al., 
1993].  
 
Sulphides 
Sulphides are mainly found in distilled garlic oil and after storage of aqueous extracts for several 
days. Sulphides are lipophilic, volatile, quite stable liquids, which are responsible for the typical 
smell and taste after ingesting garlic. One major compound of garlic oil is diallyldisulphide 
accounting for 60% of the oil. During the last years, several sulphides have been identified and 
isolated from Allium products [Horie et al., 1925; Lawson et al., 1991a,b]. Commercially 
available steam distilled volatile oils consist almost exclusively of diallyl-methyl-, allyl- and 
dimethyl- sulphides containing one to six sulphur atoms [Sendl, 1995]. 
 
The components of flavours e.g. flavour precursors, alliinase and peptides were first isolated 
from onion and garlic bulbs, but have also been reported in the leaf blades, base plate and roots 
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of onion, garlic and leek [Freeman, 1975; Lancaster et al., 1986; McCallion and Lancaster, 
1984]. Flavour precursors are not uniformly distributed within the bulb scales and leaf blades 
[Freeman, 1975; Lancaster et al., 1986]. In the onion bulb flavour precursor concentration was 
highest in the base plate and innermost bulb scales, progressively decreasing to the outermost 
scales which were dried and almost free from flavour. Young leaf blades were higher in flavour 
precursor concentration than old leaf blades. The seeds of onions did not contain flavour 
precursors, although γ-glutamyl peptides and alliinase are present [Freeman, 1979]. A similar 
pattern was found in leek [Lancaster and Boland, 1990]. 
 
Non sulphur compounds – enzyme systems 
As already mentioned garlic and other Allium species contain enzyme systems namely alliinase 
(E.C. 4.4.1.4), which is a pyridoxal phosphate enzyme first described by Stoll and Seebeck 
(1948), γ-glutamyltransferase, cleaving the γ-glutamyl peptides in sprouting onion bulbs 
[Schwimmer and Austin, 1971]. Additionally, peroxidase and other common enzymes were also 
found [Croci et al., 1991; Koch, 1988b]. 
 
Non sulphur-compounds – carbohydrates 
The non structural carbohydrates in Allium species include glucose, fructose and sucrose 
together with a series of oligosaccharides, the fructans [Bose and Shrivastava, 1961; Darbyshire 
and Henry, 1978; Steer and Darbyshire, 1979]. The three different trisaccharides 1F-
fructosylsucrose, 6F-fructosylsucrose and 6G-fructosylsucrose are potentially possible in plants. 
1F- and 6G-fructosylsucrose have been identified in onion and have been reported in leek [Bacon, 
1959; Darbyshire and Henry, 1978]. The addition of further fructosyl groups leads to the 
formation of tetrasaccharides and higher polymers. 
 
3.1 CHEMICAL ANALYSIS 
Many attempts have been made to determine the active principles and the flavour components 
in fresh plant material and preparations thereof by means of colorimetric measurements. 
Nowadays, GC and HPLC show the sensitivity and specificity required for an exact determination 
of the active principles. In most cases, the sulphur constituents are extracted with petroleum 
ether, dichlormethan or supercritical carbon dioxide at room temperature. Allicin and other allyl 
thiosulphinates can be isolated by extracting with alcohols at room temperature or by co-
distillation with water from the crushed raw material followed by extraction of the distillate with 
ether [Sendl, 1995]. Besides HPLC and GC, the extracts are used for TLC and SFC-MS 
(supercritical fluid chromatography – mass spectrometry) analysis [Calvey et al., 1994; Jansen 
et al., 1987; Kappenberg and Glasl, 1990; Miething, 1985; Resemann and Carle, 2003; Saito et 
al., 1989].  
Ajoenes and vinyldithiins were determined by HPLC and GC, respectively [Brodnitz et al., 1971; 
Iberl et al., 1990; Koch and Jaeger, 1989]. Furthermore, allyl sulphides were extracted with 
aqueous acetonitril and also identified by GC, GC-MS, HPLC and HPLC-MS respectively [Jirovetz, 
1992; Miething, 1988; Laakso et al., 1989; Lawson and Gardner, 2005; Resemann et al. 2004b 
Vernin et al., 1986; Yan et al., 1992, 1993; ].  
 
3.2 STANDARDISATION, STABILITY 
Allium products, mainly based on garlic, have become popular in recent years and a variety of 
culinary and pharmaceutical preparations are available on the market. Analytical control of 
these products is necessary, since there are different types of applications having different 
chemical composition and dosage of the active principles. The determination of the stable 
precursors along with methods for the assay of allicin would be a reasonable evaluation method 
also in terms of testing the intact alliin-alliinase system which is a prerequisite for the formation 
of all pharmacologically active secondary products [Sendl, 1995].  
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Besides Helv VI and EB 6 requiring at least 0.3% allicin and 0.2% volatile oils in A. sativi bulbus, 
minimum requirements regarding the concentration of active constituents of Allium products 
were not found. According to Helv VI the quantitative determination of allicin depends on the 
specific reaction of pyruvic acid with 2,4-dinitrophenylhydrazine, which, together with ammonia 
and allicin, arises from the enzymatic cleavage of alliin. Since colorimetric methods are not 
selective, the determination nowadays is performed by HPLC.  
 
When fresh garlic is crushed or blended, allicin formation is completed in approximately 6 s. 
Allicin itself is rather unstable and decomposes within 20 hours at room temperature yielding 
diallyl disulphide as the major products and diallyltrisulphide, diallyl sulphide, sulphur oxide, and 
trace amounts of ajoene and dithiins [Block, 1985; Lawson et al., 1991b; Tamaki and Sonoki, 
1999].  
Generally, the stability of the thiosulphates depends on their environment, particularly in the 
presence of oils and proteins. Compounds reacting with thiosulphinates like cysteine or other 
thiol-containing components rapidly decrease the thiosulphinate content. Additionally, alkaline 
media (pH ≥ 10) cause rapid transformation of allicin to diallyl sulphide [Kice and Rogers, 1974; 
Mueller, 1989]. Lawson and Gardner (2005) investigated the stability of thiosulphinates in 
different condiments and observed a loss of allyl thiosulphinates accompanied by a nearly 
quantitative increase in diallyl disulphide and further compounds of unknown identity that were 
less polar than diallyl trisulphide. Considering crushed fresh garlic no significant decrease of the 
thiosulphinates could be determined after storage at 4°C for 12 days.  
 
 
4. PHARMACOLOGY 
Plants of the genus Allium exert antiatherogenic, lipid-lowering, antihypertensive, 
antiaggregatory, vasodilatory and antioxidant effects, which are primarily due to allicin and its 
transformation products. The data given below are based on the ESCOP monograph (2003). 
 
4.1 IN VITRO EXPERIMENTS 
4.1.1 ANTIATHEROGENIC AND LIPID-LOWERING EFFECTS 
Inhibitory effects of extracts and isolated fractions from garlic on cholesterol biosynthesis were 
observed in chicken hepatocytes and monkey livers. At equivalent doses, both the drug and its 
lipophilic and hydrophilic fractions caused 50-75% inhibition of cholesterol biosynthesis 
[Quereshi et al., 1983]. In particular, the active principles ajoene and allicin were evaluated in 
cultivated rat hepatocytes and human liver cell line HepG2. In rat hepatocytes, ajoene inhibited 
sterol biosynthesis with an IC50 of 15 µM, but allicin being almost ineffective in contrast to other 
studies observing an inhibition of cholesterol biosynthesis of standardized garlic powder (1.3% 
alliin) with an IC50 of 90 µg/mL [Gebhardt, 1991, 1993]. In HepG2 cells both compounds 
inhibited sterol biosynthesis with IC50 values of 7 and 9 µM, respectively [Gebhardt et al., 1994]. 
Besides fresh garlic and garlic powder, petroleum ether, methanol and water extracts of garlic 
and garlic preparations showed inhibition of cholesterol biosynthesis [Yeh and Yeh, 1994]. 
During a 24 hour incubation period garlic powder significantly reduced the level of cholesteryl 
esters by 26% and free cholesterol by 32% in cells of atherosclerotic plaques of human aorta 
and inhibited their proliferative activity by 55% at 1 mg/mL [Orekhov et al., 1995]. 
 
4.1.2 VASCULAR RESISTANCE, FIBRINOLYSIS AND PLATELET AGGREGATION 
In isolated arterial strips from dogs, garlic at 0.2-200 g powder/L and ajoene at 10-6 to 10-3 M 
hyperpolarised membrane potential by 9.3 mV and 4.2 mV [Siegel et al., 1991, 1992]. Similarly, 
in human coronary artery smooth muscle garlic at concentrations of 0.2-200 mg/L caused dose-
dependent hyperpolarisation (2.7 mV at maximum) and relaxation (20% at maximum). Allicin 
and Ajoene produced hyperpolarisation of up to 5.1 mV and 4.4 mV and diminished vascular 
tone by 24% and 11%, respectively [Siegel, 1998]. In isolated rat aorta lyophilised garlic powder 
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inhibited noradrenaline-induced contractions. The EC50 values were 5.28 x 10-3 g/mL in aortas 
with endothelia and 5.81 x 10-3 g/mL in aortas without endothelia [Oetztuerk et al., 1994]. 
Garlic preparations and organosulphur compounds from garlic and onion inhibited collagen-
stimulated platelet aggregation in platelet-rich plasma with IC50 values of 460 µg/mL of 
aqueous garlic extract, 190 µg/mL of total polar constituents, 205 µg/mL of alliin, 14.0 µg/mL 
of allicin and 13.2 µg/mL of total thiosulphinates [Lawson et al., 1992; Srivastava, 1989]. 
Diallyldisulphide (40-200 µg/mL) and diallyltrisulphide (5-100 µg/mL) showed dose-dependent 
inhibition of platelet aggregation and thromboxane B2 secretion induced by arachidonic acid, 
adrenaline and collagen [Bordia et al., 1998]. Additionally, some flavonoids (astragaline, 
kaempherol, kaempherol-3-O-neohesperioside) isolated from leek markedly inhibited platelet 
aggregation and ATP release induced by arachidonic acid or collagen [Fattorusso et al., 2001; 
Tzeng et al., 1991]. 
 
4.1.3 ANTIOXIDANT EFFECTS 
Allicin inhibited lipid peroxidation induced by an ascorbic acid/Fe2+ system at a concentration of 
0.18 mM [Rekka and Kourounakis, 1994]. The antioxidant effect of an aqueous garlic extract 
obtained from 1 mg of garlic powder was comparable to that of 30 nM of ascorbic acid or 3.6 
nM of α-tocopherol [Lewin and Popov, 1994]. Radical scavenging activity of preparations 
containing ACSOs has also been demonstrated [Imai et al., 1990]. 
Garlic powder strongly inhibited superoxide production in phorbol ester-activated granulocytes 
with an IC50 of 390 µg/mL, whereas an alliin-enriched but alliinase-inactivated garlic extract did 
not inhibit superoxide production at concentrations up to 1 g/mL [Siegers et al., 1999].  
An aqueous solution of garlic powder (1.3% alliin) reduced radicals generated by the Fenton 
reaction and liberated by cigarette smokers [Toeroek et al., 1994]. 
 
4.1.4 OTHER EFFECTS  
An aqueous extract from fresh garlic (100-500 µg/mL) increased the proliferation and improved 
the morphological characteristics of cultured human fibroblasts [Sevendson et al., 1994]. A 
similar extract non-competitively and irreversibly inhibited cyclooxygenase activity in rabbit 
platelets and in lung and vascular aortic tissues with IC50 values of 0.35, 1.10 and 0.9 mg, 
respectively [Ali and Thompson, 1995]. 
Sapongenins isolated from leek were tested for cytotoxic activity on two different cell lines in 
vitro. The results indicate an activity for almost all of the compounds [Fattorusso et al., 2000]. 
 
4.2 ANIMAL STUDIES  
4.2.1 ANTIATHEROGENIC AND LIPID-LOWERING EFFECTS 
Garlic powder (0.6% allicin) fed to rats for 11 days at 0.25, 0.5 and 1 g/kg body weight, 
respectively, protected against isoprenaline-induced myocardial damage as shown by 
histological examination and biochemical analysis [Ciplea and Richter, 1988]. In isolated 
perfused hearts from rats which had been given 1% of garlic powder (1.3% allicin) in their diet 
for 10 weeks, the size of the ischaemic zone, incidence of ventricular tachycardia and 
ventricular fibrillation were significantly reduced in comparison with untreated controls [Isensee 
et al., 1993; Jacob et al., 1991]. A petroleum ether extract of garlic (corresponding to dried 
garlic at 1 g/kg body weight) fed to rats for 5 days in combination with an atherogenic diet, 
significantly prevented elevation of serum cholesterol and triglyceride levels (92.4 and 93 
mg/mL, respectively, compared to 320 and 370 mg/dL in control animals), and reduced the 
incidence and grade of atherosclerotic lesions compared to animals fed on the atherogenic diet 
alone [Lata et al., 1991]. Rabbits were given cholesterol in their diet at 0.5 g/kg body weight 
daily for 2 months, then fed for 3 months on a normal diet with or without the addition of fresh 
garlic at 1 g/kg daily. Compared to rabbits receiving a normal diet over the 3 month period, 
those given garlic had reduced plaque areas with half as many lesions [Mand et al., 1985]. 
Few studies were undertaken to determine the effects of two brown onion varieties on blood 
lipid and oxidative status using pigs as a model [Gabler et al., 2005; Ostrowska et al, 2004] 
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leading to similar results. Supplementation resulted in a 21% reduction in the averaged fasted 
and postprandial plasma triacylglyceride measurements taken over a 6 weeks period in 
comparison with the control pigs. The cholesterol concentrations were significantly reduced by 
5.5 and 12.4% in pigs that consumed low (10 g onion/MJ) and high (25 g onion/MJ) doses of 
onion, respectively. Inhibition in the rate of serum lipoprotein oxidation was increased by 23%. 
The data confirmed that onion consumption provide a dietary means of diminishing some of the 
risk indices associated with heart diseases, but the responses varied with type and dose of 
onion [Gabler et al., 2005].  
Additionally, hydroalcoholic extracts of leek have been investigated on plasma lipid levels in 
rabbits divided into control, hypercholesteremic control and three treatment groups 
(hypercholesterolemic diet + 250 mg, 500 mg, 1000 mg /kg per body weight of extract). During 
the 12 weeks feeding, plasma total cholesterol decreased in all groups treated with A. porrum 
extract in a dose dependent fashion. Changes in the distribution of cholesterol in HDL or LDL 
were found indicating that this plant may be useful for the treatment of hyperlipidemia 
[Movahedian et al., 2004]. 
 
4.2.2. ANTIHYPERTENSIVE EFFECTS 
Garlic powder was given to spontaneously hypertensive juvenile rats at 1 g/kg body weight for 
several weeks. It could be shown that the development of hypertension was inhibited and 
myocardial hypertrophy reduced. In spontaneously hypertensive adult rats (6-7 month of age) 
garlic lowered blood pressure and myocardial hypertrophy [Jacob et al., 1993]. Garlic powder 
(1.3% alliin) added at 0.5% to the diet of hypertensive rats significantly prolonged their life span 
by 22 days compared to a control group of hypertensive rats given the normal diet. During the 
course of the study systolic blood pressure was significantly lower in the garlic group [Braendle 
et al., 1997]. The antihypertensive effect was confirmed by another study [Al-Qattan et al., 
1999]. 
 
4.2.3 OTHER EFFECTS 
In an animal model using guinea pigs a high protective effect following oral treatment with 
lyophilised onion extract against allergen- and platelet activating factor-induced 
bronchoconstriction could be demonstrated, identifying thiosulphinates and cepaenes as active 
compounds. Considering the isolated thiosulphinates both in vivo and in vitro, allicin was devoid 
of activity [Breu and Dorsch, 1994]. 
Effects of green leek juice were investigated on liver damage induced by CCl4 in male rats. After 
6 weeks, daily administration of 8 mL/kg body weight leek juice resulted in significant 
decreases in activities of serum glutamic oxaloacetic and pyruvic transaminase, respectively, 
hepatic glutathione peroxidase and hepatic superoxide dismutase confirming the assumption 
that green leek juice exerts a protective effect against CCl4-induced hepatotoxicity in rats [Lee, 
2001]. 
 
4.3 HUMAN STUDIES  
4.3.1 RHEOLOGICAL AND ANTIATHEROSCLEROTIC EFFECTS 
In a randomised, double-blind, placebo-controlled, crossover study, the influence on cutaneous 
microcirculation of a single oral dose of 900 mg of garlic powder (1.3% alliin) was evaluated in 
10 healthy volunteers. After 5 hours, a significant increase of 55% was observed in erythrocyte 
velocity in skin capillaries resulting from vasodilatation of precapillary arterioles, which 
increased in diameter by 8.6% [Jung et al., 1991]. Another study has shown that a daily 
ingestion of 600 mg of a standardised garlic powder preparation (1.3% alliin) lowered 
susceptibility to lipoprotein oxidation by 34% [Phelps and Harris, 1993]. 
In an open study involving 101 healthy volunteers, the effects of taking 300-900 mg of 
standardised garlic powder daily on elastic properties of aorta were investigated for at least 2 
years. Compared to results from an untreated control group, garlic intake attenuated age-
related increases in aortic stiffness. Significant differences were observed in pulse wave velocity 
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and pressure-standardised elastic vascular resistance [Breithaupt-Kroegler et al., 1997]. 
Another open study involving eight volunteers took one clove of garlic (approximately 3 g) daily 
for 16 weeks. Serum thromboxane B2 was reduced from 243 to 24 ng/mL [Ali and Thompson, 
1995]. 
Healthy volunteers (n = 30) took 10 g of fresh garlic daily for 2 months. Clotting time increased 
from 4.15 to 5.02 min and fibrinolytic activity decreased from 4.17 to 3.26 hours. There were no 
changes in the control group [Gadkari and Joshi, 1991]. 
In a randomised, double-blind study 60 young patients (average age 24 years) with constantly 
elevated spontaneous platelet aggregation and increased risk of ischaemic attack were treated 
with 800 mg of standardised garlic powder (1.3% alliin) or placebo for 4 weeks. In the garlic 
group the ratio of circulating platelet aggregation decreased by 10.3% and spontaneous platelet 
aggregation by 56.3%, whereas the placebo group remained unchanged [Kiesewetter et al., 
1993b; Kiesewetter et al., 1991]. The same amount of garlic powder was given to 80 patients 
with peripheral arterial occlusive disease daily for 12 weeks. In the garlic group plasma viscosity 
decreased by 3.6% and platelet aggregation dropped by 59% while these parameters were 
unchanged in the placebo group [Kiesewetter et al., 1993a].  
 
4.3.2 LIPID-LOWERING EFFECTS 
In a randomised, double-blind, placebo-controlled study, significant reductions of up to 30% in 
fasting and postprandial plasma triglycerides were observed in 24 volunteers after 6 weeks of 
daily treatment with 900 mg of garlic powder [Rotzsch et al., 1992]. The effects of 600 mg of 
standardised garlic powder daily taken by 68 volunteers for 15 weeks total cholesterol and 
triglycerides showed a tendency to decrease in the verum group [Saradeth et al., 1994]. In an 
open study already mentioned above eight healthy volunteers (initial total cholesterol 6.1 mM) 
took one clove of garlic (approximately 3 g) daily for 16 weeks. Total cholesterol decreased by 
21% [Ali and Thompson, 1995] and by 15.5% in 15 volunteers taking 10 g of garlic daily for 2 
months. No change was observed in the control group [Gadkari and Joshi, 1991].  
Furthermore, a large number of comparative, placebo-controlled and open clinical studies were 
conducted regarding the lipid lowering effects of garlic and preparations thereof confirming the 
reduction of total cholesterol and triglyceride levels as well as an increase in HDL-cholesterol 
[Beck and Gruenwald, 1993; De A Santos and Johns, 1995; Harenberg et al., 1988; Holzgartner 
et al., 1992; Kandziora, 1988; Kiesewetter et al., 1993a; Mader, 1990; Orekhov et al., 1996; 
Vorberg and Schneider, 1990; Walper, 1994]. Intergroup differences could not be observed [Neil 
et al., 1996; Simons et al., 1995; Superko et al., 2000]. 
 
4.3.4 ANTIHYPERTENSIVE EFFECTS 
In a randomised, double-blind, placebo-controlled study, 52 patients with hypercholesterolaemia 
were treated with 900 mg of standardised garlic powder (1.3% alliin) daily for 6 months. Systolic 
and diastolic blood pressure were reduced by 17% and 10%, respectively in the verum group, 
but remained unchanged in the placebo group [De A Santos and Gruenwald, 1993]. Another 
randomised study compared the effects of daily treatment with 600 mg of standardised garlic 
powder (1.3% alliin, 0.6% allicin release) and those of 1.98 mg garlic oil in 80 patients with mild 
hypercholesterolaemia. By the end of 4 months of treatment, initial systolic and diastolic blood 
pressures of 151 and 96 mmHg had decreased by 19 and 17%, respectively, in the garlic 
powder group, whereas no effects were observed in the garlic oil group [De A Santos and Johns, 
1995]. Auer et al. (1990) evaluated the effects of 600 mg of standardised garlic powder (1.3% 
alliin) in 47 patients with mild hypertension for 12 weeks. In the verum group, initial supine and 
standing diastolic blood pressures of 102 and 101 mmHg decreased by 13 and 11%, 
respectively, while in the placebo group initial values of 97 and 94 mmHg decreased by 4% and 
0.5%, respectively. Initial systolic blood pressures of 171 and 161 mmHg in the verum and 
placebo groups, respectively, decreased by 12% and 6%. Intergroup comparison was not 
reported. Further randomised, double-blind studies were conducted evaluating the effect of 
garlic on blood pressures in patients with hypertension and hypercholestolaemia [Holzgartner et 
al., 1992; Kandziora, 1988; Kiesewetter et al., 1993a; Vorberg and Schneider, 1990]. With the 
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exception of the study of Jain et al. (1993) garlic supplementation resulted in a significant 
decrease of systolic and diastolic blood pressures. 
 
4.3.5 OTHER EFFECTS 
The effects of the active principles of Allium species, particularly garlic, indicate the importance 
of the drugs regarding immunocompetence, prevention of cardiovascular diseases and 
antiasthmatic and antiinflammatory reactions [Milner, 2001]. The latter was described by 
Dorsch and coworkers (1989a,b, 1987) investigating the anti-inflammatory potential of fresh 
onion juice, particularly the thiosulphinates and cepaenes, often recommended in the folk 
medicine of various countries for pain and swelling after bee or wasp stings. Onion treatment 
depressed the cutaneous inflammation after allergen or anti-IgE-testing and oedema formation 
was particularly reduced. Additionally, a reduction of immediate and late bronchial reactions of 
human patients after allergen inhalation and subsequent treatment with onion juice has been 
observed [Breu and Dorsch, 1994].  
Furthermore, there is some evidence that garlic has a precise role in the cancer process, 
although major limitations still exist. Laboratory based studies with model cancers designate 
garlic and its related sulphur components suppressing the incidence of breast, colon, skin, 
uterine, esophagus, and lung cancers and alter the biological behaviour of tumours. This 
protection may arise from several mechanisms, including blockage of N-nitroso compounds 
formation, suppression of the bioactivation of several carcinogens, enhanced DNA repair, 
reduced cell proliferation, and/or induction of apoptosis. It is possible and quite probable that 
several of these cellular events are modified simultaneously.  
 
4.4 ADME (ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION) 
Several studies investigating the absorption behaviour of flavonols have shown that quercetin 
and isorhamnetin glucosides were significantly elevated and accumulated in plasma following 
ingestion of onions [Aziz et al., 1998; Boyle, et al., 2000; McAnlis et al., 1999]. The effective 
jejunal permeability (Peff) and percentage absorbed were 8.9 x 10-4 cm/s and 60%, respectively, 
for quercetin-3,4-glycoside. Furthermore, a portion approximately 0.5% of the amount absorbed, 
was excreted back into the lumen as quercetin-3´-glucuronide and finally eliminated in urine 
[Hollman et al., 1995; Petri et al., 2003] 
The pharmacokinetic behaviour of ACSOs and vinyldithiin was investigated after oral 
administration to rats, mice, and dogs. ACSOs were rapidly and easily absorbed in the 
gastrointestinal tract and distributed mainly in plasma, liver, and kidney. The bioavailability was 
98.2, 103.0, and 87.2% in rats, mice, and dogs, respectively. ACSOs are subsequently N-
acetylated by N-acetyltransferase in to S-allyl mercapturic acid and other metabolites and 
excreted both into urine and breath [De Rooij 1996a,b; Laakso et al., 1989; Minami et al., 1989; 
Verhagen et al., 2001]. However, mice excreted both ACSOs and the N-acetyl form. The half-life 
of ACSOs was longer in dogs than in rats and mice [Nagae et al., 1994]. 1,3-Vinyldithiin 
appeared to be less lipophilic and is rapidly eliminated from serum kidney and fat tissue, 
whereas 1,2-vinyldithiin was more lipophilic and showed a tendency to accumulate in fat tissue 
[Egen-Schwind et al., 1992]. 
The metabolism of fresh garlic and its purified components was researched in rats by extracting 
the metabolites from hepatocytes and identifying the components using GC-MS [Sheen et al., 
1999]. Little is known about the pharmacokinetic of allyl sulphur compounds in vivo. It is 
hypothesised that allicin would be rapidly transformed in the liver to diallyl disulphide and allyl 
mercaptan already mentioned above [Egen-Schwind et al., 1992b; Sheen et al. 1999]. Diallyl 
disulphide is transformed to allyl mercaptan, allyl methyl sulphide, allyl methyl sulphoxide and 
allyl methyl sulphone [ Germain et al., 2002; Sheen et al., 1999]. Recently, it is concluded that 
diallyl disulphide might be reconverted to allicin in tissues principally by oxidation due to 
cytochrome P450 monooxygenases and flavin-containing monooxygenases [Teyssier, et al., 
1999]. However, it is quite unclear how much allicin might be formed under physiological 
conditions. Brady et al. (1991) have shown the conversion of diallyl sulphide to diallyl sulphoxide 
and diallyl sulphone both in vivo and in vitro. 
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5. MICROBIOLOGY 
The findings in scientific works support the historical use of garlic, onion and leek in the 
treatment of varieties of infections. Considerable evidence indicates that garlic extracts and 
leek juice can inhibit a range of Gram-negative and Gram-positive bacteria and serve as an 
antifungal agent [Arora and Kaur, 1999; Yin and Tsao, 1999], whilst onion and shallot juice 
showed no effect upon Gram-negative bacteria [Dankert et al., 1979]. Besides its antibacterial 
and antifungal actions, garlic shows also antiviral and antiprotozoal effects [Harris et al., 2001]. 
 
5.1 ANTIPROTOZOAL PROPERTIES 
The extract of garlic is effective against a host of protozoa including Opalina ranarum, O. 
dimidicita, Balantidium entozoon, Entamoeba histolytica, Trypanosomes, Leishmania, 
Leptomonas and Crithidia [Reuter et al, 1996]. Its possible use as an antiprotozoal against 
Entamoeba histolytica was observed by Mirelman et al. (1987) who found an inhibitory activity 
with crude extracts at 25 µg/mL and a lethal dosage at 50 µg/mL. Based on these results 
further studies were conducted to investigate the antigiardial activity of garlic removing the 
symptoms of giardiasis from all patients within 24 hours [Soffar and Mokhtar, 1991]. 
The active principles are allicin, which degrades to diallyl trisulphide exhibiting also antigiardial 
activity [Lun et al., 1994], ajoene and organosulphides.  
 
5.2 ANTHELMINTIC PROPERTIES  
Garlic extracts have been shown to exert anthelmintic activity against common intestinal 
parasites, including Ascaris lumbricoides and hookworms [Bastidas, 1969; Vohora et al., 1973]. 
 
5.3 ANTIBACTERIAL PROPERTIES 
Garlic has been proven to be effective against a vast number of Gram-positive, Gram-negative 
and acid-fast bacteria, including Pseudomonas, Proteus, Staphylococcus aureus, Escherichia 
coli, Salmonella, Klebsiella, Micrococcus, Bacillus subtilis, Clostridium, Mycobacterium and 
Helicobacter. It has been documented that garlic exerts a differential inhibition between 
beneficial intestinal microflora and potentially harmful enterobacteria [Rees et al., 1993]. The 
antibacterial activity is mainly attributed to allicin, since the antibacterial effectiveness of garlic 
extract is greatly reduced.  
 
5.4 ANTIFUNGAL PROPERTIES 
Several fungi were shown to be susceptible, including Candida, Torulopsis, Trichophyton, 
Cryptococcus, Aspergillus, Trichosporon and Rhodotorula. Again, allicin showed antifungal 
activity but also diallyl trisulphide and ajoene [Cai, 1991, Yoshida et al., 1987]. 
 
5.5 ANTIVIRAL PROPERTIES 
Only few studies have been done to investigate antiviral properties against influenza A and B, 
cytomegalovirus, rhinovirus, HIV, herpes simplex virus 1 and 2, viral pneumonia and rotavirus 
[Fenwick and Hanley, 1985; Meng et al., 1993; Tsai et al., 1985; Weber et al., 1992]. 
 
 
6. EFFICACY 
6.1 HENS 
Northern fowl mites (NFM) are external parasites that can lower egg production and cause 
anaemia and even death in laying hens. The topical application of garlic (10% garlic juice in 
Allium 
----------------------------------------------------------------------------------------------------------------- 
 
 32
water) for 3 weeks significantly reduced NFM infestation in laying hens [Birrenkott et al., 2000]. 
Furthermore, in vivo investigations revealed that garlic treatment at 2% and 4% concentrations 
in feed protected chicks from experimental candidiasis. The disease induced by oral inoculation 
of chicks with Candida albicans was successfully cured by providing a ration containing 5% 
garlic [Prasad and Sharma, 1980]. 
The inclusion of garlic supplement within chick diets and their associated effects on 
performance were studied. The birds were fed a basal wheat/soybean meal formulated to be 
low in vitamin E and supplemented with garlic (at 10g/kg) and other herbs. It has been shown 
that garlic diets resulted in the highest bodyweights and weight gains and lower FCR (feed 
conversion ratio) compared with the other plants investigated. The beneficial effects of garlic in 
the diet are evident and may indicate an antimicrobial effect in vivo. However, longer periods of 
dietary garlic inclusion (>10-20d) may affect the meat flavour as a strong odour was detectable 
in the hens [Cross et al., 2004]. 
 
6.3 SHEEP 
A diet consisting entirely of onions fed to pregnant ewes produced Heinz bodies hemolytic 
anaemia in all sheep after 21 days, what could be confirmed by Selim et al. (1999) and Kirk and 
Bulgin (1979). After 28 days of daily consumption of 20 kg onions/ewe, the anaemia stabilised 
and for the remaining 74 day the packed cell volume increased in the majority of sheep, 
although it did not return to normal. Compared to control onion-fed ewes had comparable body 
condition scores and fleece weights. There was no significant difference in pregnancy or 
lambing rate. Greater numbers of sulphate reducing bacteria and more ruminal hydrogen 
sulphide were present in onion-fed sheep. On the basis of this study it appears that pregnant 
ewes may be fed a pure onion diet with minimal detrimental effects. This adaptation to a pure 
onion diet is in part likely due to the apparent ability of the sheep’s rumen to quickly develop a 
population of sulphate-reducing bacteria that decrease the toxicity of onion disulphides, namely 
n-propyl disulphide [Knight et al., 2000]. Lincoln et al. (1992) observed similar effects after 
feeding a balanced growth diet to cattle as described for sheep.  
 
6.4 CATTLE 
Earlier attempts to use onions as a feed for cattle have induced toxicoses caused by dipropyl 
disulphide [Hutchinson, 1977; Koger, 1956; Verhoeff et al., 1985]. Cattle were more susceptible 
than other domestic animals to onion toxicosis; dogs and horses were intermediate in 
susceptibility and sheep and goats were the most resistant [Schalm et al., 1975]. Although 
toxicity of domestic onions is well documented, certain cattle feeders have successfully fed 
onions and had satisfactory feeding performance without observing toxic effects. This success in 
feeding onions appears to be dependent on mixing onions in the diet, which could be confirmed 
by Lincoln et al. (1992) who applied an onion diet containing up to 25% onions (based on dry 
matter) without having health problems.  
Berard et al. (1936) observed an undesirable odour and taste in milk when the cows consumed 
garlic. Undesirable flavour of the milk is reduced, if the consumption of such material is 4 hour 
or more before milking. The authors advise to avoid such feed from the ration and even from the 
pastureland. Contamination of crops such as wheat with especially wild Alliums may cause 
processing problems, off flavours in grain, and thus lower the quality of the product [Fenwick 
and Hanley, 1985].  
 
More information regarding the positive and negative effects, respectively, of an Allium enriched 
diet could not be found.  
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7. TOXICOLOGY 
The intravenous LD50 of allicin in mice was determined as 60 mg/kg; when administered 
subcutaneously the LD50 was 120 mg/kg [Cavallito and Bailey, 1944]. For the vast majority of 
individuals garlic, onion and leek were non toxic at the dosages commonly used.  
 
7.1 SAFETY 
7.1.1 DOSAGE/ADMINISTRATION  
Garlic: Unless otherwise prescribed an average daily dosage of 4 g of fresh garlic (one medium 
clove) and equivalent preparations, respectively for internal use [Blumenthal et al., 1998a,b]. 
Onion: Unless otherwise prescribed an average daily dosage of 50 g of fresh bulb or 20 g of cut 
dried bulb (Commission E), pressed juice from fresh onions used as infusion (5-10 mL in 120 mL 
water [Lust, 1974]) and tincture (5 mL 3 to 4 times daily [Lust, 1974; Fleming et al., 1998]), 
respectively.  
Note: If onion preparations are used over several months, the daily maximum amount for 
diphenylamine is 0.035 g. 
Leek:  At the date of write no information available 
 
7.1.2 SIDE EFFECTS/ADVERSE REACTIONS/CONTRADICTIONS/PRECAUTIONS 
Garlic: Garlic is classified as GRAS including during pregnancy and lactation and in children, 
when ingested in amounts commonly found in foods. Serious toxicity has not been reported, but 
in rare instances gastrointestinal symptoms such as irritations and distress, changes of the 
intestinal flora or allergic reactions may occur. Chronical application of large amounts of raw 
garlic to rats resulted in anemia, weight loss and failure to grow. Genotoxicity and mutagenicity 
were not found in the micronucleus and Ames test, respectively [Abraham and Kesavan, 1984; 
Yoshida et al., 1984] 
Note: The odour of garlic may pervade the breath and skin. 
Onion: None known. 
Leek:  At the date of write no information available 
 
7.1.3 INTERACTIONS WITH OTHER DRUGS 
Garlic: None known 
Onion: None known 
Leek:  At the date of write no information available 
US 
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ALOE SP 
 
 
Aloe vera a: leaf epidermis, b: latex ducts, c: mesophyll 
 
1. INTRODUCTION 
Aloe is native to southern and eastern Africa, and subsequently introduced into northern Africa, 
the Arabian peninsula, China, Gibraltar, the Mediterranean countries and the West Indies. It is 
commercially cultivated in Aruba, Bonaire, Haiti, India, South Africa, the United States of 
America, Central America and Venezuela. [WHO] 
Aloe has been called the "plant of immortality" because it can live and bloom without soil. It was 
given as an offering at the funerals of pharaohs and used in the baths of Egyptian queens. 
Today, Egyptians still hang an aloe plant over the door of a new house to provide a long and 
fruitful life for its occupants.  According to the Roman scholar, Pliny, the plant was also used for 
embalming. The Greek physician Dioscorides used aloe gel for mouth infections, sores, wounds, 
hair loss, genital ulcers, hemorrhoids, boils, inflammation, and as a laxative. In India, the whole 
leaves and the fresh gel have been used as a laxative, to improve appetite and digestion, to 
promote menstrual flow, and to destroy and expel intestinal worms. In the seventh century, aloe 
gel was used in Asia for inflammatory skin conditions and sinusitis. Aloe latex (taken from the 
bundle sheath cells inside the leaf) has been used for its laxative effect; however, in 2002, the 
FDA banned the use of aloe latex in over-the-counter drug products in the United States. 
Three distinct preparations of the aloe plant are used in a medicinal capacity: aloe latex, aloe 
gel, and aloe whole leaf extract. The constituents of aloe are purported to have anti-
inflammatory, antibacterial, antitumor, antiallergic, and immunostimulatory properties. 
Topically, aloe gel is used to treat burns, abrasions, bruises, cuts, and may be effective in 
treating herpes simplex and psoriasis. Internally, aloe gel is beneficial for healing gastric and 
mouth ulcers, and may be beneficial in lowering blood glucose in diabetic patients and reducing 
blood lipid levels in patients with hyperlipidemia (high levels of fats in the blood). The extract is 
beneficial in the treatment of asthma, and potentially useful in treating cancer and AIDS. 
Clinical trials are in progress to obtain conclusive evidence for the use of aloe in the treatment 
of arthritis, cancer, AIDS, gastric ulcer, and colitis. Aloe is shown to increase collagen and elastin 
formation, which may reduce wrinkling, aid in wound healing, and protect against damage from 
ultraviolet rays. 
Aloe vera is a very common household plant due to wound and burn healing abilities. Aloe gel is 
found in various personal care products such as moisturizers, cleansers, sun lotions, 
toothpastes, mouthwashes, deodorants, and shampoos. Aloe is processed into various flavored 
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and unflavored drinks that are ingested with the belief that this bitter liquid will stimulate the 
appetite and digestion. Aloe is also used for its bitter taste to discourage nail biting. 
 
History of use (WHO): 
 
Aloe drug 
It was used as treatment of seborrhoeic dermatitis, peptic ulcers, tuberculosis, fungal infections 
and for reduction of blood sugar (glucose) levels. (WHO) 
 
Aloe Vera Gel 
It is widely used for the external treatment of minor wounds and inflammatory skin disorders. 
The gel is used in the treatment of minor skin irritations, including burns, bruises, and abrasions. 
The gel is further used in the cosmetics industry as a hydrating ingredient in liquids, creams, sun 
lotions, shaving creams, lip balms, healing ointments, and face packs for humans. 
The treatment of acne, haemorrhoids, psoriasis, anaemia, glaucoma, peptic ulcers, tuberculosis, 
blindness, seborrhoeic dermatitis, and fungal infections. (WHO) 
 
2. DESCRIPTION OF THE PLANT 
 
The genus contains laut Crosswhite and Crosswhite (1984) at least 324 species of herbs, 
shrubs, and trees, primarily African, with some in Madagascar and the Arabian Peninsula. 
 
Aloe vera (L.) Burm. f. 
It is a succulent, almost sessile perennial herb. The leaves are 30-50 cm long and 10 cm broad 
at the base; the colour is pea-green (when the leaf is young it´s spotted with white). It has bright 
yellow tubular flowers, 25-35 cm in length, arranged in a slender loose spike. The stamens are  
frequently project beyond the perianth tube. (WHO) 
 
Aloe ferox Mill. 
It is an arborescent perennial shrub with a single stem of 2-3 m in height, crowned by a large 
rosette of numerous leaves which are glaucous, oval-lanceolate, 40-60 cm in length, thorny on 
the ridge and the edges; inflorescence an erect raceme 60 cm in height. The flowers have a 
perianth of 2,5 cm in length and are red, yellow or orange. (WHO) 
 
 
2.1  SYSTEMATICS: 
Aloe vera (L.) Burm. f.: 
Aloe barbadensis Mill., Aloe chinensis Bak., A elongata Murray, A. indica Royle, A. officinalis 
Forsk., A. perfoliata L., A. rubescens DC, A. vera L. var. littoralis König ex Bak., A. vera L. var. 
chinensis Berger, A. vulgaris Lam. 
In most reference books, Aloe barbadensis Mill. is regarded as the correct species name, and 
Aloe vera (L.) Burm. f. is considered a synonym. However, according to the International Rules of 
Botanical Nomenclature, Aloe vera (L.) Buem. f. is the legitimate name for this species. The 
genus Aloe has been placed taxonomically in a family called Aloeaceae. [WHO] 
 
Aloe ferox Mill.: 
Aloe horrida Haw., A. perfoliata Thunberg., A. pseudoferox Salm. Dyck, A. socotrina Masson., A. 
supralaevis Haw., Pachydendron ferox Humb. & Bonpl., P. supralaeve Haw. (WHO) 
 
2.2  PLANT MATERIAL USED: 
Aloe drug 
It is a solidified juice originating in the cells of the pericycle and adjacent leaf parenchyma, and 
flowing spontaneously from the cut leaf, which is allowed to dry with or without the aid of heat. 
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Aloe vera Gel 
Aloe vera Gel is not to be confused with the juice, which is the bitter yellow exsudate originating 
from the bundle sheath cells of the leaf. Aloe Vera Gel is the colourless mucilaginous gel 
obtained from the parenchymatous cells in the fresh leaves of Aloe vera (L.) Burm. f. (Liliaceae). 
(WHO) 
The Preparation of fresh gel: harvest the leaves and wash them with water and a mild chlorine 
solution. Remove the outer layers of the leaf including the pericyclic cells, leaving a "fillet" of 
gel. Care should be taken not to tear the green rind which can contaminate the fillet with leaf 
exudate. (WHO) 
 
3. INGREDIENTS / CONSTITUENTS 
Aloe drug 
The main active constituents are aloins A and B and 5-hydroxyaloin A, which are aloe-emodin 
anthrone-C-glycosides. Aloinosides A and B, which are anthrone-C- and O-glycosides, are also 
considered as active constituents contributing to the sum of hydroxy-anthracene glycosides. 
Other constituents include 2-acetonyl-5-methyl-chromones (also known as aloeresins), small 
quantities of 1,8-dihydroxy-anthraquinones (e.g. aloe-emodin) cinnamic acid and 1-methyl-
tetralin derivatives. (ESCOP) 
It contains not less than 18.0 per cent of hydroxyanthracene derivatives, expressed as barbaloin 
(C21H22O9; M r 418.4) and calculated with reference to the dried drug. (ESCOP) 
The main active constituents of the latex are anthraquinones, including the hydroxyanthracene 
derivatives 25-40 percent aloins A and B, barbaloin, isobarbaloin, and emodin (Bradley, 1992; 
Newall et al., 1996; Wichtl and Bisset, 1994). Aloe  perryi contains approximately 25 to 28 
percent aloin and A. ferox approximately 10 percent (Duke, 1985). Also included are 3 to 4 
percent 7-hydroxyaloins A and B, aloe-emodin, resins, aloesin and its aglycone aloesone, 
chromone derivatives and chrysophanol (Wichtl and Bisset, 1994; Wren, 1988). 
 
Aloe Vera Gel 
Aloe Vera Gel consists primarily of water and polysaccharides (pectins, hemicelluloses, 
glucomannan, acemannan, and mannose derivates). It also contains amino acids, lipids, sterols 
(lupeol, campesterol, and beta-sitosterol), tannins, and enzymes. Mannose 6-phosphate is a 
major sugar component. (WHO) 
Acemannan, a fraction obtained from the gel, may be related to the reported wound healing, 
antiviral (Womble and Helderman, 1988) and immune-stimulating activities of aloe (Zhang and 
Tizard, 1996). 
In the United States the internal use of the gel is approved by the FDA only as a “dietary 
supplement.” Manufacturers cannot claim that their products can cure, treat, or prevent any 
disease. The external use of the gel is approved by the FDA only as a cosmetic ingredient.  
 
3.1. CHEMICAL ANALYSIS 
Chemical assays: 
 
Aloe drug 
Thin-layer chromatography and microchemical analyses are employed for the qualitative 
analysis for the presence of anthracene glycosides. Quantitative analysis of total anthracene 
glycosides, calculated as barbaloin, is performed by spectrophotometry. 
 
Curacao or Barbados Aloe, derived from Aloe vera (L.) Burm. f. 
Contains not less than 28% of hydroxyanthracene derivatives, expressed as barbaloin. 
 
Cape Aloe, derived from A. ferox Miller and its hybrids with A. africana Mill. and A. spicata Baker 
Contains not less than 18% of hydroxyanthracene derivatives, expressed as barbaloin. 
(WHO) 
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Aloe Vera Gel 
Carbohydrates (0,3%), water (98,5%). Polysaccharides composition analysis by gas-liquid 
chromatography. 
 
3.2. STANDARDISATION 
 
Stability: 
 
Aloe Vera Gel 
At present no commercial preparation has been proved to be stable. Because many of the active 
ingredients of Aloe Vera Gel appear to deteriorate on storage, the use of fresh gel is 
recommended. The gel may be stabilized by pasteurization at 75-80°C for less than 3 minutes. 
Higher temperatures held for longer times may alter the chemical composition of the gel. (WHO) 
 
 
4. PHARMACOLOGY 
Aloe drug 
 
Experimental pharmacology 
Aloe´s mechanism of action is twofold. It stimulates colonic motility, augmenting propulsion 
and accelerating colonic transit, which reduces fluid absorption from the faecal mass. It also 
increases paracellular permeability across the colonic mucosa probably owing to an inhibition of 
Na+, K+ -adenosine triphosphatase or to an inhibition of chloride channels, which results in an 
increase in the water content in the large intestine. (WHO) 
 
Clinical pharmacology 
The laxative effects of Aloe are due primarily to the 1,8-dihydroxyanthracene glycosides, aloin A 
and B (formerly designated barbaloin). After oral administration aloin A and B, which are not 
absorbed in the upper intestine, are hydrolysed in the colon by intestinal bacteria and then 
reduced to the active metabolites (the main active metabolite is aloe-emodin-9-anthrone), which 
acts as a stimulant and irritant to the gastrointestinal tract. The laxative effect of Aloe is not 
generally observed before 6 hours after oral administration, and sometimes not until 24 or more 
hours after. (WHO) 
 
Aloe Vera Gel 
 
Pharmacology 
Clinical investigations suggest that Aloe Vera Gel preparations accelerate wound healing. 
Furthmore, acemannan, a complex carbohydrate isolated from Aloe leaves, has been shown to 
accelerate wound healing and reduce radiation induced skin reactions. The therapeutic effects 
of Aloe Vera Gel also include prevention of progressive dermal ischaemia caused by burns, 
frostbite, electrical injury and intraarterial drug abuse. 
The anti-inflammatory activity of Aloe Vera Gel has been revealed by a number of in vitro and in 
vivo studies. 
Fresh Aloe Vera Gel significantly reduced acute inflammation in rats, although no effect on 
chronic inflammation was observed. Three plant sterols in Aloe Vera Gel reduced inflammation 
by up to 37% in croton oil-induced oedema in mice. Lupeol, one of the sterol compounds found 
in Aloe Vera, was the most active and reduced inflammation in a dose-dependent manner. 
Aloe Vera Gel has been used for the treatment of radiation burns in humans. 
In preliminary human clinical studies, the gel has shown significant results in the treatment of 
asthma, peptic ulcers, and diabetes mellitus (Shida, 1985; Blitz et al., 1963). The gel has been 
sold in the health food market as a tonic, as well as for “supporting the immune system” and 
“supporting healthy breathing”. But on May  the 9th, 2002, the U.S. Food and Drug 
Administration issued a final rule banning the use of aloe (Aloe spp., Aloaceae) as a laxative 
ingredient in over-the-counter (OTC) drug products. 
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 Externally, the gel has been used in many ways: cosmetics, dermabrasion, wound-healing, and 
psoriasis (Fulton, 1990; Heggers et al., 1993; McCauley et al., 1990; Syed et al., 1996). In 
cosmetics, the gel is added to moisturizers, cleansers, shampoos, suntan lotions, and sunburn 
treatments (Bruneton, 1994; Grindlay and Reynolds, 1986).  
The drug derived from aloe latex is part of one of the strongest anthraquinone groups that 
function as stimulant laxatives (Wichtl and Bisset, 1994). The latex is officially approved as a 
laxative in the U.S., England, and Germany. The German Commission E recommends the use of 
aloe for occasional constipation and for conditions that require a soft stool, such as anal 
fissures, hemorrhoids, and after rectal or anal surgery (Blumenthal et al., 1998). Externally, the 
latex is used like the gel and as a soothing agent in treating burns and mild cuts (Bradley, 
1992). 
 
4.1  ANIMAL STUDIES 
Aloe gel has demonstrated wound healing (Davis et al., 1989; 1994a; 1994b; Heggers et al., 
1993; 1995; 1996), anti-inflammatory (Vazquez et al., 1996), antiviral (Saoo et al., 1996), 
spermicidal (Fahim and Wang, 1996), and gastroprotective (Danhof, 1991) properties. It has 
also shown immune-stimulating (Zhang and Tizard, 1996) and cholesterol-lowering (Tizard et al., 
1989) activity. 
Aloe gel is thought to speed recovery from wounds by enhancing the activity of macrophages 
and fibroblasts (Davis et al., 1994a; Heggers et al., 1993). A recent study showed aloe to be 
more effective than conventional treatments for burns, frostbite, and intra-arterial damage from 
intravenous drug abuse, as well as tissue injuries from electrical shocks (Heggers et al., 1993). 
Aloe gel also helped speed the rate of wound closure and the resistance of the healed wound to 
tearing (Heggers et al., 1995 and 1996). Its wound-healing activity has been partially attributed 
to the polysaccharide, mannose-6-phosphate (Davis et al., 1994a). 
It has been suggested that aloe works as an anti-inflammatory when used topically and when 
taken orally (Davis et al., 1989). An animal study examined the anti-inflammatory activity of 
extracts derived from aloe gel. The researchers concluded that the action may be due to 
inhibition of the arachidonic acid pathway through cyclooxygenase (Vasquez et al., 1996). 
Another study inhibited edema in mice by 37 percent and attributed the activity to the sterol 
compounds in aloe, especially lupeol (Davis et al., 1994b). 
Antiviral activity was shown in an in vitro study using a purified extract from the gel of Aloe 
barbadensis. The main activity against cytomegalovirus was shown 12-36 hours after infection 
(Saoo et al., 1996). An in vitro study using zinc acetate and lyophilized Aloe barbadensis (7.5 
and 10 percent) demonstrated an antiviral and spermicidal effect. The authors concluded that it 
may be useful as a contraceptive, especially significant in preventing the transmission of HIV. 
Spermicidal activity from Aloe was thought to be due to microelements (boron, barium, calcium, 
chromium, copper, iron, potassium, magnesium, manganese, phosphoru, and zinc) that 
immobilize the tails of sperm without causing vaginal irritation (Fahim and Wang, 1996). 
Gastroprotective properties were shown in several animal studies. When aloe gel was 
administered to rats prior to ulcer-inducing stress, the number of ulcers decreased by 80 
percent. After developing ulcers, the animals given aloe gel recovered three times faster than 
the control animals (Galal et al., 1975; Danhof, 1991). Another animal study demonstrated 
similar results (Kandil and Gobran, 1979). The triterpenoids contained in aloe were found to 
protect against the formation of gastric ulcers (Gupta et al., 1981). 
Research on immune stimulation in mice has indicated that acemannan, a polysaccharide 
within aloe, has demonstrated dose-dependent macrophage activation (Zhang and Tizard, 1996; 
Ramamoorthy et al., 1996). When given orally to animals, mannans have also been shown to 
inhibit cholesterol absorption and lower cholesterol (Tizard et al., 1989). 
The pharmacological difference between aloe gel and aloe latex is that the gel does not contain 
any anthraquinone compounds and does not, therefore, exert any laxative action (Newall et al., 
1996). Anthraquinones induce secretion of water and electrolytes into the lumen of the gut and 
inhibit the absorption of electrolytes and water by the colon. This action in turn activates 
peristalsis (Blumenthal et al., 1998; Bradley, 1992). Aloe-emodin, a degradation product of B-
glycosides in the colon, is the laxative metabolite (Blumenthal et al., 1998). Animal studies have 
found that aloe-emodin and an alcoholic extract of aloe possess antitumor and anticancer 
activity. In vitro research has reported that aloctin A could induce cells cytotoxic to syngenic and 
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allogenic tumor cells (Leung and Foster, 1996; Newall et al., 1996; Wren, 1988). However, the 
National Cancer Institute is no longer studying the latex as an anticancer treatment. 
 
4.2  RECENT HUMAN CLINICAL STUDIES 
Clinical studies have focused upon the external use of aloe gel for wound healing and psoriasis. 
In a study that compared aloe to polyethylene oxide gel dressing in the treatment of patients 
with dermabrasion (surgery to remove tattoos, acne, scars, and wrinkles), aloe accelerated 
healing by 72 hours (Fulton, 1990). The wounds of patients recovering from burns, frostbite, and 
intra-arterial drug abuse healed faster, had less tissue loss or morbidity, and fewer 
complications than those patients treated with conventional methods. Seven percent of the 
frostbite patients treated with aloe required amputation, compared with 32 percent in the 
nontreatment group (Heggers et al., 1993). In another study, aloe also was shown to assist 
patients recovering from wounds associated with frostbite (McCauley et al., 1990). One study 
contradicted these results by showing a delay of 30 days in the healing of wounds on patients 
treated with aloe gel (Schmidt and Greenspoon, 1991). A double-blind, placebo-controlled study 
examined the effect of aloe extract (0.5 percent in a hydrophilic cream) for 60 psoriasis vulgaris 
patients, aged 18 to 50 years. The aloe cream cured 25 out of 30 patients compared to a 
placebo rate of 2 out of 30. The authors concluded it was a safe alternative treatment for 
treating psoriasis (Syed et al., 1996). 
The internal use of the gel has been studied for treating asthma, peptic ulcers, and diabetes 
mellitus. A clinical study found that a fraction of aloe extract enhanced phagocytosis (causing 
the elimination of bacteria and dust particles) in adult bronchial asthma (Shida et al., 1985). 
Another study examined the effect of aloe on the blood sugar levels of 50 men and 22 women 
with a diabetic curve on glucose tolerance tests. By week two, cholesterol levels were 
unchanged, but changes to blood sugar levels and triglyceride levels were statistically significant 
(Yongchaiyadha et al., 1996). A small study of 12 peptic ulcer patients reported positive results 
from treatment with aloe. The results were attributed to the inhibition of hydrochloric acid 
secretion, coacervation of pepsin and general detoxification (Blitz et al., 1963). 
 
5. MICROBIOLOGY 
Aloe showed antiviral, spermicidal and anti- inflammatory effects and macrophage activation is 
reported. More see 4. 
 
6. EFFICACY 
Aloe gel is reported to contain glycoproteins, polysaccharides, and other contituents (enzymes, 
etc.) and is essentially used for the treatment of various skin conditions, like burns, abrasions, 
bruises, cuts, psoriasis, herpes simplex, etc. On the other hand, there is a general agreement 
that aloe gel used in a fresh state, not on storage, is more able to show anti-inflammatory 
properties. 
The internal use of Aloe drug has a laxative effect. It acts as a stimulant and irritant to the 
gastrointestinal tract. 
 
7. TOXICOLOGY 
Aloe drug 
The major symptoms of overdose are griping and severe diarrhoea with consequent losses of 
fluid and electrolytes. Treatment should be supportive with generous amounts of fluid. 
Electrolytes, particulary potassium, should be monitored, especially in children and the elderly. 
[WHO] 
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Aloe Vera Gel 
No information available. 
 
7.1. SAFETY 
Aloe drug 
The decreased intestinal transit time may reduce absorption of orally administered drugs. 
Existing hypokalaemia resulting from long-term laxative abuse can potentiate the effects of 
cardiotonic glycosides (digitalis, strophanthus) and antiarrhythmic drugs such as quinidine. The 
induction of hypokalaemia by drugs such as thiazide diuretics, adrenocorticosteroids, and 
liquorice root may be enhanced, and electrolyte imbalance may be aggravated. 
Laxatives containing anthraquinone glycosides should not be used continuously for longer than 
1-2 weeks, owing to the danger of electrolyte imbalance. (WHO) 
 Pregnancy 
No teratogenic or fetotoxic effects were seen in rats after oral treatment with aloe extract (up to 
1000 mg/kg) or aloin A (up to 200mg/kg) [WHO] 
Strong indirectly- induced uterus contractions can  be induced, therefor could Aloe induce abort 
in pregnant animals Reichling et al., 2005). 
 Nursing animals 
Anthranoid metabolites appear in the milk.The milk has a yellow-greenish to red colour and a 
bitter taste. The milk of animals, which are treated with Aloe has a laxative effect. These 
specialties of Aloe have to be considered by application and for the release of milk for 
consumption (Reichling et al., 2005). 
 Contraindication 
Pregnant or lactating animals; Inflammation in the Gastric- and Intestinaltract (Reichling et al., 
2005). 
 Dosages 
The correct individual dose is the smallest amount required to produce a soft-formed stool. 
Short internal use is useful in case of obstipation. Aloe is a perfect laxative for horses. 
Therapeutic use in case of obstipation and chronical meteorism [Rabinovich 1981] 
Horses are very sensitive on the laxative effects of Aloe. The laxative effect is only moderate for 
Cattle, small ruminants and pigs. [Rabinovich 1981] 
 
Internal Use of Aloe (Aloe drug): 
Dosages 
recommended daily allowance: 
Cattle    25,0 - 40,0 g 
Horse    20,0 - 35,0 g 
Sheep, Goat     5,0 - 15,0 g 
Pig       3,0 - 10,0 g 
Dog      0,5 -   3,0 g 
Cat       0,2 -   1,0 g 
Fowl      0,2 -   0,5 g 
(changed by Rabinovich 1981; Gachnian and Assenov 1986, 1990) (Reichling et al., 2005). 
 
 
 
7.2. PRECAUTIONS 
Aloe drug 
Drug aloe should not be taken for more than 10 days. It should not be used by pregnant or 
lactating women and is contraindicated in the following conditions: intestinalobstruction or 
inflammation (e.g., appendicitis, colitis, Crohn’s disease, irritable bowel syndrome, etc.), 
abdominal pain of unknown origin, hemorrhoids, kidney dysfunction, menstruation, and in 
children less than 12 years old (McGuffin et al., 1996; Wichtl and Bisset, 1994). 
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Aloe vera Gel 
It should not be used externally after laparotomy or caesarean delivery because it may delay 
wound healing (McGuffin et al., 1996).  
Care should be taken for the preparation of fresh gel: harvest the leaves and wash them with 
water and a mild chlorine solution. Remove the outer layers of the leaf including the pericyclic 
cells, leaving a "fillet" of gel. Care should be taken not to tear the green rind which can 
contaminate the fillet with leaf exudate. [WHO] 
Aloe Vera Gel is contraindicated in cases of known allergy to plants in the Liliaceae. [WHO] 
No information is available concerning general precautions, or precautions dealing with 
carcinogenesis, mutagenesis, impairment of fertility; drug and laboratory test interactions; drug 
interactions; nursing mothers; paediatric use; or teratogenic or non-teratogenic effects in 
pregnancy. [WHO] 
 
Legal status of other use than as feed additives: 
It is allowed to use Aloen, Barbados and Cape, standardised dried extract and preparations out 
of the dried extract, as an active agent for foodstuff delievering animals in the EU. [VO (EWG) Nr. 
2377/90] (Reichling et al., 2005). 
__________________________________________________________________________________
KBB 
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ASTRAGALUS GUMMIFER 
 
 
 
Astragalus gummifer   
1. INTRODUCTION 
Astragalus gummifer (Labill.), A. microcephalus and some other Astragalussp.,  family Fabaceae 
(formerly Leguminose), habitat Asia minor, Persia and Kurdistan, are the most important 
sources of tragacanth gum. From wounds in Astragalus shrubs exudes gum tragacanth and 
hardens as curled ribbons or flakes, which can be collected after a few weeks.  
Gum tragacanth is defined by JECFA as: “a dried exudation obtained from the stems and 
branches of Astragalus gummifer Labillardiere and other Asiatic species of Astragalus (Fam. 
Leguminosae)” (FAO 1992b), to be not confused with gum karaya that is a dried gummy 
exudation from Sterculia urens Roxburgh and other species of Sterculia, or from 
Cochlospermum gossypium or other species of Cochlospermum Kunth (Weiping, 2000). 
Tragacanth occurs in two main forms, ribbons and flakes. Ribbons are considered to be of 
superior quality (Gecgil et al., 1975). The flakes break with a short fracture, are odourless and 
nearly tasteless. In EU countries, tragacanth gum is used as a food and feed additive (E413). In 
non-food application it is widely used as an effective suspending agent, as a stabilizer in 
dermatological creams, and as a binding agent in the production of tablets. Iran dominates the 
gum tragacanth market and supplies the highest quality gum. Turkey is the second largest 
producer, but Turkish gum is considered of inferior quality. Much smaller amounts of gum are 
exported from Afghanistan and Syria (Anderson et al., 1975). 
 
2. DESCRIPTION OF THE PLANT 
Astragalus sp. L. is the largest genus of the Fabaceae family consisting of more than 1.500 
species mainly distributed over the northern hemisphere. In tropical regions on high mountains 
only, missing in Australia, Astragalus has its center of diversity in South-West Asia. 
 
These small shrubs, varying in height from hardly 10 cm (A. microcephalus) up to 1 m (A. 
gummifer), grow in the highlands and deserts of Turkey, Iran, Iraq, Syria, Lebanon, Afghanistan, 
Pakistan, and Russia. Exudate gums are produced by many trees and shrubs as a natural 
defense mechanism, particularly in semiarid regions. When the plants bark is injured, an 
aqueous gum solution is exuded to seal the wound, preventing infection and dehydration of the 
plant. The solution dries in contact with air and sunlight, to form hard, glass-like lumps which 
can easily be collected. The primary source of the gum are the rather large tap roots of the bush, 
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inside of which gum is contained in a central gum cylinder. Incisions are also made in the bark 
of the branches, although this usually yields gum of an inferior quality. After collection, the gum 
is sorted manually into various grades of ribbon and flake. Iranian tragacanth ribbons are sorted 
into five grades, while flakes are sold in seven different grades (FAO, 1995). After arrival in the 
importing country, the gum is usually ground into powder, with particle size varying according to 
the desired viscosity.  
 
Most commercial gum tragacanth is obtained from  Astragalus gummifer Labill. and A. 
microcephalus Willd., but the contribution of other Astragalus species such as A. adscencens 
Boiss., A. echidnaeformis Sirjaev, A. gossypinus Fisch., and A. kurdicus Boiss. is also significant.  
 
From other Astragalus sp. as e.g. A. membranaceus and A.mongholicus indigenous to East Asia 
the roots are used due to their content on saponins and flavonoids. In traditional Chinese 
medicine (TCM) preparations are used at cardiovascular, gastrointestinal and immune disorders. 
This drug should not be mixed up with tragacanth (gum). 
 
3. INGREDIENTS/CONSTITUENTS (CHEMICAL ANALYSIS, STANDARDIZATION) 
Gum tragacanth is a complex, highly branched, heterogeneous polysaccharide, naturally 
occurring as a slightly acidic calcium, magnesium, and potassium salt. It has a molecular mass 
of about 8,4x105 Da and an elongated shape of 4,500x109 Å (Verbeken et al., 2003).  
Gum tragacanth contain 20 – 30% of a water soluble fraction called tragacanthin (consisting of 
tragacanthic acid and an arabinogalactan) and 60-70% of a water-insoluble fraction called 
bassorin. Both fractions contain small amounts of proteinaceous material and methoxyl groups, 
the latter present in higher amounts in the watersoluble fraction. The ratio of the two fractions 
strongly varies between species. The water-swellable tragacanthic acid fraction has a high 
molecular weight and a rodlike molecular shape. The main chain is formed by 1,4-linked d-
galactose residues with side chains of d-xylose units attached to the main chain by 1,3 linkages. 
The water-soluble tragacanthin is a neutral, highly branched arabinogalactan with a spherical 
molecular shape. Its structure probably consists of a core composed of 1,6- and 1,3-linked d-
galactose with attached chains of 1,2-, 1,3- and 1,5-linked l-arabinose.  
When solubilized in water, gum tragacanth forms viscous solutions, even at low concentrations.  
Depending on the grade, the viscosity of 1% solutions may range from 0.1 Pa s up to 3.5 Pa s. 
Higher viscosities are obtained with ribbon types than with flake types. When shear is increased, 
the viscosity of the solution decreases, indicating pseudoplastic behavior. This decrease is 
reversible and the viscosity regains its original level as shear is reduced. 
 
3.1  CHEMICAL ANALYSIS  
A gas chromatographic method is described for the determination of food grade gums in milk 
products, salad dressings and meat sauces. The extraction method essentially involves removal 
of fat followed by starch degradation and precipitation of protein. The isolated gums are 
hydrolysed with trifluoroacetic acid, and the resulting neutral monosaccharides are converted to 
their aldonitrile acetate derivatives for gas chromatographic analysis on a 1 m x 2 mm stainless 
steel column packed with Gas Chrom Q (100-200 mesh) coated with 3% 
neopentylglyclosuccinate. Samples components did not interfere in the determination of the 
gum. Recoveries of gum added to 13 different foods averaged 85%; where more than 1 gum is 
present in a food, estimation is best accomplished by using monosaccharide peaks which are 
unique for a particular gum (Lawrence et al., 1985). 
In another analytical method the monosaccharide constituents of plant gums were separated by 
capillary electrophoresis at pH 12.1 and detected with indirect UV absorbance. The 
monosaccharides obtained after hydrolysis with 2 M trifluoroacetic acid and lyophilisation of the 
hydrolysate were arabinose, galactose, mannose, rhamnose, xylose, fucose, and glucose, and 
the two sugar acids galacturonic and glucuronic acid, in accordance with the literature. They 
were separated in a background electrolyte consisting of NaOH to adjust the pH, 20 mM 2,6-
pyridinedicarboxylic acid as chromophore for detection and 0.5 mM cetyltrimethylammonium 
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bromide as additive to reverse the electroosmotic flow. Based on their electropherograms, the 
plant gums could be identified by their typical composition as follows: peaks of galacturonic 
acid and fucose point to gum tragacanth (Groessl et al., 2005).  
Furthermore the complex structure of the arabinogalactan is now further elucidated using GC-
MS, NMR, and ESI-MS techniques. 
 
3.2 STANDARDIZATION, STABILITY 
Gum tragacanth is one of the most acid-resistant gums. The pH of a 1% solution varies between 
5 and 6, but the viscosity remains quite stable over a broad range (pH 2–10). Because of this 
high acid stability, which is more pronounced for flake types, the gum is widely used in acidic 
conditions. Traganth is also heat stable. The gels were unaffected by storage and the pH of the 
gels suggest that the gum substance was totally neutral in reaction (Leung et al., 2003). 
4. PHARMACOLOGY 
4.1 ANIMAL STUDIES 
In a study, bassorin was administered for 2 weeks to piglets. No alterations of bile acids, lipidic 
composition, or lithogenicity of bile were observed in piglets. 
In rats tragacanth increased fecal SCFA (Short Chain of Fatty Acid) and fecal water (Edwards et 
al., 1995).  
In rats fed ground barley, gum tragacanth accelerated the passage of digesta trough the 
gastrointestinal tract, gave the faeces a lighter colour and increased their size and water content 
(Gohl et al., 1977).  
Fe absorption was not inhibited by gum tragacanth (Gillooly et al., 1984).  
In rats that were fed hyperlipidaemic diet containing gum tragacanth, a marked improvement in 
the plasma LDL cholesterol and total cholesterol concentration was observed. No significant 
difference in the plasma triglyceride concentration was detected. Plasma HDL concentration 
was significantly higher in the non-hyperlipidaemic group. Addition of gum tragacanth to the 
hyperlipidaemic diet significantly improved the plasma HDL concentration. These results 
suggest that fiber from gum tragacanth lowers plasma cholesterol and LDL in hyperlipidaemia 
(Amer et al., 1999).  
In rabbit tragacanth mucilage exhibited a considerable potency for wound healing. 
 
4.2 HUMAN STUDIES 
In a study on volunteer males, with age ranging from 21-57 yr, gum tragacanth increased stool 
weight, with no effect on serum cholesterol or on hydrogen excretion but increased fecal bile-
acid excretion Eastwood et al., 1986).  In man the addition of TG significantly reduced blood 
glucose at one or more points, during the glucose tolerance test, and reduced serum insulin 
concentration. The reduction in the mean peak rise in blood glucose concentration and the delay 
in mouth-to-caecum transit time, were correlate positively with viscosity (Eastwood et al., 1984, 
Jenkins et al., 1978). 
Tragacanth gum evidenced beneficial pharmaceutical and nutraceutical properties for its 
protective effect of LDL from oxidation (Nikolaos et al., 2003). 
 
4.3 ADME 
In a study with ten Bacteroides  species from human colon, gum tragacanth was completely 
fermented during 21 h as its viscosity was abolished and SCFA and gases were produced. 
Bacteroides species were able to ferment plant polysaccharides including gum tragacanth. The 
ability to utilize plant polysaccharides varied considerably among the Bacteroides species 
(Salyers et al., 1977). 
The mechanisms by which non-starch polysaccharides (NSP) increase faecal output, and in 
particular faecal water, are not fully understood. NSP which are resistant to fermentation by 
bacteria in the large intestine are the most effective faecal bulkers, probably because they 
retain their water-holding capacity (WHC). The extent to which a NSP is fermented in the large 
intestine of an animal is dependent not only on the ease of fermentation but also on the time it 
remains within the large intestine (Van Soest et al. 1982). The effect of fermentation products 
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on motility has not been investigated thoroughly and short-chain fatty acids (SCFA) have been 
shown to inhibit motility in the caecum of the sheep (Svendsen, 1972) and the isolated rat colon 
(Squires et al. 1992), but to stimulate contractions in rat mid- and distal colonic strips (Yajima, 
1985). 
The osmotic activity of the SCFA has been largely discounted as it has been shown that they are 
rapidly absorbed (McNeil et al. 1978). The major sites of fermentation are thought to be the 
caecum and proximal colon but it maybe possible, if propulsion is stimulated before 
fermentation is complete, for fermentation of a NSP to continue further along the large 
intestine. If this occurs, the SCFA produced at distal sites may have a greater effect on stool 
output as the water remaining in the gut. In addition, as SCFA have been shown to influence the 
metabolism and turnover of colonic enterocytes, higher concentrations of SCFA at more distal 
sites, where disease is more common, may have an important role in pathology and treatment. 
Tragacanth had no significant effect on amount or concentration of SCFA. Tragacanth 
significantly reduced the molar proportions of acetic acid in the caecum but significantly 
increased the molar proportion of acetic acid in faeces and significantly decreased the 
proportion of butyric acid The predominance of acetic acid is generally higher in the faeces than 
in the caecum and reflects either a change in fermentation pattern in more distal colon or a 
difference in the utilization or absorption of the SCFA (Edwards et al., 1995). 
5. MICROBIOLOGY 
Tragacanthin polysaccharides were evaluated in mice infected with Punta Toro Virus (PTV), a 
phlebovirus member of the Bunyaviridae family. The polysaccharides administered as single 
intraperitoneal treatments protected the majority of mice from mortality not by activate 
lymphocytes or natural killer cell, nor interferon induced in treated mice but by activation of 
peritoneal macrophages (Smee et al., 1996).   
The purified polysaccharides from the gum exudates of Astragalus species, Tragacantha, are 
immunomodulators and inhibit cancer cells and viruses in vitro. 
6. EFFICACY 
Tragacanth gum was studied in a 6-7 week feeding study on rats aiming to evaluate the effect 
on adaptive responses of nutritionally-controlled parameters in rats by feeding a fibre-free diet 
containing increasing additions of polysaccharides (0, 10, 20, and 40%). In general, the 
supplements reduced growth rates due to lower energy intakes, but did decrease energy 
utilization.  All polysaccharides increased small intestine weights by up to about 30% without 
grossly altering mucosal protein or DNA per unit of length. On the large intestine, 
tragacanth gum had a pronounced effect on caecum weight, which increased by factors of 1.8, 
2.0, and 4.2 for additions of 10, 20, and 40%, respectively. 
Gum tragacanth was used to replace 2% starch in diets for chickens from 1 to 24 days old, 
Japanese quail from 4 to 35 or 37 days, Sprague-Dawley rats from weaning to 36 days and 
Tribolium castaneum larvae from 6 to 14 days. Gum tragacanth inhibited growth of chickens 
only. Growth of rats was not affected by any fibre (Vohra, 1979). 
7. TOXICOLOGY 
Following a 7-day control period, 5 male consumed 9.9 g gum tragacanth daily for 21 days. The 
results do not reflect any adverse toxicological effects arising from the ingestion of large daily 
doses of gum tragacanth. The intestinal transit time decreased and faecal fat concentration 
increased. These changes may be of nutritional and physiological interest but do not reflect any 
adverse toxicological effects arising from the ingestion of large daily doses of tragacanth. 
No mutagenic activity of tragacanth gum was observed following in vitro microbial assays, with 
and without activation, on Salmonella typhimurium (strains TA1535, TA1537, TA1538, TA98, 
and TA100) and Saccharomyces cerevisiae strain D4.  Tragacanth gum was not mutagenic in a 
number of tests using mammalian systems: Host Mediated Assay in vivo in rats and mice using 
Salmonella typhimurium strain TA1530 and G46 or mitotic recombination frequency in S. 
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cerevisiae D3, cytogenic study in vivo of rat bone-marrow cells, and in vitro study with human 
lung cells (wt. 38) in tissue culture (Litton Bionetics 1972; 1977). 
Tragacanth gum showed no evidence of maternal toxicity or teratogenicity after oral 
administration (as a suspension in corn oil) at levels up to 1200 mg/kg b.w./day to pregnant 
mice (days 6-16 of gestation) or to pregnant hamsters at dose levels up to 900 mg/kg b.w./day 
(days 6-10 of gestation). Similar studies with pregnant rats at dose levels up to 1200 mg/kg 
b.w. (days 6-15 of gestation) and with pregnant rabbits at dose levels up to 700 mg/kg b.w. 
(days 6-18 of gestation) resulted in significant maternal mortality in rats at the 1200 mg/kg 
b.w. dose level and in rabbits at dose levels of 150 and 700 mg/kg b.w. 
Although there are only a few reports on sensitization to tragacanth gum, the available 
information indicates that tragacanth gum is a powerful allergen capable of causing extremely 
severe reactions. Allergic reactions may occur as a result of inhalation or oral ingestion. The 
immunogenicity of tragacanth gum was demonstrated in an in vivo test using a foot pad 
swelling test in mice. Purification of the gum led to a marked reduction of the immune response 
(Gelfand, 1943; 1949). 
Groups of 50 male and 50 female Osborne-Mendel rats (approximately 21 days of age) were 
maintained on diets containing 0, 0.006, 0.06, 0.6, or 6.0% ppm tragacanth gum. After 13 
weeks on the test diets, the rats were bred to produce an F1 generation. Both males and 
females in the 6% group showed significantly lower body weights, as well as decreased food 
efficiency, than the controls. Lower body weights were also observed in the F1 generation, 
particularly in the males. Haematological measurements showed no compound-related effects. 
Only minor effects were noted in the various clinical chemistry parameters. Reproduction data 
were comparable for test and control animals. Histological studies did not show any compound-
related effects. Enlarged livers were noted in the 6% group, but the enlargement was not 
associated with any significant change in liver composition or with histological changes. The 
ATP/ADP ratio in liver preparations for F0 animals was markedly decreased, but this effect was 
not observed in F1 animals (Graham et al., 1985). 
 
7.1 SAFETY  
Depending on the oil content. In low-calorie, oilfree dressings, gum tragacanth is used to imitate 
the creamy mouthfeel and body of dispersed oil droplets. In fish and citrus oil emulsions with a 
long shelf-life, gum tragacanth is used in combination with gum arabic. The interaction between 
the two gums reduces viscosity, allowing the production of thin, pourable, smooth emulsions. 
Gum tragacanth is used in ice cream to provide texture to the product. It also prevents texture 
changes during storage due to the formation of ice crystals. In water ices, sorbets, and ice pops, 
the gum prevents the migration of flavor and color components during storage and 
consumption. It is also used in milkshakes as a viscosity control agent, providing texture and 
stabilizing incorporated air. 
Gum tragacanth is used in bakery fruit-based toppings and fillings to give a shiny, clear 
appearance and a creamy texture. In chewy sweets, such as lozenges, it acts as a thickener and 
provides texture. The gum is used in fruit tablets, gum drops, and pastilles as a binding agent 
during compression. It also provides body and mouthfeel and ensures good flavor-release during 
consumption. In icings, gum tragacanth is used as a waterbinder, maintaining pliability and 
preventing cracks and breaks. It also provides consistency, smooth texture, and creamy taste to 
the product. Gum tragacanth is also an excellent emulsifying agent for oil-in-water emulsions. It 
is very effective in lowering the interfacial tension, even at low concentrations, and 
simultaneously acts as a thickener of the continuous phase of the emulsion, preventing 
flocculation and coalescence of the dispersed oil droplets.  
 
Recentely, there have been fatal accidents, mainly in children and elderly persons resulting from 
asphyxiation following the ingestion of jelly mini-cups due to their consistence, shape, size and 
manner of ingestion, giving rise to a risk that they remain blocked in the throat and provoke 
choking. In view of this situation, on 13 april 2004, a Commission Decision (adopted on 12 july 
2004) suspended the placing on the market of jelly mini-cups containing one or more of the gel 
forming food additives, among others E413, in order to protect human health. 
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Non-food applications 
Gum tragacanth is widely used in the pharmaceutical industry. It is an effective suspending 
agent and prevents insoluble materials, which are usually the active ingredients, from settling-
out in aqueous mixtures. By stabilizing the emulsion and keeping the oil droplets uniformly 
distributed throughout the product, the gum facilitates the absorption of the water-insoluble 
components, thus improving the action of the pharmaceutical. Gum tragacanth is used as a 
stabilizer in dermatological creams and lotions, also contributing a protective coating and 
smooth handfeel. Combined with glycerin, it acts as a binding agent in the production of tablets.  
 
Interactions with other drugs 
In vitro digestibility of casein was substantially decreased by tragacanth. The loss appeared to 
be related to the structure of the gum (degree of branching and extent of ionization) (Acton et 
al., 1982). 
 
Caution 
Tragacanth gum from Astragalus gummifer or A.microcephalus may not be admixed with 
Astragalus roots 
from East Asia (TCM). 
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BORAGO OFFICINALIS 
 
Borago officinalis 
 
1. INTRODUCTION 
Borage is also known by the names Bugloss, Burage and Burrage. Some authorities consider 
that the Latin name Borago, from which our popular name is taken, is a corruption of corago, 
from cor, the heart, and ago, I bring, because of its cordial effect.  However, some assert that 
the name might be derived from the Latin "borra", which means "rough hair" due to the hairy 
leaves and stems of this plant. In all the countries bordering the Mediterranean, where it is 
plentiful, it is spelt with a double “r”, so the word may be derived from the Italian “borra” French  
“bourra”, signifying hair or wool, in reference to the thick covering of short hairs which clothes 
the whole plant.  Some suggest that the name is a Celtic derivative from "borrach", meaning 
"courage". Borage flowers nourish the adrenal glands, acts as a restorative agent on the adrenal 
cortex, and may be why it has long been thought to bolster courage. The parts of this plant used 
medicinally are the leaves, flowers, and the oil from the seeds. The seeds contain essential fatty 
acids, linoleic acid, and gamma-linolenic acid (GLA), the same substance as in Evening Primrose 
oil. The oil from Borage seeds is used for inflammatory disorders, immunomodulatory effects, 
dermatitis,   menstrual and menopausal problems, eczema, arthritis and rheumatism. 
The herb can be confused with Echium vulgare. 
 
2. DESCRIPTION OF THE PLANT 
Borago officinalis is an annual plant native of southern Europe and Asia minor, but is now found 
all over Europe and the U.S.  
The whole plant is rough with white, stiff, prickly hairs. The round stems, 15 – 100 cm high, are 
branched and hollow; the leaves are alternate, large, wrinkled, deep green, oval and pointed.  
The flowers, which terminate the cells, are bright blue and star-shaped, with prominent black 
anthers which form a cone in the centre. The fruit consist of four brownish-black nutlets.  
 
2.1 SYSTEMATICS 
The genus Borago comprises of 3 species, B.longifolia Poiret in North-West Africa, B.pymaea 
(D.C.) Chater and Greuther, and Borago officinalis L., the only one used as herb and crude drug. 
It belongs to the Family Boraginaceae, closely related to Scrophulariaceae and Lamiaceae. 
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2.2 PLANT PARTS USED 
Borago officinalis (the common Borage) is grown for its leaves, which are used in flavorings, and 
its flowers, which are used in potpourri. Borage has been used medicinally and in the 
preparation of various cordials and cups. The young leaves are used in salads to which they add 
a  cucumber flavour. Seed oil (28% - 38% lipids) get recent interest as the richest source of γ-
linolenic acid (GLA) 17 – 25%.  
 
3. INGREDIENTS / CONSTITUENTS 
The leaves contain small amounts of pyrrolizidine alkaloids including lycopsamine, intermedine, 
their acetyl derivatives, supinine, supinidine, plus amabiline and choline; Amabiline (I) was 
found in seeds and leaves and thesinine (II) was found in flowers and seeds of Borago officinalis. 
(Fig. 1). 
 
 
 
 
 
 
 
 
                               
 
Figure 1 Chemical structure of pyrrolizidine, amabiline, thesinine  
 
Dry matter is mainly constituted by neutral detergent fiber, ash, protein and 9,1% fatty acid, 
including α-linolenic acid (55%) and γ-linolenic acid (>4%). Borage has also adequate levels of 
minerals, and K reaches a higher proportion than either elements.  Whole leaves include: K 400, 
Na 63, Ca 130, Mg 30, Fe 1.8, Mn 0.44, Zn 0.23, and Cu 0.13 mg/100 g. Also present are small 
amounts of silicic (1,5– 2,2%), acetic, lactic and malic acid.  
Aerial blooming parts contain larger quantities of heterogeneous polysaccharides (19,90 - 20,30 
g%), polyphenolcarboxilic acids (0,545 - 0,546 g%) and smaller quantities of flavonoids (0,028 - 
0,029 g%) than seeds (11,9 - 12,51 g%; 0,402 - 0,403 g%; 0,032 - 0,033 g% respectively) (Dinu 
et al., 2002). 
Fresh leaves contain up to 30% mucilage hydrolyzing to glucose, galactose, arabinose and 
allantoin. 
Seed oil is obtained from seeds of Borago officinalis L. by extraction and/or pression and it is 
then refined. A suitable antioxidant may be added.   
Solubility: practically insoluble in water and in ethanol (96 %), miscible with light petroleum. 
Relative density: about 0.921. 
Refractive index: about 1.476. 
Seed oil (28% - 38% lipids) get recent interest as the richest source of γ-linolenic acid (GLA) 17 – 
25% (Fig. 2).  
 
 
 
 
 
 
  Figure 2 Chemical structure  of gamma linolenic acid 
 
Other seed fatty acids include linoleic (30% - 41%), oleic (14,5% – 23%), α-linolenic acid (max 
0,5%), palmitic acid (9% - 12%), palmitoleic acid (max 0,6%) and stearic (2% - 6%)  (Leung and 
Foster, 2003; PDR for Herbal Medicines, 2004; Ph.Eur. 5, 2005)   
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Ferulic acid represents a high proportion of the free phenolic acids, but hydroxycaffeic acid is the 
major constituent of phenolic acids liberated from esters of borage seeds. New compounds 
were found: rutoside in aerial blooming parts, quercitol in aerial blooming parts and seed . 
The evolution of the quality of borage is closely related to the ageing of the plant, with a 
progressive increase in the fibrous fraction and N-free extracts and a slight decrease in crude 
protein content and organic matter digestibility. The fatty acid components of borage are 
myristic, palmitic, stearic and oleic acids, and four polyunsatd. fatty acids (PUFA): linoleic (LA), α-
linolenic (ALA), y-linolenic (GLA), and stearidonic (SDA).  The n-6/n-3 PUFA ratio increases from 
0.43, at late vegetative stage, to 1.59 at early seed stage, as the relative GLA and LA content 
increase during the growth cycle, while the SDA and ALA content decrease (Peiretti et al., 2004). 
The content  of γ-linoleic acid and other fatty acids of the seed oil of germoplasm is different in 
wild and cultivated borage. GLA showed an important range of variation, from 8.7% to 28.6% of 
the seed oil.  Oleic, linoleic and erucic acid also showed wide ranges of variation.  White 
flowered cultivated genotypes had higher contents of GLA than blue flowered wild material 
collected in Spain.  Blue flowered germplasm from Northern Europe showed higher values of 
erucic acid (De Haro et al., 2002). 
 
3.1 CHEMICAL ANALYSIS: METHODS TO DETERMINATE THE COMPOUND 
Analytical methods specifications for oil evaluation 
from borage have been published (European Pharmacopea 5.1; 04/2005:2105). The oil is clear, 
light yellow or yellow liquid and the official method for the chemical identification of fatty acid is 
the Thin-Layer Chromatography. 
The total chemical composition of  lipophilic extracts from Borago officinalis seeds was 
determinated by capillary Gas-Chromatography/Mass-Spectrometry, revealing the presence of 
tocopherols and sterols along with important quantities of fatty acids. The composition of 
phenolic acids, both free and liberated from esters and glycosides, was determinate in  borage 
seeds by GC and MS. 
The pyrrolizidine alkaloid content of crude borage oil and borage oil from different processing 
stages was deteterminated by GC-MS.  The results showed that no pyrrolizidine alkaloids were 
present above a detection limit of 20 ppb.  The reduction factors for pyrrolizidine alkaloids at 
various stages in the oil refining process were determined by means of spiking experiments 
using the available pyrrolizidine alkaloid crotaline.  The pyrrolizidine content in crude borage oil 
was reduced overall by a factor of approximately 30,000 in the refining process (Wretensjoe and 
Karlberg,  2003).   
 
3.2 STANDARDIZATION, STABILITY 
The oil is kept under an inert gas, in a well-filled, airtight container, protected from light. 
It was stated that plant oils rich γ-linolenic acid (borago oil) become subject to oxidation 
processes very easily.  One of the methods to increase their oxidative stability is to introduce 
antioxidants. The addition of alpha tocopherol, ascorbyl palmitate and lecithin was the most 
effective for borago oil.  
Edible flowers were stored in polyethylene bags at -2.5 to 20 °C. Borago officinalis L. stored at 
0-5 °C were marketable after 1 week, and those stored at -2.5°C were still marketable after 2 
weeks.  
 
4. PHARMACOLOGY 
Borage  is a plant of renewed interest because the seeds are rich in γ-linolenic acid, an 
important polyunsaturated fatty acid of medicinal value in human and animal diets, helpful in 
the treatment of a wide range of disorders.   
GLA play an important role in hormone regulation and fatty acid metabolization. Furthermore it 
is also the biological precursor of a group of molecules, including prostaglandins, leukotrienes 
and thromboxanes. Small number of oilseed plants produce γ-linolenic acid but the majority 
produce linoleic acid (LA, C18:2delta9.12) as its substrate. There are reports that vegetable oils 
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containing gammalinolenic acid (GLA) may exert beneficial effects on inflammatory skin 
disorders. Different in vitro and in vivo studies have been carried out. 
 
4.1 IN VITRO STUDIES 
Antioxidative activity 
Crude extract of meal of borage was prepared under optimum extraction conditions and were 
subjected to Sephadex LH-20 column chromatography. Six fractions from each of the crude 
extracts were obtained and their content of total, hydrophilic and hydrophobic phenolics 
determined. 
The objective of this study was to investigate the ROS-scavenging properties of extracts of 
borage (defatted ground seeds). The crude extracts and their fractions (at 100 and 200 ppm as 
sinapic acid) were investigated for their reactive-oxygen species- (ROS; H2O2, O2-, OH) and 2,2-
diphenyl-1-picrylhydrazyl- (DPPH) scavenging efficacies. At 200 ppm, borage crude extract and 
some its fractions, exhibited a 100% scavenging of H2O2. Borage crude extracts and their 
fractions, separated via a column chromatographic procedure, possess strong ROS- and DPPH 
scavenging properties. These effects are attributable to varying hydrogen-donating and metal-
chelating capacities of the phenolic compounds present in the crude extracts/fractions 
((Wettasinghe and Shahidi, 2000).  
The rapid evaluation of antioxidant activity and a screening of several radical scavenging 
components of crude borage (Borago officinalis L.) extract was determinate by HPLC-DPPH free 
radical method. The extract of borage showed very high hydrogen-donating capacity towards the 
2,2'-diphenyl-1-picrylhydrazyl (DPPH) radical. The dominant antioxidative compound in the crude 
extract of borage leaves was identified by HPLC as rosmarinic acid ( Bandoniene and Murkovic, 
2002). Rosmarinic acid is separated and identified on the basis of high-performance liquid 
chromatographic (HPLC)-UV-mass spectrometry data in 80% methanol in water extracts from 
the leaves of  Borago officinalis. The amount of rosmarinic acid in borage leaves is similar 
compared with Salvia officinalis (15 mg/g) (Bandoniene et al., 2005).  
 
4.2 ANIMAL STUDIES 
Immunological modulation  
The effect of diets enriched in gamma linolenic acid (GLA) enrichment were considered in the 
rat subcutaneous air pouch and in rats with adjuvant induced arthritis. It was observed that the 
diet with plant seed oils rich in GLA may provide a way to alter generation of prostaglandins and 
leukotrienes and to influence acute and chronic inflammatory responses. Gamma linolenic acid 
can also have an influence on immune system. It has been shown that dietary supplementation 
with borage oil can affect the activation response of polimorphonuclear neutrophils. Studies on 
mice have shown that oral feeding of gamma-linolenic acid-rich plant lipid markedly affects the 
disease course of acute experimental autoimmune encephalomyelitis (EAE).  
Feeding γ-linolenic acid-rich plant (Borago officinalis) to mice, had protective effects on EAE 
associated with production of PGE2 and gene transcription and secretion of TGF-β1.  EAE was 
induced by an encephalitogenic peptide (92-106) of myelin oligodendrocyte glycoprotein (MOG), 
and mice were fed the plant lipid daily from 7 days after EAE induction. The clinical incidence 
and histological manifestations of acute EAE, and the clinical relapse phase of chronic relapsing 
EAE (CREAE) were markedly inhibited by ω-6 fatty acid feeding. A significant increase in the 
production of TGF-β1 and PGE2 were detected in spleen mononuclear cells from fatty acid-fed 
mice. There was no difference in interferon-γ, IL-4, and IL-2 production between the fatty acid-
fed and control groups.  Significantly higher TGF-β mRNA expression was found in the spleens of 
ω-6 fatty acid-fed mice at day 21. γ-linolenic acid-rich plant lipid markedly affects the disease 
course of acute EAE and CREAE and is associated with an increase in cell membrane long chain 
ω-6 fatty acids, production of PGE2 and gene transcription and, on activation, secretion of TGF-
β1 (Harbige et al., 2000).  In an other study using a classical oral ovalbumin gut-induced 
tolerance protocol in BALB/c mice, the effects of dietary n-6 polyunsaturated fatty acids (PUFA) 
on high-and low-dose oral tolerance (and in non-tolerised animals, i.e. effects of antigen 
challenge alone) in relation to lymphoproliferative, cytokine and antibody responses was 
investigated. Borage (Borago officinalis) oil rich in n-6 PUFA, of which gamma-linolenic acid is 
rapidly metabolised to longer-chain n-6 PUFA, increased Th1-like responses and decreased Th2-
like responses, and possibly enhanced suppressor cell or Th3-like activity.  These findings 
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explain more precisely and broadly the immunological regulatory mechanisms involved (Harbige 
et al., 2001).   
The effects of dietary supplements of oils rich in EPA or GLA on neutrophil (PMN) membrane 
potential (delta gamma), secretion, and superoxide (O2-) responses were evaluated in guinea 
pig. At 4-week intervals, 12% sterile casein-elicited peritoneal neutrophils (PMN) were assessed 
for membrane polyunsaturated fatty acid (PUFA) profiles. The peritoneal PMN of all groups 
demonstrated in vivo activation and this was significant only with borage oil ( Fletcher and 
Ziboh, 1990). 
 
Lipid metabolism 
The polyunsaturated fatty acid (PUFA) composition of murine peritoneal macrophage 
phospholipids was altered in vivo following the four-week feeding of specific dietary oils. So fish 
oil (containing 20:5n-3 and 22:6n-3) feeding significantly increased macrophage 20:5n-3, 
22:5n-3, and 22:6n-3 (P<0.05), while borage oil (containing 18:2n-6 and 18:3n-6) increased 
(P<0.05) the macrophage 20:3n-6/20:4n-6 ratio, relative to safflower oil (containing 18:2n-6) 
and hydrogenated coconut oil (containing 12:0)-fed animals. 
Male rats were given liquid diets by pair-feeding for 24-30 days, and phosphatidylinositols in 
pancreas were analyzed as derivatives of diacylglycerols and fatty acids.  Addition of arachidonic 
acid or changing the fat component (35 energy%) in the liquid diet from olive oil/corn oil to oil 
from Borago officinalis, which contains 22% γ-linolenic acid, increased the fraction of 
arachidonoyl species. 
Hypocholesterolemic effects in older animals after long-term feeding are unknown.  Therefore, 
aged rats (24 wk of age) fed a conventional diet were shifted to diets containing 10% perilla oil, 
borage oil, evening primrose oil  mixed oil, or palm oil with 0.5% cholesterol for 15 week in this 
experiment.  The results of this study demonstrate that both n-6 fatty acid and n-3 fatty acids 
such as gamma-linolenic acid and alpha-linolenic acid inhibit the increase of serum total 
cholesterol and VLDL + IDL + LDL-cholesterol concentrations of aged rats in the presence of 
excess cholesterol in the diet compared with dietary saturated fatty acid.  
In an other this study was evaluate the effect of different doses and sources of dietary gamma-
linolenic acid (GLA) on the tissue phospholipid fatty acid composition.  Rats fed four different 
levels of GLA (2.3, 4.6, 6.4 and 16.2 g of GLA/kg diet) in the form of either borage oil or evening 
primrose oil during 6 week were compared with animals fed corn oil.  The levels of dihomo-
gamma-linolenic acid (DHLA) and GLA showed a significant dose-related increase in liver, 
erythrocyte and aorta phospholipids.  Moreover, the arachidonic acid/DHLA ratios in tissues 
decreased with increasing intake of dietary GLA.   
 
Blood pressure activity 
Blood pressure in hypertensive mammals is reduced by administering a compound comprising a 
combination of eicosapentaenoicacid (EPA) and γ-linolenic (GLA) in a ratio of (2-8):1.  
The combination increases the production of PG1 prostaglandins from GLA which cause 
vasodilation and prevents the production of PG2 prostaglandins from arachidonic acid which 
cause vasoconstriction.  EPA/GLA ratio of 8:1 were most effective in reducing blood pressure in 
hypertensive subjects.   
The effects of dietary gamma-linolenic acid upon blood pressure, aortic reactivity and 
cholesterol metabolism were evaluated in spontaneously hypertensive (SHR) and normotensive 
Wistar-Kyoto (WKY) rats. SHR and WKY rats were fed a purified diet containing either sesame or 
borage oil rich in gamma-linolenic acid for 7 weeks. Dietary borage oil has a blood pressure 
lowering effect in hypertensive and normotensive rats.  However, the effect cannot be explained 
by altered sensitivity to humoral and neural vasoconstrictors or changes in cholesterol 
metabolism. This effect may be attributed to changes in the metabolism of GLA to dihomo-γ-
linolenic (DGLA) and arachidonic acids (AA).  GLA and DGLA levels in the plasma, liver, aorta, 
and renal artery tissues increased both in SHR and WKY.  AA levels were also increased in both 
plasma and liver of SHR and WKY rats fed the borage oil-enriched diet.  Thus, dietary borage oil 
produces marked changes in the metabolism of GLA which may contribute to its blood pressure-
lowering effect in WKY and SHR.   
The effects of dietary GLA on established hypertension in adult rats, as well as its effects on 
components of the renin-angiotensin-aldosterone axis were evaluated. The borage-enriched diet 
Borago 
----------------------------------------------------------------------------------------------------------------- 
 
 66
reduced adrenal ANG II receptor density and affinity compared to the control group.  Results 
suggest that borage inhibits adrenal responsiveness to ANG II by an action on adrenal receptors.   
This effect may be mediated, at least in part, by interference with the renin-angiotensin-
aldosterone system at the level of adrenal ANG II receptors. 
 
Platelet interaction  
Effects of a dietary intake of the polyunsaturated omega-6 essential fatty acids (EFAs) linoleic 
and gamma-linolenic acids (GLA) on blood lipids, platelet function, and vascular prostacyclin 
production were studied 12 hyperlipidemic patients (doses of 3 g/day) and 12 male Wistar rats 
(doses of 3 mg/kg/day) for 4 months.  In humans, GLA supplementation decreased plasma 
triglyceride (TG) levels by 48% and increased HDL-cholesterol concentration by 22%.  Total 
cholesterol and LDL-cholesterol levels were significantly decreased by omega-6 EFAs.  Platelet 
aggregation induced by low concentrations of adenosine diphosphate (ADP) and epinephrine, 
and serum thromboxane B2 decreased by 45% both in humans and animals after GLA 
supplementation.  Bleeding time increased 40%.  In rats, vascular prostacyclin production 
measured by radioimmunoassay of 6-keto-PGF1 alpha was enhanced by GLA intake.   
 
Skin disease 
The fatty acid constituents of dietary oils exert their effects by altering the levels of cutaneous 
eicosanoids. It has been shown that guinea pigs supplemented with dietary borage oil had 
elevated levels of 20:3(n-6) in epidermal phospholipids and elevated epidermal levels of 15-
hydroxyeicosatrienoic acid compared with animals fed olive oil or fish body oil. There were no 
significant changes in epidermal levels of prostaglandins. Both 15- hydroxyeicosapentaenoic 
(HEPE) and 15- hydroxyeicosatrienoic (HETrE) have been identified as possible anti-inflammatory 
metabolites, and their elevated presence in the epidermis of animals fed oils rich in 20:5(n-3) or 
18:3(n-6) may provide a mechanism for the beneficial effects of these oils on inflammatory 
conditions. 
The effects of conjugated linoleic acid (CLA), γ-linolenic acid (GLA), linoleic acid (LA), and their 
combinations, on skin composition in mice were investigated. Mice (8 weeks old) were orally 
administered with either LA, GLA, CLA, LA + GLA, LA + CLA, or CLA + GLA for 4 weeks. Then, the 
skin was analysed for triacylglycerol content, fatty acid composition and collagen content. 
Additionally, thicknesses of the dermis layer and subcutaneous tissue layer, and the size and 
number of adipocytes were measured histologically. The skin fatty acid composition was 
modified depending upon the fatty acid composition of supplemented oils. In each oil-alone 
group, skin triacylglycerol content was the highest in LA, followed by GLA and CLA treatments. 
No significant changes in collagen content were observed among any treatments. The effects on 
subcutaneous thickness were similar to the results obtained in the triacylglycerol contents. 
However, no significant difference was detected in the thickness of the dermis layers.  
To determine whether or not dietary GLA exerts any modulatory role on cutaneous eicosanoids, 
guinea pigs were fed either a control diet containing safflower oil (less than 0.5% GLA) or borage 
oil, a GLA-rich diet containing 25% GLA.  After an 8-week feeding period, epidermal samples 
from both animal groups were analyzed for fatty acid composition and tissue eicosanoids.  
Analysis of epidermal neutral lipids and phospholipids in borage oil-fed animals showed a 
marked increase in GLA and its elongase product, dihomogammalinolenic acid (DGLA).  
Similarly, analysis of epidermal eicosanoids in the borage oil-fed animals revealed significant 
increases in the amounts of the 15-hydroxy fatty acid (15-OH-20:3n-6) and prostaglandin PGE1, 
both metabolites of DGLA. Since these metabolites have anti-inflammatory potential, the results 
suggest that increased dietary GLA result in the generation of local anti-inflammatory 
metabolites. 
 
Diabetes and pregnancy 
Unsaturated fatty acids are a major target for ROS and essential fatty acid metabolism is 
impaired by diabetes.  γ-Linolenic acid stimulates vasodilator prostanoid production and there 
are marked synergistic interactions between γ-linolenic acid and antioxidants.  
Experimental diabetes in rats is associated with excessive electrolyte loss in the urine, which is 
further accentuated by pregnancy, particularly of Ca.  Supplementation with essential fatty acids 
has proven beneficial in treating several types of complications, including nephropathy. The 
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effect of γ-linoleic acid (GLA; 500 mg/kg per day) was investigated on urinary electrolyte output 
and skeletal compound in pregnant streptozotocin-diabetic rats.  The treatments reduced urine 
volume with no effects on electrolyte concentration.  A reduced bone size and bone Ca content 
was partially ameliorated by the diet supplementation.  The authors have concluded that GLA , 
alone or in combination, prevent urinary electrolyte loss in pregnant rats and do so by reducing 
urine production. 
 
4.3 HUMAN STUDIES 
Immunological modulation  
In a study borage seed oil (9 capsules/day) was administered for 12 weeks to 7 normal controls 
and to 7 patients with active rheumatoid arthritis. Significant reductions in prostaglandin E2, 
leukotriene B4, and leukotriene C4 produced by stimulated monocytes were seen after 12 
weeks of GLA supplementation. The anti-inflammatory effects of GLA administration observed 
in animal models, and the apparent clinical improvement experienced by 6 or 7 rheumatoid 
arthritis patients given borage seed oil may be due in part to reduced generation of arachidonic 
acid oxygenation products. 
 
Platelet interaction  
The authors studied the effects of 3 g/day borage oil supplementation on platelet aggregation 
and biological and clinical parameters over a 6-week treatment period in 30 healthy male 
volunteers aged 18 to 45 year.  The results showed that borage oil supplementation could be 
used as a source of polyunsaturated fatty acid, in particular γ-linolenic acid, without any adverse 
effects on platelet aggregation or any increased risk of platelet mediated thrombosis.   
 
Anti-Hepatoma Activity 
Borage was evaluated for anti-hepatoma activity on five human liver-cancer cell lines. The 
samples were examined by in vitro evaluation for their cytotoxicity.  The results showed that the 
effects of crude drugs on hepatitis B virus genome-containing cell lines were different from 
those against non hepatitis B virus genome-containing cell lines. The results  indicated that B. 
officinalis  exhibited an inhibition percentage of 38.1. 
 
4.4 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
In tissues, dietary essential fatty acids (EFA), EFA, should be converted into fatty acids of longer 
and more unsaturated chain by alternate desaturation (delta 6, delta 5, delta 4)-elongation 
reactions.  Animal tissues are more active in this biosynthesis than human tissues.  Liver is one 
of the most active organs and its role is critical in providing less active tissues, particularly the 
brain, with long-chain PUFA secreted in VLDL (very low density lipoprotein).  In liver, many 
nutritional, hormonal and physiological factors act on the PUFA biosynthesis.  Dietary fatty acids 
exert a great influence and are often inhibitory.   The desaturation products AA, EPA, and DHA 
inhibit delta 6 desaturation of LA and delta 5 desaturation of DGLA (dihomo-gamma-linolenic 
acid). 
With regard to hormones, insulin and thyroxin are necessary to delta 6 and delta 5 desaturation 
activities, whereas other hormones (glucagon, epinephrine, ACTH, glucocorticoids) inhibit 
desaturation.  Concerning the physiological factors, the age of individuals is critical. Just after 
birth, in animals, the delta 6 desaturation activity increases in the liver and decreases in the 
brain.  In aging, the capacity of the whole liver to desaturate LA and DGLA is equal at 1.5 and 25 
months of age in rats. 
In rats, parenteral nutrition with 2.7%, 4.4%, and 6.1% gamma-linolenic acid from borage oil 
increased the plasma percentages (mol%) of gamma-linolenic acid and dihomo-gamma-
linolenic acid in a dose-dependent fashion. Supplementation with gamma-linolenic acid did not 
increase the plasma percentage of arachidonic acid as compared with the 0% gamma-linolenic 
acid lipid emulsion. The ratio of dihomo-gamma-linolenic acid to arachidonic acid was 
significantly increased in response to 4.4% and 6.1% gamma-linolenic. In conclusion: 
supplementation of parenteral nutrition with gamma-linolenic acid had the following effects: a) 
increased plasma gamma-linolenic acid, dihomo-gamma-linolenic acid, and bicyclo-
prostaglandin E; b) increased the plasma ratio of dihomo-gamma-linolenic acid to arachidonic 
acid (Karlstad et al., 1993). 
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Hoey et al. (1995) examined borage oil,  and other seed oils,  with respect to fatty acid profile 
and fatty acid composition.  Only borage oil was specifically structured with respect to 18:3n-6, 
this fatty acid being preferentially esterified in the sn2 position.  During absorption, the 
composition of the lymph largely reflected the fatty acid profiles of the oils administered.  The 
total absorptions as indicated by the transport of fatty acids in the lymph indicated that borage 
oil was well absorbed.  In the chylomicrons, a redistribution of 18:3n-6 from the sn2 position to 
the sn1/3 positions in the borage oil-fed rats was found.   
Dietary oils influence the distribution of PUFA in epidermal phospholipids and the epidermal 
levels of PUFA-derived hydroxy fatty acids.  Animals supplemented with esters of borage oil 
preferentially incorporated dihomogammalinolenic acid (DGLA), and epidermal elongase 
product of GLA, into the epidermal accumulation of 15-hydroxyeicosatrienoic acid (15-HETrE) 
(Craig et al.,1991).   
 
5. MICROBIOLOGY 
Antibacterial activity 
Borage oil is generally regarded as lacking in antimicrobial activity. 
 
6. EFFICACY 
Borage is occasionally used in salads and soups and is stated to possess diaphoretic, 
expectorant, tonic and galactogogue properties. Traditionally, borage has been used to treat 
many ailments including fevers, coughs and depression. Thus, no documented pharmacological 
data were located to support the  traditional uses. Interest has focused on the Borage oil as a 
source of γ-linolenic acid. 
 
6.1 QUALITY OF THE ANIMAL PRODUCT 
The use of Borage oil in animal diets is indicated when an important source of essential fatty 
acid (especial γ-linolenic acid) is necessary.   
Borage meal is derived from the processing of borage  seeds extraction.  The crude protein 
content of borage meal is 334 g/kg. A series of experiments was conducted to determinate the 
nutritive value of Borage meal as a protein supplement for ruminants and pigs.  
In situ ruminal effective crude protein degradability (ECPD) was determinate relative to four 
other protein supplements using two ruminally fistulated cows in a randomized complete block 
design. The protein supplements used for comparison purposes included soybean (SBM) and 
canola (CM) meals (high rumen degradable protein) and corn gluten (CGM) and heated canola 
(HCM) meals (high rumen undegradable protein). ECPD of borage meal was intermediate with 
the following order observed: SBM > CM >BM > HCM > CGM.    
In ruminants no effect of borage meal inclusion rate was observed on voluntary intake, nutrient 
digestibility coefficients and digestible energy (DE) values.  Relative to four other protein source 
selected for their extremes in rumen crude protein degradability, the effective CPD of borage 
meal was high. Inclusion of borage meal in rations of growing lambs up to 18% of the diet DM, 
had no adverse effects on intake or nutrient digestibility.  
In two experiments with swine, borage meal was included at 0, 10, 20, 30, and 40% in grower 
diets and 0, 6.75, 13.5, 20.25 and 27% in finisher diets.  Both rate and efficiency of gain were 
depressed in a linear fashion (P<0.05) as the level of BM in the diet increased.  Digestibility 
coefficients for dry matter, crude protein and gross energy also declined linearly as dietary BM 
increased. However, results of the pig experiments showed poor performance when BM was 
included in grower and finisher diets. Borage meal inclusion resulted in reduced intake and poor 
nutrient utilization especially for growing pigs. The adverse effects of borage meal on pig 
performance were attributed to bitter taste and to its poor digestibility. 
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The reduction in feed intake with borage can likely be attributed to the presence of pyrrolizine 
alkaloids in borage. Pyrrolizine alkaloids have been reported to have a bitter taste which may 
cause limit intake. In addition, these compounds are toxic and have been shown to cause liver 
damage at high concentration. Some authors suggested that the concentration of pyrrolizine 
alkaloids in borage is likely too low to cause a significant health hazard, caution should be 
exercised before including high levels of borage meal in swine diets.  
 
7. TOXICOLOGY 
Pyrrolizidine alkaloids (Pas) are very common in plants used in livestock feeds and in rangeland 
weeds such as tansy ragwort, Senecio jacobea, Heliotropium spp. and Crotolaria spp.. It appears 
that the pyrrolizidine alkaloids themselves are not toxic, rather, some of their metabolites, 
primarily their "pyrrolic" derivatives are highly toxic. Toxic alcohols can also be produced as 
secondary metabolites. The common PAs, heliotrine and lasciocarpine, are partially reduced to 
the non-toxic 1-methylene and 7-hydroxy-1 methyl derivatives in the rumen. 
However, these can be activated by oxidases in the animal's liver to pyrrolic derivatives and thus 
have pathological effects in the heart, liver, kidney and respiratory system. Especially 
unsaturated PAs have been shown to be hepatotoxic and carcinogenic. The basis for alkaloid 
regulation and its effects in the ruminal ecosystem are not yet fully understood, but is a well-
known fact that its degradation is directly proportional to its concentration in the rumen. 
Heliotrine degrading bacteria have been isolated and identified in the rumen. Although these 
bacteria appear to get very little useful energy from the clevage of heliotrine, this characteristic 
may well improve their ability to successfully compete in the rumen of an animal exposed to this 
type of alkaloid. 
The glycosylated pyrrolizidine alkaloid, thesinine-4'-O-β-D-glucoside, has been isolated from the 
aqueous methanol extract of dried, defatted seeds of Borago officinalis (Boraginaceae). So far 
seven Pas were identified in leaves, flowers and seeds of borage with thesinine, a saturated and 
therefore probably non toxic necine base described as a major alkaloid. Besides thesinine six 
unsaturated PAs, amabiline, supinine, lycopsamine, intermedine, acetyllycopsamine and 
acetylintermedine, were identified as minor constituents.  
The total alkaloid amount of the plant was determined as less than 0.001% whereas mature 
seeds yielded about 0.03% crude alkaloids.  
The pyrrolizidine alkaloid content of crude borage oil and borage oil from different processing 
stages was deteterminated by GC-MS.  The results showed that no pyrrolizidine alkaloids were 
present above a detection limit of 20 ppb.  The reduction factors for pyrrolizidine alkaloids at 
various stages in the oil refining process were determined by means of spiking experiments 
using the available pyrrolizidine alkaloid crotaline.  The pyrrolizidine content in crude borage oil 
was reduced overall by a factor of approximately 30,000 in the refining process (Wretensjoe and 
Karlberg,  2003).   
 
7.1 SAFETY (INFORMATION ON THE DOSAGE) 
Administration – Dosage 
Borago officinalis is marketed as oil or as food supplement containing natural gamma linolenic 
acid (GLA).  
The parts used are the nutlets (seeds), leaves and flowers. The leaves are used in flavoring and 
fresh flowers with saline, cucumber like flavor (free of toxic pyrrolizidine alkaloids) are used in 
salads. 
The edible part of the plant corresponds to the basal leaf petioles.  In this part, water was the 
major constituent with a value of 94%. Borage (Borago officinalis communis) is a plant 
commonly cultivated for consumption in Spain and other countries. 
Borage is included in the food  tables within the leafy vegetable group.   
Borage contains toxic pyrrolizidine alkaloids although at concentrations considerably lower than 
comfrey for which human toxicity has been documented . However, it would seem wise to avoid 
excessive or prolonged ingestion of borage. Borage is included in the food tables within the leafy 
vegetable group. 
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Borage seed oil, clear, light yellow or yellow liquid, is a rich source of the essential fatty acid g-
linolenic acid and is, therefore, used in nutritional, cosmetical and medical applications. Dried 
tops sometimes are used in teas. 
Capsulated seed oil are products as dietary supplement, used as an alternative source of γ-
linolenic acid. As additive γ-linolenic acid, or equivalent ester or salt is used in infant foods, 
geriatric preparations or externally in skin care products (cosmetics, bath preparations and 
detergents).  The content of these compounds  in the formula may vary from 0.005-1.0%. 
The food additive may contain from 1-90% of germ oil obtained from Oenothera lamarkiana 
biennis or from Borago officinalis instead of the essential fatty acid compounds.  The germ oils 
of both plants contained 2-26% y-linolenic acid.  
 
Side effects/ Adverse reaction /Contraindications/ Precautions  
No data in literature suggest possible adverse effects in animals. 
The unsaturated pyrrolizidines, lycopsamine and supinidine viridiflorate, are suspected poisons, 
but are found in borage at very low concentrations.  The low alkaloid level may account for the 
lack of acute toxicity reports during borage use. A mixture of lycopsamine and intermedine has, 
however, been reported to carcinogenic. 
Borago officinalis preparations should not be to used during pregnancy in view of the 
documented pyrrolizidine constituents. Borage oil is recommended to be used with caution in 
epileptic patients. 
In oil products from Borago officinalis no toxic pyrrolizidine alkaloids were detected.  
 
Interactions with other drugs 
 
No negative interactions are known. 
 
DT/SG/LG/AT 
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CALENDULA OFFICINALIS 
  
Calendula officinalis L  
 
1. INTRODUCTION 
Marigold owes its botanical name Calendula officinalis L. to the Latin word “Calendae”, the first 
day of the month, reflecting the fact, that the blossom opens and closes daily [Genaust, 1996]. 
In folk medicine the drug is used as a diaphoretic, diuretic, antispasmodic, anthelmintic, 
emmenagogue, and for liver complaints. However, a scientific basis of these applications is 
lacking. Therapeutic indications described in the ESCOP monograph are the treatment of minor 
inflammations of the skin and mucosa as well as an aid to the healing of minor wounds.  
Synonyms are Calendula, Mary bud, Gold Bloom, Garden Marygold, Common Marygold, and Pot 
Marigold, however it should be noted that the trivial name marigold is also used for members of 
the genus Tagetes. 
 
 
2. DESCRIPTION OF THE PLANT 
The annual or biennial plant grows to a height of 30-60 cm. The stem is angular, hairy and solid. 
Lower leaves are spatulate, 10-20 cm long and 1-4 cm wide; higher leaves oblong and 
mucronate, 4-7 cm long. The flower heads range from bright yellow to orange. Marginal flowers 
in cultivated plants are often multi-seriate, corolla oblong-spatulate, 15-25 mm long and 3 mm 
wide. The corolla of disc flowers is rounded, at the top tridentate, 1.5-2.5 cm long and 4-7 mm in 
diameter with 5 mm long tubular florets [Auster and Schäfer, 1958; Bisset and Wichtl, 2001]. 
 
2.1 SYSTEMATICS 
The genus Calendula L. includes 12 predominantly Mediterranean species: C. arvensis L., C. 
eckerleinii OHLE, C. incana WILLD., C. lanzae MAIRE, C. maroccana BALL, C. meuselii OHLE, C. 
officinalis L., C. pachysperma ZOH., C. suffructicosa VAHL and C. tripterocarpa RUPR. For 
pharmaceutical purposes only the annual C. arvensis and the annual or perennial C. officinalis 
are used [Hänsel et al., 1992]. 
Due to the commercial cultivation of Calendula officinalis L., confusions with other species of 
the genus Calendula are very scarce.  
 
2.2 OCCURRENCE 
Indigenous to central, eastern and southern Europe Calendula officinalis is nowadays cultivated 
in Mediterranean countries, in North America, in the Balkans, in eastern Europe and to a smaller 
Calendula 
----------------------------------------------------------------------------------------------------------------- 
 
 75
extent in Germany. Imported drug also originates from Egypt, Poland, and Hungary [Bisset and 
Wichtl, 2001; Leung and Foster, 1996].  
 
2.3 PLANT PARTS AND PRODUCTS  
The plant parts used are the dried ligulate florets (Calendulae flos, Calendulae flos sine calyce), 
the composite flowers (Calendulae flos cum calyce), and the dried or fresh aerial parts of the 
herb (Calendulae herba), collected in flower [Hänsel et al., 1992]. The flowers are harvested 
manually or automatically from May to August. Continuous and frequent harvest stimulated 
flower formation, and therefore increased the production [Helemiková, 1991]. For therapeutical 
use, the flowers should be dried expeditiously in the shade or at of 35-40°C to avoid carotenoid 
and flavonoid losses. Storage of freshly collected plant material for 3.5 h decreased carotenoid 
and flavonoid content by 28-30% and 24-26%, respectively, whereas the loss was independent 
of temperature. Due to the hygroscopicity of the dried flowers, the drug should be stored in well-
closed container protected from light [Isaac, 1992; Omel’chuk et al., 1984]. 
 
 
3. INGREDIENTS/CONSTITUENTS 
The major constituents of Calendula flowers are triterpene saponins (2-10% on a dry weight 
basis) based on oleanolic acid, i. e. calendulosides [Kasprzyk et al., 1965; Vidal-Ollivier et al., 
1990]. The structures of saponosid A-F are given in Figure 3.1. [Vidal-Ollivier et al., 1989]. The 
triterpenoid content increased until the stage of full development of flowers is reached 
[Kasprzyk et al., 1970a]. 
 
 
 
 
 
 
 
 
 
 
 
 
 R1 R2 
Oleanolic acid - H - H 
Saponoside A - Glu - (2→1) - Glc 
 
   (3→1) - Gal 
- Glc 
Saponoside B - Glu - (2→1) - Glc 
 
   (3→1) - Gal 
- H 
Saponoside C - Glu - (3→1) - Gal - Glc 
Saponoside D - Glu - (3→1) - Gal - H 
Saponoside D2 - Glu - Glc 
Saponoside F - Glu - H 
Glu = Glucuronic acid; Gal = Galactose; Glc = Glucose 
 
Figure 3.1. Structures of triterpene saponins from Calendulae 
 
Besides the triterpeneglycosides, a number of pentacyclic triterpenic alcohols 
(monohydroxyalcohols, dihydroxyalcohols and trihydroxyalcohols), predominantly acylated, were 
identified [Kasprzyk and Pyrek, 1968; Kasprzyk et al., 1969]. They are derived from Ψ-taraxen, 
taraxen, lupane, oleanane and ursane (Figure 3.2). Triterpene monols are esterified with acetic 
CH3 CH3
CH3 CH3
CH3
CH3CH3
COOR2
R1O
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acid, whereas triterpene diols are mainly esterified with lauric, myristic and palmitic acids 
[Wojciechowski et al., 1972]. The main diol esters are monoesters (98%) and only 2% are 
diesters [Adler and Kasprzyk, 1976]. Dried flowers contain 0.6% triterpene monols, with 14% α-
amyrin, 26.1% β-amyrin, 6.0% lupeol, 2.8% taraxasterol and 51.1% Ψ-taraxasterol. About 11% 
of the triterpene monols are esterified [Stevenson, 1961; Kasprzyk and Pyrek, 1968; Kasprzyk  
 
 
 
 
 
 
 
 
 
 
 
 
 
R1 = R2 = R3 = H: Ursane    R1 = R2 = R3 = H: Ψ-Taraxen 
R1 = OH; R2 = R3 = H: α-Amyrin   R1 = OH; R2 = R3 = H Ψ-Taraxasterol 
R1 = R2 = OH; R3 = H: Brein    R1 = R2 = OH; R3 = H: Faradiol 
R1 = R2 = R3 = OH: Ursatriol    R1 = R2 = R3 = OH: Heliantriol B0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R1 = R2 = R3 = H: Lupane   R1 = R2 = R3 = H: Taraxen 
R1 = OH; R2 = R3 = H: Lupeol    R1 = OH; R2 = R3 = H Taraxasterol 
R1 = R2 = OH; R3 = H: Calenduladiol   R1 = R2 = OH; R3 = H: Arnidiol 
R1 = R2 = R3 = OH: Heliantriol B2    R1 = R2 = R3 = OH: Heliantriol B1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R1 = R2 = R3 = H: Oleanane  
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R1 = OH; R2 = R3 = H: β-Amyrin  
R1 = R2 = OH; R3 = H: Maniladiol  
R1 = R2 = R3 = OH: Longispinogenin 
 
Figure 3.2: Structures of triterpenic alcohols from Calendula officinalis  
 
et al., 1969; Wilkomirski and Kasprzyk, 1979]. The content of triterpendiol-3-monoester 
averages 2.0 to 4.0% with 85.4% faradiol esters, 6.0% calenduladiol esters, 4.9% brein esters, 
and 3.3% ursadiol esters. The remaining 0.4% are esters of erythrodiol, maniladiol and arnidiol 
[Zimmermann, 1946; Kasprzyk and Pyrek, 1968; Wilkomirski and Kasprzyk, 1979; 
Wojciechowski et al., 1972; Pyrek, 1997a, b; Kasprzyk et al., 1970b]. Moreover, 0.2% 
triterpentriols, mainly in the free form, were found in the flowers [Kasprzyk and Wilkomirski, 
1973; Pyrek, 1979; Wilkomirski, 1985; Wilkomirski, 1986]. 
 
 
Throughout the whole plant free sterols, their esters and glycosides were found. The period of 
flowering is characterized by sterol accumulation in all plant organs, particularly in the flowers. 
The sterol content of the dried flowers ranged from 0.06-0.08%, whereof 15-20% were esterified 
with acetic, lauric, myristic or palmitic acid [Kasprzyk et al., 1968; Wojciechowski et al., 1972; 
Wilkomirski and Kasprzyk, 1979].  
 
Furthermore, carotenoids with lutein and zeaxanthin being the major compounds (88-92%), 
were identified in flowers. In orange flowering species lycopene is responsible for the colour, 
whereas in yellow flowering species xanthophylls are dominant. In deep orange coloured ligulate 
flowers carotenoid contents of 1.5g/100g were determined [Andreeva, 1961; Quackenbush and 
Miller, 1972; Isaac, 1992]. 
 
Flavonoid derivatives identified in flowers of Calendula officinalis are glycosides composed of  
isorhamnetin and quercetin as well as free isorhamnetin. Other methoxylated flavonoids 
characteristic of Compositae were not detected. Flavonoid contents in the flowers ranged from 
0.3 to 0.8% [Steinegger and Hänsel, 1988; Hegnauer, 1989; Vidal-Ollivier et al., 1989b; Isaac, 
1992].  
 
Other constituents include essential oil (0.03% and 0.2% in fresh and dried flowers, 
respectively), phenolic acids (salicyl-, ferulic-, p-hydroxybenzoic-, caffeic-, chlorogenic acid), and 
polysaccharides [Isaac, 1992].  
 
3.1 CHEMICAL ANALYSIS 
The carotenoid composition in petals of three orange-flowered and yellow-flowered cultivars of 
Calendula was analysed by HPLC [Kishimoto et al., 2005]. 
Mrugasiewicz et al. (1979) proposed a photometric determination of saponosides after 
hydrolysation to oleanolic acid and reaction with vanillin in acidic medium. HPLC quantification 
of the saponosides A, B, C, and D was performed using a Water µ-Bondapak C18 column, 
aqueous methanol phosphoric acid eluent and UV detection at 210 nm [Vidal-Ollivier et al., 
1989c]. 
Triterpenoid monoesters were quantified in a dichloromethane extract of dried flowers after 
semi-purification through TLC on silica gel using reversed-phase HPLC with isocratic elution 
[Neukirch er al., 2004]. Reversed-phase HPLC and micellar electrokinetic capillary 
chromatography have been used to separate flavonol-2-O-glucosides from Calendula officinalis 
[Pietta et al., 1992]. Zitterl-Eglseer et al. (2001) quantified triterpendiol esters (faradiol laurate, 
faradiol myristate, and faradiol palmitate) in ligulate and tubular florets, involucral bracts, 
receptacles, and leaves by means of reversed-phase HPLC.  
The constituents of the essential oil were analysed by GC-MS after steam distillation of flowers 
and whole plants [Chalchat et al., 1991]. 
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3.2 STANDARDISATION, STABILITY 
According to the European Pharmacopoeia, Calendulae flos contains not less than 0.4% of 
flavonoids, calculated as hyperoside. The storage of the drug protected against air and light 
should not exceed 3 years (DAC 79).  
A combined method of 2-dimensional thin-layer chromatography and HPLC was used for the 
determination of flavonoid glycosides and saponins in Calendula officinalis flowers [Heisig and 
Wichtl, 1990]. 
 
 
4. PHARMACOLOGY 
Preparations of Calendula officinalis are mainly externally applied in form of infusions, tinctures, 
and ointments as a wound-healing remedy for inflammation of the skin and mucous 
membranes, for poorly healing wounds, bruises, boils, and rashes, e.g. pharyngitis, and leg 
ulcers [Bisset and Wichtl, 2001]. In contrast, the internal use as an antiphlogistic and 
spasmolytic for cholecystitis, cholangitis, gastritis, cystitis, and gastrointestinal spasms is scarce 
[Luckner et al., 1969; Madaus, 1976; Braun and Frohne, 1987]. The data given below are based 
on the ESCOP monograph (2003). 
 
In vitro experiments 
Immunomodulatory effects 
A dry 70% ethanolic extract of Calendula flower exhibited an inhibitory effect in the mitogen-
induced lymphocyte proliferation assay. In the mixed lymphocyte reaction the extract showed 
stimulatory effects at 0.1-10 µg/mL, followed by inhibition at higher concentrations 
[Amirghofran et al., 2000]. Phagocytosis of human granulocytes was stimulated by 
polysaccharides isolated from Calendula flowers [Varljen et al., 1989].  
 
Antioxidant effects 
Extracts of Calendula flowers of differing polarities exhibited antioxidative effects on liposomal 
lipid peroxidation induced by Fe2+ and ascorbic acid. Marked activity was observed with ether, 
butanol and aqueous extracts. In combination with pro-oxidants different antioxidative effects 
were obtained: with pyralene the butanol and aqueous extracts were most effective; with carbon 
tetrachloride the chloroform and ethyl acetate extracts showed the strongest activity. 
Combination of the antioxidant fullerenol with each extract resulted in a further decrease in lipid 
peroxidation [Popovic et al., 1999; 2000]. 
 
Angiogenic effects 
The angiogenic activity of a lyophilised aqueous infusion (1:10) of Calendula flowers was tested 
in the chick chorioallantoic membrane (CAM) test. The numbers of micro-vessels in tissue 
sections of treated CAMs were significantly higher (p<0.0001) than in control CAMs. All treated 
CAMs were positive for hyaluronan, while no hyaluronan was detected in control CAMs [Patrick 
et al., 1996].  
 
Anti-inflammatory effects 
Three isorhamnetin glycosides from Calendula flower at concentrations of 1.5 x 10-5 M showed 
inhibitory effects on arachidonate 12-lipoxygenase from rat lung cytosol [Bezákova et al., 1996].  
 
Effects on buccal membranes 
In a test system based on porcine buccal membranes, strong concentration-dependent adhesive 
processes were observed with a low-viscosity polysaccharide-enriched extract (98% 
carbohydrates) of Calendula flowers. These findings suggested that the polysaccharides may 
contribute to therapeutic effects in the treatment of irritated mucosa [Schmidgall et al., 2000]. 
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4.1 ANIMAL STUDIES  
Effects on wound healing 
Dried alcoholic and aqueous extracts of Calendula flower in combination with allantoin, applied 
topically as a 5% ointment, stimulated epithelisation in surgically-inflicted standard wounds in 
rats [Klouchek-Popova et al. 1981; 1982]. Experimental incisions in rats were infected with 
Staphylococcus epidermidis. Topical treatment with a Calendula cream (not further specified) 
resulted in accelerated cicatrisation compared to controls. The results were confirmed by 
histological examination [Perri de Carvalho et al., 1991].  
In a study in rabbits, the time taken for complete cicatrisation of experimental wounds was 
shortened by approximately 25 % after topical treatment with hydrogel or powder preparations 
containing 10% of an ethanolic dry extract of Calendula flower in comparison with vehicle-only 
controls [Oana et al., 1995]. 
Enhanced healing of experimental wounds in buffalo calves was observed after topical 
treatment with an ointment containing 5% of a dry extract of Calendula flower. Epithelization 
accelerated and histopathological parameters improved in comparision with wounds treated 
with normal saline only [Ansari at al., 1997]. 
 
Immunomodulatory effects 
Polysaccharide fractions from aqueous extracts of Calendula flower appeared to enhance 
phagocytosis in the carbon clearance test in mice [Wagner et al., 1985]. The unsaponifiable 
fraction of a hydroalcoholic extract, administered intraperitoneally, protected mice from lethal 
sepsis due to Escherichia coli [Delaveau et al., 1980].  
 
Anti-inflammatory effects 
A lyophilised extract suppressed inflammatory effects and leukocyte infiltration induced by 
simultaneous injection of carrageenan and prostaglandin E1 into rats [Shipochliev et al., 1981]. 
A dry 80% ethanolic extract of Calendula flower, given orally 1 hour before oedema elicitation, 
inhibited carrageenan-induced rat paw oedema by 11% at a dose of 100 mg/kg body weight. In 
the same experiment indometacin at 5 mg/kg resulted in 45% inhibition of oedema [Mascolo et 
al., 1987]. 
A 70% alcoholic extract and a supercritical CO2 extract were applied topically in the croton oil 
ear oedema test in mice. The hydroalcoholic extract had a mild dose-dependent effect, 
inhibiting oedema by 20% at a dose of 1200 µg/ear, corresponding to 4.16 mg of crude drug. 
The CO2 extract produced 30% inhibition at 150 µg/ear, corresponding to 3.6 mg of the crude 
drug, and 71% inhibition at 1200 µg/ear, corresponding to 28.6 mg crude drug. The activity at 
the higher concentration was comparable to that of indometacin at 120 µg/ear [Della Loggia et 
al., 1990]. In the same model, triterpenoids were shown to be the most important anti-
inflammatory principles in the CO2 extract [Della Loggia et al., 1994]. A faradiol monoester 
mixture (faradiol-3-myristic acid ester, faradiol-3-palmitic acid ester and Ψ-taraxasterol) isolated 
from Calendula flower showed significant (p<0.05) anti-oedematous activity in male albino 
Swiss mice at doses of 240 and 480 µg/cm2 compared to controls [Zitterl-Eglseer et al., 1997]. 
Faradiol, which is not present in the free form in Calendula flowers, proved to be even more 
active than the esters with an anti-edematous effect comparable to that of an equimolar dose of 
indometacin, but 3-esterification reduces the activity by more than 50% [Della Loggia et al., 
1994; Zitterl-Eglseer et al., 1997].  
Helianol and Ψ-taraxasterol from Calendula flowers inhibited inflammation induced by 12-O-
tetra-decanoylphorbol-13-acetate (1 µg per ear topically) in female ICR mice. The 50% inhibitory 
doses were 0.1 mg/ear for helianol and 0.4 mg/ear for Ψ-taraxasterol, compared to 0.3 mg/ear 
for indometacin [Akihisa et al., 1996].  
 
Antitumour effects 
A triterpene-enriched fraction given orally to mice inoculated with Ehrlich mouse carcinoma 
prevented the development of ascites and increased survival time compared to control 
[Boucaud-Maitre et al., 1998]. 
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Other effects 
An isolated saponin fraction administered orally at 50 mg/kg body weight to hyperlipaemic rats 
reduced the serum lipid level [Samochowiec, 1983; Wojcicki and Samochowiec, 1980]. 
 
4.2 HUMAN STUDIES  
In a randomized, open, controlled study, the effects of three ointments were compared after 
topical treatment of patients with 2nd or 3rd degree burns for 17 days: a Calendula flower 
ointment (prepared by digestion in vaseline) (n = 53) or vaseline only (n = 50) or a proteolytic 
ointment (n = 53). The success rates were considered to be 37/53 for Calendula flower 
ointment, 27/50 for vaseline and 35/53 for the proteolytic ointment. Calendula flower ointment 
was marginally superior to its base, vaseline (p = 0,05) [Lievre et al., 1992]. 
In an open, uncontrolled pilot study 30 patients with burns or scalds (Degrees 1 and 2a) were 
treated 3 times per day for up to 14 days with a hydrogel containing 10% of a hydroethanolic 
extract. The symptoms reddening, swelling, blistering, pain, soreness and heat sensitivity were 
scored before, during and at the end of treatment. Total score and individual scores for each 
symptom improved [Baranov, 1999]. 
 
4.3 ADME (ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION) 
No data available. 
 
 
5. MICROBIOLOGY 
Antimicrobial, antifungal and antiviral effects 
Various hydroalcoholic extracts exhibited antibacterial activity, especially against 
Staphylococcus aureus and Streptococcus fecalis [Dumenil et al., 1980]. The essential oil of 
Calendula was active against Campylobacter jejuni in a microplate assay [Mendel et al., 2002]. 
Antifungal activity was observed with a 10% methanol extract [Wolters, 1966]. In a study to 
evaluate the antibacterial activity of different herbs against anaerobic and facultative anaerobic 
periodontal bacteria, extracts of C. officinalis showed an inhibiting activity against 
Porphyromonas gingivalis, Fusobacterium nucleatum, Capnocytophaga gingivalis, Veilonella 
parvula, Eikenella corrodens, Peptostreptococcus micros and Actinomyces odontolyticus [Iauk 
et al., 2003]. A flavonoid fraction isolated from the flowers inhibited exhibited in vitro 
antibacterial activity against Staphylococcus aureus, Sarcina lutea, Escherichia coli, Klebsiella 
pneumoniae and Candida monosa [Tarle and Dvorzak, 1989]. 
The essential oil of the flowers inhibited the in vitro growth of Bacillus subtilis, Echerichia coli, 
Staphylococcus aureus, Pseudmonas aeruginosa and Candida albicans [Janssen et al., 1986]. 
A 70% hydroalcoholic tincture of Calendula flowers had high virucidal activity against influenza 
viruses and a marked ability to suppress the growth of herpes simplex virus [Bogdanova et al., 
1970]. 
A dry extract (dichloromethane-methanol 1:1) exhibited anti-HIV activity in an in vitro MTT 
(dimethylthiazole-diphenyltetrazolium)-based assay. In the presence of 10-30 µg/mL of the 
extract, 90% inhibition of HIV-1 replication in acutely infected lymphocytic Molt-4 cells was 
observed. In the concentration of 500 µg/mL the extract suppressed cell fusion and protected 
uninfected Molt-4 cells against subsequent HIV-induced cytolysis caused by cocultivation with 
persistently infected U-937/HIV-1 cells for up to 24 hours. The extract (50, 100 and 200 µg/mL) 
also caused marked dose- and time-dependent inhibition of HIV-1 reverse transcriptase activity 
by up to 85% in a cell-free system [Kalvatchev et al., 1997].  
Extracts from the flowers have trichomonacidal activity [Samochowiec et al., 1979; Fazakas and 
Racz, 1965], which has been attributed to oxygenated terpenes [Gracza, 1987].  
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6. EFFICACY 
An extract of freshly cut flowers and leaves of Calendula officinalis given orally to broiler 
chickens had an immunomodulatory effect against three different live viruses, resulting in 
reduction in the immune response to viruses, which were associated with improvements in body 
weights [Barbour et al., 2004]. 
Dried petals of Calendula officinalis supplemented in a rate of 2% in the diet of hens intensified 
the egg yolk pigmentation [Neamtu et al., 1981]. 
External applications in form of ointments and extracts are used to heal bad curatively wounds 
(lacerations, contused wound, burns) [Sviridonov, 1986; Lipnizkiji et al., 1987; Isaac, 2003]. 
 
7. TOXICOLOGY 
The intravenous LD50 and the intraperitoneal LD50 of an aqueous extract from Calendula flowers 
was determined as 375 mg/kg and 580 mg/kg body weight, respectively [Manolov et al., 1964]. 
For a hydroalcoholic extract (drug to extract ratio 1:1, 30% ethanol) the subcutaneous LD50 was 
45 mg in mice and the intravenous LD50 was 526 mg/100 g in rats [Boyadzhiev, 1965]. An 
ethylene glycol extract (drug to extract ratio 2:1) was non-toxic in albino mice after 
subcutaneous administration of 10 mL/kg [Russo, 1972]. 
 
7.1 SAFETY 
Dosage/Administration  
According to the German Commission E monograph: Unless otherwise prescribed, 1-2 g of drug 
to a glass of water (150 mL) or 1-2 teaspoonfuls (2-4 mL) of tincture in 0.25-0.5 mL water or as 
an ointment with the equivalent of 2-5 g of drug in 100 g of ointment.  
 
Side effects/Adverse Reactions/Contraindications/Precautions 
Weak skin sensitisation has been shown experimentally, but there are no clearly recorded cases 
of contact dermatitis [Hausen and Vieluf, 1997]. 
 
Interactions with other drugs 
None known. 
__________________________________________________________________________________
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ECHINACEA SP 
  
Echinacea pallida 
 
 
1. INTRODUCTION 
American Indians were the first to use Echinacea species for many different ailments, including 
cough, sore throat and tonsillitis (Caruso and Gwaltney, 2005). 
 At present, mainly E. purpurea, E. angustifolia and E. pallida are used as medicinal plants.  
The plant parts used include the rhizomes of E. purpurea, E. angustifolia and E. pallida; the fresh 
or dried aerial parts of E. purpurea; and (in homoeopathy) the whole plant of E. angustifolia and 
E. pallida (Harborne and Williams, 2004). Tinctures or extracts in alcohol are the form most 
herbal authorities recommend. In Germany, the freshly pressed E. purpurea juice stabilized with 
alcohol is very popular. The preparations are for internal and (less often) for external use (Yu and 
Kaarlas, 2004).  
The main indications nowadays are internally for the adjuvant therapy and prophylaxis of 
recurrent infections of the upper respiratory tract (common colds) and the derivative urinary 
tract, and externally as an adjuvant for the treatment of poorly healing superficial wounds 
(Blumenthal, 1998; ESCOP, 2003a-c, WHO, 1999).  
 Although the immunomodulatory activity of Echinacea preparations has been demonstrated in 
many in vitro and in vivo studies, the nature of active constituents, bioavailability, 
pharmacokinetics, physiologic actions and their relevance for human health are not yet fully 
understood. Also the outcome of the clinical studies performed up to now is not fully conclusive. 
The number of studies dealing with potential immunostimulatory and growth promoting effects 
on productive livestock is limited, and also in this case results are not conclusive. In most of the 
studies no real growth promoting effect was demonstrated, but in some cases an enhanced 
feed conversion and also a positive influence on the immune system were found. Generally it is 
difficult to interprete and compare study results concerning Echinacea, because the tested 
preparations widely differ in used species, extraction procedure and content of marker 
compounds. 
 
Key words: Echinacea purpurea, E. pallida, E. angustifolia, immune system 
 
2. DESCRIPTION OF THE PLANT 
 
The genus Echinacea belongs to the Asteraceae family, subfamily Asteroideae, tribus 
Heliantheae, subtribus Ecliptinae (Bauer and Liersch, 1992). The genus Echinacea has recently 
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been reclassified to comprise four species and eight varieties, together with a group of 
introgressant hybrids. E. purpurea, E. angustifolia and E. pallida are revised as E. purpurea (L.) 
MOENCH, E. pallida var. angustifolia (DC.) Cronq and E. pallida var. pallida (Nutt.) Cronq (Yu and 
Karlaas, 2004).  
The genus naturally is endemic to North America, but nowadays cultivation has spread to 
Europe, South America, Australia and other areas of the world. In 2001, the global cultivation 
area of Echinacea was roughly estimated as several thousand hectares (Yu and Kaarlas, 2004).  
E. purpurea is a herbaceous, perennial plant becoming 60-150 (-180) cm high. The stem is 
green to red, upright and slighty branched. The leaves are alternate, ovate to ovate-lanceolate, 
irregularly serrate, rugose on both surfaces, dark green with prominent light green veins. The 
involucral bracts of the large capitulum are arranged in 2 or 3 rows. Each of the outer violet 
ligulate florets (4-6 cm) and of the inner violet-pink tubular florets is attached to a reddish acute 
and coriaceous bract. The fruits are green to light brown achenes bearing a pappus.  
E. angustifolia is becoming less high (10-50 cm), is coarsely hirsute, the leaves are more narrow 
and the ligulate florets rather short (2-3.8 cm). A typal anatomic characteristic are 
sclerenchymatic fibers in the pith tissue of the stem. It is very often mistaken for E. pallida, 
which becomes higher (40-120 cm), has white pollen, longer ligulate florets and oil tubes in 
pith and stem bark. Discrimination between the two species is also possible by the number of 
chromosomes (Bauer and Liersch, 1992). 
 
2.1 SYSTEMATICS 
The genus Echinacea belongs to the Asteraceae family, subfamily Asteroideae, tribus 
Heliantheae, subtribus Ecliptinae (Bauer and Liersch, 1992). The genus Echinacea has recently 
been reclassified to comprise four species and eight varieties, together with a group of 
introgressant hybrids. E. purpurea, E. angustifolia and E. pallida are revised as E. purpurea (L.) 
MOENCH, E. pallida var. angustifolia (DC.) Cronq and E. pallida var. pallida (Nutt.) Cronq (Yu and 
Karlaas, 2004).  
 
2.2 OCCURENCE 
The genus naturally is endemic to North America, but nowadays cultivation has spread to 
Europe, South America, Australia and other areas of the world. In 2001, the global cultivation 
area of Echinacea was roughly estimated as several thousand hectares (Yu and Kaarlas, 2004).  
 
2.3 PLANT PARTS AND PRODUCTS 
Purple coneflower herb consists of the fresh or dried, flowering aerial parts of E.  purpurea (L.) 
MOENCH (ESCOP, 2003b). A monograph for the European pharmacopea is in preparation.  As 
the morphologic discrimination of the aerial parts is difficult, the herbs of the three species are 
often mixed up with each other. A chemical discrimination is more adequate. 
Pale coneflower root consists of the dried, whole or cut underground parts of E. pallida Nutt., 
and narrow leaved coneflower root consists of the dried, whole or cut underground parts of E. 
angustifolia (DC). The materials comply with the respective monographs in the European 
Pharmacopoea (Ph. Eur. 5). For purple coneflower root, a monograph is in preparation.  
Also the roots of the three species are often mistaken for each other. Additionally, the 
adulteration with the roots of Parthenium integrifolium L. occurs (Bauer and Liersch, 1992). The 
roots can be discerned by macroscopic and microscopic characteristics, but the better method 
is chemical discrimination by TLC as described in the European Pharmacopoea (Ph. Eur. 5 a,b) 
or by HPLC. 
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3. CHEMICAL CONSTITUENTS 
The lipophilic alkamides, the hydrophilic caffeic acid derivatives (CADs) such as echinacoside 
and cynarin, polysaccharides and glycoproteines are considered to be the most relevant 
constituents for activity. Additionally polyacetylenes, flavonoids, essential oil compounds and 
pyrrolizidine alkaloids have been isolated from the plants (ESCOP, 2003 a-c, Harborne and 
Williams, 2004). Variation in type and amount of constituents depending on species, varieties, 
cultivating stage and region, plant part and processing of plant products have to be considered 
in phytochemical standardization and batch to batch consistency of Echinacea preparations (Yu 
and Kaarlas, 2004). At present, mainly TLC and HPLC fingerprints of CADs and alkamides are 
used for standardization, quality control, and for the phytochemical discrimination of the 
Echinacea species (Bauer, 1999; Yu and Kaarlas, 2004). The European Pharmacopoea specifies 
the minimum echinacoside content to be 0.2% of dried drug for E. pallidae radix and 0.5% for E. 
angustifoliae radix (EAB, 2005a,b).  
The use of CADs for product standardization has been shown to be problematic due to the 
polyphenol oxidases (POs) present in the plant material. POs can lead to the enzymatic 
degradation and oxidation of CADs in hydroalcoholic solutions during the extraction process 
(Nüsslein et al., 2000, Wölkart et al., 2004).  
There are also efforts to use glycoproteins as marker compounds in Echinacea products. 
Classen and co-workers (2004) have developed a monoclonal antibody against an 
arabinogalactan protein from E. purpurea which might be a tool for quality control of E. purpurea 
preparations. 
 
4. PHARMACOLOGY 
4.1 IN VITRO AND ANIMAL TESTING 
In vitro and animal studies have demonstrated the ability of various Echinacea preparations to 
enhance the activities of immune cells. Activity was found for hydrophilic and lipophilic extracts 
and fractions. The effect most widely demonstrated is the activation of macrophages and the 
increased activity of polymorphonuclear granulocytes resulting in an increased phagocytic 
activity. Stimulation of natural killer cells has also been reported (ESCOP, 2003a-c, Barrett, 
2003). Other activities demonstrated in vitro or in animal studies are antioxidant and anti-
inflammatory effects, wound healing and hyaluronidase inhibitory activity (ESCOP 2003 a-c).  
 
4.2 VETERINARY STUDIES 
Echinacea has been widely researched in laboratory animals for its potential clinical uses. 
Research on livestock is at best limited, however, some data exist which provide species-specific 
information on efficacy of Echinacea to various livestock species, including poultry, cattle, 
horses and swine. Practical applications are predominately, although not exclusively, associated 
with immune system stimulation (Pearson, 2004). 
 
4.2.1 POULTRY 
Schranner et al. (1989) studied the effect on the humoral immune response of a complex drug 
containing E. angustifolia homoeopathic mother tincture and E. angustifolia mother tincture 
alone on normal and immunodeficient chickens. The administration of the complex drug 
enhanced humoral immune parameters both types of chickens, but E. angustifolia mother 
tincture alone had no significant effect. Roth-Maier et al. (2005), who fed cobs prepared from E. 
purpurea aerial parts to healthy broiler and layer chickens, found no beneficial effect on feed 
intake and growth performance of the animals and concluded that E. purpurea cobs are not 
useful as a replacement of feed antibiotics.  
There are two studies dealing with coccidia infections: Allen (2003) showed that feed 
supplementation with powdered E. purpurea root during the first two weeks of life of processed 
broiler chickens that were given a live oocyst vaccine, enhanced growth before coccidia 
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challenge and protected challenged chickens up to a certain extent against weight gain 
suppression and development of intestinal lesions. This indicates that E. purpurea may 
potentiate the immune response to live vaccination and may provide protective 
immunostimulation in the presence of natural coccidia populations in the litter.  
Christaki et al. (2004) compared the effect of a mixture of herbal extracts containing E. 
angustifolia (plant part not given) to the anticoccidial drug lasolacid in broiler chickens 
experimentally infected with Eimeria tenella. The herbal feed supplement led to a certain 
coccidiostatic effect, which was however significantly lower than that of lasolacid.  
 
4.2.2 SWINE 
The outcomes of studies recently performed in pigs are rather controverse: 
Holden and co-workers performed two series of experiments dealing with the potential of 
Echinacea as a growth promoter: In their first study (Holden et al., 1998), they fed 0-2% 
Echinacea (plant part not specified) to weaned pigs for a period of 5 weeks and compared their 
performance to pigs receiving a subtherapeutic level of the common antibiotic Mecadox and a 
negative control not receiving any feed supplement. In weeks 0-3 and 0-4 the the groups 
receiving 0.5 and 2% Echinacea were significantly better in feed efficiency but daily gain and 
feed intake and also the total performance for the entire experiment (weeks 0-5) were not 
statistically different. These data suggested that higher levels of Echinacea enhanced the feed 
efficiency compared to 0% Echinacea during the first two weeks and were greater than with the 
Mecadox diet during the weeks 0-3 and 0-4 (Holden et al., 1998). In a second study, the authors 
performed two experiments using lower (0.1-0.5%) and higher (1.5-3%) doses of Echinacea 
under the same conditions as described above. Compared with low dose Echinacea 
supplementation, the Mecadox diet performed significantly better whereas 3% Echinacea 
enhanced overall gain in the week 0-5 period compared to 0 and 1.5% Echinacea and supported 
gains equal to the Mecadox treatment (Holden and McKean, 2000). As the authors gave no 
information on the used Echinacea species (only a echinacoside content of 0.08% was given) 
and plant part, it would be of great value to repeat the experiment with a characterized and 
standardized Echinacea product (Pearson, 2004). 
Hermann and coworkers challenged weaned pigs by inoculation with porcine reproductive and 
respiratory syndrome virus in order to study the potential antiviral and immunostimulatory effect 
of E. purpurea root powder containing 1.35% cichoric acid. The authors did not find any growth 
enhancing, antiviral or immune enhancing effects of Echinacea supplementation (Hermann et 
al., 2003). 
Maass et al. (2005) studied the effect of supplementation with cobs and juice from the aerial 
parts of E. purpurea on general performance and immune parameters of sows during gestation 
and lactation, piglets and grower/finisher pigs. In all three groups no effect on growth 
performance was found, but supplemented grower/finisher pigs showed a significantly better 
feed conversion. No significant effects were found concerning blood and immune parameters of 
sows and piglets but since there was no response to flavomycin too, the authors concluded that 
the experimental conditions were not appropriate to effectively address the capacity of the 
Echinacea preparations due to the high hygienic conditions of the experiments. They suggest 
that there may be more efficiency under sub optimal ambient conditions. As an indicator of the 
specific reaction of the immune system, the antibody production after the vaccination of 
grower/finisher pigs with Swine erysipelas was tested, and the immune response turned out to 
be significantly higher in the Echinacea supplemented groups. The efficiency of the cobs was 
comparable to that of the commercial juice product, even though there was a great difference in 
the content of marker compounds present in the preparations.  
In an experiment with 13 sows (6 Echinacea, 7 control), Kuhn et al. (2005) fed an E. purpurea 
pressed juice from the aerial parts, stabilized with alcohol (0.125 ml/kg b.w.) during the whole 
pregnant and suckling period of sows in 6 intervals. The influence on immune system, health 
status, growth performance and carcass quality of the offspring was investigated. The treatment 
resulted in immunostimulatory effects of Echinacea both in sows and piglets with highest 
changes in the peripartal period: In 1 day old piglets IgG, IgA and CRP concentrations were 
significantly increased in the Echinacea group. Up to day 70 of age the rate of therapeutical 
treatments of piglets form Echinacea-treated sows was decreased in tendency, but not 
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significantly. As in the studies mentioned before, growth performance was not influenced by 
Echinacea supplementation. 
 
4.2.3 HORSES AND CATTLE  
In a double blind, placebo controlled cross over trial O´Neill et al. (2002) investigated the effect 
of aqueous E. angustifolia root extract standardized to 4% echinacoside in 8 healthy horses. 
Animals were supplemented for 42 days. Echinacea treatment increased phagocytic activity of 
isolated neutrophils, boosted peripheral lymphocyte counts and appeared to stimulate 
neutrophil migration from peripheral circulation into the tissues. Moreover, the size and 
concentration of peripheral red blood cells and haemoglobin concentration increased 
significantly, an effect that had not been reported in previous studies with other animal species 
and may potentially improve the parameters of exercise physiology and performance. 
The same extract was tested in a 14 day pilot study with 8 dairy heifers aged between 2 and 52 
days. A trend to an increase in neutrophils and total plasma protein was observed. There were 
no significant effects on the incidence of scour or pneumonia. However this study is limited by 
its short time frame (Pearson, 2004). 
 
4.3 HUMAN STUDIES  
Clinical studies of Echinacea species have ended with mixed results. The majority of studies 
investigated whether Echinacea treatment shortens duration or decreases severity of symptoms 
of common cold over placebo, some studies also investigated the preventive effect of Echinacea 
preparations. The results of these studies are very different, and the studies are also difficult to 
compare due to different study design and Echinacea species and preparation used.  
For example Brinkeborn et al. (1999) investigated the efficacy and safety of different doses and 
preparations of E. purpurea in the treatment of common cold in a randomized, double-blind 
placebo controlled study. The commercial E.purpurea product and its concentrated preparation 
showed to be significantly more active than a different E. purpurea preparation and placebo. The 
latest clinical study concerning Echinacea was performed by Turner and coworkers (2005). In 
this trial, the authors studied the efficacy of 3 E. angustifolia extracts of different polarity in the 
treatment of persons experimentally challenged with rhinovirus type 39. None of the 3 extracts 
led to statistically significant effects in this study. 
Linde et al. (2006) reviewed 16 randomized trials investigating the effectiveness of a variety of 
Echinacea preparations for preventing and treating common colds. 2 of these trials investigated 
whether taking Echinacea preparations for 8 to 12 weeks prevents colds but found no clear 
effect. The majority of studies investigated whether taking Echinacea preparations after onset of 
cold symptoms shortens duration or decreases severity of symptoms over placebo. It seems that 
some preparations based on the herb of E. purpurea are effective for this purpose in adults, 
while it is unclear whether other preparations are effective and whether children benefit. 
 
4.3.1 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
In in vitro studies using Caco-2 monolayers, a model of the intestinal epithelial barrier, 
alkamides were shown to be transported through the monolayer, presumably by passive 
diffusion, as the authors suggest. The diffusion time was dependent on structural variations in 
the alkamides. Caffeic acid derivatives only showed poor diffusion in this model. From these 
findings the authors conclude that alkamides, but not caffeic acid derivatives are likely to cross 
the intestinal barrier (Jager et al.,  2002; Matthias et al., 2004). 
Woelkart et al. (2005) investigated the pharmacokinetics of alkamides in humans after oral 
administration of a 60% ethanolic  E. angustifolia root extract. Blood samples were taken from 
11 healthy volunteers before and in short intervals after ingestion of a single dose of the extract 
or placebo using a crossover design. The 6 major alkamides from the extract were quantified in 
the plasma samples using LC-ESI-MS/MS. The maximum alkamide concentration was already 
reached after 30 minutes, thus the authors conclude that the mucous membranes of the 
mouth and the esophagus might be an important site of absorption. The absorption rate 
differed depending on the structure of the alkamides; this observation was also made by Dietz 
et al. (2001), who performed the first study on the absorption of E. purpurea alkamides in 
humans. 
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5. MICROBIOLOGY 
A distinct antimicrobial activity of Echinacea species has not been described. Only pure 
echinacoside and some polyacetylenic compounds have been shown to exhibit low antibacterial 
activity in vitro (ESCOP 2003 a-c). 
Extracts of the roots of pale and purple coneflower demonstrated in vitro antifungal activity 
against Candida ssp. and Saccharomyces cerevisiae; this was mainly attributed to the 
ketoalkenes and ketoalkynes (ESCOP, 2003 a, c). 
Hydrophilic root extracts also showed a certain antiviral activity in vitro, and the antiviral activity 
of echinacoside against vesicular stomatitis virus in L-929 mouse cells was demonstrated in a 
plaque reduction assay (ESCOP, 2003 a,c). Also purple coneflower herb pressed juice as well as 
a decoction and a 30% ethanolic extract showed antiviral and viral resistance increasing activity 
in several in vitro models (ESCOP, 2003b). 
 
6. EFFICACY 
Echinacea preparations are regarded to be effective in humans in the adjuvant therapy and 
prophylaxis of recurrent infections of the upper respiratory tract (common colds) and the 
derivative urinary tract, and externally as an adjuvant for the treatment of poorly healing 
superficial wounds (Blumenthal, 1998; ESCOP, 2003a-c; WHO, 1999). Full documentation of 
efficacy in these indications still remains problematic. Even though a considerable amount of 
clinical studies, especially concerning the efficacy for the prevention and treatment of common 
cold, have been performed, the outcome of these studies does not allow definite conclusions. 
As studies concerning the efficacy of Echinacea as a growth promoter and immune enhancer in 
productive livestock are limited, no final conclusions are possible yet. In most of the studies no 
real growth promoting effect was demonstrated, but in some cases an enhanced feed 
conversion and also a positive influence on the immune system were found. 
 Generally it is difficult to interpret and compare study results concerning Echinacea, because 
the tested preparations widely differ in used species, extraction procedure and content of 
marker compounds. 
No data exist concerning the potential of Echinacea preparations as a sensory and flavouring 
agent in animal feed. The plant parts used in medicine have a weak aromatic smell and their 
taste is sourly, bitter and in some cases they have a weak anaesthetic effect on the tongue due 
to their alkamide content (Bauer and Liersch, 1992). Thus it can be assumed that the plant is 
(at least for humans) not very well suited as a sensory and flavouring agent. 
 
7. TOXICOLOGY 
7.1. SAFETY 
 
The toxicity of Echinacea species appears to be very low. For E. purpurea herb pressed juice 
there was found no toxicity in rats or mice at the maximum administrable dose. Also after a 
daily administration over a 4 week period, no toxic effects on rats were evident from laboratory 
or necropsy results. There was no evidence for any mutagenic potential of E. purpurea herb in 
vitro and in vivo (ESCOP, 2003b). For E. pallida and E. angustifolia, no toxicity studies are 
published. The pyrrolizidine alkaloids found in Echinacea are considered to be non toxic because 
in contrary to the hepatotoxic pyrrolizidine alkaloids from other plants they possess a saturated 
pyrrolizidine nucleus (Pearson, 2004).  
Adverse effects of Echinacea preparations oberserved in humans seem rare and mainly 
comprise allergic reactions, which can be severe. Systematic studies of adverse effects of 
Echinacea have not been done (Ernst, 2002). No dose-dependent adverse effects have been 
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characterized, and no overdoses have been reported. Interactions are unknown. 
Contraindications are theoretical and comprise chronic progressive immuno-mediated diseases 
such as tuberculosis and multiple sclerosis; this is based on the potential harm that could result 
if the immune-mediated inflammatory components of these diseases were exacerbated by 
Echinacea´s immunostimulating properties (Barrett, 2003).  
The safety of Echinacea in pregnancy has not been determined, and little relevant data is 
available. In one study, 206 women who used Echinacea during pregnancy were risk matched 
with 206 controls and assessed for adverse effects. Altough no evidence for increased risk was 
noted, the study lacked the statistical power and methodogical rigor to determine pregnancy 
associated risks with confidence (Barrett, 2003). 
 
7.2 DOSAGE 
 
E. purpurea herb pressed juice:  
Adults: 6-9 ml of pressed juice daily; other equivalent preparations at comparable dosage 
Children: Proportion of adult dose according to age or body weight. 
The duration of continuous treatment should not exceed 8 weeks. No adverse reactions have 
been reported after long term oral administration (ESCOP, 2003b). 
E. purpurea and E. pallida root tincture: 
Adults: daily dose hydroethanolic extracts corresponding to 900 mg dried root; other equivalent 
preparations at comparable dosage. 
Children: Proportion of adult daily dose according to age or body weight. 
The duration of continuous treatment should not exceed 8 weeks (ESCOP, 2003a,c).  
_________________________________________________________________________________
EMW 
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EUCALYPTUS GLOBULUS 
Eucalyptus globulus 
 
1. INTRODUCTION 
Even though Eucalyptus species are originally native to the Australian continent and Tasmania, 
their use for medical and flavouring purposes is nowadays common more or less all over the 
world. Both the medical and flavouring applications are mainly based on the essential oil 
content of the plant with 1,8-cineol (eucalyptol) as the main compound. Thus, in Europe mainly 
eucalyptol-rich species like E. globulus are used. 
In medicine, the leaves and the volatile oil have traditionally been used to treat catarrh and 
coughs, inflammation of the respiratory tract, bronchitis, furthermore in the treatment of 
cystitis, diabetes, gastritis, kidney disorders, neuralgia, laryngitis, leucorrhoea, malaria, 
pimples, ringworm sinusitis, wounds, ulcers of the skin, urethritis and vaginits (WHO, 2002a, b). 
Nowadays, the leaves are used less often in the therapy of common cold, but the essential oil 
still plays an important role (Wichtl, 2002). It is stated to be effective internally as an adjuvant 
in the treatment of chronic obstructive respiratory complaints including bronchitis and 
bronchial asthma, and for the symptomatic relief of colds and catarrh of the upper respiratory 
tract, and externally for the symptomatic treatment of colds and rheumatic complaints (ESCOP, 
2003, WHO, 2002a,b). Also in herbal veterinary medicine, the volatile oil is sometimes used as 
expectorant (Bentz et al., 1989). The essential oil is also a component of certain dental root 
canal sealers (WHO, 2002a), and because of its antiseptic properties and its fresh taste it is 
often added to medical toothpastes and mouthwashes (Brand, 1993). Besides, eucalyptus 
preparations and eucapyptol are used as flavouring agents in many food products (Barnes et 
al., 2002). 
 
 
2. DESCRIPTION OF THE PLANT 
The genus Eucalyptus belongs to the Myrtaceae family, subfamily Myrtoideae, tribus Myrteae. 
The genus is extremely diverse, comprising about 400 species. The definite classification of the 
genus is still in discussion. At the moment, it is divided into 8 subgenera, which are further 
classified to sections, series and subseries (Brand, 1993). The genus is almost exclusively 
native to Australia and Tasmania, furthermore Eucalyptus species occur naturally in the 
Eucalyptus 
----------------------------------------------------------------------------------------------------------------- 
 
 98
Malayan archipelago and New Guinea. Since the middle of the 18th century, many species have 
been cultivated all over the world in frost-free, Mediterranean, tropic and subtropic regions. E. 
globulus LABILL. is nowadays mainly grown in Spain, Portugal, southern France, Italy, the 
Caucasus, Algeria, Florida, California, Brazil, Mexico, Jamaica and India (Brand, 1993). 
E. globulus is a large tree with smooth, pale or ash-grey bark, becoming 3 to 20 m high. The 
branchlets are quadrangular and grey-green. The leaves of young trees and the first leaves of 
young shoots are opposite, sessile, oval-oblong, with a cordate base, farinaceous-glaucous, and 
the older leaves are dangling, spirally arranged, lanceolate-falcate and up to 30 cm long. The 
flowers have very short pedicels, are almost umbellate, sometimes 2-3 in a fascicle. The fruits 
are turbinate, angular and 2-2.5 cm in diameter (WHO, 2002b). 
The plant parts used are the leaves and the volatile oil, which is obtained from the leaves.  Both 
materials comply to the respective monographs of the European Pharmacopoea (EAB): 
Eucalypti folium consists of the whole or cut dried leaves of older branches of E. globulus LABILL. 
Eucalypti aetheroleum is obtained by steam distillation and rectification from the fresh leaves 
or the fresh terminal branchlets of various species of Eucalyptus rich in 1,8-cineole (eucalyptol). 
The species mainly used are E. globulus LABILL., E. polybractea R.T. BAKER and E. smithii R.T. 
BAKER (EAB, 2005a,b). Treatment with alkali and rectification is necessary for the further 
purification of the raw volatile oil in order to separate saponifiable compounds and aldehydes, 
and for the enrichment of 1,8-cineol. The different volatile oil grades on the market are not 
corresponding to a certain Eucalyptus species, but are only specified by their 1,8-cineol content.  
Adulterations of eucalyptus oil with camphor oil and with by-products of terpineol production 
have been reported. Due to the characteristic morphologic criteria of the leaves, adulterations  
of the leaves normally do not occur  (Brand, 1993). According to the EAB, adulteration with the 
leaves of young branches of eucalyptus is not allowed (EAB, 2005a). 
 
3. CONSTITUENTS 
The leaves contain 1 to 3 % volatile oil, depending on provenience (Brand, 1993). The EAB 
specifies a minimum volatile oil content of 20 ml/kg for the whole drug and 15 ml/kg for the 
cut drug, with reference to  the anhydrous drug (EAB, 2005a). The native oil contains 45 to 75% 
1,8-cineole. Additionally, myrtenole, α-pinene, β-pinene, pinocarvone, γ-terpinene, α-
phellandrene, several aldehydes and the sesquiterpenes alloaromadendrene, aromadendrene, 
globulole and α-grujunene have been described as minor constituents. The rectified essential 
oil has a 1,8-cineole content of up to 90%. Qualitative analysis of the volatile oil is performed by 
TLC with a reference solution containing 1,8-cineole. The chromatographic profile is obtained by 
GC and exactly specified by the EAB: for example less than 1.5% phellandrene, less than 0.1% 
camphor and at least 70% of 1,8-cineole have to be present in the volatile oil (EAB, 2005b). 
Apart from the volatile oil, the leaves of E. globulus contain flavonoids, wax with 50% 
triacontane-16, 18-dione, tannins, ellagitannins and 2-4% triterpenes (ursolic acid derivatives). 
Also the presence of euglobales, compounds with acylphloroglucinol-monoterpene or -
sesquiterpene structure, has been reported (Brand, 1993, WHO, 2002b).  
 
4. PHARMACOLOGY 
Many observed pharmacologic effects are caused by the volatile oil and its major constituent 
1,8-cineole. 
 
4.1: IN VITRO AND ANIMAL TESTING 
Respiratory tract and antitussive effects 
Oral administration of eucalyptus oil (50mg/kg b.w.) gave a 172% increased output in 
respiratory tract fluid in guinea pigs. Smaller increases were observed at similar dose levels in 
rabbits, cats, rats and dogs. Administration of non-lethal doses of the volatile oil by steam 
inhalation did not enhance the output of respiratory tract fluid in rabbits (WHO, 2002a, ESCOP, 
2003). 
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Inhalation of the essential oil (5% emulsified in normal saline) led to a significant antitussive 
effect in guinea pigs, compared to codeine as a positive control. Intraperitoneal injection (50 
mg/kg) of the volatile oil produced a less pronounced, but still significant effect in this model 
(WHO, 2002a). 
 
Anti-inflammatory activity 
Silva et al. (2003) tested the volatile oil of 3 eucalyptus species for their anti-inflammatory and 
analgesic acitivity in several animal models at concentrations between 0.1 and 100 mg/kg b.w. 
The oils exhibited both central and peripheral analgesic effects and produced anti-inflammatory 
effects as shown by inhibition of paw edema formation, inhibition of neutrophil migration into 
rat peritoneal cavities and decrease of vascular permeability. However, in some cases the 
results were inconsistent and the observed effects were not dose dependent in all assays.  
Santos et al. (2004) found that pre-treatment, but not post-treatment with high doses of 1,8-
cineole (200 and 400 mg/kg b.w.) significantly reduced colonic damage in rats on acute 
trinitrobenzenesulfonic acid-induced colitis. The authors suggest that the compound might be 
valuable as a dietary flavouring agent in the prevention of gastrointestinal inflammation and 
ulceration. 
E. globulus volatile oil significantly reduced inflammatory cell infiltration and bronchiolitis 
severity in rats after elicitation of chronic bronchitis by lipopolysaccharide (LPS)-instillation (Lu 
et al., 2004). Especially after administration of high doses (300 mg/kg b.w.), there were 
significant decreases of mucin content in the bronchoalveolar lavage fluid and in some other 
parameters. 
1,8-cineole was shown to inhibit the production of pro-inflammatory arachidonic acid 
derivatives and cytokines in several in vitro and ex vivo studies:  
At a cineole concentration of 10 µg/ml, significant inhibition of the LPS-stimulated production 
of LTB4, IL-1β, TXB2 and a strong inhibition of TNFα production  was observed in human blood 
monocytes in vitro (Juergens et al., 1998a). In a further in vitro study using human unselected 
lymphocytes and LPS-stimulated monocytes, Juergens et al. (2004) demonstrated that the 
compound had a stronger impact on TNFα and IL-1β production in monocytes compared to 
lymphocytes at a concentration of 10-6M, and similar effects on monocytes and lymphocytes at 
a therapeutically relevant concentration of 10-5M. The inhibitory effects on chemotactic 
cytokines were less pronounced. In an ex vivo experiment,  LTB4 and PGE2 production was 
determined in isolated monocytes after stimulation with calcium ionophore A23187 before 
cineole treatment, after 3 days of treatment (3x daily 200 mg) and four days after 
discontinuation of treatment. Mediator production was significantly inhibited after 3 days of 
treatment in asthma patients as well as in healthy volunteers (Juergens et al., 1998b).  
According to the authors, the strong inhibition of cytokine production observed in these studies 
makes the compound interesting in the treatment of airway inflammation, bronchial asthma 
sinusitis and COPD, where these mediators seem to play an important role (Juergens et al., 
2004). 
In a different in vitro model, Vigo et al. (2004) showed that a 50% ethanolic E. globulus leaf bud 
extract possesses NO-scavenging activity, and that pretreatment with this extract decreases 
iNOS and mRNA levels and inhibits NO production in J774A.1 murine macrophages stimulated 
with LPS and interferone-γ. Testing concentrations ranged from 8.5 to 84 µg/ml. From their 
findings the authors conclude, that the extract possesses an anti-inflammatory activity without 
decreasing cell viability. 
 
Antioxidant acitvity 
Eucalyptus volatile oil inhibited the liberation of ethene from α-keto-γ-methiol-butyric acid by 
the Fenton oxidant in a concentration-dependent manner, starting with significant inhibition at 
0.1% of oil. In another test, the degranulation of activated human neutrophilic granulocytes 
was quantified using a system which led to HOCl production. Eucalyptus oil strongly inhibited  
HOCl production at concentrations above 0.1%, with almost complete inhibition  at 0.25% 
(ESCOP, 2003). 
In a different study, E. globulus volatile oil was tested for free radical scavenging and 
antioxidant activity using three different in vitro models, which allow the primary and the 
secondary step of oxidation as well as the lipid soluble antioxidant capacity to be followed. The 
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oil was almost ineffective in the DPPH test and in the photochemiluminescence test and gave 
moderate results in the β-carotene-bleaching assay (Sacchetti et al., 2005).  
 
Antidiabetic activity 
In earlier investigations, a hot aqueous E. globulus leaf extract had been shown to suppress 
streptozotocin-induced hyperglycaemia in mice when added to the diet (6.25%) and drinking 
water (0.25%). The same extract did not stimulate pancreatic insulin production. However, in a 
different study, intragastric administration of aqueous or ethanolic leaf extracts at a dose of 1 
g/kg b.w. did not  suppress alloxan-induced hyperglycaemia in mice and rabbits (WHO, 2002b). 
Also Jouad et al. (2003) found, that repeated p.o. administration of an aqueous E. globulus leaf 
extract exhibited a significant, dose-dependent hypoglycaemic effect in streptozotocin treated 
diabetic rats. The basal plasma insulin concentrations were significantly increased after 
repeated oral administration. In rats with a normally functioning pancreas however, no 
significant changes in blood glucose levels were observed. Extracts were administered at high 
doses (150 and 300 mg extract/kg b.w.). An eucalyptus leaf hot water extract was furthermore 
found to significantly decrease glucose diffusion in an in vitro dialysis based model of glucose 
absorption at a concentration of 50 g/l (Gallagher et al., 2003). 
 
Other effects 
Lahlou and coauthors (2002) found that bolus injections of 1,8-cineole (0.3-10 mg/kg b.w., i.v.)  
elicit hypotension in both conscious and anaesthesized normotonic rats. According to the 
authors, the effect seems to be due to an active vascular relaxation rather than to a withdrawal 
of sympathetic tone. 
Soares et al. (2005) showed that 1,8-cineole reduces the contractile activity of isolated rat 
cardiac muscle in vitro. The compound at concentrations ranging from 0.003 to 0.3 mM 
reduced isometric tension, the rate of force development and time parameters. The authors 
suggest a possible calcium channel blocking action for the compound. 
Eucalyptus volatile oil was shown to significantly inhibit bone resorption in vivo in rats, when 
added to the feed at a daily dose of 100 mg/animal. Also pure eucalyptol, which was added at 
a dose of 24 mg/animal, was effective. In an in vitro model on osteoclast inhibitory activity, it 
was shown that eucalyptol does not have a direct inhibitory effect. The authors suggest that the 
compound might be metabolized to active derivatives in vivo (Mühlbauer et al., 2003).  
 
4.2 VETERINARY STUDIES 
Varroa destructor ANDERSON and TRUEMAN , the cause of varoosis, is the most damaging parasite 
in honey bees and represents a serious infestation of bee colonies. The use of synthetic 
acaricides is hazardous due to accumulation. So, among others, essential oil mixtures have 
been successfully tested as alternative treatment. Adamczyk et al. (2005) investigated, 
whether essential oil components accumulate in honey samples from hives treated with a 
commercial mixture of thymol, eucalyptol, menthol and camphor. They found thymol at 
concentrations ranging from 0.75 to 8.20 µg/g , low amounts of camphor and no eucalyptol or 
menthol residues. The authors conclude that the presence of these residues does not represent 
a sanitary risk or a risk for human health, but may change the taste of the honey. Thus, they 
suggest to conduct a sensorial analysis. 
 
4.3 HUMAN STUDIES 
A clinical trial without controls assessed the effects of Aetheroleum Eucalypti as a nasal 
decongestant in 31 healthy volunteers. Inhalation of the essential oil (10 ml) over a period of 5 
minutes had no effect on nasal resistance to airflow. However, the oil had a stimulant or 
sensitizing effect on nasal cold receptors, and the majority of subjects reported a feeling of 
increased airflow. A single-blind, parallel clinical trial assessed the efficacy of vaporized 
essential oil in reducing nasal congestion in 234 patients with acute respiratory tract infections. 
The oil was significantly active only in the first hour following treatment. In other studies 
including patients with acute common colds, no significant differences in nasal decongestant 
activity were reported between the essential oil and vehicle only (WHO, 2002, ESCOP, 2003). 
To compare the effects of secretolytics on lung function, a double-blind, placebo-controlled, 
three way cross-over study was carried out in 30 patients with chronic obstructive respiratory 
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complaints, with treating periods of 4 days separated by washout periods of 2-3 days. Subjects 
received either 3x daily 200 mg of cineole in capsules, 3x daily 30 mg of ambroxol.HCl in 
tablets, or placebo only. No concomitant medications were permitted. Significant 
improvements from treatment with cineole and ambroxol were observed with respect to forced 
vital capacity, forced expiratory volume in one second, and peak expiratory flow. Changes in 
cough score were not significant. In a second study, the same doses of cineole and ambroxol 
were administered for 7 day periods with 3-5 day washout periods, and concomitant 
medication was permitted. In lung function tests by body plethysmography, airway resistance 
and specific conductance significantly improved after cineole or ambroxol treatment, whereas 
inthrathoracic gas volume and residual volume were improved significantly only by cineol. The 
spirometric parameters were not significantly improved, only vital capacity increased 
significantly after cineole treatment. Scores of dyspnoea, coughing and amount of secretion 
showed improvement after both treatments without reaching significance. Based on the 
plethysmographic results, the authors conclude that cineole appears to have a bronchodilator 
and an expectorant effect (ESCOP, 2003). 
In a randomized, double blind, placebo-controlled study, 32 patients suffering from steroid-
dependent asthma (5-24 mg prednisolone as the lowest maintenance dose daily, inhaled 
steroids, other asthma medications) were additionally assigned to receive 3x200mg cineole or 
placebo daily for 12 weeks. Oral prednisolone dose was reduced by 2.5 mg increments every 3 
weeks. A decresase of 36% of daily dose level was tolerated in the cineole group, as compared 
to only 7% in the placebo group (Juergens et al., 2003). 
Studies documenting the efficacy of 1,8-cineole or eucalyptus oil in other inflammatory 
diseases do not exist so far. There is one further study investigating the analgesic effect of local 
treatment of headache with a combination eucalyptus oil and peppermint oil. Even though an 
improved cognitive performance and muscle and mental relaxation were observed, the 
preparation and also the single volatile oils had no effect on the sensitivity to headache (WHO, 
2002a). 
 
4.4 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
It is suggested, that eucalyptus oil is readily absorbed in the gastrointestinal tract after p.o. 
administration due to its lipophilic constituents. After local application, the volatile oil was 
rapidly absorbed in mice. After topical application of an ointment containing 66.5 mg cineole, 
15% of the compound were found in rat skeletal muscle after 3 hours. When the same 
ointment was applied under occlusive conditions, the resorption quote increased to 60%. 
Concerning inhalative application, humans absorb about 20% of the provided cineole amount 
at a water bath temperature of 80°C. Rabbits were shown to absorb 5 to 10% of cineole 
applied as an aerosol (Brand, 1993).  
In mice, 5 minutes after p.o. administration of 7 or 14 mg cineole, a maximum blood level of 
6.6 and 16.2 ng/ml respectively was determined. As the compound was applied in emulsified 
rosmary oil, the validity of these results for pure cineole is questionable. Inhalation of a cineole-
air-mixture over 80 minutes, equivalent to about 77 mg cineole, led to a linearly increasing 
cineole blood level with a maximum of 42 µg/ml in rabbits. Following intravenous 
administration of a solution of cineole in ethanol to rats, 1% of the administered amount was 
found in lung tissue and 4% in liver tissue after 1 hour. After the daily administration of 500 mg 
cineole/kg b.w. for 4 days, cineole passed the placenta barrier, but was not found in the milk of 
rats (Brand, 1993; ESCOP, 2003).After inhalative application, the elimination of cineole in mice 
was biphasic with a short half life of 6 minutes during the first phase and a half life of about 45 
minutes during a second phase, indicating elimination in accordance with a two-compartment 
model. In humans, a plasma half-life of 35.8 minutes was determined after a 10-minute 
inhalation of cineole. After i.v. application, rats eliminate about 4% of the administered cineole 
dose within 5 hours via exhalation (Brand, 1993, ESCOP; 2003).  
From the main constituents of eucalyptus oil, the following non conjugated metabolites have 
been found in brushtail possum (Trichosurus vulpecula): α-pinene was metabolized to myrtenic 
acid and trans-verbenol, β-pinene to myrtenic acid, p-cymene to p-cresole and cumic acid, and 
1,8-cineole to p-cresole, 9-hydroxycineole and cineol-9-oic acid (Southwell et al., 1980). 
Miyazawa et al. (1989) isolated 2-exo-hydroxycineole as the main metabolite, as well as 2-
endo-hydroxycineole, 3-exo- and 3-endo-hydroxycineole from rabbit urine after  p.o. 
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administration of 1,8-cineole. Recently, a study of Miyazawa et al. (2001) provided evidence, 
that 1,8-cineole is oxidized at position 2 forming 2-exo-hydroxy-cineole by CYP3A enzymes in 
human and rat liver microsomes in vitro. CYP3A4 is suggested to be a principle enzyme in 
catalyzing this reaction in human liver microsomes. Also Unger and Frank (2004) found in vitro 
inhibitory activity of eucalyptus oil against several CYP 450 enzymes. 
 
5. MICROBIOLOGY 
Eucalyptus oil and leaves have been shown to possess antibacterial activity against a number 
of gram positive and gram negative organisms, as well as antifungal and antiviral activity. 
The following MIC for eucalyptus oil against gram positive bacteria were determined: Listeria 
monocytogenes 0.25% (V/V), Bacillus subtilis 1% (V/V), Staphylococcus aureus  and 
Enterococcus spp. 2% (V/V); For gram negative bacteria, the following MIC´s were found: 
Shigella flexneri 0.25% (V/V), Klebsiella pneumoniae 0.5% (V/V), Salmonella choleraesuis, 
Proteus mirabilis and Enterobacter aerogenes 2% (V/V). No inhibitory effect was found against 
Escherichia coli or Pseudomonas aeruginosa in this study, however, in another study E. coli was 
also inhibited. In this investigation, a good activity against a Streptococcus isolated from 
bronchial aspirates, as well as against pathogenic strains of S. aureus, Klebsiella, Salmonella 
typhi and Proteus ssp. was demonstrated (ESCOP, 2003). 
An ethanol-water leaf extract inhibited the growth of S. aureus at a concentration of 25 µg/ml. 
An aqueous leaf extract inhibited the growth of E. coli, S. aureus, B. subtilis and Enterococcus 
faecalis (MIC 0.07-1.3 mg/ml) (WHO, 2002b).   
Eucalyptus oil shows in vitro fungicidal activity against Candida tropicalis, Rhizopus nigricans, 
Penicillium digitatum, Candida albicans, Aspergillus niger, Cryptococcus rhodobenhani, 
Saccaromyces cerevisiae, Cryptococcus neoformans, Mucor mucedo, Helminthosporium 
sativum, Alternaria solani, Nigrospora panici, Aspergillus fumigatus and Streptomyces 
venezuelae, the organisms being inceasingly susceptible in the above order (agar diffusion 
method) (Brand, 1993). It also exhibited good antifungal activity against six Trichophyton 
species that commonly cause tinea infections, with MIC´s ranging  from 0.125 to 1 mg/ml 
(Shin and Lim, 2004). 
Methanolic and hydromethanolic leaf extracts inihibit Candida albicans, and an ethanol-water 
extract showed antimalarial activity, inhibiting the growth of Plasmodium falciparum in vitro at 
a concentration of 75 µg/ml.  An aqueous leaf extract inhibited the replication of Influenza A 
virus A2 (Mannheim 57), vaccinia virus and herpes simplex virus type 2 in vitro at a 
concentration of 0.1% (WHO, 2002b) 
 
6. EFFICACY 
The efficacy of 1,8-cineole, the main constituent of eucalyptus volatile oil, for the treatment of 
chronic obstructive respiratory complaints including bronchitis and bronchial asthma, and for 
the symptomatic relief of colds and catarrh of the upper respiratory tract is quite well 
established by several clinical studies. Despite promising in vitro and in vivo results concerning 
the anti-inflammatory potential of this compound, so far no clinical trials have been conducted 
in order to demonstrate the efficacy of cineole in other inflammatory disorders such as allergic 
rhinitis and inflammatory bowel diseases. However, it has to be considered that in some in vivo 
trials mentioned above, very high doses were administered, and that therefore the results may 
not be clinically relevant. 
So far no studies have been performed to document a medical application of eucalyptus in 
productive livestock. Eucalyptus oil is occasionally used as an expectorant in herbal veterinary 
medicine (Bentz et al., 1989), but no data concerning efficacy and safety are available. 
Concerning the use as a flavouring agent, eucalyptus is listed by the Council of Europe as a 
natural source of food flavouring (leaves, flowers and preparations in category N4, with limits 
on Eucalyptol as an active principle). In the USA, eucalyptus is used for food use and eucalyptol 
is listed as a synthetic flavouring agent (Barnes et al., 2002). 
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7. TOXICOLOGY 
7.1 SAFETY 
Externally, eucalyptus oil is stated to be generally non-toxic, non-sensitizing and non-phototoxic. 
Undiluted eucalyptus oil should not be taken internally, as high doses are toxic (Barnes et al., 
2002).  In humans, the toxic dose is very difficult to determine, as the ingested doses given in 
the existing case reports differ tremendously. In some cases, the ingestion of only 4-5 ml was 
lethal, whereas in a different case, intoxication with 100 to 200 ml was survived. Intoxication 
symptoms are stomach ache, sickness and emesis, sometimes diarrhea. Sometimes breathing 
problems occur due to bronchospasm, and in most cases the CNS is affected (drowsiness, 
speech disorders, headache, in severe cases inconsciousness and coma). Severe intoxications 
are characterized by dyspnea, circulatory collapse and coma. Eucalyptus oil and preparations 
thereof should not be used for inhalation or applied in the face or nose region of babies or 
infants, because due to the intensive aroma glottis cramp, bronchospasm, asthma-like 
conditions and even apnoea can occur (Brand, 1993). Eucalyptus oil should not be taken 
internally during pregnancy, and the internal use should be avoided in case of inflammation of 
the gastrointestinal tract, gall bladder and decreased liver function. As the oil apparently 
influences liver enzymes, herb-drug interactions might be possible (ESCOP, 2003; WHO, 
2002a). 
Experimental data are available on the toxicity of eucalyptus oil and 1,8-cineole:  
The oral LD50 of eucalyptus oil has been determined as 4.44 g/kg in rats and 3.32 g/kg in 
mice. The LD50 of cineole was determined as 2.48 g/kg b.w. in rats, >5 g/kg b.w. in rabbits 
after dermal application and 100 mg/kg in mice after i.m. application (Brand, 1993; ESCOP, 
2003). In order to investigate the subacute toxicity of cineole, rats were fed 150-1200 mg/kg 
b.w. by stomach tube or cineole in encapsulated form with the diet, equivalent to 381-3342 
mg/kg b.w./day for male and 353-3561 mg/kg/day for female rats. At dose levels of 600 
mg/kg and higher, dose-dependent decrease in body weight gain and absence of a normal 
degree of hepatic centrilobar cytoplasmic vacuolization was observed in male rats. In addition,  
lesions in liver, kidneys and parotid salivary glands were found at all dose levels in male rats 
fed encapsulated cineole. 
In a long term study, groups of 52 male, pathogen-free, CFLP mice were given cineole at 0, 8 or 
32 mg/kg b.w. daily by gavage (in a toothpaste base) on 6 days per week for 80 weeks, 
followed by an observation period of 16-24 weeks. No treatment-related effects on body 
weight, food consumption, survival, weight of adrenals, kidneys, liver, lungs or spleen, or on the 
microscopic appearance of brain, lungs, liver and kidneys, or on tumor incidence, were 
observed. Studies in rats concerning the reproductive toxicity showed that 1,8-cineole 
penetrated placental tissue to give a fetal blood level sufficient to stimulate the hepatic enzyme 
activity at dose levels exceeding 500 mg/kg b.w. Mice treated with 135 mg eucalyptus oil/kg 
b.w. (s.c.) at day 6-15 of gestation (period of organ formation) showed no evidence of 
embryotoxicity or fetotoxicity. 1,8-cineole showed no mutagenic effects in the Ames test in 
various Salmonella typhimurium strains. In Chinese hamster ovary cells, the compound 
furthermore did not induce chromosome aberrations with or without metabolic activation. 
Sister chromatid exchanges were induced only without metabolic activation at cytotoxic doses 
that induced cell cycle delay, and sister chromatid exchanges induced by mitomycin C in 
cultured CHO K-1cells were not increased by post-treatment with cineole. In mice pretreated 
with subcarcinogenic doses of 9,10-dimethyl-1,3-benzanthracen, the compound appeared to be 
a weak promoter and cocarcinogen in papilloma formation (ESCOP, 2003; Brand, 1993). 
The European Commission Scientific Comitee on Food concluded from the available animal 
data that the daily eucalyptol intake from food is not a cause of concern for humans. However, 
for a more precise risk characterization, further data on exposure and toxicity would be needed 
(EC, 2002). No experimental data are available on the safety of eucalyptus and eucalyptole in 
productive livestock.  
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7.2 DOSAGE 
Volatile oil:  
for internal use 0.05 to 0.2 ml per dose; 0.3 to 0.6 ml daily; in capsules 100 to 200 mg 2-5 
times daily 
As a lozenge containing 0.2 to 15 mg dissolved slowly in the mouth, repeated every 0.1 to 1 
hour (ESCOP, 2003) 
 
Leaf: 
Daily dosage: 4-6 g crude drug or equivalent preparations (WHO, 2002b). 
 
EMW 
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FOENICULUM VULGARE 
 
Foeniculum vulgare   
 
1. INTRODUCTION 
Foeniculum was the name given to this plant by the Romans and is derived from the Latin word 
foenum, hay. The Anethum Foeniculum of Linnaeus embraced two varieties, the Common or 
Wild Fennel and the Sweet Fennel. These are considered by De Candolle as distinct species 
named respectively Foeniculum vulgare (also called bitter fennel) and Foeniculum dulce. Fennel 
was well known to the Ancients and was cultivated by the ancient Romans for its aromatic fruits 
and succulent edible shoots. There are several varieties of Fennel fruit known in commerce: 
sweet or Roman Fennel, German or Saxon Fennel, wild or bitter Fennel, Galician Russian and 
Roumanian Fennel, Indian, Persian and Japanese. The fruits vary very much in length, width, 
taste and other characters, and are of very different commercial value. The medicinal parts are 
the Fennel oil extracted from the ripe fruit and the dried ripe fruit (‘Fennel seeds’) of Foeniculum 
vulgare. One of the major constituents include the phenylpropanoid anethole. Anethole and the 
monoterpene fenchone inhibit spasms in smooth muscles, such as those in the intestinal tract, 
and this is thought to contribute to fennel’s use as a carminative (gas-relieving and 
gastrointestinal tract cramp-relieving agent). 
2. DESCRIPTION OF THE PLANT 
Fennel (Foeniculum vulgare Mill.) is a highly aromatic biennial or perennial herb, erect, glaucous 
green, and grows up to 2 m tall. The leaves grow up to 40 cm long; they are finely dissected, 
with the ultimate segments filiform, about 0.5 mm wide. The flowers are produced in terminal 
compound umbels 5—15 cm wide, each umbel section with 20—50 tiny yellow flowers on short 
pedicles. The fruit has an almost cylindrical shape with a rounded base and a narrower summit 
crowned with a large stylopod. It is generally 3 mm to 12 mm long and 3 mm to 4 mm wide. 
 
2.1 SYSTEMATICS 
Foeniculum vulgare Miller belongs to the Family Apiaceae (former Umbelliferae), the genus is 
represented by this species only, divided in two subspecies, ssp. piperitum and ssp. vulgare, the 
latter one forming three varieties, var. vulgare (bitter or medicinal fennel), var. dulce (sweet 
fennel) and var. azoricum (vegetable ‘Florentine’ fennel).  
Fennel is native to Southern Europe and South-West Asia. Indigenous to the Mediterranean 
region, it has spread inter alias to England, Germany, and even Argentina. Fennel is also found 
today in Iran, India and China. It is large scale cultivated e.g. in Egypt, India, China, Australia and 
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within Europe in France, Germany, Hungary, Poland and the Balkan countries and many 
different annual, biennial and perennial cultivars are known distinguished by their size of the 
fruits, the content and  the composition of the essential oil. 
 
2.2 PLANT PARTS AND PRODUCTS USED 
Apart from vegetable fennel bulbs, the ripe fruits and the essential oils are used commercially. 
The fruits are frequently distinguished into shorts and longs in commerce, the latter being the 
most valued. The odour of fennel seed is fragrant, its taste is warm, sweet and agreably 
aromatic. Fennel seeds consists of the dried, ripe fruits of Foeniculum vulgare. For medicinal use 
the fruits of the cultivated fennel, especially the Saxonian, Galician, Roumanian and Russian  
varieties, yield up to 6% volatile oil and these varieties are suitable for pharmaceutical use.  
 
The Fennel oil is the essential oil obtained from the dried, ripe fruits of Foeniculum vulgare by 
hydrodistillation.  
3. CHEMICAL CONSTITUENTS (CHEMICAL ANALYSIS, STANDARDIZATION) 
The principal constituents of Foeniculi aetheroleum (the oil obtained by steam distillation of the 
ripe fruits of Foeniculum vulgare Miller var. vulgare) are (Figure 1):  
Trans-anethol (50 – 75%)   
Fenchon (12 – 33%) 
Estragole (2 – 5%) 
 
O
CH3
a                                
O
CH3
 b                              
O
c 
Figure 1 Chemical structure of trans-anethole (a),  estragole (b)     and     fenchone(c) 
 
Additional components are: trans-ocimene  20 - 330 ppm, alpha-pinene  200 - 8820 ppm, 
camphor  10 - 180 ppm, estragole  64000 ppm, limonene  200 - 9420 ppm, linalool  1 - 2050 
ppm, myrcene  100 - 2700 ppm and other terpenes.  
Trans-anethole counts for the anise taste, estragole provides the sweetness, while fenchone 
gives the bitter taste. 
Fenchone is a colourless liquid possessing a pungent , camphoraceous odour and taste, and 
when present gives the disagreeable bitter taste to many of the commercial oils. It probably 
contributes to the medicinal properties of the oil, hence only such varieties of Fennel as contain 
a good proportion of fenchone are suitable for medicinal use. 
 
3.1 CHEMICAL ANALYSIS 
Separation and determination of the components of fennel oil can be achieved by either TLC or 
GLC (with mass spectrometry) (Ph.Eur. 5, 2005). International Standards specifications have 
been published for fennel seed (ISO 7927-1:1987) (Bilia A.R. et al., 2000). 
A novel and rapid headspace solvent microextraction followed by gas chromatography-mass 
spectrometry (HSME-GC-MS) for the analysis of the volatile compounds of Foeniculum vulgare 
Mill is described. The HSME-GC-MS method was simple, inexpensive and effective and can be 
used for the analysis of volatile compounds (Fang L. et al., 2006).  
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3.2 STANDARDIZATION, STABILITY 
Bitter fennel consists of the dry, cremocarps and mericarps of Foeniculum vulgare Miller sp. 
vulgare var. vulgare. It contains not less than 40ml/Kg of essential oil, calculated with reference 
to the anhydrous drug. The oil contains not less than 60.0 per cent of anethole and not less than 
15.0 per cent of fenchone (Ph.Eur. 5, 2005). 
 
Sweet fennel consists of the dry, whole fruits of Foeniculum vulgare Mill. subsp. vulgare var. 
dulce. It contains not less than 20 ml/kg essential oil, the oil contains not less than 80,0% 
anethole (ESCOP 2003).  
 
Commercial Fennel varies largely in quality , this being either due to lack of care in harvesting or 
deliberate adulteration. It may contain  much sand, dirt, stem tissues, weed seeds or other 
material, that it amounts to adulteration and is unfit for medicinal use or it may have had some 
of its oil removed by distillation.  
Much of the commercial oil is adulterated with oil from which the anethol or crystalline 
constituent has been separated. Good oil will contain as much as 60% of anethol. 
The Foeniculum oil is stored in a well-filled, airtight container, protected from light and at a 
temperature not exceeding 25°C (Ph.Eur. 5, 2005). 
4. PHARMACOLOGY 
Fennel oil and seeds are approved by ESCOP (2003) for the following indications: 
Catarrh of the upper respiratory tract, cough, and dyspeptic complaints. In the traditional 
medicine, the herb was used for fish tapeworms, skin conditions and for various eye complaints, 
including conjunctivitis. Fennel honey is used for catarrh of the upper respiratory tract in 
children.  
 
EFFECTS ON THE GASTROINTESTINAL TRACT 
Fennel and its herbal drug preparations are widely used for dyspeptic complaints such as mild, 
spasmodic gastric-intestinal complaints, bloating and flatulence (Chakurski, I. et al., 1981). 
Different studies had shown that the extract of Foeniculum vulgare is effective in the treatment 
of colic in breastfed infant (Savino F. et al., 2005).  
 
4.1 IN VITRO STUDIES 
Antioxidant activity 
The antioxidant activity of the aqueous extracts of fennel (Foeniculum vulgare) was investigated 
in comparison with the known antioxidant ascorbic acid in vitro studies. The amount of aqueous 
extract of fruits and ascorbic acid needed for 50% scavenging of superoxide radicals was found 
to be 205 μg (fennel) and 260 μg  (ascorbic acid). The amount needed for 50% inhibition of lipid 
peroxide was 4600 μg (fennel) and 5000 microg (ascorbic acid). The quantity needed for 50% 
inhibition of hydroxyl radicals was 700 microg (fennel) and 4500 microg (ascorbic acid). The 
daily intake may be beneficial as food additives (Satyanarayana S. et al, 2004). 
 
4.2 ANIMAL STUDIES 
Antinflammatory, analgesic and anti-platelet activity 
F. vulgare is claimed to have an effect in relieving inflammation. In an in vivo study with mice, 
oral administration of Foeniculum vulgare fruit methanolic extract exhibited inhibitory effects 
against acute and subacute inflammatory diseases and type IV allergic reactions and showed a 
central analgesic effect (Choi E.M. et al, 2004).  
The extract has shown also antioxidant effects, reducing malondialdehyde (MDA) (as a measure 
of lipid peroxidation) level and increasing plasma superoxide dismutase (SOD) and catalase 
activities (Ruberto G. et al, 2000).  
An effect of oil of Foeniculum vulgare on hemostasis has been evidenced, with a significant 
correlation with its phenylpropanoid content (Stashenko E.E. et al, 2002). 
 
Bronchodilatatory effects 
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The relaxant effects of aqueous and ethanol extracts and an essential oil from Foeniculum 
vulgare were compared to negative controls (saline for aqueous extract and essential oil and 
ethanol for ethanol extract) and a positive control (diltiazem) using isolated tracheal chains of 
the guinea pig precontracted by methacholine and KCl. The results confirmed the 
bronchodilatory effects of ethanol extract and essential oil from Foeniculum vulgare. The effect 
doesn’t appear to be related to a inhibitory effect of ethanol extracts and essential oil from 
Foeniculum vulgare on calcium, but suggest a potassium channel opening effect for this plant, 
which may contribute on its relaxant effect on guinea pig tracheal chains (Boskabdy M.H. et al, 
2004). 
 
Hepatoprotective effects 
Hepatoprotective activity of Foeniculum vulgare essential oil was studied using carbon 
tetrachloride (CCl4) induced liver injury model in rats. The results of this study indicate that 
Foeniculum vulgare essential oil has a potent hepatoprotective action against CCl(4)-induced 
hepatic damage in rats with evidence of decreased levels of serum aspartate aminotransferase, 
alanine aminotransferase, alkaline phosphatase and bilirubin (Ozbek H. et al, 2003). 
 
Effects on vascular system  
An intravenous administration of the lyophilized water extract of leaves produced a significant 
dose-related reduction in arterial blood pressure, without affecting the heart rate or respiratory 
rate. The hypotensive effect appeared not to be mediated via adrenergic, muscarinic, ganglionic 
or serotonergic receptors, while histamine antagonists inhibited the hypotensive effect in a 
dose-related manner (Abdul-Ghani). 
In another study the hypotensive effects of the water extract of Foeniculum vulgare were 
investigated in hypertensive and normotensive rats. After oral administration Foeniculum 
increased water, sodium and potassium excretion, suggesting that it has not a vascular relaxant 
activity, but it appeared to act mainly as a diuretic and a natriuretic (El Bardai S. et al, 2001).  
 
Effects on reproductive system 
The main constituent of the essential oils of fennel and anise, anethole, has been considered to 
be the active estrogenic agent. Foeniculum vulgare has been traditionally used as estrogenic 
agent. It has been reputed to increase milk secretion, promote menstruation, facilitate birth, 
alleviate the symptoms of the male climacteric, and increase libido (Albert-Puleo M. 1980). 
The estrogenic activity of the seed extract was confirmed in an in vivo study with male and 
female rats. Following the oral administration of acetone extract of Foeniculum vulgare seeds 
for 15 days is male rats, total protein concentration was found to be significantly decreased in 
testes and vas deferens and increased in seminal vesicles and prostate gland. In female rats, 
oral administration of the extract for 10 days led to vaginal cornification and oestrus 
cycle(Malini T. et al, 1985).  
While moderate doses caused increase in weight of mammary glands, higher doses increased 
the weight of oviduct, endometrium, myometrium, cervix and vagina (Annusuya S. et al, 1988). 
 
4.3 HUMAN STUDIES 
Effects in infantile colic 
Fennel seed oil has been shown to reduce intestinal spasms and increase motility of the small 
intestine. The use of fennel oil emulsion eliminated colic in 65% (40/62) of infants in the 
treatment group, which was significantly better than 23.7% (14/59) of infants in the control 
group (P < 0.01). Side effects were not reported for infants in either group during the trial. The 
study suggests that fennel seed oil emulsion is superior to placebo in decreasing intensity of 
infantile colic (Alexandrovich I. et al, 2003). 
 
4.4 ADME 
Few pharmacokinetic data are available for Foeniculum vulgare. Some information is found in 
literature on its main constituent. Trans-anethole is rapidly absorbed and distributed in the rat 
and in the mouse. The main metabolites found in urine are p-hydroxypropenylbenzene, p-
methoxyhippuric acid, p-hydroxycinnamic acid, and p-methoxybenzoic acid, mainly as 
glucuronides and sulfates. Trans-anethole is hydroxylated at the 3'-carbon by hepatic 
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microsomes from rats and mice. A study carried out on five human subjects given a 500 mg 
dose the 24-hour metabolites were anisic acid (52%) and p-hydroxybenzoic acid (5%) and trans-
anethole was not detectable in the blood. 
Few pharmacokinetic data are available for Foeniculum vulgare. Some information is found in 
literature on its main constituent. Trans-anethole is rapidly absorbed and distributed in the rat 
(Le Bourhis, 1973; Fritsch et al., 1975) and in the mouse (Le Bourhis, 1968; Strolin-Benedetti & 
Le Bourhis, 1972; Le Bourhis, 1973). The main metabolites found in urine are p-
hydroxypropenylbenzene, p-methoxyhippuric acid, p-hydroxycinnamic acid, and p-
methoxybenzoic acid, mainly as glucuronides and sulfates. Trans-anethole is hydroxylated at the 
3'-carbon by hepatic microsomes from rats and mice (Swanson et al., 1981). A study carried out 
on five human subjects given a 500 mg dose the 24-hour metabolites were anisic acid (52%) 
and p-hydroxybenzoic acid (5%) and trans-anethole was not detectable in the blood (Le Bourhis, 
1973). 
5. MICROBIOLOGY 
Antibacterial activity 
The antimicrobial properties of essential oils obtained from Foeniculum vulgare have been 
investigated in different trails. The oil has been shown to be effective against Streptococcus 
haemolyticus, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella 
species (Sigh G. et al., 2002), (Lo Cantore P. et al., 2004), (Kwon Y.S. et al., 2004). Another study 
has shown an activity against the foodborne pathogens Escherichia coli O157:H7, Listeria 
monocytogenes, Salmonella typhimurium, and Staphylococcus aureus (Dadalioglu I. & 
Evrendilek G.A., 2004).  
The methanol extract of fennel, as other plant species used traditionally to treat gastrointestinal 
disorders, were assessed for their effect on the growth of Helicobacter pylori in vitro. A MIC of 
50 µg/mL was assessed (Mahady G.B. et al., 2005).  
 
Antifungal activity 
Fennel oil possesses a strong antifungal activity. According to the results of a study carried out 
on Aspergillus spp., Penicillium spp., Trichoderma viride, Cladosporium cladosporioides, 
Fusarium tricinctum, the observed antifungal activity of all the investigated oils can be 
attributed to the main compound, trans-anethole (Mimica-Dukic N. et al., 2003), (Abu-Jawdah Y. 
et al., 2002). 
 
Repellent properties 
The repellent activity of materials derived from the methanol extract of fruits from Foeniculum 
vulgare against hungry Aedes aegypti females was examined using skin and patch tests. 
Responses varied according to compound, dose, and exposure time, but fenchone was found as 
potential mosquito repellent agent (Kim D.H. et al., 2002).  
Another study showed that fennel oil-containing aerosol and cream produced 84% and 70% 
repellency, respectively, at 90 min after exposure against mosquito belonging to the genera 
Culex, Anopheles, Aedes  and Armigeres (Kim S.I. et al., 2004).   
Acaricidal activities of components derived from Foeniculum vulgare fruit oil were found against 
Dermatophagoides farinae and Dermatophagoides pteronyssinus after direct contact 
application (Lee H.S. 2004). 
 
6. EFFICACY 
6.1 QUALITY OF THE ANIMAL PRODUCT 
In a study, three-hundred unsexed day-old Arbor Acres broiler chickens were fed with a 
commercial diet or diets enriched with fennel at 1%. At 35 days of age, each group was divided 
into 2 equal subgroups, where the first was placed under normal conditions (24 deg C) and the 
second was exposed to 38 deg C for 3 h to 6 days from 35 to 40 days of age. It was shown that 
adding fennel as natural feed additives to broiler diets under normal or high temperature 
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conditions increased (P<0.05) live body weight, liveweight gain, feed conversion, total plasma 
protein, serum albumin, globulin, plasma glucose and triiodothyronine (T3) values and 
decreased mortality rate, plasma cholesterol, plasma total lipids, alanine aminotransferase and 
aspartate aminotransferase (P<0.05). Creatinine and weights of the liver, spleen, bursa fabricii 
and intestine were not affected by the additives. Also, there was a significant (P<0.05) decrease 
in respiration rate and body temperature and a minimal increase in blood pH during heat 
exposure. There was a decrease (P<0.05) in body weight, liveweight gain, feed consumption, T3, 
plasma glucose and the total plasma proteins and an increase (P<0.05) in mortality rate, body 
temperature and respiration rate corresponding to high temperature conditions (Tollba A.A.H. 
2003). 
7. TOXICOLOGY 
Concerning the acute toxicity of the main costituents of Foeniculum vulgare, the oral LD50 of 
trans-anethole are 3.05 g/kg bw, 2.09 g/Kg bw and 2.16 g/kg bw for mce, rats and rabbits 
respectively. For trans-anethole intraperitoneal LD50 values are 1.41 and 2.67 g/kg bw for mice 
and rats respectively. Cis-anethole is 10 to 20 times more toxic than trans-anethole but the 
content in the oil is very low. Rabbits and dogs tolerate 3 g anethole per Kg bw without any toxic 
manifestation. With respect to long-term toxicity, no data for the oil are available. A one year 
feeding study  showed that the NOEL for rats is 125 mg anethole/Kg. (EMEA/MRL/418/98).  
No data are available on acute, sub-acute and sub-chronic toxicity of estragole. In 2000 the 
Committee of Experts on Flavouring Substance (CEFS) of the Council of Europe evaluated 
estragole and recommended a limit of 0.05 mg/Kg (detection limit) (EMEA/HMPWP/338/03).  
Long term studies were carried out on mice and rats. There was a reported statistically 
significant increase in the incidence of benign hepatocellular adenomas and hepatocellular     
carcinomas in female rats receiving 1% trans-anethole, but it was within the range of 
spontaneous incidence of similar lesions. In a series of experiments was performed to 
investigate the carcinogenic potential of trans-anethole in mice trans-anethole produced no 
different results from controls in necropsy histological evaluations .  
The mutagenic activities of anethole and its metabolites were studied using different bacterial 
strains, and using a mouse micronucleus assay. A study indicated that trans-anethole showed 
mutagenic activity in the Ames S. typhimurium assay but was inactive in a B. subtilis Rec assay 
and was negative in an E. coli uvr A reversion test.  
In another study no mutagenic activity was observed at concentrations of up to 50 µg trans-
anethole/plate but the addition of 3'-phosphoadenosine-5'phosphosulphate to the microsomal 
assay markedly increased the mutagenicity of trans-anethole. Negative results were also 
obtained in a mouse micronucleus assay after oral or intraperitoneal administration.  
No reproduction and teratogenicity studies are available for the compound. 
The mutagenicity of estragole, another constituent of fennel essential oil is reported (De 
Vincenzi et al., 2000) as well as its carcinogenic potential in rodents (Smith et al., 2002). 
However, this flavouring agent has a clear threshold for carcinogenicity in animals that is well 
above the levels currently approved for use in foods (Waddell, 2002). 
 
 
7.1 SAFETY 
No data in literature suggest possible adverse effects in animals due to continuative assumption 
of Foeniculum Vulgare  as flavouring agent in feed. In the United States of America trans-
anethole and fenchone are included in the GRAS-list (generally considered as safe) by the FDA.  
No safety concern at current levels of intake when used as a flavouring agent. An ADI of 0.6 
mg/kg bw for trans-anethole has been established by JECFA. A fenchone concentration of 5 
mg/kg in food is permissible. 
 
Dosage  
The oil of Foeniculum vulgare (Foeniculi aetheroleum) is contained in two veterinary medicinal 
products. One product is intended to be used as nose-spray to facilitate breathing in new born 
animals of all food producing species in a dose of 0.1 to 0.3 g (corresponding to a dose of 0.015 
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mg Foeniculi aetheroleum). The other product, containing 1% Foeniculi aetheroleum, is intended 
for the oral treatment of gut disorders, in a maximal dose of 15 mL (corresponding to 150 mg 
Foeniculi aetheroleum). The product is targeted to cattle, horses, pigs, sheep and goat.  
Foeniculi aetheroleum is included in Annex II of Council Regulation (EEC) N. 2377/90 as a 
substance that does  not need a MRL level. 
 
Interaction 
A significant interaction between fennel and ciprofloxacin was observed in a study. Absorption, 
distribution and elimination of ciprofloxacin were all affected. These changes might be because 
of the formation of a more lipophilic ciprofloxacin chelate in the presence of relatively large 
amounts of metal cations in fennel (Zhu et al., 1999). 
DT/SG/LG/AT 
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GAULTHERIA PROCUMBENS 
 
Gaultheria procumbens 
 
1. INTRODUCTION 
Gaultheria procumbens is a plant native of the United States and source of an essential oil. Once 
a popular flavoring in candies and chewing gums, wintergreen has also enjoyed long use as a 
herbal remedy. The first record of the therapeutical use of this oil, as is often the case with 
valuable medicines, is to be found in empirical medicine. Indian people, including the Sioux, 
Penobscot and Nez Perce nations, use wintergreen tea to treat arthritis pain and sore muscles. 
Later, the settlers used the leaves of the herb for similar purposes, as well as to alleviate 
headaches and colds. The proprietary remedy, very popular about the beginning of last century 
under the name "Panacea of Swaim," or "Swaim's Panacea," introduced it. The essential oil of 
Gaultheria procumbens (oil of wintergreen) is marketed for the external treatment of neuralgia, 
myalgia, arthralgia and other pains. The oil is a colourless to yellowish liquid with a 
characteristic ‘wintergreen’ odour, slightly soluble in water, soluble in organic solvents and oils. 
2. DESCRIPTION OF THE PLANT 
Wintergreen is a small, procumbent, evergreen shrub, up to 15-20 cm high, with slender 
creeping stem giving rise to erect branches, bearing towards their ends 3-8 leaves. The leaves 
are alternate, thick, toothed, glossy, lanceolate, 2,5 – 5 cm long and dark green. The flowers are 
white, bell-like, often with a touch of pink, in 2 or 3 flower umbels. The fruit is a berry, reddish 
violet, globose, 6-9 mm long, minty, with a rather spongy texture. The seeds are orange-yellow, 
wedge shaped, 1-1.3 mm long, 0.8-1 mm wide, wingless. 
 
2.1 SYSTEMATICS 
Wintergreen, Gaultheria procumbens, belongs to the Ericaceae family. 
The plant, native of North America, is distributed from Alaska to Newfoundland (Kron et al., 
1999). 
Other common names include Box Berry, Checkerberry, Deerberry, Eastern Teaberry, Ground 
Holly, Mountain Tea, Creeping Wintergreen, Ground Tea, Partridge-Berry, Petit the du bois 
(Quebec, "little tea of the woods"), Redberry Wintergreen, Spice Berry, Teaberry, Winisibugons 
(Ojibwe, "dirty leaf"). 
 
2.2 PLANT PARTS AND PRODUCTS 
The leaves of G. procumbens are used for the extraction of the essential oil known as 
“wintergreen oil”.  
Almost the same oil can be obtained from sweet birch (Betula lenta L.). 
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3. INGREDIENTS/CONSTITUENTS (CHEM. ANALYSIS, STANDARDIZATION) 
Gaultheria procumbens is a source of "wintergreen oil," which is used as a flavoring in candies, 
chewing gum, and some medicine. The oil is extracted from the leaves, previously macerated in 
water, by steam distillation. The leaves contain an odorous volatile oil, which may be obtained in 
the same manner as oil of peppermint. The specific gravity of the oil is 1.173 at 10° C. (50° F.). 
It is colorless at first, but subsequently becomes more or less of a pinkish color, has a hot and 
aromatic taste. The main chemical components of wintergreen oil are methyl salicylate and 
gaultherin. 
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Figure 1. Chemical structure of methyl salicylate (a) and gaultherin (b). 
The dried leaves are used as a tea or as flavouring agent. 
According to Ribnicky et al. (2002) wintergreen contains 10 mg/g FW of total salicylate - the 
highest levels observed in plants. The level of free salicylate and methyl salicylate were 
significantly less in the intact leaves of wintergreen. High levels of total salicylate were also 
observed in flowers, stems and berries of the plant. The salicylate was present predominantly as 
a derived form of methyl salicylate called gaultherin. 
The following species also contain gaultherin: G. acuminata, G. fragrantissima, G. leucocarpa, G. 
punctata, G. rudis, G. cuneata, G. griffithiana, G. hookeri, G. itoana, G. yunnanensis. 
Methyl salicylate determination can be achieved by sodium hydroxide titration according to the 
European Pharmacopoiea (01/2005:0230). 
The application of a 2H NMR method in determining the naturalness of an important flavor, 
methyl salicylate, has been proposed by Le Grand et al. (2005). Extraction was performed on dry 
wintergreen leaves. One kilogram of raw material was left to soak overnight with 10 L of warm 
water. Such maceration causes hydrolysis of the primeveroside of methyl salicylate (also known 
as gaultherin) and frees methyl salicylate, the chief constituent of wintergreen oil (95-99%). In 
fact, methyl salicylate does not occur in the plant in the free form, but as a glycoside. The 
distillate obtained over 6 h was separated by condensation. Distillation was ended by the 
addition of 40 mL of cyclohexane. The aqueous phase was extracted two times by 50 mL of 
cyclohexane. Cyclohexane phases were combined and concentrated under N2 flow. The purity of 
samples was checked by 1H NMR. 
4. PHARMACOLOGY 
4.1 ANIMAL STUDIES 
The pharmacological properties of Gaultheria are due to its content in methyl salicylate and its 
derivative gaultherin, that have antinflammatory and analgesic properties. The mechanism of 
action of the salicylates is based mainly on the inhibition of the cyclo-oxygenase enzyme that 
intervenes in the synthesis of prostanoids from arachidonic acid, just as all salicylic acid 
derivatives. They also inhibit the release of PGF2a and PGE2 from thrombin-stimulated platelets 
as well as the synthesis of thromboxanes and favour the production of prostacyclin PGI2 
(Atkinson and Collier, 1980; Amann and Peskar, 2002; Vane and Botting, 2003; Zhang et al., 
2006). 
The glycoside gaultherin has also been studied for its analgesic and anti-inflammatory effects 
and it has less adverse effect then other salicylates. Gaultherin (200 mg/kg, orally) significantly 
Gaultheria 
----------------------------------------------------------------------------------------------------------------- 
 
 118
inhibited the abdominal contractions in the acetic acid-induced writhing test in mice. The anti-
inflammatory effect of gaultherin was demonstrated in the croton oil-induced ear edema model 
in mice, after oral administration: gaultherin (400 mg/kg/day, for 3 days) and equimolar dose 
of aspirin (200 mg/kg/day, for 3 days) produced comparable inhibitory effects. Gaultherin has 
less negative effects on gastric mucosa with respect to aspirin: no lesion was observed in the 
stomach when gaultherin (100 mM; 330 mg/kg) was given orally to mice. The reason could be 
that gaultherin released salicylate in intestine slowly, not in stomach and it left the 
cyclooxygenase-1 unaffected, which was the source of cytoprotective prostaglandins in gastric 
epithelium (Zhang et al., 2006). 
The main component of Gaultheria procumbens, methylsalicylate, is used in cattle, horses, 
sheep, goats and poultry. It is used topically in emulsion in the treatment of muscular and 
articular pain. The recommended dose is 600 μg/kg bw twice a day. The duration of treatment 
is usually less than one week (EMEA/MRL/696/99, 1999). It is included in Annex II of Council 
Regulation (EEC) N. 2377/90 as a substance that doesn’t need a MRL level. 
Gaultheria procumbens contains a glycoside that, when hydrolyzed, releases methyl salicylate. 
Gaultheria procumbens has not to be used as flavouring in pet food since salicylates are toxic to 
dogs and cats. Since cats metabolize salicylates much more slowly than other species they are 
more likely to be overdosed. Use of methylsalicylate in combination with anticoagulants such as 
warfarin can result in adverse interactions and bleedings (Chow et al., 1989, Ramanathan, 
1995, Tam et al., 1995, Yip et al., 1990). 
 
4.2 HUMAN STUDIES 
Even though the use of wintergreen oil as a topical anti-inflammatory is quite common in 
human medicine, there’s a lack of scientific literature on the efficacy on human patients. 
Human studies have been focused mainly on the toxicology and pharmacokinetics, and are here 
reported in the corresponding sections. 
 
4.3 ADME 
In rats, after oral administration of 500 mg methylsalicylic acid/kg bw, the drug is nearly 
completely hydrolysed to salicylate within 1 hour and at this time the concentrations of free 
salicylates in plasma and brain were 278 and 42 μg/ml. These levels are similar to those 
observed after the administration of acetylsalicylic acid. A similar pattern of hydrolysis has been 
also observed in dogs (EMEA/MRL/696/99, 1999). 
The liver is the main site of methyl salicylate hydrolysis in rats, rabbits, dogs and monkeys 
(EMEA/MRL/696/99, 1999). In dogs 0.2 to 0.5% of an oral dose and 14% of an intramuscular 
dose are excreted as unchanged methylsalicylic acid in the urine. Rabbits excrete 
methylsalicylic acid mainly as glucuronate (12 to 55%) but also as sulphate (10%) conjugate 
(Behrendt et al., 1989). 
Methyl salicylate is extensively metabolised to salicylic acid in dermal and subcutaneus tissues 
following topical administration. 
In humans approximately 12 to 20% of topically applied methylsalicylic acid is systemically 
absorbed within 10 hours of application (Martin et al., 2004, Morra et al., 1996, Pratzel, 1990). 
When methylsalicylic acid was given orally to 6 healthy adults, about 21% of unhydrolysed ester 
was present in plasma after 90 minutes. In a case of an accidental oral intake of wintergreen oil 
21% was present in the circulation after 1.5 hours (EMEA/MRL/696/99, 1999). After 
application of a topical formulation containing 20 % methylsalicylate on rat skin, the compound 
penetrated into underlying tissues (dermis, subcutaneous and superficial muscle) reaching a 
maximum concentration in the first hour after the treatment. Furthermore, salycilates were 
cleared in the systemic circulation where their concentration rose rapidly after 1 hour (Cross et 
al., 1999). No data on oral bioavailability are available. 
Studies on the metabolism of gaultherin showed that after administration of a single dose of 
gaultherin (200 mg/kg in mouse, 140 mg/kg in rat), the parent compound was not detected in 
plasma of mice and rats, but it has been found that the concentration of a metabolite of 
gaultherin was increasing in the first few hours after administration. The metabolite was 
demonstrated to be salicylate in animals by HPLC and it was the only metabolic product of 
gaultherin. The maximum plasma concentration (Cmax) of salicylate in mouse and rat was 60 
and 70 μg/ml, respectively and the time to reach Cmax (Tmax) was 5 and 7.5 h after dosing. 
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However, it has been reported that the concentration of salicylate in the gastric mucosa and 
blood rose promptly after administration of aspirin and the peak was reached within 1 h before 
declining rapidly. The results showed that gaultherin was a pro-drug and could be metabolically 
converted to the active salicylate slowly (Zhang et al., 2006). 
After incubation with intestinal microflora in anaerobic conditions, the concentration of 
gaultherin declined slowly and the metabolite was identified as methyl salicylate by HPLC. The 
results suggested that orally administered gaultherin was hydrolyzed by glycosidase from 
intestinal bacteria to produce methyl salicylate, the aglycone from which the sugars of the 
administrated compound had been removed, and then absorbed. 
The ester linkage of gaultherin had to be hydrolyzed to give the final salicylate. Gaultherin was 
incubated with animal and human plasma which contained plenty of esterase to investigate 
whether it can be hydrolyzed by esterase. The results showed the ester linkage could be cleaved 
by esterase to produce the final salicylate metabolite. These results strongly suggested that 
orally administered gaultherin did not act by being directly absorbed and metabolized to 
salicylate in the liver, but rather only after it was transformed into methyl salicylate by intestinal 
bacteria and then the absorbed methyl salicylate was hydrolyzed rapidly by esterases in 
intestine, blood and liver to produce salicylate (Zhang et al., 2006). 
5. MICROBIOLOGY 
Essential oils and extracts from Gaultheria spp. have been studied for their antibacterial activity. 
A significant inhibitorial effect was found for extracts of Gaultheria leucocarpa var. yunnanensis 
against Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Anti-bacteria 
test with extracts of water, acetic ester and n-butanol showed that 3 extracts from 22 samples 
had anti-Staphylococcus aureus action, and the extracts from root and stem showed the same 
result. 2 extracts could kill Escherichia coli and Pseudomonas aeruginosa, suggesting that not 
only essential oil but also other ingredients have antibacterial activity. Anti-fungi test of the 
same extracts was also performed but didn't indicate remarkable action (Ma et al., 2001a,b).  
6. EFFICACY 
Methyl salicylate is  used as a flavouring agent for food, beverages and tooth powders, liquid 
dentifrices, etc. No safety concern at current levels of intake when used as a flavouring agent. 
The JECFA established ADI is 0,1-0.5 mg/kg bw (JECFA, 2001). 
Other species of Gaultheria have been studied for their antioxidant properties, attributable to 
their content in polyphenols like catechins. Catechins are recognized to have antioxidant 
properties that can confere an antioxidant protection to meat products, thus improving their 
quality and shelf life (Tang et al., 2000, Tedesco et al., 2004). 
It has to be taken into account that the use of methylsalicylate for topical application in 
combination with anticoagulants such as warfarin can result in adverse interactions and 
bleedings (Chow et al., 1989; Yip et al., 1990; Tam et al., 1985; Ramanathan, 1995). 
7. TOXICOLOGY 
The acute oral toxicity of methylsalicylic acid has been investigated in several animal species. 
Oral LD50 values of 1110 mg/kg bw in mice, 887 and 1250 mg/kg bw in rats, 2100 mg/kg bw 
in dogs, 1300 and 2800 mg/kg bw in rabbits have been reported (Davison et al., 1961, Taylor et 
al., 1964) Administration of 600 to 4700 mg/kg bw of methylsalicylic acid to dogs produced 
nausea, vomiting, intense hyperpnoea, excitation of the nervous system, diarrhoea and a 
hypermetabolic state as a result of uncoupling of oxidative phosphorylation 
(EMEA/MRL/696/99, 1999). 
In dogs methylsalicylic acid given at doses of 0, 50, 150, 250, 500 and 800 mg/kg bw for up to 
10 weeks, induced weight loss, liver fatty degeneration and death at doses of 500 mg/kg bw or 
higher. No adverse effects were noted after doses as high as 250 mg/kg bw. As only summary 
information was available no NOEL could be established (EMEA/MRL/696/99, 1999). 
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Chronic toxicity studies were performed in rats and dogs. In dogs, growth retardation, liver 
enlargment with enlarged hepatocytes were observed at doses of 150 mg/kg bw or more. In 
rats, the dose of 500 mg/kg bw induced signs of toxicity, such reduced growth rate, increase in 
relative eight of testes, heart and kidneys, while gross pituitary lesions were observed in animals 
treated with 250 mg/kg bw (EMEA/MRL/696/99, 1999). 
In hamsters methylsalicylic acid was also found to provoke teratogenic effects at both high oral 
doses (1750 mg/kg bw) and high topical doses (1750 to 14000 mg/kg bw) 
(EMEA/MRL/696/99, 1999). 
 
7.1 SAFETY 
No informations are available in literature about quality of food products derived from animals 
fed/treated with G. procumbens or wintergreen oil respectively. 
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GENTIANA LUTEA 
 
  
Gentiana lutea L  
 
1. INTRODUCTION 
All species belonging to the genus Gentiana have intense bitter properties residing in the root 
and herbage. The most commonly used species is Gentiana lutea L., the Yellow Gentian. Gentian 
root has a long history of use as an herbal bitter in the treatment of digestive disorders and is an 
ingredient of many proprietary medicines. In some pharmacopoeias Gentiana asclepiada L., 
Gentiana pannonica SCOP., Gentiana punctata L. and Gentiana purpurea L. have been used as 
substitutes. Its name is derived from Gentius, King of Illyria (180-167 BC) who discovered the 
plant's healing value. It was used in the Middle Ages as an antidote to certain poisons. Gentian 
root contains some of the most bitter compounds known and is used as a scientific standard for 
measuring bitterness. Other names include Yellow Gentian, Bitter Root, Bitterwort, Centiyane, 
and Genciana. 
 
2. DESCRIPTION OF THE PLANT 
Gentaina lutea L. is a perennial plant growing at least up to 1 m. The adult plants have thick 
roots and rhizomes, which function as storage organs. The broad lanceolate to elliptic leaves are 
deeply veined, 12-25 cm long and 4-10 cm broad. Most of them belong to a basal rosette until 
flowering. It is important to realise that Gentiana lutea L. has opposite leaves differing from the 
highly toxic Veratrum album [Garnier et al., 1985; Zagler et al., 2005]. Gentiana lutea L. has 
brightly yellow trumpet-shaped flowers, which are arranged in terminal and axillary clusters. The 
terminal flowers are mostly pentamerous, i.e. with 5-7 corolla lobes (petals) and 5 sepals 
without folds between lobes. This is one of the few species in Gentiana that has rotated, very 
deeply divided corollas and no glandular disk at the base of the ovary.  
Gentiana differs from Gentianella (see below 2.1) in that it has plicae (thin folds between corolla 
lobes), intracalycine membrane on the calyx (thinner areas between the calyx lobes) and a disk 
at the base of the ovary. 
 
2.1 SYSTEMATICS 
Gentiana lutea L. belongs to the genus Gentiana comprising more than 400 species. The 
description of this large genus has changed considerably, since various species have been 
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repeatedly excluded and included from the genus [Struwe et al., 2002]. Two genera that earlier 
belonged to Gentiana were separated into Gentianella and Gentianopsis.  
 
2.2 OCCURRENCE 
Gentian species are wide-spread in the alpine habitats of Europe, Asia and North America. Some 
species also occur in northwest Africa, eastern Australia and New Zealand. Gentiana lutea L. 
grows in the mountains of central and southern Europe up to the altitude of 2500 m. In Italy, it 
is relatively frequent in the pastures of Western and Central Alpine and Subalpine plains [Buffa 
et al., 1991]. The most important crops originate from collections of wild plants in Spain and 
Switzerland. To a smaller extend Gentiana is cultivated in France and Germany. 
 
2.3 PLANT PARTS AND PRODUCTS  
The medicinal parts of Gentiana lutea L. are the dried, underground parts of the plant. 
Sometimes the fresh, above-ground parts are used. The best quality crude drug for medicinal 
use is harvested either in autumn, at the end of the vegetative cycle, or in spring before the 
plants start sprouting. After harvesting, the roots are quickly dried and then left to season for at 
least 6 – 8 months until they are yellow or yellow-brown in colour [Buffa et al., 1991].  
Commercial gentian root extracts are normally obtained by percolation with about 60-70% 
ethanol in water, yielding extracts with the characteristic bitter taste and aroma. To facilitate 
solute diffusion and increase the extraction yield pre-treatment of the material with pectolytic 
enzyme preparations has been proposed [cited in: Arino et al., 1997]. 
 
3. INGREDIENTS/CONSTITUENTS 
The roots and rhizomes accumulate a variety of compounds such as soluble carbohydrates (30-
50% on dry weight), mainly gentianose and sucrose and a smaller percentage of glucose, 
fructose and gentiobiose [Franz et al., 1985; Rossetti et al., 1984], lipids (6-7% on dry weight) 
and insoluble carbohydrates, mainly pectin. Important constituents of gentian are the 
secoiridoid bitter constituents amarogentin (0.05-0.15%; bitter index: 58 x 106; Figure 1A), 
gentiopicroside (2.5-3.5%; Figure 1B), swertiamarin (0.15-0.20%; Figure 1C) and sweroside (< 
0.1%; Figure 1D). The latter compounds have a bitter index of 12 x 103. Recently another bitter 
principle was identified as loganic acid in Gentiana lutea L. for the first time [Carnat et al., 
2005]. Since the bitter compounds are located in the rhizoderm, their contents are highest in 
the younger, thinner roots, whereas in older roots gentiopicroside is dominating [Buffa et al., 
1991]. 
The root and rhizome also contain small quantities of free amino acids [Rossetti et al., 1984], 
essential oil, mainly composed of limonene, linalool, carvacrol, cis-linalyl oxide and α-terpineol 
[Arberas et al., 1995; Arino et al., 1997; Chialva et al., 1986], polyphenolics, i.e. gentianine 
gentioflavin and the xanthones gentisin, isogentisin and gentioside. Gentian root is devoid of 
starch and ash content ranges from 3 to 4%. 
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Figure 1 Structures of the bitter principle of gentian (A: amarogentin; B: gentiopicroside;  
  C: swertiamarin; D: sweroside)      
        
 
 
Several studies dealt with the composition of the aerial parts of Gentiana lutea L.. Hostettmann 
et al. (1973) reported the presence of isogentisin and two flavonic heterosides (isoorientin-4´-O-
glucoside and isovitexin-4´-O-glucoside) in the leaves of Gentiana lutea L.. Mangiferin has been 
found in the aerial parts [Lubsandorzhieva et al., 1986] showing antioxidative, antidepressant 
and other pharmacological activities [Born et al., 1996; Ghosal et al., 1996, 1975]. In a recent 
study the chemical composition and seasonal variations in the amounts of secondary 
compounds in Gentiana lutea L. leaves and flowers has been investigated by means of HPLC 
[Menkovic et al., 2000]. Additionally, seasonal variations in the contents of the individual 
components were observed. It could be concluded that during flowering, leaves are rich in 
compounds possessing C-glycoside structures while O-glycoside structures accumulate mainly 
before flowering. The accumulation of secoiridoids (Gentiopicroside, Swertiamarin) more or less 
constantly increased during the vegetation period reaching the maximum in October.  
 
3.1 CHEMICAL ANALYSIS 
The bitter principles amarogentin and gentiopicroside are extracted with aqueous alcohol. 
Maximum concentrations of amarogentin and gentiopicroside were obtained with ethanol: 
water 55: 45 (v/v). With ethanol: propylene glycol: water 20: 20: 60 (v/v/v), the yields of bitter 
compounds were 5% lower for amarogentin and 16% lower for gentiopicroside. Using propylene 
glycol: water 30: 70 (v/v) the yields further decreased by 12% and 25%, respectively [Arino et 
al., 1997]. Identification and quantification is performed by HPLC and LC-MS at 233 and 270 
nm, respectively, using methanol and water as the mobile phase [Arino et al., 1997; Sticher and 
Meier, 1980; Wolfender et al., 1997; Wolfender et al., 1993]. Additional methods, e.g. TLC 
A 
B 
C 
D 
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densitometry, micellar electrokinetic capillary chromatography, were used for the quantification 
of the bitter principles [Bodart et al., 1996; Glatz et al., 2000; Krupinska et al., 1991]. 
Essential oils are determined by steam distillation of gentian roots. After fractionation on a silica 
gel column, individual compounds were characterised by GC and GC-MS [Arberas et al., 1995; 
Chialva et al., 1986].  
 
3.2 STANDARDIZATION, STABILITY 
According to DAB 10 (Ph. Eur) the identity of gentian roots is proved by DC as described by 
Wagner and Vasirian (1974). Gentian tinctures and dry extracts are similarly analysed by DC 
detection of gentianin which emerges from gentiopicroside in alkaline media [DAB 10; Floss et 
al., 1964].  
Dried gentian roots shall yield 30% of extract and have a bitter index of at least 103 according to 
DAB 10. DAB 10, ÖAB 90 and Helv VII require a bitter index of at least 102 and 30-40, 
respectively, for liquid preparations (tinctures, liquid extract). For dry extracts the bitter index 
ranges between 400-500 and at least 40,000, according to Helv II and ÖAB 90, respectively. 
Studies regarding the stability of gentian extracts and the bitter principles, respectively, are 
scarce. Air-drying of the gentian roots resulted in considerable hydrolysis of gentiopicroside 
caused by native enzymes. The degradation could be reduced by gentiopicroside stabilisation 
using alcohol vapours [Beguin, 1929; Beguin, 1928; Beguine-Golovine, 1927], thus enabling to 
prepare stabilised extracts. The stabilising effect of alcohol on the bitter principle of 
Gentianaceae could be confirmed by Ishida et al. (1973) proving 6 months stability. The impact 
of drying was also studied by Carnat et al. (2005). Artificial drying at 40°C was found to 
minimise the loss of iridoids (gentiopicroside, longanic acid, swertiamarin) resulting in the 
retention of bitterness of the fresh gentian roots. In contrast, natural drying caused marked 
changes and might therefore affect the flavour of gentian roots. 
Hayashi and Kosiro (1976) examined the stability of gentiopicroside and sweriamarin in 0.1 N 
NaHCO3. In this study, both constituents were readily degraded and only 12% of gentiopicroside 
and 14% of swertiamarin were retained after 7 days.  
4. PHARMACOLOGY 
Gentian roots and other intensively bitter plants have been used for centuries by herbalists in 
Europe as digestive aids. Other folk uses included the topical application on skin tumours, 
treatment of fevers and diarrhoea. Nowadays, the Commission E and the British Herbal 
Compendium recognised the bitter substances contained in the herb, particularly amarogentin, 
the essential active principle. The bitter compounds stimulate gustatory receptors in the taste 
buds, causing a reflex promotion of saliva, gastric juice and bile secretion, thereby stimulating 
appetite [Hartke and Mutschler, 1987; Schmid, 1966]. Additionally, the ingredients of the 
gentian root are anti-inflammatory, antiseptic, emmenagogue, febrifuge and refrigerant.  
The Commission E, the British Herbal Compendium and ESCOP approved the internal use of 
gentian root for digestive disorders, such as loss of appetite, flatulence, anorexia, atonic 
dyspepsia, gastrointestinal atony, and as a tonic and anti-emetic [Blumenthal et al., 1998; 
Bradley, 1992; ESCOP, 1997]. According to the German Standard Drug Authorisation digestive 
problems, such as insufficient production of gastric juice [Braun, 1997] are the accepted 
indication for infusions from gentian root. The external use or the use of the essential oils is not 
noted.  
 
4.1 ANIMAL STUDIES  
Gentiana lutea L. roots, particularly its bitter principles, caused an increasing secretion of saliva 
and digestive juices, thus alleviating digestive disorders. These pharmacological activities have 
been confirmed by animal studies. Gentian tincture orally administered to dogs in an 
experiment which prevented the tincture reaching the stomach, caused a 30% increase of 
gastric juice in comparison with untreated animals [Meier and Meier-Liebi, 1993]. Ethanol 
extracts of Gentiana lutea L. ssp. symphandra roots, containing 20.93% gentiopicroside, 5.27% 
swertiamarin and 2.55% swertioside, showed positive effects on bile production in rats. The bile 
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flow was decreased by CCl4 treatment. A single dose of the lyophilised extracts (500mg/kg) 
administered intraduodenally normalised the bile flow compared to control rats [Oeztuerk et al., 
1998]. Aqueous extracts of gentian directly stimulate acid production in cultured cells from rat 
gastric mucosa, causing a concentration-dependent 1.7-fold acid increase at 100 µg/mL 
[Gebhardt, 1997]. Gentian root extract perfused into the stomach of anaesthetised rats showed 
a dose-dependent increase of gastric secretion (12%, 27% and 37% higher than controls). At 
dosage of 0.5 mL/kg of the same gentian preparation the incidence of gastric ulceration in 
pyloric ligation tests in rats was not affected. Gentian root infusion orally administered to sheep 
at a daily dose of 5 g before feeding, produced a stimulant effect on secretion of enzymes in the 
small intestine [cited in: ESCOP, 2003]. Bronchosecretion in rabbits was elevated in comparison 
with control animals after administration of gentian root extract directly into the stomach over 
three days at a dosage equivalent of 12.6 mg/kg/day of dried root [Chibanguza et al., 1984]. 
Ozturk et al. (2002) investigated the effect of a methanol extract of Gentiana lutea L. ssp. 
symphyandra roots for its possible effect on the central nervous system of mice. They found that 
doses of 250 and 500 mg/kg (i.p.) of the methanol extract caused a significant increase in the 
swimming endurance test and exhibited slight analgesic activity, but no lethality in mice, 
suggesting some activity on the central nervous system. However, there was no evidence of 
sedation or muscular fatigue at the doses employed. The presence of gentiopicroside, 
swertiamarin and sweroside in the methanol extracts of Gentiana lutea L. roots, which were 
made responsible for the CNS, were proved by HPLC analyses.  
Amarogentin showed induction of detoxification enzymes, which was accompanied by 
significant reduction in lipid peroxidation and inhibition of incidence as well as multiplicity of 
dimethylbenzanthracene (DMBA) induced papillomas. Purified amarogentin enriched extracts 
significantly inhibited cell proliferation and induced apoptosis, suggesting the chemopreventive 
potential of active constituents from Gentianaceae [Saha et al., 2004]. 
Gentiopicroside, assumed to be the major antispasmodic component, was shown to inhibit the 
spontaneous contractions of isolated guinea pig ileum. Contractions of the ileum induced by 
histamine, acetylcholine, BaCl2 and KCl were also significantly blocked by this constituent which 
suggests that it might be interfering with calcium influx into the smooth muscle cells [Rojas et 
al., 2000]. Additionally, gentiopicroside treatment significantly suppressed the increase of the 
tumour necrosis factor (TNF), a major inflammatory mediator, in serum at the therapeutic doses 
(30-60 mg/kg/day for 5 consecutive days), suggesting that gentiopicroside protected against 
hepatitis by inhibiting the production of TNF [Kondo et al., 1994] 
 
4.2 HUMAN STUDIES  
Gentian root tincture (2 x 20 drops/day) was administered for 8 days to patients with 
inflammatory conditions of the gastrointestinal tract, colitis ulcerosa, morbus Crohn and non-
specific inflammatory disorders, all of whom had elevated secretory immunoglobulin (slgA) 
levels (20-200 mg/dL) in their saliva. Additionally, a group of eight healthy individuals (3-25 
mg/dL) was treated in the same way. With the exception of two patients, slgA levels steadily 
decreased in both groups. [El-Sedawy et al., 1989].  
Secretion of gastric juice in ten healthy individuals was stimulated after a single oral dose of 
alcoholic gentian root extract equivalent to 0.2 g of dried root. In the same experiment emptying 
of the gall bladder was increased and prolonged, which was interpreted as cholagogic effect 
[Glatzel and Hackenberg, 1967]. Chou et al. (2003) investigated a common herbal Chinese 
medicine, composed of Gentiana root, Scutellaria root, Gardenia fruit, Alisma rhizome and 
Bupleurum root, and its beneficial effect in patients with hepatocellular carcinoma. In a 
cytotoxicity test of the isolated major ingredients gentiopicroside had only little effect on 
induced cell apoptosis in Hep3B cells. 
In an open study, 205 patients with various dyspeptic symptoms (heartburn, vomiting, stomach 
aches, nausea, loss of appetite, constipation, flatulence) were treated with a hydroethanolic dry 
extract (5:1) of gentian root at a dosage of 240 mg twice or three times daily (average daily 
dose 576 mg of extract equivalent to 2.9 g of dried root) for about 15 days. Improvements in 
symptoms were evident after 5 days in most cases, and by the end of the study the average 
level of improvement was 68%. Efficacy of the preparation was assessed by the doctors as 
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excellent (symptoms eliminated) in 31% of the patients, good in a further 55%, moderate in 9% 
and inadequate in 5% [ESCOP, 2003; Wegener, 1998]. 
 
4.3 ADME (ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION) 
Only few studies regarding the absorption, distribution and metabolism of the bitter principle 
gentiopicroside were found. Its absorption and metabolism in rabbit blood for 24 h were 
monitored by Wang et al. (1994) observing a recovery of 99.2%.  
The pharmacokinetics and tissue distribution of gentiopicroside was studied following oral and 
intravenous administration in mice fitted to a 2-compartments open model. The blood serum 
half-life of gentiopicroside was 6.1 h and 2.8 h for intravenous and oral administration, 
respectively. The Tmax of gentiopicroside after oral administration was 0.50 h, and the 
bioavailability was 39.6%.  The AUC (area under curve) gradient in individual tissues following 
intravenous administration was kidney >serum >liver >spleen >lung >thymus >fat >heart 
>muscle >stomach >intestinal >brain. The MRT (magnetic resonance tomography) gradient was 
muscle >serum >lung >spleen >lung >intestinal>heart >stomach >brain >liver >thymus >kidney 
>fat. Overall, the data show that gentiopicroside was absorbed rapidly in mice, but with a low 
bioavailability, and was extensively distributed to tissues, but was generally cleared quickly with 
short MRTs. The study demonstrated the need for repeated dosage, or better, a slow release 
formulation as an ideal means of administering gentiopicroside [Wang et al., 2004].  
Metabolic conversion of gentiopicroside was demonstrated in vitro, using human intestinal 
bacteria. Gentiopicroside anaerobically incubated with Veillonella parvula ssp. parvula, produced 
five metabolites which were identified as erythrocentaurin, gentiopicral, 5-hydroxymethyl-
isochroman-1-one, 5-hydroxmethyl-isochromen-1-one and trans-5,6-dihydro-5-hydroxymethyl-6-
methyl-1 H, 3 H-pyrano[3,4-c]pyran-1-one [El-Sedawy, 1989]. 
 
Studies including excretion data could not be found.  
5. MICROBIOLOGY 
In a patent application the extract of Gentiana lutea L. obtained from roots, leaves and stems 
was shown to be useful as a drug in the treatment of bacterial infections including Gram-
positive bacteria, particularly Clostridia, Streptococcus, Staphylococcus aureus. Its antimicrobial 
effect corresponded to that of ampicillin [Stierna et al., 2005]. The patented preparation is 
claimed to be particularly suitable in the treatment of infections of the upper and lower 
respiratory tracts, such as rhinosinusitis and bronchitis. 
Additionally, several selective antifungal activities of gentian root extracts have been reported 
[Meier and Meier-Leibi, 1993]. 
6. EFFICACY 
At the date of write no information available. 
7. TOXICOLOGY 
7.1 SAFETY 
Gentian root extracts showed no toxicity and were generally well tolerated [Meier and Meier-
Liebi, 1993]. The acute oral LD50 in mice of 25 mL/kg of gentian extract was the same as that 
of 30% ethanol [cited in: ESCOP 2003].  
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Dosage/Administration  
Unless otherwise prescribed an average daily dosage of 1-3 g of tincture, 2-4 g of fluid extract 
and 2-4 g of roots, respectively. The comminuted drug and dried extracts are used for infusions; 
bitter-tasting forms of medications are used for oral administration. 
 
Side effects/Adverse Reactions/Contradications/Precautions 
People sensitive to bitter substances may experience headaches occasionally after using 
gentian root preparations. Mutagenic activity has been noted for gentian in animal studies and 
therefore, large dosages are not recommended. The European Council listed gentian root as a 
natural source of food flavouring (category N2). This category indicates that gentian can be 
added to foodstuffs in small quantities, with a possible limitation of an active principle (as yet 
unspecified) in the final product. Gentian root is contraindicated in cases of stomach and 
intestinal ulcers and also in cases of high blood pressure, although no rationale is given to this 
restriction. Gentian is also contraindicated during pregnancy and lactation, in view of the 
documented mutagenic activity of the herb and also due to an effect of the herb on the 
menstrual cycle.  
 
Interactions with other drugs 
None known. 
US 
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LAVANDULA SP. 
 
Lavandula sp..   
 
 
 
 
1. INTRODUCTION 
Lavandula angustifolia, formerly known as L. vera or L. officinalis, (Common Lavender, English 
Lavender, French lavender, Garden Lavender, Lavender) is a flowering plant in the family 
Lamiaceae, native to the western Mediterranean region, primarily in the Pyrenees and other 
mountains in northern Spain and is cultivated extensively (Lis Balchin et al. 2002). 
Other Lavandula species have similar ethnobotanical properties and major chemical 
constituents. The main species are: Lavandula latifolia (Spike Lavender), a Mediterranean grass-
like lavender; Lavandula stoechas, which has butterfly-like bracts on top of the flowers and is 
sometimes known as Spanish Lavender; and Lavandula  intermedia or Lavandula hybrida,  
which is a sterile cross between L. latifolia and L. angustifolia largely cultivated in many varieties 
in mediterranean countries and also outside Europe. 
The medicinal parts are the essential oil from the fresh flowers and/or the inflorescence, the 
flowers collected just before opening and dried, the fresh flowers and the dried flowers. The 
primary active constituents are monoterpenes, expecially linalool and linalyl acetate. In Europe, 
Lavender is used in phytomedicine preparations for digestive and mild nervous disorders as an 
antispasmodic, carminative and mild tranquilizer. Lavender oil is used as a fragrance 
component in products such as antiseptic ointments, creams, lotions and jellies. All types of 
lavender products are used as a fragrance ingredients in cosmetics products, including soaps, 
detergents, creams, lotions and perfumes.  
2. DESCRIPTION OF THE PLANT 
Lavandula angustifolia is a strongly aromatic shrub growing up to 0,5 -0,8 m tall. The leaves are 
evergreen, 2-6 cm long and 4-6 mm broad. The flowers are pinkish-purple (lavender-coloured), 
produced on spikes 2-8 cm long at the top of slender leafless stems 10-30 cm long. 
 
2.1 SYSTEMATICS 
Lavender belongs to the family Lamiaceae (Labiatae), the Genus Lavandula comprises of more 
than 30 species of which only very few are commercially used: Lavandula angustifolia Mill. (syn. 
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L.vera, L.officinalis) , L.latifolia Medik., L.hybrida (L.angustifolia x L.latifolia), L.dentata Boiss. and 
L.stoechas Ging. 
 
2.2 OCCURRENCE 
The plant is indigenous to the mountainous regions of the countries bordering the western half 
of the Mediterranean, and cultivated extensively for its aromatic flowers in various parts of 
France, in Italy , Hungary, Bulgaria and in England -  and even as far north as Norway. Outside 
Europe it is large scale cultivated in Australia (Tasmania), New Zealand and China. 
 
2.3 PLANT PARTS USED AND PRODUCTS 
‘English lavender flower’ consists of the dried flower of Lavandula angustifolia, gathered shortly 
before fully unfolding as well as its preparation. Flowering shoots are harvested when the 
middle section of the spike is flowering; it is cut 10 cm beneath the insertion of the spike. 
The most common product is the essential oil being distilled from fresh or wilted flower spikes 
and stems of hybrid Lavandula called ‘lavandin’ and its varieties/cultivars. 
 
3. INGREDIENTS/CONSTITUENTS (CHEM. ANALYSIS, STANDARDIZATION) 
Lavender oil has been reported to contain more than 100 components. 
The essential oil (1 to 3%) of Lavandula angustifolia is rich in linalool (30 to 55%) and linalyl 
acetate (20 to 35%). Further aroma components are β-ocimene, cineol, camphor and 
caryophyllene epoxide. Linalyl acetate is the major compound found in flowers (240 to 7200 
ppm). The plant contains also rosmarinic acid (12000 ppm), and coumarin (1000 to 1500 ppm). 
The same compounds are found in the other Lavandula species: in Lavandula latifolia linalyl 
acetate (1-198 ppm), linalool (1490 - 5104 ppm), rosmarinic acid (7000 ppm), coumarin (22 
ppm). 
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CH3
a                                    
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Figure 1. Chemical structure of linalyl acetate (a) and linalool (b). 
 
3.1 CHEMICAL ANALYSIS: METHODS TO DETERMINATE THE COMPOUND 
The major distinction among the three oils is in their relative contents of linalyl-acetate, linalool, 
1,8-cineole and camphor. The linalool concentration is usually higher in Spike lavender oil than 
in English lavender oil. The amounts of linalool, linalyl-acetate, cineole and camphor in Lavandin 
oil are between those of the other two oils.  The quantitative standards of Lavandula angustifolia 
(DAC 1986) are reported: volatile oil not less than 1,3%; foreign matter, entirely grayish brown 
or grey flowers not more than 10%; leaves and steams not more than 5%; other foreign matter, 
not more than 12%. Ash, not more than 7,0%. 
Separation and determination of the components of Lavandula oil can be achieved by gas 
chromatography with mass spectrometry or infra-red spectrometry. According to Ph.Eur. 5 
(2005) identity is tested by TLC and the purity by GLC 
 
3.2 STANDARDISATION, STABILITY 
International Standards specifications have been published for Lavandula angustifolia oil (ISO 
3515:2002). Lavandulae aetheroleum is also included into the Ph.Eur. 5 (2005) with standard 
contents of 20 – 45% linalool, 25 – 46% linalyl acetate, terpinene-4-ol up to 6,0% and Cineol 
less than 2,5%. Lavender oil, stored in a cool and dark place, is stable up to six month. 
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4. PHARMACOLOGY 
4.1 ANIMAL STUDIES 
Spasmolytic effect 
Oral administration of lavender has been shown to have antispasmodic effect on intestinal and 
uterine smooth muscle in animal studies. The mechanism of this action has not been fully 
explained, but it doesn’t seem to be related to an action on adrenergic or cholinergic receptors, 
nor action at calcium and potassium channels.  It has been observed that linalool and linalyl 
acetate can increase intracellular cAMP (Lis-Balchin andHart, 1999). 
 
Antimutagenic activity 
A concentration-dependent antimutagenic activity of Lavandula angustifolia oil has been found 
by the bacterial reverse mutation assay in Salmonella typhimurium TA98 and TA100 strains and 
in Escherichia coli WP2 uvrA strain (Evandri et al., 2005). 
 
Anticancer 
Preliminary data from animal studies suggest that perillyl alcohol (the hydrogenated form of d-
limonene) and other monoterpenes found in lavender can have an antineoplastic effect (Liston 
et al., 2003). Studies on rats have demonstrated the regression of mammaty tumors after oral 
administration of limonene and perillyl alcohol (Haag and Gould, 1994). Perillyl alcohol has 
shown to inhibit the growth of pancreatic adenocarcinoma in hamsters (Burke et al., 1997).  
 
Anticholesterolhaemic effect 
Cineole, a cyclic monoterpene found in lavender, lowers cholesterol in rats via inhibition of the 
HMG-CoA enzyme (Clegg et al., 1982); the lavender constituent perillyl alcohol has been shown 
to inhibit the conversion of lathesterol to cholesterol (Ren and Gould, 1994). 
 
4.2 HUMAN STUDIES 
Lavender oil is widely used in aromatheraphy due to the sedative effects of the inhaled volatile 
compounds (Buchbauer et al., 1991; Lewith et al., 2005). The mechanism of action is unknown 
but some authors have suggested that Lavandula angustifolia can have a similar action to the 
benzodiazepines and to enhance the effects of gammaminobutyric acid in the amygdale (Salah 
and Jager, 2005). It has been found that linalool inhibits acetylcholine release and alters ion 
channel function at the neuromuscular junction (Re et al., 2000). Human trials dealing with 
human patients suggest that aromatherapy with lavender have a small positive effect in reliving 
anxiety (Cavanagh and Wilkinson, 2002).  
In vitro and in vivo studies had shown that linalyl acetate and linalool have local anaesthetic 
activity following topical application  (Ghelardini et al., 1999; Barocelli et al., 2004). 
Internally, English Lavender is used for mood disturbances such as restlessness or insomnia and 
functional abdominal complaints (nervous stomach irritation, meteorism, nervous intestinal 
discomfort). Externally, English Lavender is used for treatment of functional circulatory 
disorders.  
Lavandula is approved by the German Commission E monographs (BAnz no. 228, dated 
05.12.1984) in following condition: nervousness and insomnia, loss of appetite, circulatory 
disorders, and dyspeptic complaints. 
 
4.3 ADME 
Lavender oil is quickly absorbed by the skin. The main constituents, linalool and linalyl acetate, 
are detectable in the blood five minutes after topical application, peak at 19 minutes, and 
largely disappear from the blood within 90 minutes (Jager et al., 2002). 
No data are available on kinetics following oral administration of lavender. The constituents 
limonene and perillyl alcohol (POH) are metabolized into perillic acid (PA) and dihydroperillic 
acid (DHPA) (Boon et al., 2000). In rats fed a diet containing POH or limonene, peak levels of PA 
can be seen at 1-2.5 hours, peak levels of DHPA are noted at 2-3.5 hours, and half-lives for each 
metabolite are 1-2 hours (Haag and Gould, 1994). POH, PA, and DHPA are detectable in 
subjects’ urine following high doses of POH ingestion. Approximately 9% of the total dose can be 
recovered in the first 24 hours. PA is the major metabolite found, with <1% of recovered POH. 
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The absorption of POH does not appear to be affected by concomitant ingestion of foods (Ripple 
et al., 1998). 
5. MICROBIOLOGY 
An in vitro trial with a batch culture of rumen microrganisms the ethanol extract of Lavandula 
angustifolia have shown to increase the production of volatile fatty acids and to increase the 
fermentation yield up to 50% (Brodiscou et al., 2000) 
 
Antimicrobial properties 
Lavender oil (primarily L. angustifolia) has been found to be active against many species of 
bacteria and fungi. For example, L. angustifolia oil was demonstrated to have in vitro activity 
against both MRSA (methicillin-resistant Staphylococcus aureus) and VRE (vancomycin-resistant 
Enterococcus faecalis) at a concentration of less than 1% (Edward-Jones et al., 2004).  
Antimicrobial effects of oil Lavandula angustifolia and Lavandula latifolia essential oils have 
been found against Staphylococcus aureus, Salmonella Typhimurium, and Listeria 
monocytogenes (Larrondo et al., 1995; Dedalioglu and Evrendilek, 2004; Rota et al., 2004).  
Concerning the antifungal effect, L. angustifolia (1% and 10%) inhibited conidium germination 
and germtube growth of the fungus Botrytis cinerea (Antonov et al., 1997), although conidial 
production of Penicillium digitatum was not affected by L. angustifolia at concentrations up to 
1000 µg/mL (Daferera et al., 2000). Lavender oil has shown both fungistatic and fungicidal 
activity against Candida albicans strains. At lower concentrations, it inhibits germ tube 
formation and hyphal elongation, indicating that it is effective against C. albicans dimorphism 
and may thus reduce fungal progression and the spread of infection in host tissues (D’Auria et 
al., 2005). 
Several papers have demonstrated that both linalool and L. angustifolia oil have ascaricidal and 
repellent activity (Perrucci et al., 1994; Cavanagh and Wilkinson, 2002; Choi et al., 2002; 
Traboulsi et al., 2002, Pavela et al., 2005).  
6. EFFICACY 
Lavandula angustifolia leaves, flowers and essential oil are used as flavouring agent for food 
preparations and beverages. No information is available about the quality of animal products 
following Lavandula administration.  
7. TOXICOLOGY 
Linalyl acetate is of very low acute toxicity to mammals, the acute oral LD50 is 13360 mg/kg 
body weight (bw) in mouse and 14550 mg/kg bw in rat (Taylor et al., 1964). In a 12-week 
feeding study on 15 males and 15 females, using mixed esters, retardation of growth of female 
rats occurred at a level of 24.3 mg/kg/day. Linalyl acetate is an ester that is expected to be 
hydrolysed to linalool and acetic acid in the gastro-intestinal tract (FAO, 1967).  
The main effects of the hydrolysis product, linalool, in a 28-day oral rat study were increased 
liver and kidney weight, thickened liver lobes and pale areas on the kidneys and in females only 
hepatocellular cytoplasmic vacuolisation. Other findings were related to local irritation of the 
gastro-intestinal tract. Based on the effects on liver and kidney a NOAEL of 160 mg/kg bw/day 
was derived for linalool (equivalent to 148 mg/kg bw/day linalyl acetate). In this study no 
effects on male and female gonads were found (OECD SIDS, 2002).  
Linalool was tested in a reproduction screening test. The NOAEL for maternal toxicity based on 
clinical signs and effects on body weight and food consumption was 500 mg/kg bw/day for 
linalool (equivalent to 464 mg/kg bw/day linalyl acetate). The NOAEL on reproduction toxicity 
and developmental toxicity is 500 mg/kg bw/day (equivalent to 464 mg/kg bw/day linalyl 
acetate) based on the decreased litter size at birth and pup morbidity/mortality thereafter. 
Linalyl acetate does not induce gene mutations or chromosomal effects in vitro (OECD SIDS, 
2002). 
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7.1 SAFETY  
No data in literature suggest possible adverse effects in animals due to continuative assumption 
of Lavandula spp. as flavouring agent in feed. In the United States of America Lavandula spp. 
has been included in the GRAS-list (generally considered as safe) by the FDA.  
No safety concern at current levels of intake when used as a flavouring agent. An ADI of 0-0.5 
mg/kg bw for citral, geranyl acetate, citronellol, linalool, and linalyl acetate, expressed as citral, 
has been established by JECFA. Linalyl acetate is commonly use ad food additive at a dose of 1-
15 ppm. 
 
Administration - Dosage 
The essential oil of Lavandula angustifolia (Lavandulae aetheroleum) is used in veterinary 
medicinal products for topical use together with other plant extracts or essential oils for 
antiseptic and healing purposes. The product is used in horses, cattle, sheep, goats, rabbits and 
poultry. It is included in Annex II of Council Regulation (EEC) N. 2377/90 as a substance that 
does not need a MRL level (EMEA, 1999). 
The essential oil is also used in human medicinal products to induce sleep and to treat 
functional disorders of the upper gastrointestinal tract at oral doses of 20 to 80 mg/person.  The 
whole drug is used for infusions, as an extract and as a bath additive. 
 
Interactions with other drugs 
Due to its sedative properties, essential oil of Lavandula spp. can show interaction with other 
sedating drugs: in rats, concomitant use of lavender and pentobarbital or chloral hydrate has 
significantly increased sleeping time and narcotic effects (Gilani et al., 2000). Lavender contains 
varying amounts of coumarins and may therefore theorically increase the effect of 
anticoagulant medications (Basch et al., 2004). 
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MACLEAYA/SANGUINARIA 
  
Macleaya, Plume Poppy 
 
 
 
 
1. INTRODUCTION 
 
Macleaya cordata, Sanguinaria canadensis and Chelidonium majus have been used for 
centuries as alternative medicines. Currently the extracts from these medicinal plants are 
components of veterinary and human phytopreparations, and of oral-hygiene agents such as 
dentifrices mouthrinses and chewing gums. Sanguinarine (SA) and chelerythrine (CHE) are 
biologically active components of these extracts. They display distinct antibacterial and 
antiinflammatory properties, but, on the other hand, they have been reported as having adverse 
effects - genotoxicity and hepatotoxicity (Kosina et al., 2004). 
 
Macleaya has sometimes been merged with neotropical Bocconia (Hutchinson, 1920), which 
differs in having perennial stems, long-stipitate ovaries, fleshy, single-seeded capsules dehiscing 
from the base, and much larger seeds. 
 
Synonym: Bocconia cordata (Willd.), Bocconia japonica, Federmohn, Plume-poppy, tree-
celandine 
 
Varieties: Macleaya microcarpa = Macleaya kewensis Turrill, Macleaya cordata var. yedoensis, 
Family: Papaveraceae 
 
The caryotype of Sanguinaria canadensis (x=9) shows that this species may constitute an 
independent tribe. Macleaya (x=10) is similar to Bocconia and differs from the other genera of 
subfamily (Safonova, 1994). 
 
 
2. DESCRIPTION OF THE PLANT 
 
Macleaya cordata is a fast growing deciduous perennial that grows to 2.0 m high by 1.0 m wide. 
Stems simple or branching distally, hollow, leafy. Leaves: 10-30 cm long and wide, alternate, 
petiolate; blade 1-2 subpalmately or pinnately lobed, margins irregularly and coarsely toothed; 
abaxial surface usually whitish and densely short-pubescent, adaxial glabrous. Plumelike 
inflorescences to 30 cm or more, terminal, paniculate, many-flowered; bracts present. Flowers: 
pedicels 4-10 mm, sepals 2, distinct, white to cream colored, spatulate, 5-10 mm; style to ca. 1 
mm; petals absent; stamens 25-30; pistil 2-carpellate; ovary substipitate, 1-locular; style short; 
stigma 2-lobed. Capsules nodding, substipitate, 2-valved, dehiscing from apex. Seeds 4-6, dark 
brown, reticulate arillate (Chittendon, 1959), x = 10. 
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It is hardy to zone 3. It is in flower from July to August. The flowers are hermaphrodite (have 
both male and female organs). 
The plant prefers light (sandy), medium (loamy) and heavy (clay) soils and requires well-drained 
soil with a pH ranging from acid to alkaline and partial (light woodland) to full sun with 
moderate moisture (grassy places, open meadows and the grassy floors of Cryptomeria 
plantations (Phillips and Rix, 1991)). This plant might do well located in cultivated beds. 
It might be found almost anywhere in temperate North America east of the Mississippi River at 
elevations below 1000 m. Native to temperate eastern Asia (China and Japan). 
 
Sanguinaria canadensis L. is a perennial plant, one of the earliest and most beautiful spring 
flowers. It has a lovely white flower and produces only a single leaf and a flowering scape about 
15 cm high. When the leaf first appears it is wrapped round the flower bud and is a greyish-
green colour covered with a downy bloom. The leaves are palmately 5 to 9 lobed, the lobes 
either cleft at the apex or having a wavy margin, and are borne on leaf stems about 12 to 35 cm 
long. After flowering the leaves increase in size, the underside paler showing prominent veins. 
The flower measures about 2.5 cm across, is white, rather waxlike in appearance, with 
numerous golden-yellow stamens in the center. The petals soon fall off, and the oblong, narrow 
seed pod develops, attaining a length of about 2.5 cm. The rootstock is thick, round and fleshy, 
slightly curved at ends, and contains an orange-red juice, and is about 2 to 10 cm long, with 
orange-red rootlets. When dried it breaks with a short sharp fracture, little smell, taste bitter 
acrid and persistent, powdered root causes sneezing and irritation of the nose. The root is 
collected in the autumn, after leaves die down; it must be stored in a dry place or it quickly 
deteriorates.  
 
 
3. INGREDIENTS / CONSTITUENT 
 
Macleaya cordata contains several alkaloids: Allocryptopine, angoline, berberine, bocconine, 
bocconoline, chelerythrine, chelilutine, chelirubine, coptisine, cyptopine, dehydrocheilanthifoline, 
ethoxychelerythrine, ethoxysanguinarine, heleritrine, homochelidonine, macarpine, 
oxysanguinarine, protopine, protopine-N-oxide, sanguinarine (Duke, 1992; Kiryakov et al., 1967). 
Active Ingredients: Sanguinarine, chelerythrine. 
It was shown that a suspension culture of Macleaya cordata accumulated 
benzo(c)phenanthridine alkaloids in the cell biomass. By the composition of the alkaloids and 
their content the cell culture markedly differed from the intact plant and callus tissue. The 
benzo(c)phenanthridine compounds in the cell culture were mainly represented by the reduced 
forms: dihydrosanquinarine and dihydrochelirubine. In the green plant they were mainly 
represented by the oxidized forms: sanquinarine and chelerythrine. The cell culture practically 
contained no chelerythrine characteristic of the intact plant (Fonin et al., 1995). 
 
M. kewensis is recommended as source of raw materials for the manufacture of the drug 
Sanguinarine. The highest content of the alkaloids sanguinarine and chelerythrine was found in 
the leaves (Abizov et al., 2003). 
 
In Sanguinaria canadensis and Chelidonium majus similar alkaloids have been found. The 
rhizomes also contain red resin and an abundance of starch. 
 
 
3.1 CHEMICAL ANALYSIS 
 
Sanguinarine forms colourless crystals. Chelerythrine is also colourless and crystalline. 
Protopine (also found in opium) is one of the most widely diffused of the opium alkaloids. 
A high-performance liquid chromatographic method is described for the analysis of the 
benzophenanthridine alkaloid, sanguinarine, found in plant extracts. The method is 
demonstrated to be applicable to analyzing samples such as saliva and gingival crevicular fluid 
for sanguinarine following a simple acidified methanolic extraction step. The method utilizes an 
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ethyl silane column with acidic and basic ion-pairing reagents in the mobile phase with a limit of 
detection of 3 ng of sanguinarine in a sample (Reinhart et al., 1991). 
Furthermore, a method for quantitative determination of sanguinarine is described, whereby the 
content of the alkaloid can be measured in the biomass of M. cordata. For this, the biomass is 
treated with ammonia, after which the alkaloids are extracted with chloroform and separated by 
TLC (standard silica plates), using a 25 : 25 : 3 (v/v/v) mixture of diethyl ether, petroleum ether, 
and methanol, respectively, as the solvent system. The extracts thus obtained are then 
subjected to spectrophotometry (Fonin et al., 1999). 
Sanguinarine, the main compound of Sangrovit®, can be determined by HPLC-analysis in the 
feed, in the feed additive (Krause, 1996) and after oral application to pigs in the blood and 
faeces (Tschirner, 2004). Different procedures of extraction and systems of ion-pair 
chromatography were described. 
Capillary electrophoresis was employed to determine the principal quaternary 
benzo(c)phenanthridine alkaloids, sanguinarine and chelerythrine, in plant extracts and an oral 
hygiene product. Phosphate-Tris buffer of pH 2.5 was used as a background electrolyte, limits of 
detection were 3 mumol L-1 (sanguinarine) and 2.4 mumol L-1 (chelerythrine) using UV 
detection at 270 nm. The method, which correlated well with HPLC, is suitable for serial 
determination of sanguinarine and chelerythrine in plant products and pharmaceuticals (Sevcik 
et al., 2000). 
The metabolism of the phenolic 1-benzyltetrahydroisoquinoline alkaloids was studied in cell 
cultures of Macleaya and Corydalis species. The crude alkaloid fraction obtained from feeding 
experiments was investigated by application of the combined LC/NMR and LC/APCI-MS (/MS) 
techniques. Several metabolites were detected, and their structures were identified. 
Bioconversion of the phenolic 1-benzyltetrahydroisoquinoline into the pseudoprotoberberine was 
demonstrated. LC/APCI-MS and LC/CD experiments carried out on a chiral column permitted 
the deduction of the major enantiomeric form of the chiral metabolites. Thus, the combination 
of NMR, MS, and CD data permitted the structural elucidation and stereochemical analysis of 
the metabolites in the extract matrix solution, without isolation and sample purification prior to 
the coupling experiments (Iwasa et al., 2005). 
 
3.2 STANDARDIZATION 
 
Sangrovit® is produced from the rhizomes or herbs of bloodroot plant (Sanquinaria canadensis), 
Chelidonium majus or Macleaya cordata with a standardized amount of sanguinarine and 
recommended as feed additive for rearing pigs, broilers and dairy cattle 
(www.phytobiotics.com). It leads to a secretion of enzymes in the intestine, has bacteriostatic, 
mucolytic and anti-inflammatory effects, inhibits aminoacid degrading enzymes and enhances 
the availability of lysin and tryptophan (Lindermayer, 2005). 
 
M. cordata extract (YIXIN HERBS TECH) mainly constains sanguinarine and chelerythrine. 
Specifications: Total Alkaloids 40%-60%. 
 
 
4. PHARMACOLOGY 
 
The whole plant of Macleaya cordata is analgesic, antioedemic, carminative, depurative and 
diuretic (Duke and Ayensu, 1985). The juice from the stems of the leaves is used to treat insect 
bites (Grieve, 1984). A decoction of the leaves and stems is used in the treatment of ringworm 
(Duke and Ayensu, 1985). The poisonous sap is used to counter poisonous sores (Duke and 
Ayensu, 1985). 
Other Uses: The dried hollow stems can be used as whistles (Stuart, 1911; Stuart, 1979). M. 
cordata kills insects and mosquito larvae. The flowers are used to kill maggots whilst the whole 
plant is used to kill larvae and insects (Duke and Ayensu, 1985; Yuan and Zhang, 1999). 
 
In isolated, isometrically contracting left guinea pig atria, sanguinarine, a benzophenanthridine 
alkaloid from the papaveracea Sanguinaria canadensis, produced a concentration-dependent 
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positive inotropic effect. Between 2.3 x 10(-6) M and 6.5 x 10(-5) M, sanguinarine increased 
contractility by 108% which was comparable to the maximal inotropic effect of ouabain. Within 
the same concentration range, sanguinarine caused inhibition of Na+,K+-ATPase isolated from 
guinea pig myocardium. 100% inhibition of Na+,K+,ATPase activity occurred at 1 x 10(-4) M 
sanguinarine. The I50 for enzyme inhibition and the ED50 for the inotropic action of 
sanguinarine were the same (6-6.5 x 10(-6) M) indicating that both effects may be causally 
related (Seifen et al., 1979). 
Quarternary Benzophenanthridine alkaloids possess antiinflammatory activity (Lenfeld at al., 
1981). 
In assays carried out in vitro with rat liver postmitochondrial supernatant, sanguinarine and 
chelerythrine were found to possess an inhibitory effect on the activity of the alanine and 
aspartate aminotransferases. A more pronounced inhibitory effect on the activity of alanine 
aminotransferase was observed. The measurements of the concentration dependency of the 
inhibitory effects of sanguinarine, chelerythrine and nitidine revealed that alanine 
aminotransferase activity was inhibited only by alkaloids with substituents in position 9 and 10 
of ring D. Sanguinarine was a more powerful inhibitor than chelerythrine. Nitidine, a structural 
isomer of chelerythrine had no inhibitory effect even when a tenfold concentration compared to 
that of sanguinarine and chelerythrine was used (Walterova et al., 1981). 
Chelidonine, sanguinarine, and chelerythrine are natural benzophenanthridine alkaloids that 
inhibit taxol-mediated polymerization of rat brain tubulin in the micromolar range. Chelidonine is 
a weak, competitive inhibitor of colchicine binding to tubulin but does not inhibit 
podophyllotoxin binding. On the other hand, sanguinarine inhibits both colchicine and 
podophyllotoxin binding to tubulin with I50 values of 32 and 46 microM, respectively, and 
chelerythrine inhibits with I50 values of 55 and 60 microM, respectively. The inhibition by these 
two agents is of the mixed type. Tubulin forms an acid-reversible pseudobase with the 
imminium ion of sanguinarine, probably through several of its sulfhydryl groups, as shown by the 
loss of the yellow color of sanguinarine and its 596-nm fluorescence emission peak. 
Chelidonine, on the other hand, cannot undergo such pseudobase formation, and we conclude 
that it acts by a different mechanism. A number of previously described pharmacologic effects 
of these agents may be due to their inhibition of microtubule function (Wolff and Knipling, 
1993). 
The inhibitory activity of the quarternary benzophenanthridine alkaloid, sanguinarine (isolated 
from M. cordata), on rat brain glutamate decarboxylase (GAD) was studied in vitro. The Ki value 
for sanguinarine was 7 x 10-4 mol/L. The inhibition was irreversible and increased during the 
period of preincubation of sanguinarine with the GAD preparation. The results suggest that 
reaction of the iminium bond in the benzophenanthridine molecule with thiol groups of the 
enzyme participates in GAD inhibition. As GAD catalyses the rate-limiting step of GABA [gamma-
amino butyric acid] synthesis, its inhibition by sanguinarine may contribute to its physiological 
action in vivo (Netopilova et al., 1996). 
Starting with an extract derived from the stem of M. cordata (Papaveraceae) that was active in 
the process of inhibiting phorbol 12,13-dibutyrate binding to partially purified protein kinase C 
(PKC), the benzophenanthridine alkaloid angoline was isolated and identified. This discovery 
appeared in context, as a related benzophenanthridine alkaloid, chelerythrine, has been 
reported to mediate a variety of biological activities, including potent and selective inhibition of 
protein kinase C (PKC). However, angoline was not observed to function as a potent inhibitor of 
PKC. Moreover, the authors were unable to confirm the reported inhibitory activity of 
chelerythrine. In a comprehensive series of studies performed with various PKC isozymes 
derived from a variety of mammalian species, neither chelerythrine nor angoline inhibited 
activity with high potency. To the contrary, chelerythrine stimulated PKC activity in the cytosolic 
fractions of rat and mouse brain in concentrations up to 100 microM. In addition, chelerythrine 
and angoline did not inhibit [3H]phorbol 12,13-dibutyrate binding to the regulatory domain of 
PKC at concentrations up to 40 microg/ml, and no significant alteration of PKC-alpha, -beta, or -
gamma translocation was observed with human leukemia (HL-60) cells in culture. Further, 
chelerythrine did not inhibit 12-O-tetradecanoylphorbol 13-acetate-induced ornithine 
decarboxylase activity with cultured mouse 308 cells, but angoline was active in this capacity 
with an IC50 value of 1.0 microg/mL. A relatively large number of biological responses have 
been reported in studies conducted with chelerythrine, and alteration of PKC activity has been 
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considered as a potential mechanism of action. In light of the current report, mechanisms 
independent of PKC inhibition should be considered as responsible for these effects (Lee et al., 
1998). 
The nuclear factor NF-kappaB is a pleiotropic transcription factor whose activation results in 
inflammation, viral replication, and growth modulation. Due to its role in pathogenesis, NF-
kappaB is considered a key target for drug development. It was shown that sanguinarine (a 
benzophenanthridine alkaloid), a known anti-inflammatory agent, is a potent inhibitor of NF-
kappaB activation. Treatment of human myeloid ML-1a cells with tumor necrosis factor rapidly 
activated NF-kappaB, this activation was completely suppressed by sanguinarine in a dose- and 
time-dependent manner. Sanguinarine did not inhibit the binding of NF-kappaB protein to the 
DNA but rather inhibited the pathway leading to NF-kappaB activation. The reversal of inhibitory 
effects of sanguinarine by reducing agents suggests a critical sulfhydryl group is involved in NF-
kappaB activation. Sanguinarine blocked the tumor necrosis factor-induced phosphorylation and 
degradation of IkappaBalpha, an inhibitory subunit of NF-kappaB, and inhibited translocation of 
p65 subunit to the nucleus. As sanguinarine also inhibited NF-kappaB activation induced by 
interleukin-1, phorbol ester, and okadaic acid but not that activated by hydrogen peroxide or 
ceramide, the pathway leading to NF-kappaB activation is likely different for different inducers. 
Overall, it was demonstrated that sanguinarine is a potent suppressor of NF-kappaB activation 
and it acts at a step prior to IkappaBalpha phosphorylation (Chaturvedi et al., 1997). For further 
explanations on NF-kappaB see page 13. 
The results of a pharmacodynamic study showed that M. cordata could improve liver function of 
acute hepatic injuries in rats caused by tetrachloromethan or galactosamine. M. cordata could 
lessen the level of serum LDH and mortality of rats, increase ratio of serum A/G, protect cellular 
membrane effectively and inhibit fibrosis in rats with chromic heptic injury caused by 
tetrachloromethane. M. cordata still enhanced the function of T and B lymphocytes (Yang et al., 
1999). 
M. cordata extract (YIXIN HERBS TECH) mainly contains sanguinarine and chelerythrine. It was 
shown to be a reversible inhibitor of the enzymatic hydrolysis of acetylthiocholine. 
Specifications: Total Alkaloids 40% - 60% (http://www.organic-herb.com). 
The possible inhibitory action was investigated on the enzymatic hydrolysis of acetylthiocholine 
by human erythrocyte acetylcholinesterase of principal alkaloids isolated from Chelidonium 
majus L. and Macleaya (Bocconia) cordata and M. microcarpa (namely sanguinarine, 
chelidonine, berberine), and of drugs "Ukrain" (thiophosphoric acid derivative of a sum of the 
alkaloids isolated from Chelidonium majus L.) and "Sanguirythrine" (a mixture of unseparated 
closely related to benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine, isolated 
from Chelidonium majus L. and other plants of Papaveraceae family). All agents under study 
have been shown to be reversible inhibitors of the enzymatic hydrolysis of acetylthiocholine. On 
the basis of the kinetic data it has been determined that chelidonine belonged to reversible 
inhibitors of a competitive type. All other examined agents have been demonstrated to be 
inhibitors of a mixed competitive-noncompetitive type, and a greater contribution to the 
inhibition was made by the competitive constituent. Among all examined agents berberine, 
sanguinarine and "Sanguirythrine" were the strongest inhibitors of this reaction (the values of 
generalized inhibitory constants being 0.23, 0.23 and 0.29 microM, respectively) and 
cheliodonine and "Ukrain" were much weaker (2.0 and 2.5 microM, respectively). Judging from 
the data obtained, sanguinarine and chelerythrine exert similar inhibitory effects on the reaction 
of enzymatic hydrolysis of acetylthiocholine, since sanguinarine and "Sanguirythrine" have 
nearly equal generalized inhibitory constants (Kuznetsova et al., 2001). 
Chelerythrine, sanguinarine and an alkaloid extract from M. cordata, sanguiritrin, were found to 
be inhibitors of aminopeptidase A and dipeptidyl peptidase IV, while fagaronine inhibited 
dipeptidyl peptidase IV only. At 50 microM, chelerythrine, sanguinarine and sanguiritrin inhibited 
aminopeptidase N by 82%, 85%, 88%, DPP IV by 38%, 62%, 57%, and fagaronine by 34%, 
respectively. When bovine serum albumin (500 microg/mL) was added, the inhibition of both 
proteases by quaternary benzo[c]phenanthridine alkaloids (QBA) (50 microM) was significantly 
diminished. Strong interaction of chelerythrine and sanguinarine with bovine and human serum 
albumin was proved by electrophoretic determination of their respective conditional binding 
constants (Sedo et al., 2002). 
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The quarternary benzo(c)phenanthridine alkaloid extract from M. cordata and the alkaloids 
fagaronine, sanguinarine and chelerythrine exerted differential inhibitory effect on the hydrolytic 
activity of particular dipeptidyl peptidase-like enzyme isolated from human blood plasma and 
from human and rat glioma cell lines. The alkaloid inhibitory effect was concentration-
dependent in the range 25-150muM and directly pH-related (Sedo et al., 2003). 
In a further study it has been shown that the major alkaloids from plants Chelidonium majus L. 
and Macleaya (Bocconia) cordata and M. microcarpa, namely, berberine, sanguinarine, 
chelidonine, and drugs "Ukrain" (thiophosphoric acid derivative of a sum of the alkaloids 
isolated from Ch. majus L.) and "Sanguirythrine" (a mixture of the alkaloids sanguinarine and 
chelerythrine, w/w 3:7, isolated from Macleaya), are irreversible inhibitors of oxidative 
deamination reaction of serotonin and tyramine as substrates, catalyzed by rat liver 
mitochondrial monoamine oxidase (MAO). At the same time these substances do not influence 
the oxidative deamination reaction of benzylamine as substrate (in concentration 1 mM or less). 
The substrate specificity of this inhibition manifests that mainly the oxidative deamination 
reactions catalyzed by MAO form A are inhibited by the agents studied. Among the examined 
agents, alkaloid chelidonine and drug "Ukrain" are the strongest inhibitors of the reaction. 
Alkaloids berberine and sanguinarine and drug "Sanguirythrine" exhibit a weaker action. Judging 
from the data obtained, sanguinarine and chelerythrine appear to exert similar inhibitory effects 
in this reaction, since sanguinarine and "Sanguirythrine" have similar values of bimolecular rate 
constants of their interaction with mitochondrial MAO. As it is well known, the MAO inhibitors 
appear to be, as a rule, pronounced antidepressants. The combination of malignotoxicity and 
antidepressive activity in drug "Ukrain" seems to be favourable for its clinical applications 
(Iagodina et al., 2003). 
250 mu M sanguinarine and 250 mu M chelerythrine caused complete inhibition of 1.9 nkat 
alpha-amylase from porcine pancreas and 23.9% and 7.5% inhibition, respectively, from human 
saliva using a biosensor method which utilises a flow system equipped with a peroxide electrode 
(Zajoncova et al., 2005). 
Benzo(c)phenanthridine and diisoquinoline alkaloids isolated from Chelidonium majus L. and 
Macleaya (Bocconia) cordata and M. microcarpa (berberine, sanguinarine, chelidonine) and 
drugs “Ukrain” and “Sanguirythrine” inhibited the enzyme activity of acetylcholinesterase from 
human erythrocyte and monoamine oxidase from the rat liver. All agents have been shown to be 
reversible inhibitors of the enzymatic hydrolysis of acetylcholine. Chelidonine is a reversible 
inhibitor of a competitive type, all others are inhibitors of a mixed competitive-noncompetitive 
type. Berberine, sanguinarine and “Sanguirythrine” were stronger inhibitors and as chelidonine 
and “Ukrain”. All tested agents acted as irreversible inhibitors of the oxidative deamination 
reaction of serotonine and tyramine and did not influence the oxidative deamination reaction of 
benzylamine as a substrate (Kuznetsova et al., 2005). 
To observe the cytotoxic effects in vitro and antitumor effects in vivo of total alkaloid of M. 
cordata a MTT assay was used to assess the proliferation of Hep3B and H22 cells in vitro 
treated with the alkaloid. The inhibitory effects of the alkaloid on H22 and S180 tumors were 
observed in mice with subcutaneous inoculation of the tumor cells. The total alkaloid 
significantly inhibited the proliferation of human Hep3B cells and murine H22 cells in a dose-
dependency in vitro. IC(50) of the alkaloid in 3 repeated experiments was 3.04, 3.98 and 2.98 
mug/mL respectively in Hep3B cells, and was 2.89, 2.21 and 2.34 mug/mL in H22 cells. In the 
tumor-bearing mice, the alkaloid inhibited the development of H22 tumor and prolonged the 
survival of S180 tumor-bearing mice. At the daily dose of 1, 2, and 4 mg/kg.b.w (i.p.) and 4 
mg/kg.b.w. (i.g.) for 10 days, the inhibition rates of the alkaloid on H22 tumor in 3 repeated 
experiments were 18.6%, 35.1%, 44.9% and 7.9% respectively, and the rates of survival 
prolongation of the tumor-bearing mice were 24.8%, 48.9%, and 52.7%, respectively. The 
alkaloid possesses antitumor effects both in vitro and in vivo (Pang et al., 2005). 
The quaternary benzo[c]phenanthridine alkaloids (QBA) produce a plethora of species- and 
tissue-specific effects but the molecular basis of their biological activities remain mysterious. 
 
4.1 BIOAVAILABILITY 
 
4.1.1 ANIMAL STUDIES 
Macleaya 
----------------------------------------------------------------------------------------------------------------- 
 
 146
Pharmacokinetic studies of sanguinarine after oral application of Sangrovit® to pigs showed that 
the alkaloid was marginally absorbed out of the intestine and excreted for the most part 
unaltered in the faeces (Tschirner, 2004). 
Adult rats were orally administered with a single dose of sanguinarine (10mg SA per kg body 
weight in 1 mL water). In the plasma and the liver, dihydrosanguinarine (DHSA) was identified as 
a metabolite of SA by high performance liquid chromatography-electrospray ionization mass 
spectometry (HPLC/ESI-MS). Significantly higher levels of DHSA were found in both the plasma 
and the liver in comparison with those of SA. SA and DHSA were not detected in the urine. The 
formation of DHSA might be the first step of SA detoxification in the organism and its 
subsequent elimination in phase II reactions. Benz(c)acridine, in the literature cited SA 
metabolite, was found neither in urine nor in plasma and liver (Psotova et al., 2006). 
 
5. MICROBIOLOGY 
5.1 ANTIMICROBIAL ACTIVITY 
The colonization on rat molars of S. sobrinus OMZ 176, S. mutans OMZ 376, or a combination S. 
sanguis OMZ 9 and S. sobrinus OMZ 176 after a short exposition to various fluoride solutions 
and disinfectants was tested in vitro. The test solutions included Act, Candida, Veadent 
(sanguinaria extract), sodium fluoride, amine fluoride, stannous fluoride, zinc fluoride 
hexetidine, stannous fluoride/amine fluoride solutions, chlorhexidine and water. The sterilized 
rat molars were immersed in the above test solutions for 60 seconds, then incubated with 
streptococci in broth for 8 hours, again dipped into the same test solutions for 60 seconds and 
reincubated for an additional 30 hours. The streptococcal suspension contained 14C labelled 
sucrose solutions. The deposits on the molars were dissolved in 6N potassium hydroxide during 
16 hours. Finally, the beta rays emitted by the dissolved radiolabelled suspension were counted 
using a scintillation counter. The sodium fluoride containing solutions exerted no or a very 
limited effect on the bacterial deposits. In contrast to the other test solutions, sanguinaria 
extract (Veadent mouth rinse) mildly inhibited the S. sobrinus and S. mutans deposits, but 
plaque formation by the combination of streptococci was not hampered. Zinc 
fluoride/hexetidine, amine fluoride and stannous fluoride/amine fluoride solutions had a 
distinct and significant inhibitory effect on S. sobrinus and S. mutans deposits, but only a weak 
effect when mixed cultures were used for plaque formation. Chlorhexidine significantly inhibited 
the deposits of the three bacterial strains used in these experiments (Altenhofen et al., 1989). 
Minimum inhibitory and minimum bactericidal concentrations (MIC and MBC values) for 
sanguinarine were determined for common and etiologically important plaque bacteria. 
Because the efficacy of sanguinarine is believed to be enhanced by zinc, isobolograms were 
assessed to determine their mode(s) of interaction. Hydrogen ion concentration influenced the 
inhibitory activity of both sanguinarine and zinc. For sanguinarine, at the optimum pH (6.5), MIC 
values were 4 or 8 micrograms/ml for Streptococcus mutans, Streptococcus sobrinus, 
Streptococcus sanguis, Actinomyces viscosus and Actinomyces naeslundii. MIC values were 
0.125-0.50 mmol Zn/ml. MBC values ranged from 1 to 8 mmol Zn/ml at pH 5.5. Isobologram 
data revealed that sanguinarine and zinc interacted synergistically. Viadent oral rinse, which 
contained 300 micrograms sanguinaria extract/ml and 0.2% zinc chloride (14.9 mmol Zn/l), 
was inhibitory to all strains tested. MIC values were 1 or 2% (ml Viadent oral rinse/100 ml 
aqueous solution) for all strains except A. viscosus for which the MIC value was 12% (vol/vol) 
(Eisenberg et al., 1991). 
Sanguinarine and chelerythrine display distinct antibacterial properties (Kosina et al., 2004). 
Sanguinarine has bacteriostactic effects (Lindermayer, 2005). 
 
 
6. EFFICACY 
 
6.1 HUMAN STUDIES 
The sap of Macleaya has been used in traditional Chinese medicine as an antiseptic for 
wounds (Grey-Wilson, 1993). 
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6.2 ANIMAL STUDIES 
In a feeding trial the effect of 50 ppm extractives of Sanguinaria canadensis as growth promotor 
on pig performance was tested. Supplementation of sanguinarine showed a significant 
improvement of daily weight gain of 7.5% in the first period till 60kg average body weight and 
an improvement of 6.9% over the whole test period with a finishing weight of 95kg. Continuing 
the trial to a body weight of 106kg showed a difference of 4.5% for daily weight gain in 
comparison with the control group (Neufeld K., 1992). 
 
Sangrovit®, a phytogenic feed additive is produced of dryed and grounded herbs of Macleaya 
cordata, Sanguinaria canadensis or Chelidonium majus. All plants contain alkaloids. The main 
active compound is sanguinarine. It leads to a secretion of enzymes in the intestine, has 
bacteriostatic, mucolytic and anti-inflammatory effects, inhibits aminoacid degrading enzymes 
and enhances the availability of lysin and tryptophan (Lindermayer, 2005).  
Sangrovit®, derived from Sanguinaria canadensis and Chelidonium majus, was investigated for 
its properites as phytogenic feed additive concerning fattening efficiency and carcass 
performance in pigs. The daily weight gain of the pigs was found high (826g) but no influence on 
fattening data could be observed. Positive effects could be stated in the quality of the carcasses. 
Muscle meat and the thickness of the bacon were found improved (Seskeviciene et al., 2003). 
Sangrovit®, derived from Sanguinaria canadensis, was tested on the performance of lactating 
pigs and weaners. Supplementation of 30 ppm Sangrovit® tended to results in an enhanced 
weight of new born pigs. Though the results of the aminoacid-analysis in the blood indicated 
that Sangrovit® causes a higher intermediar availability of the essential aminoacids Lys and Trp, 
in an N-bilanz-study no effect of the feed additive on the N-retention in growing pigs could be 
observed. Feed intake and daily weight gain of the pigs in the Sangrovit®group were found 3 % 
higher than in the controls (p > 0.05) (Tschirner, 2004). 
Furthermore, the effects of daily administration of the extract from Macleaya cordata (2 mg and 
100 mg in 1 kg feed, sanguinarine:chelerythrine 3:1) were evaluated in the diet on the health 
status of swine. After 90-day administration, alkaloids were retained to a different extent in 
tissues. The highest SA/CHE retention was detected in the gingiva (0.55 micro g/g) and liver 
(0.15 micro g/g), no SA/CHE were detected in muscles. Plasma SA levels attained 0.11 micro 
g/ml. Treated animals did not display any results of haematological, biochemical or histological 
assay different from controls. A 32P-postlabelling assay proved that no DNA-adducts with 
SA/CHE were detected in pig livers. Not any symptom was observed linked to epidemic dropsy 
syndrome often attributed to sanguinarine. In conclusion, an average daily oral dose of alkaloids 
up to 5 mg per 1 kg animal body weight was proved to be safe (Kosina et al., 2004). 
In investigations with rearing pigs Sangrovit®, derived from Macleaya cordata, was tested as 
growth promotor. The weight gain was 2-4% enhanced compared with the controls. Feed 
consumption was reduced by about 4% (Lindermayer, 2005). 
 
6.3 PREPARATIONS AND DOSAGES 
Fluid extract of Sanguinaria, U.S.P., dose 1 1/2 minims. Tincture of Sanguinaria, U.S.P., 15 
minims. Powdered root, 10 to 30 grains. Sanguinarin, 1/4 to 1 grain. Fluid extract, 10 to 30 
drops (www.botanical.com). 
 
 
7. TOXICOLOGY 
 
The sap of Macleaya cordata is very poisonous (Stuart, 1979). 
 
Sanguinarinchloride, mouse, i.v., LD50 (mg/kg LW): 15.9 
Sanguinarinchloride, mouse, s.c., LD50 (mg/kg LW): 102.5 
Sanguinarinchloride, rat, i.v., LD50 (mg/kg LW): 29.0 
Sanguinarinchloride, rat, oral, LD50 (mg/kg LW): 1658.0 
Sanguinaria-extract A, rat, oral, LD50 (mg/kg LW): 1440.0 
Sanguinaria-extract B, rat, oral, LD50 (mg/kg LW): 1250.0 
Sanguinaria-extract B, rabbit, dermal, LD50 (mg/kg LW): > 200 
(Becci et al., 1987; Schwartz, 1986; Walterova et al., 1981). 
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Reproductive and developmental toxicology studies were conducted with orally administered 
sanguinaria extract in rats and rabbits. Groups of animals which received no test article served 
as controls in all studies reported. No adverse effects on estrous cycling, male or female 
copulatory and fertility indices or gestation/lactation parameters were observed in rats given 
10-100 mg/kg/day. Reduced body weights in the offspring during lactation were observed at 
the 100 mg/kg/day treatment level concomitant with maternal toxicity. No developmental 
toxicity, including teratogenicity, was observed on the fetuses of rats following maternal 
administration of 5-60 mg/kg/day. An increase in post-implantation loss was observed at 
maternally toxic dosage levels of 50 and 75 mg/kg/day in rabbits. Oral administration of 
sanguinaria extract in a perinatal and postnatal study in rats caused no adverse effects on litter 
size, parturition, or lactation of female rats nor on survival and growth of their offspring at 
dosage levels of 5-60 mg/kg/day. Maternal oral toxicity thresholds were 60 mg/kg/day in rats 
and 25 mg/kg/day in rabbits. It was concluded that the oral intake of sanguinaria extract has 
no selective effect on fertility, reproduction or fetal and neonatal development in rats or rabbits 
(Keller and Meyer, 1989). 
The effects of benzo[c]phenanthridine alkaloids sanguinarine (SA), chelerythrine (CHE), 
fagaronine (FA) and their dihydroderivates were tested on human leukocytes and lymphocytes, 
rat peritoneal mastocytes and primary cultured hepatocytes. The cytotoxicity of SA and CHE on 
hepatocytes is dose (35-100 microM) and time (1-3 h) dependent. Both alkaloids decrease 
chemiluminiscence of leukocytes and inhibit a creation of active E-rosets. The degranulation of 
mastocytes is inhibited only by CHE. Dihydroderivates of SA and CHE did not display any effect 
on studied cells, dihydrofagaronine exhibits a hepatotoxicity after 3 h (Vavreckova et al., 1994). 
The hepatotoxic effects of sanguinarine and chelerythrine (isolated from Macleaya cordata) and 
fagaronine were examined in rats. Daily administration of sanguinarine or chelerythrine (10 
mg/kg, i.p.) produced marked liver degeneration and necrosis not observed in fagaronine-
treated rats. Degradation and/or necrosis were not observed following chronic administration of 
sanguinarine (daily dose of 0.2 mg/kg, i.p., for 56 days). The hepatotoxic effects of the alkaloids 
were tested against isolated rat hepatocytes. Sanguinarine was the most cytotoxic followed by 
chelerythrine; fagaronine exhibited no toxicity. Sanguinarine increased plasma membrane 
permeability; chelerythrine was less potent. Alkaloid treatment did not increase lipid 
peroxidation or damage to mitochondrial membranes (Ulrichova et al., 1996). 
The antitumor activities of a synthetic benzo[c]phenanthridine, NK109 (7-hydroxy-2, 3-
methylenedioxy-5-methyl-8-methoxybenzo[c]phenanthridinium hydrogensulfate dihydrate), and 
of natural benzo[c]phenanthridines were tested in vitro and in vivo. NK109 had the highest 
activity among them. NK109 is similar in structure to fagaronine and fagaridine; however, it has 
a phenolic-OH at C-7. NK109 exists as a resonance hybrid, the keto-amine and zwitterionic 
forms in neutral media. The resonance hybrid is cationic and has molecular planarity; these 
have been considered to be essential for the antitumor activity of the benzo[c]phenanthridinium 
salts. On the other hand, the structurally similar benzo[c]phenthridine alkaloids, chelerythrine 
and sanguinarine, exist as pseudobases under the same conditions. The latter do not exhibit 
antitumor activity in vivo, probably because they lose both the immonium region and molecular 
planarity. Thus, NK109 may be considered to be novel category of benzo[c]phenanthridinium 
salt from the viewpoint of its structure under biological conditions (Nakanishi et al., 1999). 
In a further study the cytotoxicity of QBA alkaloids, sanguinarine (SA), chelerythrine (CHE), 
fagaronine (FA), and the extract from Macleaya cordata in primary cultures of human and 
porcine hepatocytes was investigated. The cellular damage was assessed by the MTT assay, 
lactate dehydrogenase (LDH) leakage and the determination of intracellular glutathione (GSH) 
levels. The results are summarised as follows: (i) The alkaloids tested in doses 0.1 and 10 
microM did not display statistically significant cytotoxicity for 0-3 h incubation; (ii) SA and CHE 
showed the dose- and time-dependent toxicity within the range 25-100 microM whereas FA was 
not toxic; (iii) the LDH leakage into the medium was higher for SA than for CHE, thus revealing a 
potent potential of SA to disturb cell-membrane integrity; (iv) after 3 h incubation with 100 
microM SA/CHE, mitochondrial dehydrogenase activity (MTT assay) and the cellular GSH levels 
decreased to residual values of about 40% suggesting that mitochondria are unlikely to be a 
primary target for SA/CHE in the cell; (v) no differences were found in the response to QBA 
application in human versus porcine hepatocyte (Ulrichova et al., 2001). 
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No toxic effects were observed in rats fed up to 150ppm sanguinarine in the diet for 14d and in 
rats treated by gavage with up to 0.6mg/kg body weight for 30d (Becci et al., 1987). 
No toxic effects were found with a mixture of 60% sanguinarine and 30% chelerythrine at a dose 
of 2 and 100 ppm, respectively, (0.1 and 5 mg/kg LW) in the feed of pigs, which were observed 
for 90 days. For that reason an average daily oral dose of alkaloids up to 5 mg per 1 kg animal 
body weight is proved to be safe (Kosina et al., 2004). 
 
7.1 SAFETY 
 
All rats survived when sanguinarine was administered in the feed to the animals over 14 days in 
a dose of 15, 45 and 150 ppm, respectively (Becci et al, 1987). 
In some studies a liver toxicity was observed, when high doses (10mg/kg LW/day, i.p.) were 
administered (Dalvi, 1985; Ulrichová et al., 1996; Williams et al., 2000). With small amounts of 
sanguinarine (0.2 mg/kg LW/day, i.p.) no liver toxic effects could be found even when 
administered chronically (for 56 days) (Ulrichová et al., 1996). 
An Expert Panel on the safety on Sanguinaria extract used in Viadent oral rinse and toothpaste 
products stated that Sanguinaria extract is safe in its present use in Viadent products based on 
a large margin of safety between levels of human exposure and levels found to produce 
minimum effect or to be without adverse effect in animals. The panel further concluded that 
published literature suggesting an association between human exposure to Sanguinaria extract 
and potential reproductive, cardiovascular, or ocular toxicity, or carcinogenicity is largely 
anecdotal, unfounded, and not corroborated by or consistent with the substantial data base that 
was subjected to peer review (Frankos et al., 1990). 
__________________________________________________________________________________
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9. EXPLANATION OF NUCLEAR FACTOR KAPPA B 
 
Nuclear factor kappa B (NF-kB) is a transcription factor found in a great variety of immune cells 
that plays an important role in the inflammatory and immune response by regulating pro- 
inflammatory cytokines (interleukin-1, -2, -6, -8) and proinflammatory mediators (ICAM-1, iNOS 
and COX-2). NF-kB is activated by a protein known as IKKs. IkBa is a strong inhibitor of NF-kB but 
is rapidly degraded in response to a proinflammatory stimulus. This degradation allows the NF-
kB to be free to translocate into the nucleus.  
Recent breakthroughs in the transcription and translation of a variety of mediators have led to 
increased interest in therapeutic approaches directed at the level of gene transcription (e.g. 
COX2, iNOS, IL1beta, TNFalpha, ICAM, etc.). One of the most important mediators is NF-kappaB 
which plays a key role in the regulated expression of a large number of pro-inflammatory 
mediators including cytokines such as IL-6 and IL-8, cell adhesion molecules, such as ICAM and 
VCAM, and inducible nitric oxide synthase (iNOS). These Proinflammatory mediators are known 
to play a role in inflammation and in the case of iNOS, may lead to organ destruction in some 
inflammatory and autoimmune diseases. 
The importance of NF-kappaB in inflammatory disorders is further strengthened by studies of 
airway inflammation including asthma, in which NF-kappaB has been shown to be activated. 
This activation may underlie the increased cytokine production and leukocyte infiltration. Recent 
findings show that glucocorticoid also works by inhibition of NFkappaB. Further evidence for a 
role of NF-kappaB in inflammatory disorders comes from studies of rheumatoid synovium. 
Although NF-kappaB is normally present as an inactive cytoplasmic complex, recent 
immunohistochemical studies have indicated that NF-kappaB is present in the nuclei, and hence 
active, in the cells comprising rheumatoid synovium. Furthermore, NF-kappaB has been shown 
to be activated in human synovial cells in response to stimulation with TNF-alpha. This signifies 
increased cytokine and eicosanoid production. NF-kappaB is also likely to play a key role in 
neoplastic transformations, which are seen in 20-25% of certain human lymphoid tumors. 
Sodium salicylate and its semi-synthetic derivative, aspirin, and a number of new natural 
products of different chemical classes have demonstrated NF-kB inhibitory activity. Recently, an 
important mechanism of the inhibition of NF-kappaB suggests the possible activation of the 
receptors for peroxisomes.  
 
9.1 RESEARCH ON NFKB 
9.1.1 Inhibition of Nuclear Factor Kappa B (NFkB): An Emerging Theme in Anti-Inflammatory 
Therapies. Fulvio D'Acquisto, PhD, Michael J. May, PhD and Sankar Ghosh, PhD. Section of 
Immunobiology and Department of Molecular Biophysics and Biochemistry Howard Hughes 
Medical Institute Yale University School of Medicine New Haven, CT 06510. Molecular 
Interventions 2:22-35 (2002)  
The application of anti-inflammatory therapies began thousands of years ago with the use of 
readily available natural resources. It is only recently, however, that the cellular and molecular 
mechanisms of inflammation have been appreciated sufficiently to design anti-inflammatory 
strategies with limited side effects. For example, salicylates and glucocorticoids, two widely 
used anti-inflammatory drug classes, are now known to inhibit the activation of NF- B, a 
transcription factor that regulates the inducible expression of a wide range of proinflammatory 
mediators. New generations of NF- B–targeting anti-inflammatory agents that are specific, 
efficacious, and cost-effective may therefore complement or replace current therapies. In this 
review, we describe various classes of NF- B inhibitors and discuss important unresolved issues 
regarding their use. 
9.1.2 Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through 
covalent modification of reduced cysteine 62 of p50. Xia YF, Ye BQ, Li YD, Wang JG, He XJ,Lin X, 
Yao X, Ma D, Slungaard A, Hebbel RP, Key NS, Geng JG. J Immunol. 2004 Sep 15;173(6):4207-
17. 
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NF-kappaB is a central transcriptional factor and a pleiotropic regulator of many genes involved 
in immunological responses. During the screening of a plant extract library of traditional Chinese 
herbal medicines, we found that NF-kappaB activity was potently inhibited by andrographolide 
(Andro), an abundant component of the plant Andrographis that has been commonly used as a 
folk remedy for alleviation of inflammatory disorders in Asia for millennia. Mechanistically, it 
formed a covalent adduct with reduced cysteine (62) of p50, thus blocking the binding of NF-
kappaB oligonucleotide to nuclear proteins. Andro suppressed the activation of NF-kappaB in 
stimulated endothelial cells, which reduced the expression of cell adhesion molecule E-selectin 
and prevented E-selectin-mediated leukocyte adhesion under flow. It also abrogated the 
cytokine- and endotoxin- induced peritoneal deposition of neutrophils, attenuated septic shock, 
and prevented allergic lung inflammation in vivo. Notably, it had no suppressive effect on 
IkappaBalpha degradation, growth rates. Our results thus reveal a unique pharmacological 
mechanism of Andro's protective anti-inflammatory actions. 
9.1.3 Nuclear factor-kappaB: the enemy within. Aggarwal BB. Cytokine Research Laboratory, 
Department of Experimental Therapeutics, Unit 143, The University of Texas M.D. Anderson 
Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. aggarwal@mdanderson.org 
Cancer Cell. 2004 Sep;6(3):203-8. Numerous lines of investigation suggest that nuclear factor 
NF-kappaB, a proinflammatory transcription factor, could promote tumorigenesis. Various 
inflammatory agents, carcinogens, tumor promoters, and the tumor microenvironment activate 
NF-kappaB. NF-kappaB proteins themselves and proteins regulated by it have been linked to 
cellular transformation, proliferation, apoptosis suppression, invasion, angiogenesis, and 
metastasis. Constitutively activated NF-kappaB is common in wide variety of tumors. 
Furthermore, there exists genetic evidence that NF-kappaB mediates tumorigenesis. Thus, 
suppression of NF-kappaB activation should be effective in the prevention and treatment of 
cancer.  
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MATRICARIA RECUTITA 
  
Matricaria recutita L  
 
1. INTRODUCTION 
Chamomile flowers belong to those drugs that experienced a wide range of medical applications 
in ancient times. The curative effect of chamomile has been known by physicians since 2500 
years. Hippocrates described chamomile as a medicinal plant, and Galen and Asclepios 
recommended the use of infusions prepared from chamomile flowers. Furthermore, Mathiolus 
propagated the use of essential oil from chamomile as a antispasmodic. Today, chamomile 
ranks among the most important medicinal plants and has therefore already been 
monographed in many modern pharmacopoeias. However, studies regarding its application in 
animal nutrition are scarce. 
Synonyms are Matricaria chamomilla L., Chamomilla recutita (L.) Rauschert 
 
2. DESCRIPTION OF THE PLANT 
True chamomile is an annual plant with thin spindle-shaped roots only penetrating flatly into the 
soil. The branched stem is erect, heavily ramified and grows to a height of 10-80 cm. The long 
and narrow leaves are bi- to tripinnate. The flower heads are placed separately, they have a 
diameter of 10 to 30 mm, and they are pedunculate and heterogamous. The golden yellow 
tubular florets with five teeth are 1.5 to 2.5 mm long, ending always in a glandulous tube. The 
11 to 27 white plant flowers are 6 to 11 mm long and 3.5 mm wide and arranged 
concentrically. The receptacle is 6 to 8 mm wide, flat in the beginning and conical, cone-shaped 
later, hollow - the latter being a very important distinctive characteristic of Matricaria - and 
without paleae. The fruit is a yellowish brown achene.  
True chamomile is very often confused with plants of the genera Anthemis. Special attention 
has to be paid to confusions with Anthemis cotula L. a poisonous plant with a revolting smell. In 
contrast to true chamomile A. cotula just as A. arvensis L. and A. austriaca Jacq. has setiform, 
prickly pointed paleae and a filled receptacle. Latter species are nearly odorless [Franke, 2005].  
 
2.1 SYSTEMATICS 
Although the systematic status is quite clear nowadays, there are a number of inaccuracies 
concerning the names. Apart from misdeterminations and confusion, the synonymous use of 
the names Anthemis, Chamomilla, and Matricaria leads to uncertainty with regard to the 
botanical identification. Moreover, the nomenclature is complicated by the fact that Linneaus 
made mistakes in the first edition of his ´Species Plantarum´ that he corrected lateron.  
The best known botanical name for true chamomile is Matricaria recutita (syn. Matricaria 
chamomilla, Chamomilla recutita (L.) Rauschert, belonging to the genus Chamomilla S. F. Gray). 
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2.2 OCCURRENCE 
Indigenous to southern and eastern Europe and western Asia chamomile is nowadays found 
throughout found in Europe, North America, and also Australia. The commercial product is 
mainly cultivated in Argentina, Chile, Egypt (not always of pharmacopoeial quality, often for the 
food industry), Bulgaria, Slovakia, Hungary, and to a small extent from Spain, Czech Republic, 
and Germany [Franke et al., 2005]. 
 
2.3  PLANT PARTS AND PRODUCTS 
Chamomile is widely cultivated and used all over the world. Interest in these drugs extends 
far beyond their role as medical plant but also for their great importance in food and cosmetic 
industries. Generally, extracts, the drug itself and tea mixtures were used for the pharmaceutical 
industry and foodstuff sector, whereas cosmetic industries preferred the essential oils. 
Therefore, different specifications are required depending on their field of applications [Franke, 
2005]. 
 
Chamomile flowers – Matricariae flos 
The flowers are usually used medicinally. Since the quality demands are arranged by the 
pharmacopoeias of the different countries, they can vary in a wide range. Pharmaceutical 
chamomile includes complete flowers, sometimes fallen apart to a very small extend with little 
amounts of fines.  
 
Chamomile fines 
The fines contain the seeds, the petals and the tubular flowers, which are separated during the 
mechanical cleaning-up procedure. Depending on the essential oil contents, the fines are used 
for pharmaceutical and foodstuff purposes. 
 
Chamomile herb with flowers 
The material includes flowers with higher amounts of stems due to mechanically harvesting. 
Therefore, quality parameters usually do not confirm with pharmacopoeias´ requirements, but 
can easily be used as food teas. 
Chamomile herb 
After harvest the flowering Chamomile herb is minced and dried without any further cleaning-up 
or processing.  
 
Chamomile for extraction, Industrial Chamomile 
This material includes chamomile flowers, which quality standards are in accordance with the 
pharmacopoeia. Because of the mechanical harvest and its preparation, ist external structure is 
in such a condition that this material is not suitable as pharmaceutical chamomile. From this 
quality medicinally used extracts are produced. Because of their high oil content flower heads 
fallen apart should not be regarded as worthless. If used in tea mixtures/blends a limitation of 
the fines is, however, justified due to the tendency of showing inhomogeneities.  
 
Chamomile root 
The roots are used for pharmaceuticals of the anthroposophical therapy. The essential oil differ 
considerably from the aerial parts [Reichling et al., 1984]. 
 
Chamomile oil, Matricariae aetheroleum 
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The oil is produced by steam distillation of fresh or dried flower heads including the stems of 
chamomile flowers. The essential oil from fresh plant material results in higher yield and a 
better quality. 
 
3. INGREDIENTS/CONSTITUENTS 
Chamomile contains a large number of therapeutically interesting and active compound 
classes. The most important ones are the components of the essential oil and the flavonoid 
fraction. Apart from them, the following compound classes were detected and characterized: 
mucins, coumarins, phenol carboxylic acids, amino acids, phytosterols, choline, and mineral 
substances. The chamomile constituents are classified in a lipophilic fraction containing 
individual components of the essential oil, coumarins, methoxylated flavone aglyca, 
phytosterols, lipidic and waxy substances, and a hydrophilic fraction including flavonoids, 
mucilage, phenyl carboxylic acids, amino acids, and choline. 
The essential oil comprising the lipophilic compounds is present in the roots and in the flowers, 
whereas the latter are the main plants part for essential oil production. Furthermore, the 
composition of the essential oil in roots differs from that in flowers. Thus, therapeutic relevant 
compounds like chamazulene and bisabolol are absent in the roots. The oil content changes 
during ontogenesis, reaching a maximum of 0.3-1.5% in flowers just before full blossom [Franz 
1981; Schilcher, 1985]. The approximate ratio of the main components in the essential oil is as 
follows: 
• Up to 15% chamazulene and its precursor matricin [Stahl, 1954a-c] 
• Up to 50% bisabolols and bisabolol oxides [Franz 1981; Schilcher, 1985]  
• Up to 45% trans-ß-farnesene [Carle et al., 1987; Schilcher, 1985] 
• Up to 25% cis- and trans-isomers of the spiroethers [Schilcher, 1985] 
 
The individual lipophilic and hydrophilic components in chamomile are described in the 
following sections. 
 
Matricin/Chamazulene 
Matricin is the precursore of chamazulene and present in ligulate florets and tubular florets of 
chamomile, but not in the bottom of the flower heads. Chamazulene is formed from matricin by 
the elemination of water and acetic acid and following decarboxylation. The structure of 
matricin and chamazulene is given in Figure 4.1.. 
 
       
 
  
 
 
 
 
 
 
             Matricin            Chamazulene 
 
Figure 4.1. Structure of matricin and chamazulene  
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Bisabolols and bisabolol oxides 
(-)-α-bisabolol, bisabololoxid A, B and bisabolonoxid A are important constituents of chamomile 
oil. Bisabololoxide C was only found in small quantities in flowers and is synthetically obtained 
from (-)-α-bisabolol by oxidation. The structures of (-)-α-bisabolol and its oxidation products are 
given in Figure 4.2. Depending on the main constituent of the essential oil (-)-α -bisabolol, 
bisabololoxid A, bisabololoxid B and bisabolonoxid A the species can be classified in four 
different chemotypes [Franz 1981;Schilcher, 1973]. With regard to the significantly higher 
pharmacological activity of (-)-α-bisabolol, only the first chemotype should be used for 
pharmaceutical products. 
       
 
 
 
      Bisabolol   Bisabolol oxide A                        Bisabolol oxide B        Bisabolol oxide C 
 
 
 (-)-α-Bisabolone oxide A 
 
Figure 4.2. Bisabolol and its oxidation products 
 
Trans-ß-farnesene 
Beside trans-ß-farnesene, which can represent up to 45% of the essential oil, trans-α-farnesene 
was present only in traces [Lembercovics, 1979].  
 
Spiroethers 
Two spirocyclic polyines, the isomeric cis and trans enyne dicycloether, were found in 
chamomile flowers [Bohlmann et al., 1961]. The cis spiroether is the major component in most 
plant specimens. The trans spiroether was predominant only in certain commercially available 
chamomile flowers [Schilcher, 1985].  
 
Coumarins 
Both the 7-methoxy-coumarin herniarin and the 7-hydroxy-coumarin umbelliferone are of 
pharmacological interest. In chamomile flowers from different origins a range of 37.4-
98.5mg/100g of herniarin and 6-17.8mg/100g of umbelliferone were determined. Both were 
detected in ligulate and tubular florets. The average content in ligulate florets was significantly 
higher [Schilcher, 1985, 1987].  
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Flavonoids 
Flavonoids represent the major fraction of the water-soluble components in chamomile. The 
most abundant derivatives thereof are apigenin 7-glucoside and its acetylated derivatives, as 
well as luteolin, quercetin and their glycosides. Beside hydroxylated aglyca, methoxylated 
flavonoids like chrysosplenol, jaceidin, chrysoeriol, patuletin, spinacetin, 6-methoxykaempferol, 
axillarin, chrysosplenetin, eupatoletin and eupalitin were identified in chamomile flowers [Carle 
and Isaac, 1985]. 
 
3.1 CHEMICAL ANALYSIS 
Quality control methods for chamomile flowers and preparations thereof are contained in 
Ph.Eur. 5. The essential oil is extracted by steam distillation (Ph. Eur. 5) or dichlormethane 
(quantitative determination of single components) and analyzed by GC, headspace GC and TLC, 
respectively [Schilcher, 1987; Wagner and Bladt, 1986; Reichling et al., 1979; Carle et al., 
1987; Hölzl et al., 1975; Stuppner et al., 1993].  
The analysis of flavonoids is usually performed by extraction and subsequent identification and 
quantification by TLC and HPLC coupled to mass spectrometry. Adulterations of chamomile oil 
with (-)-α-bisabolol from other sources were detected using stable isotope and 2H-NMR methods 
[Hörhammer et al., 1963; Kunde and Isaac, 1979; Reichling et al., 1979; Wagner and Bladt, 
1986; Redaelli et al., 1981; Dölle et al., 1985; Carle et al., 1993; Miething and Holz, 1989; 
Schmidt and Ness, 1993; Schmidt and Vogel, 1992; Tschiersch and Hölzl, 1992; Carle et al., 
1990; Carle et al., 1992; Carle et al., 1993]. 
The solvent system applied for the extraction of the essential oil can be used for the separation 
of the coumarins. Identification and quantification is performed by HPLC [Schilcher, 1985]. 
 
 
3.2 STANDARDISATION, STABILITY 
Matricin is very unstable and decomposes visibly to chamazulene by turning blue after a short 
time, particularly in aqueous solution [Schmidt et al., 1991].  
 
4. PHARMACOLOGY 
Chamomile and its preparations are mainly used because of their anti-inflammatory, 
spasmolytic, and carminative activity. Moreover, chamomile showed bacteriostatic and 
fungistatic properties. The data given below are based on the ESCOP monograph (2003). 
 
4.1  IN VITRO EXPERIMENTS 
 
Anti-inflammatory effects 
Ethanolic (48% V/V) and isopropanolic (48% V/V) extracts of Matricaria flower inhibited 5-
lipoxygenase, cyclooxygenase and the oxidation of arachidonic acid with IC50 values of 0.05-
0.3%, while a supercritical carbon dioxide extract had an IC50 of 6-25 µg/mL for these activities. 
Investigations of individual constituents revealed that apigenin inhibited 5- and 12-lipoxygenase 
(IC50: 8 and 90 µM respectively); chamazulene and (-)-α-bisabolol inhibited only 5-lipoxygenase 
(IC50: 13 and 40 µM respectively); apigenin, cis-spiroether and (-)-α-bisabolol inhibited 
cyclooxygenase (IC50: 70-80µM); only chamazulene showed antioxidative activity (IC50: 2 µM) 
[Ammon and Sabieraj, 1996]. 
Trans-spiroether inhibited the provoked degranulation of rat mast cells in concentrations above 
0.1 mM [Miller et al., 1996]. 
Apigenin markedly inhibited the transcriptional activation of cyclooxygenase (IC50: 8.7 µM) and 
of nitric oxide synthase (IC50: 3.1 µM) in lipopolysaccaride-activated macrophages [Liang et al., 
1999]. 
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Spasmolytic effect 
 
The Chamomile flavonoids especially the aglyca are responsible for the spasmolytic effects, 
whereas musculotropic effects were stronger than the neurotopic ones [Hörhammer, 1961; 
Hörhammer and Wagner, 1962; Hörhammer et al., 1963a; Salfner, 1963]. Extracts, in particular 
alcoholic extracts obtained from ligulate flowers (in contrast to tubular florets) seemed to exert 
stronger activity. Beside flavonoids, components of the essential oil were assumed to contribute 
to the spasmolytic effects. (-)-α-bisabolol, (+)-α-bisabolol and to a lower amount their oxides, the 
chamomile oil itself, cis-spiroether, a standardised hydroalcoholic extract (Kamillosan®) and the 
coumarin derivatives umbelliferone and herniarin showed spasmolytic activity. The hydrophilic 
(flavonoids) and the lipophilic components (essential oil) contributed to the musculotropic 
antispasmodic effect [Achterrath-Tuckermann et al., 1980; Carle and Gomaa, 1992]. 
 
Sedative effects 
Apigenin competitively inhibited the binding of flunitrazepam to the central benzodiazepine 
receptor (Ki = 4 µM) but had no effect on muscarinic receptors, α1-adrenoreceptors or on the 
binding of muscimol to GABAA receptors [Viola et al., 1995]. 
HPLC fractions of a methanolic axtract of Matricaria flower were able to displace flunitrazepam 
from its receptors in rat cerebellar membranes, the ligand Ro 5-4864 from ‘peripheral’ 
benzodiazepine receptors in rat adrenal gland membranes and muscimol from GABA receptors 
in rat cortical membranes. This last activity is mainly due to GABA present in the fractions 
[Avallone et al., 1996]. 
Apigenin inhibited the binding of Ro 15-1788, a specific ligand for central benzodiazepine 
receptors with an IC50 of 0.25 mM. Apigenin also reduced GABA-acticated Cl- currents on 
cultured cerebellar granule cells dose-dependently by 15 ± 3% (0.1d µM apigenin), 24 ± 2% (1 
µM apigenin) and 32 ± 4% (10 µM apigenin). This effect was blocked by coapplication of Ro 15-
1788 [Avallone et al., 2000]. 
 
4.2  ANIMAL STUDIES  
Anti-inflammatory effects 
The anti-inflammatory principles of chamomile were identified as chamazulene, matricin, 
chazulene carboxylic acid, guiazulene, (-)-α-bisabolol and the bisabololoxide [Pommer, 1942; 
Nöcker and Schleusing, 1958; Kristen and Schmidt, 1957; Roeckerath, 1950; Isaac, 1979; 
Goeters, 2001]. However, bisabololoxide show a lower activity than (-)-α-bisabolol [Jakovlev et 
al., 1979]. The cis-enynedicycloether have less antiphlogistic activity as compared to the 
components mentioned above, but show edema inhibition in rats [Breinlich and Scharnagel, 
1968; Verzár-Petri et al., 1979]. Since these compounds are chemically unstable, their 
contribution to the total activity may be low, but their participation is apparent in certain test 
models. Additionally, the flavonoids provide antiphlogistic activity, which was examined recently 
[Baumann et al., 1980; Carle and Gomaa, 1992; Della Loggia, 1985; Della Loggia et al., 1986]. 
In particular, apigenin and luteolin exert an antioedematous effect similar to that induced by the 
non-steroidal anti-inflammatory drug indomethacin. 
 
 
Anti-ulcerogenic effect 
The development of ulcers induced in rats by indometacin, stress or ethanol was inhibited by an 
orally administered extract of Matricaria flower with an ED50 of 1 mL per rat and by (-)-α-
bisabolol with an ED50 of 3.4 mg/kg body weight. These substances also reduced healing times 
for ulcers induced in rats by chemical stress (acetic acid) or heat coagulation [Szelenyi et al., 
1979]. 
 
 
 
Matricaria 
----------------------------------------------------------------------------------------------------------------- 
 
 161
 
Wound healing effect 
The wound healing activity of azulene has been demonstrated in studies on the thermally 
damaged rat tail and of Matriacaria flower constituents in accelerated healing of experimental 
injuries [Deininger, 1956; Zita, 1955]. 
 
Sedative effects 
A sedative effect of Matricaria flower was demonstrated trough prolongation of hexobarbital-
induced sleep, reduction of spontaneous mobility and reduction of explorative activity in mice 
[Dell Loggia et al., 1981; 1982]. 
Restriction stress-induced increases in plasma ACTH levels in normal and ovariectomised rats 
were decreased by administration of diazepam and inhalation of Matricaria flower oil vapour. 
Inhaling the vapour induced greater decreases in plasma ACTH levels in ovariectomised rats 
then treatment with diazepam; this difference was not observed in normal rats. Furthermore, 
the inhalation of Matricaria flower oil vapour induced a decrease in plasma ACTH level that was 
blocked by pre-treatment with fumazenil, a potent and specific benzodiazepine receptor 
antagonist [Yamada et al., 1996]. 
Apigenin (25 and 50 mg/kg) significantly reduced the time of latency (p<0.05) in the onset of 
picrotoxin-induced (6 and 8 mg/kg) convulsions [Avallone et al., 2000]. Apigenin also reduced 
locomotor activity after interperitoneal injections in rats (minimal effective dose: 25 mg/kg) but 
showed no anxiolytic, myorelaxant or anti-convulsant activity [Zanoli et al., 2000]. 
 
4.3 HUMAN STUDIES  
Anti-inflammatory effects 
In a comparative open study involving 20 healthy volunteers with chemically-induced toxic  
dermatitis, the smoothing effect on the skin of an ointment containing Matricaria flower extract 
was significantly superior (p<0.01) to that of 0.1% hydrocortisone acetate or the ointment base 
[Nissen et al., 1988]. 
In an open study on 12 healthy subjects, a cream containing Matricaria flower extract (20mg/g) 
did not suppress UV-induced erythema but it reduced visual scores of skin redness in the 
adhesive tape stripping test (p=0.0625) [Korting et al., 1993]. In an analogous study, the cream 
produced 69% of the effect of a hydrocortisone-27-acetate ointment [Albring et al., 1983]. 
In a randomized, double-blind study, 25 healthy volunteers with UVB light-induced erythema 
were treated with various Matricaria flower preparations, hydrocortisone cream or the respective 
vehicle. Ranking the preparations according the visual assessment scores and mean values 
from chromametry, a cream containing a hydroalcoholic extract of Matricaria flower gave the 
best result [Kerscher, 1992]. 
In a bilateral comparative study 161 patients with inflammatory dermatoses, who had been 
treated initially with 0.1% of diflucortolone valerate, were treated during maintenance therapy 
with a cream containing Matricaria flower extract or one of three alternatives: 0.25% 
hydrocortisone, 0.75% fluocortin butyl ester of 5% bufexamac. The therapeutic results with the 
extract were quivalent to those of hydrocortisone and superior to those of fluocortin butyl ester 
and bufexamac [Aertgeerts et al., 1985]. 
In an open study involving 98 cancer patients, a Matricaria flower extract preparations 
containing 50 mg of α-bisabolol and 150-300 mg of apigenin 7-glucoside per 100 g , applied 
three times daily, reduced oral mucositis caused by localized irradiation or systemic 
chemotherapy [Carl, 1994]. 
In a phase III double-blind, placebo-controlled study involving 164 patients, mouth-wash 
containing Matricaria flower extract did not decrease 5-fluorouracil-induced stomatits [Fidler et 
al., 1996]. 
In a randomized, partially double-blind, comparison study, 72 patients with medium-degree 
atopic eczema were treated with a cream containing a Matricaria flower extract, of a 0.5% 
hydrocortisone cream or a placebo cream. After 2 weeks of treatment the Matricaria cream 
proved superior to the hydrocortisone creame and marginally superior to the placebo cream 
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with respect to the symptoms pruritus, erythema and desquamation [Patzelt-Wenczler and 
Pone-Pöschl, 2000]. 
 
Anti-inflammatory and antispasmodic effects 
In an open multicentric study, 104 patients with gastrointestinal complaints such as gastritis, 
flatulence or minor spasms of the stomach were treated orally for 6 weeks with Matricaria 
flower extract preparation (standardised to 50 mg of α-bisabolol and 150-300 mg apigenin 7-
glucoside per 100 g) at a daily dose of 5 mL. Subjectively evaluated symptoms improved in all 
patients and disappeared in 44.2% of patients [Stiegelmeyer, 1978]. 
 
Wound healing effects 
 
In an open study, 147 female patients episistomized during childbirth were treated for 6 weeks 
with either an ointment containing Matricaria flower extract or a 5% dexpanthenol cream. The 
healng effect of the two preparations was comparable [Kaltenbach, 1991]. 
In a randomised, open placebo-controlled study on 14 patients, weeping dermatoses following 
dermabrasion of tattoos were treated topically with a Matricaria flower fluid extract 
preparations (standardised to 50 mg of α-bisabolol and 3 mg of chamazulene per 100 g). After 
14 days the decrease in weeping wound area and the improvement in drying tendency were 
significant in the Matricaria flower group (p<0.05) [Glowania et al., 1987]. In another study with 
120 patients with second degree haemorrhoids were treated with rubber band ligature alone, 
rubber band ligature with anal dilator and vaseline, or rubber band ligature with anal dilator and 
an ointment containing Matricaria flower extract. The last group showed the best results in 
amelioration of haemorrhage, itching, burning and oozing [Förster et al., 1996]. 
 
4.4 ADME (ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION) 
After cutaneous administration of [14C](-)-α-bisabolol on mice, 82% of the radioactivity was 
found in the urine [Hölz and Hahn, 1985; Hahn and Hölzl, 1987]. 
Apigenin and luteolin are also readily absorbed by the skin. Skin preparation studies using 
hydroethanolic solutions of apigenin and luteolin on the upper arms of 9 healthy female 
volunteers gave steady state fluxes of 10.31 ng/min/cm² and 6.11 ng/min/cm² respectively 
[Merfort et al.,1994]. After oral administration of apigenin 7-glucoside to rats, free apigenin was 
detected in the urine [Griffiths and Smith, 1972]. 
After oral administration of 40 mL of a hydroethanolic Matricaria flower extract (containing 
225.5 mg of apigenin 7-glucoside, 22.5 mg of apigenin and 15.1 mg of herniarin per 100 mL) to 
a female volunteer, no flavones could be detected in blood plasma nor in 24-hour urine, while 
herniarin was found in both (maximum plasma concentration of ca. 35 ng/mL; 0.324 mg in 24-
hour-urine) [Tschiersch and Hölzl, 1993]. 
In germ-free rats no hydolysis of flavone glycosides could be observed; obviously intestinal 
microflora can effect the cleavage of the glycosidic bonds [Griffiths and Smith, 1972, Griffiths 
and Barrow, 1972]. Furthermore, orally administred Apigenin was detected in the blood serum 
of animals [Redaelli et al., 1980]. 
 
5. MICROBIOLOGY 
Antibacterial and antimycotic effects 
The essential oil showed bacteriostatic and bactericidal activity, including gram positive, gram 
negative bacteria and fungi [Aggag and Yousef, 1972; Cinco et al., 1983; Schilcher, 1987]. 
Again, (-)-α-bisabolol exhibited strongest antibacterial, fungistatic and fungicidal activity 
compared with the oxides and enyne dicycloethers. Chamazulen was shown to have also 
fungistatic activity, but at higher concentrations [Szabo-Szalontai and Verzár-Petri, 1976]. In a 
recent study has observed chamomile oil extracts inhibited the production of urease of 
Helicobacter pylori. This enzyme is known to be very important for the survival of this 
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microorganism under acid condition. Therefore, chamomile oil extract is supposed to inhibit the 
adhesion of H. pylori and is promising for the application in complex therapy of stomach ulcer 
and duodenal intestine [Shikov et al., 1999]. 
 
6. EFFICACY 
Kraszewki (2003) studied herbal mixtures, including chamomile, due to their efficiency in the 
nutrition of high-yielding cows. The milk from the cows was characterised by significantly better 
technological suitability for processing into hard cheese. Herb feeding also exerted a beneficial 
influence on the composition of fatty acids in milk, decreasing the amount of saturated acids 
and increasing that of unsaturated acids, including mono- and polyunsaturated acids that have 
a hypocholesterolemic effect. In contrast to this study, El-Nor, S. A. H. Abo, Fathy, F., Abdou, M. 
M. A. (2004) could not observe significant changes in the fatty acid profile, but significant 
increase in fat, total solids, total proteins, lactose and ash contents in milk from those cows 
getting herb supplemented feed (ratio of Chamomile 15mg/kg cow). This made milk more 
valuable in terms of cheese production and human nutrition. 
Feeding a herbal mixture, containing chamomile flowers was effective in promoting weight gain 
compensation in weaned pigs suffering from runting-stunting syndrome [Kolacz et al., 1997]. 
Ground chamomile flowers (50 mg/rat/day – 100 mg/rat/day) and the essential oil (0.2-0.35%) 
stimulated liver regeneration in partially hepatectomised rats when added to the diet 
[Gershbein, 1977].  
Furthermore, aqueous extracts (decoctions, infusions and macerates) of dried flower heads of 
chamomile were tested in vitro against the mite Psoroptes cuniculi Delafond, responsible for 
otoacariosis in domestic animals. All extracts tested showed highly significant acaricidal activity 
when compared to the controls [Macchioni et al., 2004] 
 
7. TOXICOLOGY 
Chamomile oil has been granted the GRAS status in the Unites States, and is admitted for foods 
and cosmetics by the FDA. The LD50 of chamomile oil exceeds 5g/kg weight for oral toxicity in 
rats and acute dermal toxicity in rabbits [Moreno, 1973; Opdyke, 1974]  
The acute toxicity of orally administered (-)-α-bisabolol in mice and rats was very low with an 
LD50 of about 15 mg/kg weight. Subacute toxicity studies showed lowest toxic dose of (-)-α-
bisabolol to be between 1 and 2 ml/kg oral for rats and dogs. Oral doses up to 1 ml/kg of (-)-α-
bisabolol produced no discernible effects on the prenatal development of rats or rabbits. None 
of the tested dosages caused any deformations [Habersang et al., 1979]. 
 
7.1 SAFETY  
DOSAGE/ADMINSTRATION 
Undesirable effects were observed only at high doses. Doses of 12.6-15.9 ml/kg of (-)-α-
bisabolol caused retching and vomiting. Considering prenatal development of rats and white 
New Zealand rabbits intolerance was only observed with doses that were toxic for the adult 
animal by itself (approx. 3.0ml/kg) [Habersang et al., 1979]. 
Topical exposure of guinea pigs to extracts from the bisabolol oxide B-chemotype of Ch. recutita 
was found to cause a moderate allergenic reaction. However, evidence was given that 
chamomile allergy is due to anthecotulid, a linear sesquiterpene lactone, which is detectable in 
this chemical strain at variable but low levels [Hausen et al., 1984].  
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Side effects/Adverse Reactions/Contraindications/Precautions 
Rare cases of contact allergy have been reported in persons with known allergy to Artemisia 
species [Schilcher, 1987]. 
 
Interactions with other drugs 
None. 
US/KS 
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MENTHA SP 
 
 
 
Mentha x  piperita  
 
1. INTRODUCTION 
The true mints (genus Mentha) are perennial herbs in the Family Lamiaceae. There are about 25-30 
species in the genus, seven from Australia, one in North America, and the others from Europe and 
Asia; several hybrids also occur. In the following list, the most important species and hybrids are in 
bold types. 
Selected species  
Mentha aquatica – Water mint, or Marsh mint, Mentha arvensis, Corn Mint, Wild Mint and Japanese 
Peppermint, Mentha asiatica, Mentha australis, Mentha canadensis (syn. M. arvensis var. 
canadensis), Mentha cervina, Mentha citrata (syn. M. odorata) – Bergamot mint (smells like 
Bergamot) Mentha crispata, Mentha cunninghamii, Mentha dahurica , Mentha diemenica, Mentha 
gattefossei, Mentha grandiflora, Mentha haplocalyx, Mentha japonica, Mentha kopetdaghensis , 
Mentha laxiflora Mentha longifolia, Mentha micrantha , Mentha microphylla, Mentha pulegium – 
Pennyroyal, Mentha requienii – Corsican mint, Mentha sachalinensis Mentha satureioidesMentha 
spicata – Spearmint, Curly mint, Mentha suaveolens (syn. M. rotundifolia) – Apple mint (smells like 
apples) and Pineapple mint (a variegated cultivar of Apple mint), Mentha sylvestris – Horsemint, 
Wild mint Mentha vagans  
Selected hybrids  
Mentha × dalmatica [= M. arvensis × M. longifolia], Mentha × dumetorum [= M. aquatica × M. 
longifolia], Mentha × gracilis [= M. arvensis × M. spicata], Mentha × maximilianea [= M. aquatica × 
M. suaveolens], Mentha × muelleriana [= M. arvensis × M. suaveolens], Mentha × piperita [= M. 
aquatica × M. spicata] – Peppermint, Chocolate mint, Mentha × rotundifolia [= M. longifolia × M. 
suaveolens], Mentha × verticillata [= M. arvensis × M. aquatica], Mentha × villosa [= M. spicata × M. 
suaveolens]  
(http://en.wikipedia.org/wiki/Mentha) 
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The genus name Mentha is from the Greek Mintha, the name of a mythical nymph who 
metamorphosed into this plant; its species name piperita is from the Latin piper, meaning pepper, 
alluding to its aromatic and pungent taste (Tyler et al., 1988). Mint leaves have been used in 
medicine for several thousand years, according to records from the Greek, Roman, and ancient 
Egyptian eras (Briggs, 1993; Evans, 1991). The origin of peppermint cultivation is disputed, though 
there is some evidence that it was cultivated in ancient Egypt. Roman naturalist Pliny the Elder (ca. 
23–79 C.E.) wrote of its uses by the Greeks and Romans. Peppermint was first recognized as a 
distinct species by botanist John Ray in his Synopsis Stirpium Britannicorum (second edition, 1696), 
and his Historia Plantarum (1704). It became official in the London Pharmacopoeia in 1721 (Briggs, 
1993; Grieve, 1979; Tyler et al., 1988). Today, peppermint leaf and/or its oil are official in the 
national pharmacopeias of Austria, France, Germany, Great Britain, Hungary, Russia, and 
Switzerland, and the European Pharmacopoeia (Ph.Eur. 5, 2005; BP, 1988; Bradley, 1992; DAB 10, 
1991; AB, 1981; Ph.Fr.X, 1990; Ph.Helv.VII, 1987; Ph.Hg.VII, 1986; USSR X, 1973; Wichtl and 
Bisset, 1994). 
In Germany, peppermint leaf is one of the most economically important individual herbs, 
demonstrated by the fact that in 1993 nearly four thousand tons were imported, and in 1994 
almost five thousand tons. It is also one of Germany's own most important medicinal plant crops 
(Lange and Schippmann, 1997). It is licensed as a standard medicinal tea, is official in the German 
Pharmacopoeia, and approved in the Commission E monographs (leaf and oil). It is used as a 
monopreparation and also as a component of many cholagogue, bile-duct, gastrointestinal, and 
liver remedies, and some hypnotic/sedative drugs (BAnz, 1998; Bradley, 1992; Braun et al., 1997; 
DAB 10, 1991; Wichtl and Bisset, 1994). In German pediatric medicine, peppermint leaf (67%) is 
combined with chamomile flower (33%) as an herbal tea to treat gastric upset in children. It is also 
used as a component of various "kidney and bladder" teas for children. Peppermint oil is used as a 
component of Inhalatio composita (45% eucalyptus oil, 45% pumilio pine oil, 10% peppermint oil) 
specifically indicated for coryza and nasal catarrh in children (Schilcher, 1997). In the United States, 
peppermint leaf is used singly and as a main component of a wide range of digestive, common 
cold, and decongestant dietary supplement and OTC drug products, in fluid and solid dosage forms. 
Peppermint leaf and peppermint oil are official in the U.S. National Formulary. Peppermint oil is 
used in the United States as a carminative in antacids, a counterirritant in topical analgesics, an 
antipruritic in sunburn creams, a decongestant in inhalants and lozenges, and as an antiseptic or 
flavoring agent in mouthwashes, gums, and toothpastes (Briggs, 1993; Leung and Foster, 1996; 
Tyler et al., 1988). 
The historical use of peppermint is not dramatically different than its use in modern herbal 
medicine. Classified as a carminative herb, peppermint has been used as a general digestive aid 
and employed in the treatment of indigestion and intestinal colic by herbalists. 
Most modern human studies have investigated peppermint oil rather than peppermint leaf as a 
treatment for stomachache (May et al., 1996), spastic colon syndrome (Somerville et al., 1984), 
postoperative nausea (Tate, 1997), relief of colonic muscle spasm during barium enema (Sparks et 
al., 1995), irritable bowel syndrome (Carling et al., 1989; Dew et al., 1984; Fern ndez, 1990; Koch, 
1998; Lawson et al., 1988; Lech et al., 1988; Liu et al., 1997; Nash et al., 1986; Pittler and Ernst, 
1998; Rees et al., 1979), prevention of abdominal distension in postoperative gynecological 
patients (Feng, 1997), and headaches (Gobel et al., 1994; Gobel et al., 1996). The use of 
peppermint oil for irritable bowel syndrome is based on preparations in enteric-coated capsules, 
causing a spasmolytic activity on smooth muscles of the gut. In animal tests, the probable 
mechanism of action has been shown to be the inhibition of smooth muscle contractions by 
blocking calcium influx into muscle cells (Forster et al., 1980; Giachetti et al., 1988). 
Pharmacopeial grade peppermint leaf must be composed of the dried whole or cut leaf with not 
more than 5% stem fragments greater than 1 mm in diameter and not more than 10% leaves with 
brown spots caused by Puccinia menthae. The whole leaf must contain not less than 1.2% (ml/g) 
and the cut leaf must contain not less than 0.9% volatile oil. Botanical identity must be confirmed 
by macroscopic and microscopic examinations and organoleptic evaluation (Ph.Eur.3, 1997; Wichtl 
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and Bisset, 1994). The ESCOP peppermint leaf monograph requires that the material comply with 
the European Pharmacopoeia (ESCOP 2003, Ph.Eur. 5, 2005). 
The herb Pennyroyal (Mentha pulegium, family Lamiaceae), is also a member of the mint genus; an 
essential oil extracted from it is used in aromatherapy. Pennyroyal has a traditional folk medicine 
use in inducing abortions and is an abortifacient. These oils are high in pulegone, a highly toxic 
volatile, which can stimulate uterine activity. The oil of Mentha pulegium is also used as a flea 
repellant for pets. This latter usage is the origin of the plant's Latin species name, the flea being 
Pulex irritans (http://en.wikipedia.org/wiki/Pennyroyal) 
Pulegone is a naturally occurring organic compound obtained from the essential oil of Pennyroyal. It 
is a clear colorless oily liquid with pennyroyal odor. It is classified as a monoterpene and has the 
molecular formula C10H16O.                                               Synonyms for pulegone are R-(+)-5-methyl-2-
(1-methylethylidene)cyclohexanone, p-menth-4(8)-en-3-one and delta-4(8)-p-menthen-3-one.  
2. DESCRIPTION OF THE PLANT 
Mentha x piperita is a perennial herb, which is 30-90 cm high. Stems are square, erect or 
ascending, branched and the upper portion is always quadrangular. 
Leaves are arranged opposite to each other and are petiolate, ovate-oblong to oblong-lanceolate, 
serrate and pointed. The upper surface of the leaves is dark green. 
The flowers of Mentha x piperita are purplish and occur in thick, terminal, spicoid racemes of 
verticillasters. Each flower shows a tubular calyx with 5 sharp, hairy teeth, a purplish, irregular, 4-
cleft corolla, 4 short stamens, a 4-celled ovary and a projecting style ending in a bifid stigma. 
The fruit consists of 4 ellipsoidal nutlets. 
Plant material of interest are the dried leaves and the essential oil. The leaves are whole, broken or 
cut. 
 
Nowadays, the therapeutic indication for Menthae piperitae folium is the symptomatic treatment of 
digestive disorders such as dyspepsia, flatulence and gastritis. The internal use of the essential oil 
of Menthae piperitae is also the  symptomatic treatment of digestive disorders, such as 
flatulence. But it is also used in the treatment of irritable bowel syndrome and the symptomatic 
 treatment of coughs and colds. Menthae piperitae aetheroleum is also used in external 
treatments, such as the relief of coughs and colds, the symptomatic relief of rheumatic complaints 
and tension-type headache, pruritus, urticaria and pain in irritable skin conditions. (ESCOP) 
Pennyroyal (Mentha pulegium) is a perennial mint with a variable habit, ranging from low-growing, 
spreading plants to lanky, upright subshrubs. The pale or deeper pink, blue, or violet flowers are 
clustered in dense whorls at the upper nodes. The plant has a powerful and pungent minty odor. The 
stems are square in cross-section, ascending from rhizomes. Branches and simple leaves are 
opposite on stems. Unlike many mints, the flowers are not strongly bilateral, but only slightly two-
lipped. (California Invasive Plant Council database: http://ucce.ucdavis.edu/datastore/detailreport)  
 
3. INGREDIENTS / CONSTITUENT 
The main active compount of the leaves is the essential oil (1-3%), of which the principal contituent 
is usually menthol, in the form of (-)-menthol (usually 35-55%) with smaller amounts of 
stereoisomers such as (+)-neomenthol (ca. 3%) and (+)-isomenthol (ca. 3%), together with 
menthone (10-35%) menthyl acetate, menthofuran, cineole, limonene and other monoterpenes. 
The structure of Menthol and the other seven stereoisomers: 
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Over 100 components have been identified in the oil including numerous other monoterpenes and 
small amounts of sesquiterpenes, notably viridoflorol (ca. 0,5%), which is characteristic of oil from 
Mentha x piperita. 
To comply with the European Pharmacopoeia the oil must contain menthol (30-55%), menthone 
(14-32%), isomenthone (1,5-10%), menthyl acetate (2,8-10%), menthofuran (1-9%), cineole (3,5-
14%), limonene (1-5%), not more than 4% of pulegone and not more than 1% of carvone, with a 
ratio of cineole content to limonene content greater than 2. 
Various flavonoids are present in the leaves including luteolin and its 7-glycoside, rutin, hesperidin, 
eriocitrin and highly oxygenated flavones. Other constituents include phenolic acids and small 
amounts of triterpenes. (ESCOP) 
 
Peppermint oil (Ph Eur) contains maximum 4.0 % pulegone and between 1.0 and 9.0 % 
menthofuran. Mint oil, partly dementholised (Ph Eur) contains maximum 2.0 % pulegone, but no 
limit is given for menthofuran. There is no Ph Eur monograph on pennyroyal or pennyroyal oil. It is 
known from the literature that pennyroyal herb contains 1-2% essential oil of which pulegone is the 
principal component (60-90%) (Barnes et al., 2002). (EMEA, 2005) 
Other mints may contain rather different constituents: Mentha pulegium (pennyroyal) contains 80% 
pulegone, and M. crispa (crispate mint) contains 50% carvone. Another famed cultivar, spearmint, 
owes its aroma to carvone, limonene, dihydrocarvone, menthone, pulegone, 1,8-cineol and β-
pinene. (www.uni-graz.at/~katzer) 
3.1. CHEMICAL ANALYSIS 
 
European pharmacopeial grade peppermint oil is the volatile oil distilled with steam from the fresh 
aerial parts of the flowering plant. Its relative density must be between 0.900 and 0.916, refractive 
index between 1.457 and 1.467, optical rotation between –10 and –30?, among other quantitative 
standards. Identity must be confirmed by thin-layer chromatography (TLC), organoleptic evaluation, 
and quantitative analysis of internal composition by gas chromatography. 
 
3.2. STANDARDISATION 
 
Peppermint leaves consist of the whole or cut dried leaves of Mentha x piperita L. The whole drug 
contains not less than 12 ml/kg essential oil, the cut drug contains not less than 9 ml/kg. 
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The essential oil consists of 35-55% (-)-menthol, 10-35% menthone, menthyl acetate and other 
monoterpenes (Ph.Eur. 5, 2005; ESCOP 2003). Minimum requirements for food are lower. 
 
4. PHARMACOLOGY 
Carminative: The exact mechanism of this action is not known. However, one proposition is 
relaxation of the esophageal sphincter leading to release gas pressure into the stomach. 
Antispasmodic: Inhibits contraction of smooth muscles by blocking the influx of Ca+2 into muscle 
cells. 
Choleretic: Stimulates the flow of bile. May also improve the solubility of bile. 
Analgesic: Stimulates nerves which perceive cold, while depressing those that perceive pain. The 
body reacts to this sensation quite strongly by increasing blood flow to the area of application, thus 
producing a period of warmth. (http://www.geocities.com) 
 
 
4.1. HUMAN STUDIES 
 
Most modern human studies have investigated peppermint oil rather than peppermint leaf as a 
treatment for stomachache (May et al., 1996), spastic colon syndrome (Somerville et al., 1984), 
postoperative nausea (Tate, 1997), relief of colonic muscle spasm during barium enema (Sparks et 
al., 1995), irritable bowel syndrome (Carling et al., 1989; Dew et al., 1984; Fern ndez, 1990; Koch, 
1998; Lawson et al., 1988; Lech et al., 1988; Liu et al., 1997; Nash et al., 1986; Pittler and Ernst, 
1998; Rees et al., 1979), prevention of abdominal distension in postoperative gynecological 
patients (Feng, 1997), and headaches (Gobel et al., 1994; Gobel et al., 1996). The use of 
peppermint oil for irritable bowel syndrome is based on preparations in enteric-coated capsules, 
causing a spasmolytic activity on smooth muscles of the gut. In animal tests, the probable 
mechanism of action has been shown to be the inhibition of smooth muscle contractions by 
blocking calcium influx into muscle cells (Forster et al., 1980; Giachetti et al., 1988). 
In one double-blind, placebo-controlled multicenter trial, Enteroplant®, consisting of peppermint oil 
(90 mg) and caraway oil (50 mg) in an enteric-coated capsule, was studied in 45 patients with non-
ulcerous dyspepsia. After four weeks of treatment both the intensity of pain and the global clinical 
impression were significantly improved for the group treated with the peppermint/caraway 
combination compared with the placebo group (p=0.015 and 0.008, respectively) (May et al., 
1996). 
Against headache: 
The effectiveness of peppermint oil was studied for use against tension-type headaches. The liquid 
test preparation contained 10 g of peppermint oil and ethanol (90%). The external application of 
peppermintoil reduced the headache-intension significantly compared with Paracetamol (Schulz 
and Hänsel, 2004). 
Carminative and spasmolytic activity: 
In human, during endoscopy, peppermint oil injected into the lumen of the colon relieved colonic 
spasms (Leicester and Hunt, 1982). The Indian Pharmacopoeia reported carminative activity (IP, 
1996). The volatile oil of peppermint leaf is carminative and a potent spasmolytic, acting locally to 
produce smooth muscle relaxation (Bradley, 1992; Leicester and Hunt, 1982). The spasmolytic 
activity of the essential oil is stronger than of the single components (Wichtl, 1997). 
Secretolytic, mucolytic and antibacterial Effect: 
The essential oil shows secretolytic, mucolytic and antibacterial effects in the area of the respiratory 
tract. (Wagner and Wiesenauer, 2003). 
The Commission E approved the internal use of peppermint oil for spastic discomfort of the upper 
gastrointestinal tract and bile ducts, irritable colon (in enteric-coated capsules), catarrhs of the 
respiratory tract, and inflammation of the oral mucosa; and external use for myalgia and neuralgia. 
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ESCOP indicates its internal use for flatulence, irritable bowel syndrome, and coughs and colds. Its 
external use is indicated for coughs and colds, rheumatic complaints, pruritus, urticaria, and pain in 
irritable skin conditions (ESCOP, 1997). Peppermint oil is used in Western and Eastern cultures to 
treat indigestion, nausea, sore throat, diarrhea, colds, and headaches (Leung and Foster, 1996). 
Topical use 
Antiseptic and anaesthetic effect: 
The cooling effect of menthol is because of the affection of the cold-receptors in skin and mucous 
membranes. Menthol also has an antiseptic effect and in higher dosages an anaesthetic effect. 
(Braun, 1994). 
 
 
4.2. VETERINARY STUDIES 
 
Menthol is often used as a repellent against insects and in lotions to cool legs (especially for 
horses). 
Treatment of mastitis: 
Mentha piperita is used in a pharmaceutical preparation for treatment of mastitis in animals and 
humans, which consists of a mixture of a decoction and infusion, in ammonia spirit, of 16 medicinal 
herbs. (Deryabin AM; PCT International Patent Application 1990; -13305) 
 
Ruminants: 
 
Effect on digestibility, ruminal fermentation and protozoa: 
A study showed the positive effect on the digestibility by feeding peppermint. The authors constitue 
that peppermint  has a great potential as a natural manipulator of rumen fermentation by 
depressing ammonia-nitrogen concentration or numbers of protozoa. (Ando et al., 2003). 
 
Antioxidative activity: 
An experiment was done to examine the effects of peppermint feeding on antioxidative activity in 
milk of cows and showed positive results (Uegaki R. et al., 2001) 
 
Pigs: 
 
Peppermint leaves are used in herbal mixtures for piglets to enhance weight gain (Rekiel A., 1998). 
A herbal mixture with Peppermint as one component was successfully used as an alternative for an 
antibiotic substitute. Pigs obtained good average body weight gains (Urbanczyk J. et al., 2002). 
Another herb mixture, Peppermint as one component, represented good results in feeding on 
rearing performance of calves (Wawrzynczak S. et al., 2000). 
 
5. MICROBIOLOGY 
Antimicrobial activity 
Aetheroleum Menthae Piperitae inhibited the growth in vitro of Staphylococcus aureus, 
Pseudomonas aeruginosa, Bacillus subtilis, Enterococcus faecalis and Escherichia coli, but did not 
affect the growth of Bacillus cereus, Penecillium cyclopium or Aspergillus aegyptiacus. The 
essential oil inhibited the growth in vitro of Trichophyton equinum and T. rubrum (at a concentration 
of 0,4μg/ml), Aspergillus flavus, A. fumigatus and A. niger. (WHO Monographs, 2002) 
Extracts of Folium Menthae Piperitae have antibacterial and antiviral activity in vitro. Addition of 
ground leaves to the agar medium inhibited the growth of Salmonella typhimurium, Staphylococcus 
aureus and Vibrio parahaemolyticus at concentrations of 0.1–2.0%. Aqueous and ethanol extracts 
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of the leaves reduced the number of plaques of the rinderpest virus at concentrations of 4–8mg/ml 
(17). Aqueous extracts of the leaves demonstrated activity against 
the following viruses in egg and cell culture: Newcastle disease, herpes simplex, vaccinia, Semliki 
Forest and West Nile (WHO, 2002) 
 
Essential oil of peppermint induced inhibitory effect on the growth of Aeromonas isolates (Zaki HM. 
et al., 2001) 
 
6. EFFICACY 
The leaves and the essential oil of peppermint, Mentha × piperita L., have traditionally been 
used as carminative and antispasmodic herbal drugs. Spasmolytic effects of the essential oil 
have been demonstrated both in vitro on isolated gut segments and in vivo on healthy 
volunteers and in gastrointestinal endoscopy. In short-term studies, peppermint oil was 
revealed to be superior to a placebo in the treatment of irritable bowel syndrome. Due to the 
lack of well designed and carefully executed long-term studies, the significance of peppermint 
oil in the treatment of irritable bowel syndrome has not yet been elucidated. Menthol, the 
main component of peppermint oil, contributes to its spasmolytic effect. In human plasma and 
urine, mentholglucuronide has been detected as its main metabolite. Aqueous extracts from 
peppermint leaves show antiulcerogenic and cholagogic effects. In combination with the 
spasmolytic properties of the essential oil, hydrophilic compounds may contribute to the 
efficacy of peppermint leaves on spasmodic discomfort in the gastrointestinal and biliary 
system. (van Rensen, 2004) 
 
7. TOXICOLOGY 
Intragastric administration of the essential oil (100mg/kg body weight) to rats daily for 28 days 
induced histopathological changes (scattered cyst-like spaces) in the white matter of the 
cerebellum. No behavioural or clinical symptoms due to the encephalopathy were observed. 
(ESCOP) 
Pulegone is mainly metabolised through pathways involving menthofuran and these two 
substances show similar toxicity. Evaluation of their toxicity should be made together. The 
Committee noted that only a limited database was available on pulegone and menthofuran and 
considered that these data were inadequate for the derivation of an ADI (acceptable daily intake). 
To establish a NOEL for pulegone and menthofuran, at least a further 90-day study is required 
together with studies on genotoxicity at the gene and chromosome level, and probably also 
reproductive and developmental toxicity studies. (EMEA, 2005). 
The interest in toxicity of pulegone, menthofuran and peppermint oil appears to have been 
provoked by three reports in the literature. It was reported that pulegone, when given to rats for 28 
days, caused histopathological changes in the liver (vacuolisation) and the brain (“cystlike spaces”) 
(Thorup et al. 1983a,b; Olsen and Thorup, 1984). The histopathological changes were seen in rats 
receiving 80 and 160 mg/kg/day of pulegone. However, all hematological and clinical chemical 
parameters were found to be within the normal range in all groups. There were neither obvious 
signs of clinical symptoms due to encephalopathy. Based on these studies the NOEL (no effect 
level) of pulegone was considered to be 20 mg/kg bw/day. 
Later “confirmatory” studies by the same group, however, reported that there were no significant 
histopathological changes in the liver nor the brain. The “cyst-like spaces” reported in the brain in 
the earlier studies were thus not confirmed and may have arisen from inadequate tissue fixation 
procedures (Molck et al. 1998). In this study the clinical biochemical examinations revealed 
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increased plasma glucose, alkaline phosphatase and ALAT and a decreased creatinine in the dosed 
group. 
In later studies the liver toxicity of pulegone has been confirmed and a mechanism of action has 
been proposed based on its metabolism to menthofuran and other reactive metabolites, which are 
the ultimate hepatotoxins (see SCF report). 
Pharmacovigilance information 
A literature review of cases of human intoxication with pennyroyal oil (pulegone content 62-97%) 
indicate that ingestion of 10 ml (corresponding to ca 5.4-9 g pulegone, ca 90-150 mg/kg bw for a 
60 kg person; calculated with a relative density of 0.9 as for peppermint oil) resulted in moderate to 
severe toxicity and ingestion of greater than 15 ml (corresponding to ca 8-13 g pulegone, ca 130-
215 mg/kg bw for a 60 kg person) resulted in death. The clinical pathology was characterised by 
massive centrilobular necrosis of the liver, pulmonary edema and internal haemorrhage (SCF, 
2002). 
A non-urgent information request was sent out to the member states concerning use and 
association of licensed herbal medicinal products containing pennyroyal oil, peppermint oil and 
mint oil with reports of liver damage. 
The highest recommended daily dose in EU is 1.2 ml peppermint oil i.e. 1080 mg peppermint oil, 
which contains maximum 140 mg pulegone + menthofuran (Ph Eur). For a 60 kg person this would 
correspond to a daily intake of 2.3 mg/kg bw. Clearly, this recommended daily dose of peppermint 
oil in herbal medicinal products results in an intake of pulegone/menthofuran that exceeds the TDI 
(0.1 mg/kg) set for food by CEFS. 
No certain cases of liver damage caused by peppermint oil or mint oil were reported. (EMEA, 2005) 
 
 
7.1. SAFETY 
 
Interactions with other drugs: none known for peppermint leaves 
 
Internal Use of Peppermint leaves: 
Dosages 
recommended daily allowance: 
Cattle    25,0 - 50,0 g 
Horse    20,0 - 40,0 g 
Sheep, Goat     5,0 - 10,0 g 
Pig       2,0 -   5,0 g 
Dog      1,0 -   3,0 g 
Cat       0,5 -   1,0 g 
Fowl      0,2 -   0,5 g 
(by Gachnian and Assenov 1986) 
 
Peppermint tincture: 
Cattle, Equids   5,0 - 15,0 ml 
Sheep, Goat, Pig   2,0 -   5,0 ml 
Dog    0,3 -   0,8 ml 
Cat     0,1-    0,3 ml 
(by Gachnian and Assenov 1986) 
 
Prescription: 
Rp.       Rp. 
Menthae pip. fol.    10,0   Peppermint leaves    10,0 
Aqu. comm.   190,0   Drinking water   190,0 
M.f.infus.      make an infusion. 
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D.S. Internal use for a horse with intestinal spasm [modified by Rabinovich 1987]. 
 
Presently it is not allowed to use Peppermint leaves (Menthae piperitae folium) as an active agent 
for foodstuff delievering animals in the EU, but it is allowed to use Peppermintoil (Menthae 
piperitae aetheroleum) as an active agent for foodstuff delievering animals in the EU. [VO (EWG) Nr. 
2377/90]. [Reichling et al., 2005] 
Dosages and Administrations for humans:  
Unless otherwise prescribed: 6–12 drops per day essential oil and galenical preparations for 
internal and external application. 
 
Internal: 
Essential oil: Average single dose 0.2 ml.                                                                                    Essential 
oil enterically coated form: Average daily dose 0.6 ml (for IBS).                                       Inhalant: Add 
3–4 drops of essential oil to hot water; deeply inhale the steam vapor. 
 
External: 
Essential oil: Some drops rubbed in the affected skin areas (may be diluted with lukewarm water or 
vegetable oil).                                                                                                                   Liniment: Oily 
preparation containing 5–20% essential oil in base of paraffin or vegetable oil applied locally by 
friction method.                                                                                                   Ointment or unguent: 
Semi-solid preparation containing 5–20% essential oil in base of petroleum jelly or lanolin spread 
on linen for local application.                                                      Nasal ointment: Semi-solid preparation 
containing 1–5% essential oil.                                   Tincture: Aqueous-alcoholic preparation 
containing 5–10% essential oil for local application. 
 
Peppermint oil: People with esophageal reflux should avoid use of menthol-containing herbs, such 
as peppermint; the volatile oils in these plants may decrease the pressure in the lower esophageal 
sphincter and make the reflux worse  (Sigmund CJ, McNally EF., 1969). 
Contraindications: Obstruction of bile ducts, gallbladder inflammation, severe liver damage. In case 
of gallstones, to be used only after consultation with a physician. Preparations containing 
peppermint oil should not be used on the face, particularly the nose, of infants and small children. 
[Ed. Note: Peppermint oil is contraindicated in infants and small children due to the potential risk of 
glottic spasms or respiratory arrest (Schulz et al., 1998).] 
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ORIGANUM SP. 
 
  
Origanum sp  
 
 
1. INTRODUCTION 
Oregano is the world´s comercially most valued spice. It´s name, Oregano, is the common name 
for a general aroma and flavor primarily derived from more than 60 plant species used all over the 
world as a spice. The majority of them belong to the Lamiaceae and Verbenaceae families, while a 
large distinction is made between the European (Origanum sp.) and Mexican (Lippia sp.) oregano. 
European oregano is used as a flavoring in meat and sausage products, salads, stews, sauces and 
soups. Prior to the introduction of hops, oregano was used to flavor ale and beer. The essential oil 
and oleoresin, used extensively in place of the plant material, are found in food products, 
cosmetics, and alcoholic liqueurs. Oregano is also a good salt replacement in tomato-containing 
recipes. Mexican oregano is used predominantly in flavoring Mexican foods, pizza and barbecue 
sauces. Mexican oregano has a sharper and more pungent flavor than European oregano. 
The genus Origanum (Lamiaceae) includes 39 species widely distributed in the Mediterranean 
region (Vokou et al., 1993). The species Origanum vulgare predominates in occurence, while 
Origanum dictamnus is endemic of the Island of Crete in southern Greece. The plants are perennial 
herbs spontaneously growing in calcareous substrates. One of the striking morphological 
characteristics of the Origanum plants is the presence of glandular and nonglandular hairs covering 
the aerial organs. Both types of hair originate from epidermal (protodermal) cells. Every epidermal 
cell, according to Netolitzky (1932), practically possesses the potentiality to develop into a hair. The 
glandular hairs are numerous on the vegetative organs (stems, leaves, bracts), while their density 
becomes reduced on the reproductive organs (calyces, corollas). On the stamens and the 
gynoecium of the flowers, no glandular hairs have been reported to occur (Werker et al., 1985b). 
The glandular hairs secrete an essential oil with a characteristic odour, mainly due to the major 
components of the oil, the monoterpenes carvacrol and thymol. The essential oils of Origanum have 
been found to develop strong antioxidant, antimicrobial, insecticidal and genotoxic activities 
(Scheffer et al., 1986; Sivropoulou et al., 1996; Karpouhtsis et al., 1998). 
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Table 1  Different species called ‘oregano’ 
 
Table 1. Species used commercially in the world as oregano 
 
Family Species Commercial name/s found in literature 
Labiatae Calamintha potosina Schaf. oregano de la sierra, oregano, origanum 
 Coleus amboinicus Lour. (syn. oregano, oregano brujo, oregano de Cartagena, 
    C. aromaticus Benth) oregano de Espana, oregano Frances 
 Coleus aromaticus Benth. oregano de Espana, oregano, origanum 
 Hedeoma floribunda Standl. oregano, origanum 
 Hedeoma incona Torr. oregano 
 Hedeoma patens Jones oregano, origanum 
 Hyptis albida H.B.K. oregano, origanum 
 Hyptis americana (Aubl.) Urb. oregano 
    (H. gonocephala Gris.) 
 Hyptis capitata Jacq. oregano, origanum 
 Hyptis pectinata Poit. oregano, origanum 
 Hyptis suaveolens (L.) Poit. oregano, oregano cimarron, origanum 
 Monarda austromontana Epling oregano, origanum 
 Ocimum basilicum L. oregano, origanum 
 Origanum compactum Benth. (syn. oregano, origanum 
    O. glandulosum Salzm, ex Benth.) 
 Origanum dictamnus L. (Majorana oregano, origanum 
    dictamnus L.) 
 Origanum elongatum (Bonent) oregano, origanum 
    Emberger et Maire 
 Origanum floribundum Munby oregano, origanum 
    (O. cinereum Noe) 
 Origanum grosii Pau et Font Quer oregano, origanum 
    ex letswaart 
 Origanum majorana L. oregano 
 Origanum microphyllum (Benth) Vogel oregano, origanum 
 Origanum onites L. (syn. O. * Turkish oregano, oregano, origanum 
    smyrneum L.) 
 Origanum scabrum Boiss et Heldr. oregano, origanum 
    (syn. O. pulchrum Boiss et Heldr.) 
 Origanum syriacum L. var. syriacum oregano, origanum 
    (syn. O. maru L.) 
 Origanum vulgare L. subsp. gracile oregano, origanum 
    (Koch) letswaart (syn. O. gracile 
    Koch, O. tyttanthum Gontscharov) 
 Origanum vulgare subsp. hirtum oregano, origanum 
    (Link) letswaart (syn. O. hirtum Link) 
 Origanum vulgare subsp. virens oregano, origanum, oregano verde 
    (Hoffmanns et Link) letswaart 
    (syn. O. virens Hoffmanns et Link) 
 Origanum vulgare subsp. viride * Greek oregano, oregano, origanum 
    (Boiss.) Hayek (syn. O. viride) 
    Halacsy (syn. O. heracleoticum L.) 
 Origanum vulgare L. subsp. vulgare oregano, origanum 
    (syn. Thymus origanum (L.) Kuntze) 
 Origanum vulgare L. oregano, orenga, Oregano de Espana 
 Poliomintha longiflora Gray oregano 
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 Salvia sp. oregano 
 Satureja thymbra L. oregano cabruno, oregano, origanum 
 Thymus capitatus (L.) Hoffmanns et * Spanish oregano, oregano, origanum 
    Link (syn. Coridothymus capitatus 
    (L.) Rchb.f.) 
Verbenaceae Lantana citrosa (Small) Modenke oregano xiu, oregano, origanum 
 Lantana glandulosissima Hayek oregano xiu, oregano silvestre, oregano, origanum 
 Lantana hirsuta Mart. et Gall. oreganillo del monte, oregano, origanum 
 Lantana involucrata L. oregano, origanum 
 Lantana purpurea (Jacq.) Benth.& oregano, origanum 
    Hook. (syn. Lippia purpurea Jacq.) 
 Lantana trifolia L. oregano, origanum 
 Lantana velutina Mart.&Gal. oregano xiu, oregano, origanum 
 Lippia myriocephala Schlecht.&Cham. oreganillo 
 Lippia affinis Schau. oregano 
 Lippia alba (Mill) N.E. Br. (syn. L. oregano, origanum 
    involucrata L.) 
 Lippia Berlandieri Schau. oregano 
 Lippia cordiostegia Benth. oreganillo, oregano montes, oregano, origanum 
 Lippia formosa T.S.Brandeg. oregano, origanum 
 Lippia geisseana (R.A.Phil.) Soler. oregano, origanum 
 Lippia graveolens H.B.K. * Mexican oregano, oregano cimarron, oregano,  
    origanum 
 Lippia helleri Britton oregano del pais, oregano, origanum 
 Lippia micromera Schau. oregano del pais, oregano, origanum 
 Lippia micromera var. helleri (Britton) oregano 
    Moldenke 
 Lippia origanoides H.B.K. oregano, origano del pais 
 Lippia palmeri var. spicata Rose oregano 
 Lippia palmeri Wats. oregano, origanum 
 Lippia umbellata Cav. oreganillo, oregano montes, oregano, origanum 
 Lippia velutina Mart. et Galeotti oregano, origanum 
Rubiaceae Borreria sp. oreganos, oregano, origanum 
Scrophulariaceae Limnophila stolonifera (Blanco) Merr. oregano, origanum 
Apiaceae Eryngium foetidum L. oregano de Cartagena, oregano, origanum 
Asteraceae Coleosanthus veronicaefolius H.B.K. oregano del cerro, oregano del monte, oregano  
    del campo 
 Eupatorium macrophyllum L. (syn. oregano, origanum 
    Hebeclinium macrophyllum DC.) 
 
* Species of main economic importance according to Lawrence and Reynolds (1984) 
Definition:  Oregano are the dried leaves and flowers of Origanum onites L. or Origanum vulgare L. 
subsp. hirtum, or a mixture of them both (Pharmeuropa, April 2006).
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2. DESCRIPTION OF THE PLANT 
Origanum is one of over 200 genera in the Lamiaceae (mint family), and the genus includes 
culinary, fragrant, medicinal and ornamental plants. Herbaceous perennials or subshrubs, 
origanums are native to the Mediterranean and Eurasia, and grow in mountainous areas with 
rocky, calcareous soil. Some species grow in mounds that are only 2-3 inches high while others 
grow erect up to 39 inches tall. 
All members of the genus have flowers that occur in spikes; for most species these form a 
panicle with multiple branched stems growing from a central stalk. In O. onites, the spikes grow 
in a "false corymb", forming a convex or flat-topped open inflorescence. Corollas may be purple, 
pink or white depending on the species. In some species flowers are arranged in whorls. The 
calyx, or small vase-like receptacle that supports and protects the corolla and reproductive 
organs of the flower, can be bell-shaped or tubular with one or two lips. The shape of the calyx is 
the principal plant character used to distinguish between Origanum species. Flower stems can 
be erect or trailing/cascading. Trailing types like the ornamental O. rotundifolium and the 
cultivar 'Kent Beauty,' a hybrid of O. rotundifolium and another Origanum species, have a 
graceful, drooping appearance. The leaves and flowering parts of the plant contain essential oil 
glands that secrete volatile oils responsible for the plant's fragrance. 
Plants in the genus Origanum have bracts, or non-typical leaves, that surround the calyx and 
corolla. In some instances the bracts are so beautiful and colourful that the casual observer 
might mistake them for the flower. In these cases, the flower is actually hidden within the 
bracts. In some species, like O. rotundifolium and O. dictamnus (dittany of Crete), bracts overlap 
and resemble hops. 
Both the stems and leaves of origanums are often covered with fine hairs. Leaves can be of 
various shapes including round, heart-shaped and oval and may be shiny/waxy or hairy-fuzzy in 
appearance. Stems may be woody or non-woody. All species also bear tiny brown fruits called 
nutlets. 
 
3. INGREDIENTS / CONSTITUENTS 
Origanum is known widely in the world of herbs and spices for its volatile oils. Oregano is the 
commercial name of those species zhat are rich in the phenolic monoterpenoids, mainly 
carvacrol, occasionally thymol, while marjoram is the commersial name of those that are rich in 
bicyclic  monoterpenoids cis- and trans- sabinene hydrate. A number of chemically related 
compounds i.e. γ-terpinene, p-cymene, thymol and carvacrol methyl ethers, thymol and carvacrol 
acetates; also compounds such as p-cymenene, p-cymen-8-ol, p-cymen-7-ol, thymoquinone, and 
thymohydroquinone are also present. Furthermore, when cis- and/or trans-sabinene hydrate is 
the main compound, α-thujene, sabinene, cis- and trans-sabinene hydrate acetates, cis- and 
trans-sabinol and sabina ketone can also be found. Two more biochemical groups, usually of 
less significance quantitatively, are present in origanum: that of the acyclic monoterpenoids 
such as, geraniol, geranyl acetate, linalool, linalyl acetate and β-myrcene and that of bornane 
type compounds such as camphene, camphor, borneol, and bornyl and isobornyl acetate. To the 
above groups of compounds some sesquiterpenoids, such as β-caryophyllene, β-bisabolene, β-
bourbonene, germacrene-D, bicyclogermacrene, α-humulene, α-muurolene, γ-muurolene, γ- 
cadinene, allo-aromadendrene, α-cubebene, α-copaene, α-cadinol, β-caryophyllene oxide and 
germacrene-D-4-ol should also be added.  
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        carvacrol 
 
 
 
3.1 CHEMICAL ANALYSIS 
Volatile oil is quantitatively determined by water/steam distillation, and the percentage content 
of phenols expressed as thymol is determined by spectrophotometric analysis. Thin-layer 
chromatographic analysis is used for thymol and carvacrol.  
 
3.2 STANDARDISATION 
The content of essential oil should be at least 25 ml/kg related to the dry (aquatic-free) drug. 
Carvacrol and Thymol should be at least 60% of the essential oil-content (Zeitschrift 
Pharmeuropa, April 2006). 
 
4. PHARMACOLOGY 
4.1 PIG 
Effects on meat stability 
In a study the influence of feeding sage and oregano on the oxidative stability of raw belly bacon 
was demonstrated. Raw belly bacon produced from animals fed oregano demonstrated 
improved stability (P < 0.05) compared to that produced by the control group, after 34 weeks of 
storage (Bauer et al., 2001). 
 
Oreganum and its extract have an antioxidant capacity, which could be used as stabilisers of fat, 
in order to improve quality and shelf-life of meat and fat-containing food. On the one hand it 
seems possible to keep perishable fat-containing food longer by an addition of an extract of 
sage or oregano due to their antioxidative properties, on the other hand administration of feed 
additives of dried herbs (Origanum vulgare) to pigs had no effect on quality and shelf-life of fat 
obtained from these animals (Vichi et al., 2001). 
 
Effect on the weight gain and feed conversion in pigs 
A study showed the effect of high vitamin E and oregano phytogenic feed additives on the 
performance of "slow growing" fattening pigs. It was observed a significant (P < 0.01) positive 
effect of this oregano phytogenic feed additive in combination with high vitamin E regarding 
average daily gain when compared to a non-treated control group of animals, but for feed 
conversion there was no significant difference (Bilkei and Gertenbach, 2001). 
 
A study evaluated the effect of dietary oregano etheric oils as non-specific immunostimulating 
agents in growth-retarded, low-weight growing-finishing pigs. A group of pigs were fed with 
commercial fattening diet supplemented with 3000 ppm oregano additive (Oregpig®, Pecs, 
Hungary), composed of dried leaf and flower of Origanum vulgare, enriched with 500 g/kg cold-
pressed essential oils of the leaf and flower of O. vulgare, and containing 60 g carvacrol and 55 
g thymol/kg. Dietary oregano improved growth in growth-retarded growing-finishing pigs and 
had non-specific immunostimulatory effects on porcine immune cells (Walter and Bilkei, 2004).  
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A study evaluated the effects of vaccination and of a phytogenic feed additive (1000 ppm dried 
oregano [Origanum vulgare] powder) on postweaning mortality due to Escherichia coli and on 
piglet performance, that the vaccination with purified VT2e toxoid and/or oregano feed 
supplementation can prevent losses due to postweaning coli complex in weaned pigs (Ken and 
Bilkei, 2003). 
 
Effects of vaccination against Haemophilus parasuis serovar 5 (HPS 5) and E. coli and a 
phytogenic feed additive (a diet supplemented with 1000 ppm oregano) improved the 
performance of pigs in a Swiss nursery. The average daily nursery liveweight gain, feed 
efficiency and weaner mortality were recorded, observing that, from day 35, the groups of 
weaners fed the oregano supplement were significantly (P < 0.05) heavier than the groups fed 
without the supplement (Sads and Bilkei, 2003). 
 
A study revealed that the inclusion of essential oil of oregano in a pigs' diet significantly 
improved the average daily weight gain and feed conversion ratio of the pigs. Pigs fed the 
essential oils had higher carcass weight, dressing percentage and carcass length than those fed 
the basal and antibiotic-supplemented diet. In the pigs, which received the essential oil 
supplementation had a significantly lower fat thickness. Also lean meat and ham portions from 
these pigs were significantly higher. Therefore, the use of Origanum essential oil? essential oils 
as feed additives improves the growth of pigs and has greater positive effects on carcass 
composition than antibiotics (Onibala et al., 2001). 
 
Ropadiar®, an essential oil of the oregano plant, was supplemented in the diet of weaning pigs 
as alternative for anti microbial growth promoters (AMGP), observing its efficacy on the 
performance of the piglets. Ropadiar liquid contains 10% Oregano oil and has been designed to 
be added to water. Compared to the negative control (without AMGP), Ropadiar® improved 
performance only during the first fourteen days after weaning. Based on the results of this trial it 
can not be argued the usefulness of Ropadiar® as an alternative for AMGP in diets of weanling 
pigs. However its addition in prestarter diets could improve performance of these animals 
(Krimpen and Binnendijk, 2001). 
 
The objective of another trial was to ascertain, if by adding an oregano oil to the feed, there will 
be an effect on nutrient digestibilities, N-balance as well as on parameters of microbial activity 
in the gastrointestinal tract of weaned pigs. The apparent digestibility of crude nutrients (except 
fibre) and the N-balance of the weaned piglets in this study was not influenced by feeding piglets 
restrictively with this feed additive (which additive? essential oil?, at which percentage?). By 
direct microbiological methods, no influence of the additive on the gut flora could be found 
(Moller, 2001). 
Antibiotic-Resistance 
A study compared the resistance patterns of Escherichia coli isolated from pig herds receiving 
antibiotics or oregano (Oregpig®, Pecs, Hungary) as preventive feed additives. Oregano-fed pig-
herds demonstrated significantly (P < 0.001) lower MICs (minimum inhibitory concentrations; 
µg/ml) for ampicillin, doxycyclin, enrofloxacin, gentamycin, oxytetracyclin and sulfamethacin 
against Escherichia coli compared to herds with prophylactic use of antibiotics. Resistance to 
ceftiofur revealed significant (P < 0.05) differences between the antibiotic- or oregano-treated 
units (Docic and Bilkei, 2003). 
 
Effect of Origanum vulgare on weaning-to-estrus interval and farrowing rate in sows  
Sows during lactation or until the first standing oestrus were fed with a diet supplemented either 
with oregano (Origanum vulgare), chlortetracycline or no supplement. Results showed that 
weaning-to-oestrus interval was shorter in sows supplemented with oregano compared to other 
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treatments. Farrowing rate was greater in sows supplemented with either chlortetracycline or 
oregano compared to untreated sows. (Kis and Bilkei, 2003). 
Also another study reported that dietary Oregano supplementation improved the 
sows´reproductive performance. Farrowing sows receiving 1000 ppm Oregpig® (Pecs, Hungary) 
in their lactation diet showed a lower mortality rate, a lower culling rate during lactation, an 
increased farrowing rate, more liveborn piglets and less stillbirth piglets per litter compared with 
untreated females (Kovac and Bilkei, 2003). 
Alternate diets containing 1000 ppm of oregano feed supplementation (Oregpig®) were 
provided in farrowing groups of sows during lactation, from parturition throughout lactation and 
from weaning to mating. Compared to untreated sows, oregano treated sows showed lower 
annual mortality rate, lower culling rate during lactation, increased farrowing rate, more liveborn 
piglets per litter and less stillbirths. Results showed that oregano as a feed additive of natural 
origin may be useful in pig breeding (Mauch and Bilkei, 2004). 
4.2 FOWL 
Effect of oregano essential oil on performance of broilers 
A dietary supplementation of oregano essential oil (300 mg/kg) showed a positive effect on 
performance of broiler chickens experimentally infected with Eimeria tenella. Throughout the 
experimental period of 42 days, oregano essential oil exerted an anticoccidial effect against E. 
tenella, which was, however, lower than that exhibited by lasalocid. Supplementation with 
dietary oregano oil to E. tenella infected chickens resulted in body weight gains and feed 
conversion ratios not differing from the non-infected group, but higher than those of the infected 
control group and lower than those of chicken treated with the anticoccidial lasalocid 
(Giannenas et al., 2003). 
 
In another study effects of the addition of herbal mixture (which is not specified by the authors) 
or essential oil to chickens feed-ratio did not alter the final liveweight after 35 days, but the feed 
to gain ratio significantly decreased in the chicks supplemented with herbal mixture and 
essential oil. The chickens recieved 1 g essential oil (oregano/clove, 1:1?) or 1 g essential oil 
(oregano/cinnamon, 1:1?) per kg body weight. (Halle et al., 2001). 
 
4.3 RUMINANTS 
Effects of natural plant extracts on protein degradation and fermentation profile  
Eight dual-flow continuous culture fermenters were used in four consecutive periods of 10 days 
to study the effects of six natural plant extracts on ruminal protein degradation and 
fermentation profile. Fermenters were fed a 60:40 (52:48?), lucerne hay:concentrate diet (DM). 
One of the treatments was 7.5 mg/kg DM of extracts of Origanum vulgare, which increased the 
acetate and decreased the propionate proportion during the first 6 days of fermentation, in 
comparison to controls untreated with the plant extract. However, these differences disappeared 
after day 7, suggesting that rumen microbes were adapted to the additives within 7 days and 
that data from short-term in vitro fermentation studies may lead to erroneous conclusions, and 
should be interpreted with caution (Cardozo et al., 2004). 
 
4.4 HUMANS AND ANIMALS 
Treatment of mastitis 
Origanum vulgare is used in a pharmaceutical preparation for treatment of mastitis in animals 
and humans, which consists of a mixture of a decoction and infusion, in ammonia spirit, of 16 
medicinal herbs (Deryabin AM; PCT International Patent Application 1990; -13305). 
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5. MICROBIOLOGY 
5.1 ANTIFUNGAL ACTIVITY 
The antifungal activity is strongly correlated with the composition of the essential oil, its 
concentration and pH of the testing medium in vitro. Phenols are believed to be the most potent 
antimicrobials followed by alcohols, ketones, ethers and hydrocarbons. These presumptions are 
in accordance with the findings of Biondi et al. (1993), who reported that carvacrol - rich O. 
onites L. essential oil showed more potent antifungal activity against A. niger, Aspergillus 
terreus, C. albicans and against Fusarium spp. than the oregano oil, composed prevently of 
terpinene-4-ol and of γ-terpinene. A potent antifungal effect of O. vulgare essential oil (rich in 
carvacrol and thymol) at concentration of 1 μl/ml against the common spoilage fungus A. niger 
was observed also by Baratta et al. (1998a). 
Other authors documented the inhibitory effect of Origanum essential oil against Candida 
albicans in vitro as well as after oral administration to mice in vivo (Hammer et al., 1999; 
Manohar et al., 2001). 
However, there are many differences among genera of fungi with regard to sensitivity to the 
antifungal effects of oregano and of its essential oils. Also, the concentration of an essential oil 
and its origin may significantly influence their antifungal activity (Kintzios et al., 2002).  
 
5.2 ANTIBACTERIAL ACTIVITY 
Based on a broad spectra of antibacterial activity, oregano seems to be one of the most 
inhibitory spices tested. Essential oils of O.vulgare and O. majorana have been investigated for 
their activity against Acinetobacter baumanii, Aeromonas veronii biogroup sobria, Streptococcus 
faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella 
enterica subsp. enterica serotype typhimurium, Serratia marcescens and Staphylococcus 
aureus. It was found that O. vulgare (Australian origin) yielded one of the most potent 
antibacterial agents, which considerably inhibited the growth of all tested microorganisms. The 
lowest minimum inhibitory concentration of O. vulgare essential oil was 0,12 per cent (v/v) and 
0,25 per cent (v/v) of O. majorana. Among the tested bacteria, the most resistant was 
Pseudomonas aeruginosa, that was inhibited by O. vulgare essential oil at 2 per cent (v/v), but 
not by O. majorana oil (Hammer et al., 1999). 
An evaluation of the antibacterial properties of Origanum essential oil against S. aureus, Bacillus 
anthracis, E. coli, K. pneumoniae, Helicobacter pylori and Mycobacterium terrae, revealed a 
bactericidal activity to all tested organisms.  The essential oil was bacteriostatic only against B. 
anthracis (Presuss et al., 2005). 
 
5.3 ANTIOXIDANT ACTIVITY 
The antioxidative effects of O. vulgare drug (Origani herba) have been studied in the light of both 
direct use of O. vulgare as stabilisers of fat and, indirectly, as feed additives in order to improve 
the shelf-life of meat and fat-containing food obtained from animals treated with O. vulgare 
(Vichi et al., 2001). In contrast with the significant antioxidative and stabilising effects of 
oregano extracts in lard (measured by photochemiluminescence), no effect on the quality or 
shelf life of the fat obtained from animals fed with oregano additives was observed (Vichi et al., 
2001). Antioxidant properties were demonstrated also for a hydroalcoholic extract of Origanum 
vulgare leaves by its iron-reducing activity in vitro (Yoshino et al., 2006). 
 
5.4 ANALGESIC, ANTIAGGREGANT, ANTIINFLAMMATORY AND ANTISPASMODIC ACTIVITY 
Carvacrol-rich (67 per cent) essential oil of Origanum onites, collected at the Izmir locality 
(Turkey), showed a marked dose-dependent analgesic activity as assessed by the tail-flick 
method in male albino mice. After administration, at 0,33 ml/kg, the activity of O. onites oil was 
comparable to that of morphine (1 mg/kg), but at 0,03 ml/kg the essential oil was more potent 
than fenoprofen (at 8 mg/kg) (Aydin et al., 1996). Findings obtained in the study strongly 
suggested that the analgesic activity of the essential oil is related to its carvacrol content (Aydin 
et al., 1996). The antiaggregant effect of a methanol extract of O. majorana on human platelets 
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has been studied by Okazaki et al. (1998). O. majorana extract concentration-dependently 
inhibited platelet aggregation induced by collagen (2,0 μg/ml) or ADP (2,0 μg/ml). Successive 
fractionation of the methanol extract led to isolation of the hydroquinon β-D-glucopyranoside-, 
arbutin, which strongly inhibited platelet aggregation induced by (collagen, ADP, arachidonic 
acid, and thrombin (Okazaki et al., 1998). 
Only a few reports on the topical anti-inflammatory effects of O. vulgare refer to oregano-herbal 
mixtures or their decoctions, used in the treatment of inflammation as supporting therapies 
(Deryabin, 1990 and 1991). A hydroalcoholic extract of Origanum vulgare leaves, orally 
administered to mice, significantly prevented gastritis induced by cold-resistant stress, while its 
cutaneous application prevented contact hypersensitivity induced by oxazolone (Yoshino et al., 
2006). 
While analysing the antispasmodic effects of Origanum, it was found that water macerates of O. 
compactum significantly inhibited smooth muscle response induced by any of the tested 
spasmogens (acetylcholine, histamine, serotonine, BaCl2, nicotine) in the guinea-pig ileum.  
Moreover, in the pharmacological inhibition of smooth muscular activity, non-specific and non-
competitive mechanism of action was attributed to thymol and carvacrol: they caused both 
direct musculotropic (muscle relaxant activity) and indirect neurotropic (inhibition of the nerve 
action potential) actions on the smooth muscle (van den Brouke and Lemli, 1980). The same 
results were obtained by testing the antispasmodic effects of pure active components, i.e. 
thymol and carvacrol. It was concluded that both phenols act as non-competitive Ca 2+ 
antagonists, which block nerve fibre conduction and induce musculotropic and neurotropic 
spasmolyse (van den Brouke and Lemli, 1982). 
 
5.5 IMMUNOSTIMULATING, ANTIMUTAGENIC AND PROTECTIVE EFFECTS 
Some studies have been shown that oregano extracts or herbal mixtures with Origanum spp. 
possess in vitro antiviral activity or have immunostimulating effects both in vitro and in vivo. 
However, little knowledge has been attained so far on mechanism of immunomodulating 
activity or underlying active compounds (Kintzios et al., 2002). 
A strong and dose-dependent capacity of inactivating dietary mutagen Trp-P-1 in the Salmonella 
typhimurium TA 98 assay was observed for O. vulgare water extracts, that exhibited significant 
antimutagenic effects in vitro (Ueda et al., 1991). 
A study evaluated the effect of oral administration of O. majorana (volatile oil, alcoholic and 
aqueous extracts) on the toxicity induced by oral administration of lead acetate in the diet of 
mice for one month. Mice treated with the 3 different preparations of O. majorana, one month 
before and maintained with lead acetate administration, showed a significant decrease in 
serum transaminases, alkaline phosphatase, urea and creatinine, and improved the liver and 
kidney histology in comparison with lead acetate treated group. Alcoholic extract significantly 
reduced the rate of micronucleus, number of aberrant cells and different kinds of chromosomal 
aberrations. Volatile oil extract significantly reduced the rate of micronucleus and chromosomal 
fragments. Aqueous extract and volatile oil significantly reduced also the number of gaps, ring 
chromosome and stickiness. The study demonstrated that O. majorana plays an important role 
in ameliorating liver and kidney functions and genotoxicity induced by lead acetate (El-
Ashmawy, 2005). 
 
6. EFFICACY 
The claimed efficacy for this herb has not been documented. 
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7. TOXICOLOGY 
Single components of Origanum essential oils - such as d-limonene from O. majorana - showed a 
carcinogenic effect in male rats (de Vincenzi and Mancini 1997) This carcinogenic effect as well 
as other renal damages observed in male rats are species and gender specific: consequently 
they are not predictable for human toxic effects (Meek et al., 2003)! 
 and several studies confirmed the allergenic potential of Origanum spp. Origanum vulgare 
showed cross-sensitivity with other plants of the Lamiaceae family, confirmed in in vitro and in 
vivo studies (references). The potential allergic response, that could be evoked in sensitive 
patients after the ingestion of food seasened with O. vulgare, comprises an increased serum 
level of specific IgE and induced systemic allergic reactions (Benito et al., 1996). Perioral 
dermatitis has been reported to be induced by O. majorana food flavouring (Farkas, 1981). O. 
vulgare has been shown also to induce allergic contact dermatitis, as clinically evaluated by 
patch test (Futrell and Rietschel, 1993). Due to empirically proven emmenagogue and 
abortifacient effects, excessive use of O. vulgare or O. majorana should be avoided during 
pregnancy (Brinker, 1998). 
 
 
7.1 SAFETY 
Dosages for a dog: 
Internal use: 
1,5 - 2g origanum-wort, 3 times a day as an infusion. 
The dosage depends on the age and the weight of the dog (Reichling et al., 2005). 
 
Presently it is not allowed to use Origani herba as an active agent for foodstuff delievering 
animals in the EU [VO (EWG) Nr. 2377/90] (Reichling et al., 2005). 
Presently there are no experiences with Origani herba and pregnant or lactating animals 
(Reichling et al., 2005). 
KBB 
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PETROSELINUM CRISPUM 
  
Petroselinum crispum  
 
1. INTRODUCTION 
 
Parsley is known in the Mediterranean region since about 2000 years, and it was initially 
predominantly used for medical purposes. Nowadays, it is used as a spice in nearly all 
temperate regions of the world (Teuscher, 2003). It is also extensively used in food industry for 
flavouring meat, sauces and for the production of spice concentrates (Frank, 1994). 
As far as its medical use is concerned, the stimulation of gastric and bile secretion and a 
digestive action is attributed to the plant because of its essential oil content (Teuscher, 2003). 
It is also stated to possess spasmolytic, diuretic, emmenagogue, expectorant, antirheumatic 
and antimicrobial properties. Traditionally, it has been used for dyspeptic disorders, colic, 
cystitis, dysuria, bronchitic cough, dismenorrhoea, functional amenorrhoea and myalgia 
(Barnes et al., 2002). The volatile oil and its main compound apiole have been misused in high 
doses as an abortefacient (Frank, 1994). 
Most of these indications are not yet scientifically documented, and so far only the use of 
parsley root and herb as a diuretic in disorders of the urinary tract and for the prevention and 
therapy of renal gravel is recommended. The use of parsley fruits, however, has been negatively 
judged by the Commission E, due to their higher content of the volatile oil compounds apiole 
and myristicin which are associated with negative side effects (Blumenthal, 1998; Wichtl, 
2002). In herbal veterinary medicine, parsley roots are occasionally used as an ingredient of 
diuretic herbal teas (Bentz et al., 1989). However, also for this application the efficacy remains 
to be documented. 
 
2. DESCRIPTION OF THE PLANT 
 
The genus Petroselinum HILL belongs to the Apiaceae (Umbelliferae) family, subfamily 
Apioideae, tribus Ammineae. It only consists of 2 species, namely P. segetum (L.) KOCH and P. 
crispum MILL. (Synonyma: P. sativum HOFFM., P. hortense Auct. non HOFFM.), the latter one being 
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used for medical and culinary purposes. The species P. crispum MILL. is divided in two 
subspecies: P. crispum ssp. crispum is available with a unruffled and a ruffled leaf form, and 
from this subspecies mainly the leaves are used, whereas P. crispum ssp. tuberosum BERNH. ex  
RCHB. is the main source for parsley roots. Furthermore, in P. crispum three chemical races can 
be differentiated depending on the composition of the volatile oil  (Frank, 1994). 
 
2.1 SYSTEMATICS 
 
The genus Petroselinum HILL belongs to the Apiaceae (Umbelliferae) family, subfamily 
Apioideae, tribus Ammineae. It only consists of 2 species, namely P. segetum (L.) KOCH and P. 
crispum MILL. (Synonyma: P. sativum HOFFM., P. hortense Auct. non HOFFM.), the latter one being 
used for medical and culinary purposes. The species P. crispum MILL. is divided in two 
subspecies: P. crispum ssp. crispum is available with a unruffled and a ruffled leaf form, and 
from this subspecies mainly the leaves are used, whereas P. crispum ssp. tuberosum BERNH. ex  
RCHB. is the main source for parsley roots. Furthermore, in P. crispum three chemical races can 
be differentiated depending on the composition of the volatile oil  (Frank, 1994). 
The plant parts used for flavouring and medical purposes are the fruits and the volatile oil 
obtained from them, the roots and the herbs. For medical applications, normally tea 
preparations are used (Frank, 1994). 
 
2.3 PLANT PARTS USED 
 
Confusions of the leaves with the leaves from Aethusa cynapium L. or Conium maculatum L. 
have been described. The discrimination is possible by macroscopic criteria, and also by 
chemical analysis. Parsley root is sometimes mistaken with the roots of Pastinaca sativa L. In 
contrary to parsnip, parsley root bark becomes red when FeSO4 is added (Teuscher, 2003; 
Frank, 1994). 
 
3. CONSTITUENTS 
  
The whole plant contains volatile oil with the phenylpropanes myristicin and p-apiole as well as 
mono- and sesquiterpenes. Furthermore flavones and small amounts of furanocoumarins 
(bergapten, imperatorin, isopimponellin, xanthotoxin, psoralen) are present. 
The fruits have the highest volatile oil content (2-6%). Depending on the composition of the 
volatile oil in the ripe fruits, 3 chemical races can be distinguished: the myristicin-type (49-77% 
myristicin, 0-23% apiole and 1-23% allyltetramethoxybenzene, ATMOB); the apiole-type (58-
80% apiole, 9-30% myristicin, up to 6% ATMOB); and the ATMOB-type (50-60% ATMOB, 26-37% 
myristicin and apiole in traces). The main flavone is apiin, and furanocoumarins are present at 
a concentration of about 0.003%. Additionally, the fruits are very rich in fatty oil with 
petroselinic acid as the main compound (60- 80%). 
The volatile oil content of the herb is much lower (0.016-0.3% in the fresh herb; up to 1.2% in 
the dried herb). The flavonoid content of the dried herb is 1.9-5.6%. Furthermore small amounts 
of coumarins are present. The herb is very rich in chlorophyll (about 1%), why it has been  used 
for chlorophyll extraction in the past. 
The dried roots contain 0.05-0.12% essential oil, and the fresh ones up to 0.73%. The flavonoid 
content is 0.2-1.3% of the dry weight, calculated as apiin. Furthermore, small amounts of 
furanocoumarins and phthalides (ligustilide, senkyunolide) were found, and also polyacetylenes 
(falcarinol, falcarinon, falcarinonol) are present. 
The volatile oil can be qualitatively and quantitiatively analyzed by GC and/or TLC after steam 
distillation. The flavonoid spectrum can be analyzed by TLC and HPLC. Adulteration with 
Aethusa cynapium L. can be detected by the presence of volatile oil compounds like 
aethusanole and aethusin, which must not be present in the GC chromatograms of P. crispum 
(Frank, 1994). 
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4. PHARMACOLOGY 
Scientific studies to document the claimed effects of parsley are rather rare, and clinical trials 
in humans or productive livestock do not exist at all. 
 
4.1: IN VITRO AND ANIMAL TESTING 
 
According to older investigations in rats and mice, the volatile oil of parsley shows a diuretic 
effect. A diuretic and spasmolytic activity is also postulated for the flavonoids (Teuscher, 2003). 
A parsley extract (0.25-1 ml/kg, i.v.) has been reported to lower the blood pressure of cats by 
more than 40%, and to decrease both respiratory movements and blood pressure in 
anaestzesized dogs. Parsley exhibits a tonic effect on both intestinal and uterine muscle. The 
uterine effect has been attributed to the apiole content, but has also been observed with apiole-
free aqueous extracts (Barnes et al., 2002). 
A methanolic parsley herb extract exhibited estrogenic activities in an estrogen sensitive breast 
cancer cell line. Flavonoids were isolated as active compounds. Estrogenic activities were 
enhanced by removal of the glycoside moiety. Apigenin, diosmetin and kaempferol were the 
most active compounds, with estrogenic activities nearly equal to those of the isoflavones 
daidzein and genistein.  Furthermore, the crude extract, apiin and apigenin restored the uterus 
weight of ovariectomized mice after p.o. administration for 7 days (Yoshikawa et al., 2000). 
Polyacetylenes like falcarindiol, which had also been detected in parsley, were shown to 
possess medium level cytotoxicity in vitro against myeloma, leukaemia and lymphoma cell 
lines, with IC50 values around 30 µM. Colorectal cancer cell lines were less susceptible, with IC50 
values around 100 µM (Zidorn et al., 2005). Myristicin from parsley leaf oil inhibited 
benzo[a]pyrene induced tumorgenesis in female A/J mice. This could be due to its high activity 
as an inducer of the detoxifying enzyme glutathione-S-transferase, which was observed in 
mouse liver and small intestinal mucosa (Zheng et al. 1992). 
The antioxidant activity of parsley leaf and stem aqueous and methanolic extracts has been 
shown in several in vitro test systems (for example Hinneburg et al., 2006; Wong and Kitts, 
2006). 
Recently, some evidence for a potential antidiabetic effect of parsley was found: 
Yanardag et al. (2003) investigated the effect of an aqueous parsley leaf extract, which was 
administered at a dose of 2 g/kg every day for 28 days, to streptozotocin-induced diabetic rats. 
They found a significant reduction of blood glucose levels, and the activity of the extract was 
not insulin-like. The authors suggest inhibition of gluconeogenesis and direct stimulation of 
glycolysis to be ivnolved in the mechanism of action. 
 Using the same model, Bolkent and coauthors (2004) investigated the hepatoprotective effect 
of this extract. The degenerative changes observed in the hepatocytes of diabetic rats were 
significantly reduced or absent in the hepatocytes of diabetic rats treated with parsley. 
Furthermore, treated rats demonstrated significantly lower levels of alanine transaminase and 
alkaline phosphatase than untreated diabetic rats. Oszoy-Sacan et al. (2006) compared the 
hepatoprotective effect of this extract to the effect of the antidiabetic agent glibornuride using 
the same animal model. They found a better protective effect against liver damage for the 
parsley extract and suggested that it was caused by the extract´s antioxidant potential.  Göksel 
et al. (2003) showed, that the same extract reversed the effects of diabetes on tissue lipid 
peroxidation and glutathione levels in the aorta and heart tissues in this animal model. Aorta 
lipid peroxidation was significantly decreased, and the decrease of glutathione levels in the 
heart was prevented. According to the authors, these effects might be caused by the 
hypoglycaemic effect as well as by the antioxidant activity of parsley. Despite the promising 
results of these studies, the observed effects could not yet be attributed to a certain compound 
or class of compounds. Additionally, the high dose administered in these studies (2 g/kg b.w.!) 
should be considered. 
Mekhfi et al. (2004) found an inhibitory effect on platelet aggregation of an aqueous parsley  
herb extract in vitro using rat platelets. Also in this assay high doses were used (10 mg/ml).  
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Finally, an ethanolic parsley herb extract (1 or 2 g/kg b.w.) was shown to possess 
gastroprotective properties as evidenced by its significant inhibition of basal gastric secretion 
and of the formation of gastric lesions induced by pylorus ligation, hypothermic restraint stress, 
indomethacin, ethanol and strong alkali (Al-Howiriny et al. 2003). 
 
4.2 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
The only available data concern the metabolism of myristicin, a constiutent of the volatile oil. 
Lee et al. (1998) investigated the in vitro and in vivo metabolism of myristicin in rats. 
Metabolites were determined by GC-MS analysis. Myristicin was metabolized to 1,2-dihydroxy-4-
methoxy-5-allylbenzene and to a lower extent to 1´-hydroxymyristicin by rat liver microsomes in 
vitro. After p.o. administration of myristicin (100 mg/kg b.w.) to rats, the same metabolites 
were found in the urine, and enzymatic hydrolysis suggested that these metabolites were also 
conjugated to different extent. The presence of amphetamine derivatives, which had been 
found as myristicin metabolites in earlier studies, was not confirmed in this trial. Yun et al. 
(2003) investigated the importance of P450 enzymes for the formation of 5-allyl-1-methoxy-
2,3-dihydroxybenzene. The results of this study provide evidence that CYP 3A4 and CYP 1A3 
play a role in the formation of the major myristicin metabolite, thus the authors conclude that 
administration of myristicin would alter the metabolism of drugs metabolized by those 
enzymes and cause interactions. 
 
5. MICROBIOLOGY 
Lyophilized parsley leaf powder showed antibacterial activity in concentrations from 0.12 to 8% 
in the agar, depending on the microorganism. For example, the growth of Escherichia coli, 
Listeria monocytogenes, Listeria innocua and Erwinia carotovora was inhibited (Manderfeld et 
al., 1997). The inhibitory potential of a methanolic parsley leaf extract and of pure coumarins 
was tested against a variety of gram positive and gram negative bacteria, yeasts, mold and 
plant-pathogenic fungi. The extract showed modest antimicrobial activity against Pseudomonas 
aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis and Saccharomyces 
cerevisiae, and bacteriostatic activity against Bacillus subtilis at an amount of 500 µg. 
Concerning the plant pathogenic fungi, the extract clearly inhibited Heterobasidion annosum, 
but promoted the growth of Phytophtora. The tested coumarins were effective against some 
plant pathogens, but only showed very weak effects on bacteria, yeasts and mold (Ojala et al., 
2000).  
El Astal et al. (2005) tested aqueous, ethanolic, methanolic and phenolic leaf extracts and a 
commercial volatile oil of parsley against 10 pathogenic microorganisms using the hole plate 
diffusion technique. The methanolic extract inhibited Salmonella typhi and Staphylococcus 
aureus at a concentration of 5 mg/ml, and the essential oil (100 µl) additionally inhibited 
Pseudomonas aeruginosa. The other extracts were even less active. 
Wong and Kitts (2006) assessed the antimicrobial activity of aqueous and methanolic parsley 
leaf and stem extracts against E. coli and B. subtilis by determination of cell damage and 
growth inhibition. The methanolic extracts showed the higher activity than the aqueous ones. 
 
6. EFFICACY 
The efficacy in most of the indications parsley is traditionally used for is not documented by 
scientific studies so far.  At the moment, only the use of parsley herb and root as a diuretic is 
recommended. Also this indication is not documented by clinical trials. The use of parsley fruits 
is not recommended because of the negative risk-benefit ratio and the lack in documentation 
of efficacy (Blumenthal, 1998; Wichtl, 2002). Concerning the medical use in productive 
livestock, no scientific data are available so far. 
The plant is extensively used in food for flavouring purposes, and it is listed by the Council of 
Europe as natural source of food flavouring in category N2. This category indicates that parsley 
can be added to foodstuffs in small quantities, with a possible limitation of an active principle 
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(as yet unspecified) in the final product. In the USA, the plant is listed as GRAS (Generally 
Recognized As Safe) (Barnes et al., 2002). 
 
7. TOXICOLOGY 
7.1 SAFETY 
Potentially toxic constituents of parsley are the volatile oil compounds apiole and myristicin 
and the furanocoumarins like psoralen, bergapten and xanthotoxin. 
Apiole and myristicin are documented to be hepatotoxic. The compounds are documented to 
have a similar chemical structure and acute toxicity to safrole, which is known to be 
carcinogenic and hepatotoxic. The carcinogenic potenitial of apiole and myristicin has not been 
evaluated. LD50 values for apiole and myristicin have been documented as 50 mg/kg and 200 
mg/kg b.w. respectively (mouse, i.v. injection) (Barnes et al., 2002). In comparison, the LD50  
 for an ethanolic extract of the aerial plant parts was determined as 13 g/kg b.w. in rats (i.p. 
injection) (Al-Howiriny et al., 2003). 
High doses of parsley oil or apiole have been misused as abortefacient (up to 10 g apiole or 1 g 
daily for 1-2 weeks) due to the tonic effect of apiole in the uterine smooth muscle (Frank, 
1994). Also parsley tea is sometimes misused for this purpose (Ciganda and Laborde, 2003). 
Apiole intoxications are characterized by gastroenteristis, headache, elevated pulse rate, shock, 
coma, kidney irritation and liver damage (Frank, 1994). The ingestion of approximately 10 g 
apiole has been reported to cause acute haemolytic anaemia, thrombocytopenia purpura, 
nephrosis and hepatic dysfunction. However, 10 g apiole are equivalent to a dose of more than 
200 g parsley, thus the amount of apiole ingested by normal dietary consumption of parsley is 
stated to be non hazardous (Barnes et al., 2002).  
Myristicin has been documented to cause vertigo, deafness, hypotension, a lowered pulse rate 
and paralysis followed by fatty degeneration of the liver and kidney. Additionally, the compound 
is known to possess hallucinogenic properties. However, when compared to nutmeg, parsley 
contains a relatively low amount of myristicin (less than 0.05% in parsley leaf, about 0.4-0.89% 
in nutmeg). Parsley seed is potentially hazardous due to its higher volatile oil content (Barnes et 
al., 2002). 
After external application, the undiluted volatile oil was not found to be irritant on mouse and 
pig skin, but under occlusion for 24 hours it led to severe irritations in rabbits.  The external 
application of the essential oil did not elicit phototoxic reactions in mice and pigs. 2% solutions 
of the volatile oil did not provoke reactions over 24 hours in humans using the patch test 
(Frank, 1994).  
Parsley contains phototoxic furanocoumarins. Photodermatitis resulting from oral ingestion of 
parsley is thought to be unlikely due to the rather low content. The estimated daily ingestion of 
furanocoumarins from parsley is 20 µg in Switzerland; for comparison, the minimum erythema 
producing dose of xanthotoxin is 240 µg/kg b.w. per day (about 14 mg per capita per day). 
However, a phototoxic reaction from topical contact is possible (Barnes et al., 2002; Frank, 
1994; Teuscher, 2003). Allergic reactions are not very common, but are more likely, if already 
an allergy against other Apiaceae or against mugwort (Asteraceae) exists (Teuscher, 2003). 
The use of parsley should be avoided during pregnancy and lactation, and when suffering from 
inflammatory renal diseases (Wichtl, 2002). 
To summarize, the plant should not be ingested in excessive amounts by humans in view of the 
documented toxicities of apiole and myristicin (Barnes et al., 2002). To what extent these 
safety and toxicity data are also valid for the application in productive livestock, remains to be 
clarified. So far, no data exist on this issue. 
 
7.2 DOSAGE 
Leaf/ root: 2-4 g daily (infusion 3 times daily) 
(Seed: 1-2 g daily) 
Liquid extract (1:1 in 25% alcohol) 2-4 ml three times daily (Barnes et al., 2002). 
_________________________________________________________________________________
EMW 
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PIMPINELLA ANISUM 
  
Pimpinella anisum  
 
1. INTRODUCTION 
The use of anise (Pimpinella anisum L.) for flavouring and medical purposes has a long 
tradition. The fruits are extensively used as a spice for flavouring bread and bakery products, 
and the essential oil is often added to foodstuff and liqueurs as a sensory and flavoring agent. 
Aniseed is listed by the Council of Europe as a natural source of feed flavouring, and in the USA 
it is listed as GRAS (Generally Recognized as Safe) (Staesche et al., 1994, Barnes et al., 2002). 
As far as its medical use is concerned, aniseed is stated to possess expectorant, 
antispasmodic, carminative and parasiticide properties. In traditional medicine, the drug has 
been used internally for bronchial catarrh, pertussis, spasmodic cough, flatulent colic, and 
externally for pediculosis and scabies. Furthermore it has been used as an estrogenic agent. It 
has been recommended to increase milk secretion, promote menstruation, facilitate birth, 
alleviate symptoms of the male climacteric and increase libido (Barnes et al., 2002).  
Nowadays, it is stated to be effective in the treatment of dyspeptic complaints such as mild 
spasmodic gastrointestinal complaints, bloating, flatulence (internally) and against catarrh of 
the upper respiratory tract (internally and externally) (Wichtl, 2002; ESCOP, 2003). The 
documented pharmacological effects support some of the medical uses (Barnes et al., 2002). 
Additionally, the essential oil is used as a fragrance additive in pharmaceutical and cosmetic 
products (toothpastes, perfumes, soaps, detergents, creams, lotions), and as a repellent 
against flying insects and lice. The residue from essential oil distillation is often used as fodder 
in husbandry because of its high protein and fatty oil content (Staesche et al., 1994). 
 
 
2. DESCRIPTION OF THE PLANT 
Anise (Pimpinella anisum) is a herbaceous, annual plant becoming 30-50 cm high. The stem is 
terete, channelled and branched in the upper part. The leaves are not partite in the lower part 
of the plant and becoming more and more pinnatisect towards the upper part. The flowers are 
arranged to double umbels consisting of about 7 to 15 rays. The fruits consist of 2 greyish-
brown, about 2 mm long, inversely pyriform, slightly corrugated schizocarps (cremocarp), which 
normally do not fall apart. Each fruitlet has 5 straight ribs. The smell is anethole-like, the taste 
is sweetish-aromatic (Staesche et al., 1994; Wichtl, 2002). 
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2.1 SYSTEMATICS 
The genus Pimpinella belongs to the Apiaceae family, subfamily Apioideae, Tribus Apieae, 
subtribus Apiinae, and comprises about 90 species. The genus is divided into 2 sections, 
according to macroscopic criteria. P. anisum belongs to section Anisum. The original 
provenience of the plant is unknown. Nowadays it is cultivated in many parts of the world, 
mainly in southern Europe, India, China, Japan, Chile, Argentina and Mexico. 
 
2.2  PLANT PARTS USED 
 
The plant parts used are the fruits (Fructus Anisi) and the essential oil (Aetheroleum Anisi). 
Fructus Anisi consists of the whole dry cremocarp of P. Anisum. Aetheroleum Anisi is the 
essential oil obtained by steam distillation of the cremocarp of P. anisum. Both materials 
comply to the respective monographs of the European Pharmacopoea. In the past, the EAB also 
had permitted the use of the essential oil of Illicium verum L. (star anise) as Aetheroleum Anisi. 
This has changed, and according to the latest monograph version, only P. anisum oil is allowed 
(Ph. Eur. 5, 2005a, b). 
The squeezed or powdered fruits are prepared as tea, and the essential oil can be used 
internally or externally (for inhalation). The essential oil can also be processed to spirit of anise 
or distilled anise water (Staesche et al., 1994). 
As the drug is nowadays mainly obtained from cultivation, adulterations do not occur so often 
any more. The most dangerous adulteration were the toxic fruits of Conium maculatum L. 
(poison hemlock). They can be distinguished from P. anisum fruits by macroscopic criteria and 
by chemical detection of coniin. The essential oil of I. verum can be identified by the detection 
of foeniculin, which is not present in P. anisum. Admixture of synthetic anethole can be 
demonstrated by GLC-MS, as synthetic anethoel contains up to 15% cis-anethole which is 
normally only present in very small amounts in natural Aetheroleum Anisi (Staesche et al., 
1994). 
 
3. CONSTITUENTS 
P. anisum fruits  contain 2-6% essential oil, 30% fat, 20% proteins, 6-7% gum, 6-7% minerals, 
5-7% pentosane, 4% sugars, 3% furfurol; furthermore phenolic acids and flavonol and flavone 
glycosides. The predominant constituent of the essential oil is trans-anethole, which makes up 
80-95% of the total oil. The cis-anethole content is normally only 0.3-0.4%, but under the 
influence of direct sunlight, trans-anethole can partly isomerize to the more toxic cis-anethole; 
also small amounts of 4,4´-dimethoxystilben are produced due to UV-light; Oxygen leads to 
polymerization and oxidation to anise aldehyde and anisic acid. For this reason, the storage in 
closely sealed, lightproof flasks is obligatory (Staesche et al., 1994, Barnes et al., 2002). 
Furthermore, small amounts of estragol, pseudoisoeugenyl-2-methylbutrate, epoxypseudo-
isoeugenyl-2-butyrate and anisaldehyde are present in the volatile oil (Staesche et al., 1994). 
The European Pharmacopoea specifies a minimum essential oil content of 20 ml/kg or Fructus 
Anisi. The qualitative and quantitative analysis of the essential oil compounds can be 
performed by TLC and/or GC-MS. The trans-anethole content of the volatile oil has to be 
between 87 and 94% (Staesche et al. 1994, EAB, 2005). 
 
4. PHARMACOLOGY 
The pharmacological effects of aniseed are largely due to the presence of anethole, which is 
structurally related to the catecholamines adrenaline, noradrenaline and dopamine. Anethole 
dimers closely resemble the estrogenic agents stilbene and stilbestrol (Barnes et al., 2002). 
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4.1 IN VITRO AND ANIMAL TESTING 
The antispasmodic activities of the essential oil have been shown in several in vitro models 
using isolated smooth muscles. Also an aqueous and an ethanolic aniseed extract showed 
significant spasmolytic acitivity in such a model (ESCOP, 2003). The relevance of these in vitro 
results for the therapeutic use against disorders of the gastrointestinal and the upper 
respiratory tract is questionable, because plasma levels are normally much lower than the 
concentrations used in the in vitro tests. However, in case of p.o. and inhalative application, 
effective concentrations might be reached locally (Staesche et al., 1994). 
The expectorant and secretolytic activity of an aniseed infusion (200 µl, 4.6%) was shown in 
vitro using isolated ciliated epithelium of frog oesophagus. Dilutions of the essential oil 
increased respiratory tract fluid in vivo in anaesthesized guinea-pigs, rats and cats. A similar 
action was observed in anaesthesized rabbits inhaling anise oil (Barnes et al., 2002). 
Aniseed aqueous infusions and essential oil exhibited rather weak anticonvulsant effects in 
vivo, and also a sedative effect could be shown for the essential oil and for its main compound 
trans-anethole respectively (Barnes et al., 2002, ESCOP, 2003). 
For trans-anethole, also  local anaesthetic, estrogenic, anti-tumor and anti-genotoxic effects 
were found in vitro and in vivo (ESCOP, 2003). The reputed lactagogic action of anise has been 
attributed to anethole, which exerts a competitive antagonism at dopamine receptor sites, and 
to the action of polymerized anethole due to its structural similarity to the estrogenic 
compounds stilbene and stilbestrol (Barnes et al., 2002). Kassi et al. (2004) report that 
aqueous aniseed extracts show SERM (selective estrogen receptor modulator)-like effects on 
bone, breast and uterine cells in vitro. The observed effects were not attributed to a certain 
compound of the extract. Tabanca et al. (2004) tested 11 Pimpinella species for estrogenic 
activity in vitro using the yeast estrogen screen assay. Generally, the authors only found weak 
estrogenic activity, and there was no significant correlation between anethole content and 
estrogenic activity of the essential oils. This indicates that other constituents may contribute to 
the estrogenic acitivity of the essential oil. 
Antioxidative activity was reported for aqueous and ethanolic anise fruit extracts in several in 
vitro models (Gülçın et al., 2003; Al-Ismail and Aburjai, 2004). 
Additionally, the reputed insecticidal activities of aniseed have been assessed in several 
studies: Prajapati et al. (2005) found strong larvicidal and ovicidal activity of P. anisum 
essential oil against three mosquito species. Lee (2004) performed a bioassay guided 
fractionation of Anise essential oil and found, that p-anisaldehyde is mainly responsible for the 
acaricidal activity of the oil against two house dust mite species. The compound was even more 
effective then the synthetic acaricides benzoyl benzoate and N,N-diethyl-m-toluamide. It also 
showed very high activity against the stored food mite (Tyrophagus putrescentiae) (Lee, 2005). 
Also anethole, anisaldehyde and myristicin have exhibited mild insecticidal properties (Barnes 
et al., 2002). 
 
4.2 VETERINARY STUDIES 
Ruminal microbial activity is essential for the decomposition of structural carbohydrates and 
the synthesis of high-quality protein in ruminants. However, microbial fermentation may lead to 
considerable energy and protein losses due to methane and ammonia production. For this 
reason, many feed additives have been developed to improve the efficacy of nutrient use by 
decreasing methane or ammonia production. Ionophore antibiotics have been used 
successfully, however the use of antibiotics in animal feed has been prohibited in the European 
Union in 2006. So, the search for alternatives, particularly from plants, is under progress 
(Cardozo et al., 2004). 
Several in vitro studies have included anise oil and anethole, yielding mixed results: 
Cardozo et al. (2004) evaluated the effects of several plant extracts on ruminal microbial 
fermentation in vitro. Volatile fatty acid (VFA) concentration and protein degradation were 
determined in a dual-flow continuous culture system inoculated with ruminal fluid from dairy 
cows. Anise oil and some other extracts affected the molar proportions of acetate, propionate 
and butyrate during the adaption period, however these differences disappeared after day 6, 
indicating that the ruminal microbes built up a tolerance to the additive after 6 days. The 
addition of 7.5 mg/kg dry matter (equivalent to 0.22 mg/l rumen fluid) of anise essential oil 
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(86% anethole) increased the peptide N concentration by 79% 2 h after feeding, but did not 
affect the average peptide concentration throughout the 8 hours feeding interval. The higher 
average amino acid concentration, the higher ammonia concentration at 0,2,4, and 6 hours 
after feeding and the higher average ammonia concentration indicate that the anise extract 
stimulated peptidolysis and deamination. According to the authors, the accumulation of 
peptides and amino acids in ruminal fluid may stimulate microbial protein synthesis or improve 
the flow of amino acids to the small intestine. 
In a second study, Cardozo and coauthors (2005) tested among others anise essential oil and 
anethole at various doses (0.3-300 mg/l) for their influence on the ruminal microbial 
fermentation profile in an in vitro batch culture fermentation system at 2 different pH (7.0 and 
5.5).  The authors found out that the effects of plant extracts on ruminal microbial fermentation 
are pH-dependent. At high pH, the plant extracts exhibited no beneficial effects for beef 
production. At pH 5.5 however, beneficial effects were observed for some preparations. In case 
of anise essential oil and anethole the VFA concentration did not change, and ammonia 
nitrogen and branched-chain volatile fatty acid concentrations were decreased, suggesting that 
deamination was inhibited or that bacteria used peptides and amino acids as a nitrogen 
source, thus decreasing ammonia concentration. High doses of all tested extracts resulted in 
lower VFA concentrations, confirming their antimicrobial effect. Considering the pH-dependency 
of the effects of the tested plant extracts, the authors suggest that in vivo studies should be 
conducted due to the daily fluctuation of pH generally observed in vivo. 
Busquet et al. (2006) also used in vitro batch culture of rumen fluid to test several essential oils 
and pure compounds at different doses. In accordance to Cardozo and coauthors (2005), they 
reported detrimental effects on rumen microbial fermentation of many of the tested 
preparations at high doses (3000 mg/l) due to their antimicrobial activity. 
Anise oil and anethole both decreased total VFA and the proportion of acetate and propionate, 
and increased the proportion of butyrate, anethole exhibiting the stronger effects than anise oil. 
Ammonia concentration was not affected. As anethole reduced the proportion of acetate and 
propionate, which are the main precursors for ruminant fat and glucose synthesis, the authors 
suggest that they may not be nutritionally beneficial to dairy cattle. However, in this study, a pH 
of 7.0 was used, which had been reported to be unfavourable by Cardozo et al. (2005), and as a 
batch culture fermentation system was used, long-term effects such as adaption of the 
microorganisms could not be considered in this study. 
 
4.3 HUMAN STUDIES 
There is a lack of documented clinical studies on aniseed (Barnes et al., 2002). 
 
4.4 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
Few pharmacokinetic data exist about trans-anethole with regard to toxicity:  
In mice and rats, trans-anethole is reported to be metabolized by O-demethylation and by 
oxidative transformation of the C3-side chain. After ingestion of low doses (0.05 and 5 mg/kg 
b.w.) predominantly O-demethylation occurs, whereas at higher doses (up to 1500 mg/kg b.w.) 
there is a shift towards oxygenated metabolites (ESCOP, 2003). Especially in female rats, the 
hepatotoxic metabolite anetholepoxide is predominantly produced at higher concentrations 
(Newberne et al., 1999). 
In humans, already after administration of 1 mg trans-anethole the oxidative metabolism is 
predominant, with the 4-methoxyhippuric acid as the main metabolite. After p.o. administration 
of 1, 50 and 250 mg trans -anethole to healthy volunteers respectively, the substance was 
readily absorbed, and 54 to 69% of the dose (detected as 14C) were eliminated in the urine and 
at least 13-17% in exhaled carbon dioxide, irrespective of the dose level. The substance was 
nearly completely eliminated within the first 8 hours (Staesche et al., 1994, ESCOP, 2003). 
No data are available concerning the pharmacokinetics of other anise constituents, and no 
pharmacokinetic studies have been performed in productive livestock. 
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5. MICROBIOLOGY 
As many other essential oil containing plants, P. anisum shows antimicrobial activity: 
An acetone extract of aniseed inhibited the growth of a range of bacteria including Escherichia 
coli and Staphylococcus aureus. The essential oil also inhibited the growth of E. coli (MIC 0.5% 
V/V), Staphylococcus aureus (MIC: 0.25% V/V) and Salmonella typhimurium (MIC 2.0%), when 
tested using the agar dilution method (ESCOP, 2003). Singh et al. (2002) found a quite high 
activity of P. anisum essential oil against several gram positive and gram negative organisms 
using the filter paper disc agar method, but no MIC was determined. Also aqueous and 
ethanolic extracts were reported to possess inhibitory activity against a several gram positive 
and gram negative bacteria, but for testing high concentrations were used, and no MIC was 
determined (Gülçın et al., 2003). Recently, only weak activity against Helicobacter pylori was 
reported for an aniseed methanolic extract (MIC >100 µg/ml) (Mahady et al., 2005). 
The acetone extract and the essential oil exhibit antifungal effects against Candida albicans 
and other organisms (MIC of the essential oil against C. albicans 0.5% using the agar dilution 
method) (ESCOP, 2003). 
Trans-anethole was assayed for its fungicidal activity in Saccharomyces cerevisiae, grown under 
hypoxic and aerobic conditions. The results indicate that the antifungal activity of the 
compound is affected by the concentration of dissolved oxygen in the culture broth. 
Furthermore, the authors demonstrated that anethole does not exhibit fungicidal activity 
against non-growing cells, and they suggest that the compound might only be active against 
fermentatively growing cells (Fujita and Kubo, 2004). 
 
6. EFFICACY 
As far as their medical use in humans is concerned, P. anisum fruits and essential oil are stated 
to be effective in the treatment of dyspeptic complaints such as mild spasmodic 
gastrointestinal disorders, bloating, flatulence (internally) and against catarrh of the upper 
respiratory tract (internally and externally) (Wichtl, 2002; ESCOP, 2003). Up to now, no clinical 
data exist on the efficacy in these applications, so these indications are based on experience 
and on the available in vitro and in vivo data. 
  
Studies on the efficacy of P. anisum in productive livestock are very limited. The outcomes of in 
vitro studies investigating the potential of P. anisum essential oil as a feed additive to improve 
nutrient use in ruminants are inconclusive, and more and larger studies, especially in vivo 
studies, will be necessary for evaluation of efficacy. 
El-Deek and coauthors (2003) investigated the potential of aniseed as alternative growth 
promoting substance in broilers. When admixed to the feed at a concentration of 0.05% at day 
12 to 47 of age, aniseed improved weight gains significantly by 19.1% and feed conversion 
ratio by 10.85% with respect to the control group. Admixture of 0.1% only enhanced feed 
conversion ratio by 1.92%, related to a 2.97% decrease in feed intake; also fat content of the 
meat was significantly reduced with this diet. Use of a two or three way mixture of anise, ginger 
and fennel had no additive effect on growth as compared to the control group.  
Grela et al. (2003) investigated the influence of dietary supplementation with two different 
herbal mixtures, one of them containing P. anisum fruits, on the general performance and 
blood parameters of piglets. After 40 days, they compared the results to a control group 
receiving standard feed and a positive control receiving 20 mg avilamycin/kg diet. The group 
fed the mixture containing Urtica dioica leaves, Plantago lanceolata herb, lyophilized Allium 
sativum bulbs, P. anisum fruits and Echinacea purpurea fruits had the best daily gains, feed 
utilization and blood indices; the production gains were even better than with the antibiotic 
additive. Due to the complexity of the mixture, the contribution of aniseed to this effect can not 
be estimated. 
Aniseed is extensively used as a sensory and flavouring agent in humans. To what extent it is 
also suitable for this purpose in productive livestock, remains to be investigated. 
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By the Council of Europe, it is listed as a natural source of food flavouring in category N2. This 
category allows small quantities of aniseed to be added to foodstuffs, with a possible limitation 
of an active principle (as yet unspecified) in the final product. In the USA, aniseed is listed as 
GRAS (Generally Recognized As Safe). Anethole was reaffirmed as GRAS in 1997 (Barnes et al., 
2002.) 
 
7. TOXICOLOGY  
7.1. SAFETY 
Contact dermatitis reactions to aniseed and aniseed oil have been attributed to anethole. 
Reactions have been reported with products, such as creams and toothpastes flavoured with 
aniseed oil. The volatile oil and anethole have been stated to be irritant and sensitizing (Barnes 
et al., 2002). 
Most toxicity studies relevant to aniseed have been conducted on trans-anethole, the main 
constituent of the essential oil: 
As far as the acute toxicity is concerned, the LD50 in rats is 2.7g/kg b.w. for the essential oil and 
2.1-3.2 g for trans-anethole respectively. Intraperitoneal LD50  values for trans-anethole have 
been determined as 0.65-1.41 g/kg b.w. in mice and 0.9-2.67 g/kg b.w. in rats (ESCOP, 2003). 
Concerning the repeated-dose toxicity, hepatic changes have been described in rats fed trans-
anethole in their daily diet (1%) for 15 weeks, although at a level of 0.25% no changes were 
observed after 1 year. Rats fed with 0.1% trans-anethole in their diet for 90 days showed no 
signs of toxicity, but at higher doses (0.3-3%) liver edema was observed. In therapeutic doses 
trans-anethole is reported to cause minimal hepatotoxicity. 
Animal studies on the reproductive toxicity of trans-anethole (50-80 mg/kg) demonstrated that 
the compound has antifertility activity and might also have an early abortifacient activitiy. 
Significant estrogenic activity was observed, but no anti-estrogenic, progestational, anti-
progestational, androgenic or anti-androgenic activity (Barnes et al., 2002, ESCOP, 2003). 
In the Ames test, a dry ethanolic aniseed extract was only mutagenic at high concentrations (5 
mg/plate) to streptomycin dependent strains of Salmonella typhimurium TA 98. The essential 
oil and trans-anethole were mutagenic at 2 mg/plate, and mutagenicity was potentiated by S13 
activiation. Other investigations with metabolic activation have confirmed that trans-anethole is 
weakly mutagenic. Estragol,  a minor constituent of the essential oil, has also shown mutagenic 
potential in various Ames tests, demonstrating the need for carcinogenicity studies. 
Trans-anethole did not show carcinogenic potential in a 1-year experiment with mice receiving 
the compound in their diet. In another long term study of trans-anethole in mice, there were no 
histological differences between treated and control animals.  
In a study in rats, the highest dose feeding group (1% trans-anethole for 117 weeks) showed 
hyperplastic and partially neoplastic changes, only in the livers of female rats. This led to the 
review of safety data on trans-anethole as a flavouring substance by the Expert Panel of the 
Flavour and Extract Manufacturer Association (FEMA). The Expert Panel stated that the observed 
neoplastic changes in the liver of female rats were not due to a direct genotoxic effect, but were 
secondary to hepatotoxicity caused by continuous exprosures to high hepatocellular 
concentrations of anethole epoxide (AE). At low levels, trans-anethole is efficiently detoxicated in 
rodents and humans primarily by O-demethylation and ω-oxidation. At high dose levels, 
particularly in female rats, a metabolic shift occurs resulting in increased epoxidation and 
formation  of AE. The continuous intake of high levels of trans-anethole has been shown to 
induce a continuum of cytotoxicity, cell necrosis and cell proliferation due to AE production. 
However, the intake of trans-anethole as a flavouring substance was stated to be very low 
(estimated 54 µg/kg b.w./day), and at this level it is efficiently detoxicated in humans. For this 
reason the Expert Panel concludes that the neoplastic effects in female rats associated with 
dose dependent hepatotoxicity are not indicators of any significant risk to human health from 
the use of trans-anethole as a flavouring substance, and the compound was reaffirmed as GRAS 
(generally regarded as safe) (Newberne et al., 1999). However, clinical safety data do not exist.  
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The safety of aniseed taken during pregnancy and lactation has not been established. Aniseed 
may be used at the recommended dosage as an aqueous infusion only. Preparations containing 
the essential oil or ethanolic extracts should not be used (ESCOP, 2003). 
As aniseed may cause allergic reactions, the use of the volatile oil should be avoided in 
dermatitis and inflammatory or allergic skin conditions. Aniseed should not be used by persons 
with known sensitivity to anethole (Barnes et al., 2002). 
Herb-drug interactions are not known, and experimental data on weak enzyme induction in 
rodents can not directly be extrapolated to humans (ESCOP, 2003). 
 
7.2. DOSAGE 
Dried fruit: 
Adult average daily dose: 3 g of crushed fruits as an infusion or similar preparations 
Children average daily dose: 0-1 year 0.5 g crushed fruits as an infusion; 1-4 years 1g; 4-10 
years 2g; then adult dose (ESCOP, 2003). 
Oil:0.05-0.2 ml 3 times daily. 
Spirit of anise: 0.3-1 ml 3 times daily. 
Distilled anise water: 15-30 ml 3 times daily (Barnes et al. 2002). 
 
ANIMALS: 
For internal use either powdered aniseed or  infusions (1:10) out of it will be prepared and 
added to the fodder  (Reichling et al. 2005). 
 
Internal Use of Aniseed: 
Dosages 
recommended daily allowance: 
Cattle    25,0 - 50,0 g 
Horse    10,0 - 25,0 g 
Sheep      5,0 -  10,0 g 
Pig       3,0 -  10,0 g 
Chicken                                               0,2 -    0,5g 
 
 
 
EMW 
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RIBES NIGRUM 
  
Ribes nigrum  
 
1. INTRODUCTION 
The use of Ribes nigrum L. (Grossulariaceae) has a long tradition in Europe. The leaves are 
mainly used for medical purposes. The have been used in traditional medicine internally as 
diuretics, for the treatment of gout, rheumatic diseases, diarrhea, cramps and cough and 
externally for the treatment of wounds and insect bites. The drug is nowadays mainly used in 
the form of tea as a diuretic and as an adjuvant in the therapy of rheumatic disorders (Wichtl, 
2002; ESCOP, 2003). The efficacy in these indications is not yet fully documented (Seitz, 1994).   
The fruits are used in traditional medicine internally as syrup, juice, jelly or lozenges for the 
treatment of common cold, sore throat and cough and as a vitamin C source, against diarrhea 
and stomach pain. The dried berries are sometimes chewed to treat disorders of the urinary 
tract. In France, they are traditionally used in the treatment of venous disorders such as heavy 
legs, hemorrhoids and for the symptomatic treatment of hematoma. Also in this case the 
efficacy in most indications is not yet documented (Seitz, 1994).  
Furthermore blackcurrant fruits are used in industry for the production of fruit juices and 
concentrates, marmelades and  candies. The seed containing pomace is often used as animal 
feed in husbandry because of its high nutrient value. The seed oil can also be used for the 
extraction of pure γ-linolenic acid and concentrates rich in γ-linolenic acid which are for 
example used as food supplements and in cosmetic industry (Seitz, 1994; Wichtl, 2002).  
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2. DESCRIPTION OF THE PLANT 
Ribes L. is the only genus the Grossulariaceae family consists of. It comprises 140-150 species, 
which are split up into 6 subgenera. R. nigrum belongs to the subgenus Coreosma (Seitz, 
1994). R. nigrum is a deciduous shrub with a height of up to 2 meters. The leaves are divided in 
3-5 lobes, are more or less cordiform  at the leaf base,  and the leaf edges are doubly serrate. 
The flowers are greenish-white and arranged in racemous inflorescences. The fruits are 
brownish-black spheroidal berries with a peculiar smell.  The plant occurs in the European-asian 
woodland, in Canada and Australia. In central and eastern Europe, R. nigrum sometimes still 
can be found as a wild plant, but in most regions it is cultivated (Seitz, 1994; Wichtl, 2002). 
The plant parts used in medicine are the leaves and the fruits. Blackcurrant leaves consist of 
the dried leaves of Ribes nigrum L., harvested during or breviously after the anthesis. The 
material complies with the monograph of the Pharmacopée francaise (Seitz, 1994, ESCOP, 
2003). Blackcurrant fruits are harvested at full ripeness and are immediately processed to 
various preparations or frozen (Seitz, 1994).  
3. CHEMICAL CONSTITUENTS 
Blackcurrant leaves 
The most important constituents are flavonol glycosides, mainly mono- and diglycosides of 
quercetin, kaempferol, isorhamnetin and myricetin (main glycosides: isoquercitrin, rutoside) 
(Seitz, 1994, ESCOP, 2003). According to the monograph of the Pharmacopée francaise, the 
drug must contain a minimum of 1.5% flavonoids, expressed as rutin (ESCOP, 2003). 
Determination of flavonoid content can be performed photometrically after addition of 
aluminium chloride solution to a methanolic extract of the material. The identity can be 
controlled by TLC examination of the methanolic extract, using isoquercitrin and rutoside as 
standard compounds.  
Furthermore the drug contains about 0.4% oligomeric proanthocyanidines, vitamin C and 
traces of essential oil (Seitz, 1994). 
 
Blackcurrant fruits 
The main constituents are anthocyanins (up to 2% of fresh weight), with cyanidin-3-glucoside 
(17% of anthocyanin fraction), cyanidin-3-rutinoside (35%), delphinidin-3-glucoside (13%) and 
delphinidin-3-rutinoside (30%) as the main compounds (Seitz, 1994). The anthocyanins can be 
analyzed and quantified by HPLC with PDA and/or MS detection (for example Rubinskiene et 
al., 2005).  Using this method, the authors did not only quantify the main anthocyanins present 
in various R. nigrum cultivars, they also investigated the effect of temperature, light and 
storage time on the stability of these compounds.  They found that all anthocyanins are to a 
certain extent susceptible to UV light and to a variable degree also to temperature. The 
anthocyanin showing the best thermal stability was cyanidin-3-rutinoside. After storage at 8°C  
for 12 months it could be shown that rutinosides were more stable than glucosides.  
Additionally, flavonol glycosides are present in blackcurrant fruits, with isoquercitrin, myricetin-
D-glucopyranoside and rutoside as the main compounds. Organic acids and hydroxycinnamic 
acid derivatives like caffeoylquinic acids, p-coumaroylquinic acids and feruloylquinic acids are 
also present. The specifications concerning the vitamin C content vary tremendously from 10 to 
300 mg/100 g, depending on the used determination method. 
The seeds contain up to 30% fatty oil which is a rich source of γ-linolenic acid.  Besides, 6-8% 
invert sugar and pectins are present (Seitz, 1994). 
4. PHARMACOLOGY 
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4.1 IN VITRO AND ANIMAL TESTING 
4.1.1 BLACKCURRANT LEAVES 
A 14%-ethanolic extract from blackcurrant leaves produced dose-dependent anti-inflammatory 
effects in carrageenan induced rat paw edema after oral administration (ESCOP, 2003).  Tits et 
al. (1991) isolated prodelphinidin oligomers from R. nigrum leaves that also showed inhibitory 
activity in this model. 
In another study, a lyophilized 15%-ethanolic extract showed dose dependent anti-
inflammatory activity in several animal models of inflammation. The same lyophilizate 
exhibited potent analgesic activity in the acetic acid-induced writhing test after single dose 
intraperitoneal administration to mice (ESCOP, 2003). 
Garbacki et al. (2002) tested proanthocyanidins isolated from R. nigrum leaves to evaluate 
their chondroprotective potential and their COX inhibition properties using human cartilage, 
purified COX-1 and COX-2 enzymes and a COX whole blood assay. The compounds stimulated 
type II collagen production and inhibited purified COX with a certain selectivity against COX-2, 
but they had no effect on COX in the whole blood assay.  
In 2004, Garbacki et al. found, that the anti-inflammatory activity of proanthocyanidins isolated 
from blackcurrant leaves is related to an interference with the migration of leukocytes, 
associated with the reduction of pro-inflammatory factors such as TNF-α, IL-1β and CINC-1, a 
decrease of NOx level and a decrease of plasma exsudation. 
The transvasation of the leukocytes from blood to the inflammatory exudates requires 
activation of leukocytes and the expression of adhesion molecules on the surface of endothelial 
cells. Garbacki et al.  (2005) showed that the proanthocyanidins did not significantly reduce the 
expression of adhesion factors on the surface of the leukocytes, but greatly reduced the 
production of adhesion molecules on the surface of endothelial cells in vivo during carrageenin-
induced pleurisy. This indicates that the anti-inflammatory activity of R. nigrum procyanidins is 
related to the down-regulation of endothelial adhesion molecules. 
 
Furthermore, diuretic and antihypertensive effects have been shown in several animal studies, 
and a reduction of capillary permeability has been shown in a rat model (Seitz, 1994; ESCOP, 
2003). 
 
4.1.2 BLACKCURRANT FRUITS AND SEEDS 
4.1.2.1 ANTIOXIDANT AND FREE RADICAL SCAVENGING ACTIVITY 
The antioxidant activity of blackcurrant fruit extracts and polyphenolics has been tested in vitro 
in many different assays using various reference antioxidants such as trolox, L-ascorbic acid or 
α-tocopherol. This makes the comparison of results very difficult.  
For example, Ehala et al. (2005) used an ABTS radical cation decolorization assay for 
determination of the antioxidant activity of various berry extracts. The radical was produced 
with potassium persulfate. Bermúdez-Soto et al. (2004) determined the antioxidant activity of 
fruit juice concentrates in the ABTS-assay using MnO2 for radical production and in the DPPH-
assay. Wu and coauthors (2004) used hydrophilic and lipophilic ORACFL assays for the 
determination of the antioxidant activity of berry extracts. Blackcurrant showed very high 
hydrophilic antioxidant capacities, whereas the lipophilic antioxidant capacity was rather low. 
In all of these studies, the antioxidant activity of the extracts showed quite good correlation 
with their  total phenolic content. 
The relevance of these in vitro results for in vivo effects is difficult to estimate and the 
antioxidant activity of blackcurrant could not yet be verified by clinical studies. 
In foods, lipid oxidation can cause protein oxidation due to close interaction between lipids and 
proteins. Viljanen et al. (2004) investigated the effect of black currants and other berries on the 
oxidative stability of proteins and lipids in a liposome system.  They found an antioxidant effect 
in both assays. The effect was more pronounced toward lipid than protein oxidation. According 
to the authors, this antioxidant protection may result in an improved quality of foods, especially 
of dairy origin. 
Večeřa and coauthors (2003) compared the effects of blackcurrant seed oil rich in (ω-3) and (ω-
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6) polyunsaturated fatty acids in rats fed a diet rich in cholesterol to the effects of lard fat rich 
in saturated and monounsaturated fatty acids on antioxidant parameters, the lipoprotein 
profile and liver lipids. The results of the study indicate that currant oil, when substituted to lard 
fat in a high cholesterol diet, partly exerts a positive effect on lipid metabolism in the liver, but 
has partly adverse effects on the antioxidative status, especially in the blood.  
 
4.1.2.2 ANTI-INFLAMMATORY, ANTITUMOR AND IMMUNOSTIMULATORY ACTIVITY 
A polysaccharide rich fraction from blackcurrant fruit juice showed macrophage stimulating 
activity in vitro and antitumor activity in Ehrlich carcinoma-bearing mice with a certain 
cytotoxicity directly against tumor cells (Takata et al., 2005). 
Because the eicosanoid cascade is regulated in part by the distribution of arachidonic acid 
among phospholipid subclasses, the effects of feeding blackcurrant seed oil, which is rich in  γ- 
and α- linolenic acid, were studied in mouse peritoneal macrophages after 4 weeks of dietary 
treatment. The authors could show that feeding with γ- and α- linolenic acid can increase 
potential anti-inflammatory precursor levels of 20:3 (ω-6) and (ω-3) polyunsaturated fatty acids 
in the macrophages (Chapkin et al., 1990). 
 
4.1.2.3 OTHER ACTIVITES 
In vivo antihypertensive (Seitz, 1994) activity and in vitro vasorelaxant effects (Nakamura et al., 
2002) were found. 
 
4.2 VETERINARY STUDIES 
The effect of a herbal mixture containing extracts from R. nigrum, Echinacea angustifolia, 
Agrimonia eupatoria and Cinchona succirubra (plant parts not given) was tested in broiler 
chickens challenged with Eimeria tenella using lasolacid as a positive control. The herbal feed 
supplement led to a certain coccidiostatic effect, which was however significantly lower than 
that of lasolacid (Christaki et al., 2004). The contribution of R. nigrum to the observed effect 
can not be estimated.  
 
4.3 HUMAN STUDIES 
The effect of dietary supplementation with blackcurrant seed oil (BCO) was investigated in 
patients suffering from rheumatoid arthritis (RA) as well as in healthy volunteers, using 
sunflower oil as a placebo. A significant improvement in morning stiffness was noted in the RA 
patients receiving BCO. Cytokine and PGE2 production of the cultured macrophages was 
markedly altered in subjects given BCO. The results suggest that the beneficial effects of 
polyunsaturated fatty acids in inflammatory diseases may be due to a reduction of the 
secretion of proinflammatory cytokines via redirection of eicosanoid metabolism (Watson et al., 
1993). 
Also Levental et al. (1994) found certain positive effects of BSO administered to patients with 
RA and active synovitis in a double blind, placebo controlled, 24 week trial. BSO treatment 
resulted in in a reduction in signs and symptoms of disease activity in patients with RA, but 
overall clinical responses were not significantly better than in the placebo group.  
Møller et al. (2004) performed a three- week, controlled, parallel intervention study 
investigating the antioxidative effect of blackcurrant juice and of an anthocyanin-rich drink in 
humans. They determined the steady state level of oxidative DNA damage in mononuclear 
blood cells using the alkaline comet assay. Daily doses ranged from 475 to 1000 ml juice 
according to body weight (mean anthocyanin intake for blackcurrant juice and anthocyanin 
drink was 397 and 365 mg respectively). The study shows that even large amounts of dietary 
antioxidants did not decrease the (already low) steady state levels of oxidative DNA damage in 
healthy, adequately nourished humans.  
 
4.4 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
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There are some data available concerning the pharmacokinetics of blackcurrant anthocyanins 
in humans and animals: 
Netzel et al. (2000) analyzed urinary samples from 3 men before and after ingestion of 200 ml 
blackcurrant juice for delphinidin-3-glucoside, delphinidin-3-rutinoside, cyanidin-3-glucoside and 
cyanidin-3-rutinoside. The cumulative amounts of excreted unchanged anthocyanins in the 
urine were only 0.02-0.05% of the ingested doses. Degradation during the digestion process, 
losses in feces and intermediary metabolism may contribute to the low urinary output.  
Wu and coauthors (2005) investigated the metabolism of anthoycanins in weanling pigs fed 
with freeze dried powder of chokeberry, black currant or elderberry in a single meal.  Blood and 
urine samples were collected at particular times after ingestion and analyzed by HPLC-
ESIMS2.The authors found that the aglycone and sugar moieties can alter absorption and 
metabolism of the anthocyanins: Delphinidin was not metabolized to any measurable extent. 
Cyanidin was metabolized via methylation and/or glucuronidation, the same happened to 
monoglycosides other than the glucoside. Di-or triglycosides were excreted in the urine primarly 
in the intact form (over 80% of the anthocyanins containing rutinose or sambubiose). 
According to the authors, also the total anthocyanin composition of the respective berry 
influences uptake and metabolism, thus the results must be interpreted in the context of the 
composition of the complete berry.  
Nielsen et al. (2003) performed a study to compare the pharmacokinetics of blackcurrant 
anthocyanins in humans and Watanabe heritable hyperlipidemic (WHHL) rabbits, a model for 
human homozygous familial hypercholesterolemia due to LDL receptor deficiency. In a single 
dose study, the rabbits were intubated with black currant juice concentrate, blackcurrant 
anthocyanins dissolved in aqueous citric acid or aqueous citric acid only. The normolipidemic 
volunteers participating in the study received either a blackcurrant concentrate alone, 
blackcurrant concentrate in combination with a rice cake, or control solution in a partial 
crossover study. Blood and urine samples were taken at particular times after ingestion, and 
the four major blackcurrant anthocyanins were quantified in plasma and urine by HPLC 
(metabolites were not analyzed). In the rabbit study a food matrix effect was observed resulting 
in a higher absorption of anthocyanins from juice than from anthocyanin solution. In the human 
study the plasma concentration and urinary excretion of anthocyanins were found to be dose 
dependent and not influenced by intake of the rice cake. A higher plasma concentration and 
urinary excretion of anthocyanin rutinosides than of glucosides was found, whereas the nature 
of the aglycone did not influence the bioavailability. This might be due to the cleaveage of the 
anthocyanin glucosides but not rutinosides by intestinal β-glucosidases. The anthocyanins did 
not affect the antioxidant capacity of plasma measured as trolox equivalent antioxidant 
capacity and ferric acid reducing ability in rabbits. This indicates that a possible protective 
effect on the development of atherosclerosis is unlikely to be due to an increased redox 
capacity of the plasma. 
 
5. MICROBIOLOGY 
Puupponen-Pimiä et al. (2001) measured the antimicrobial activity of several berry extracts 
against selected gram positive and gram negative bacteria, including probiotic bacteria and 
intestinal pathogens. Among the 8 extracts tested, blackcurrant showed the least antimicrobial 
activity. In liquid culture, only Escherichia coli CM 871  (a DNA repair-deficient strain)  and 
Salmonella enterica were strongly inhibitied by the extract,  the growth of several Lactobacillus 
rhamnosus and paracasei strains was slightly increased. 
Cavanagh and coauthors (2003) tested several commercial berry drinks (100% fruit) as well as 
fresh berries for their inhibition of the growth of various bacteria and the yeast Candida 
albicans. The blackcurrant drink inhibited all 12 bacteria and C. albicans when diluted 1:5. 
Crude and purified polysaccharides from blackcurrant seeds were investigated on their effect 
against Helicobacter pylori in in situ adhesion studies on sections of human gastric mucosa. 
After pre-treatment of H. pylori with the polysaccharide solutions, the epithelial binding of the 
bacteria was considerably reduced in a concentration dependent manner. As none of the active 
fractions showed inhibitory effects on bacterial growth in vitro, the authors concluded that the 
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polysaccharides are able to block H. pylori surface receptors, thus inhibiting their interaction 
with specific binding factors located on  human gastric epithelia (Lengsfeld et al., 2004). 
There are also two reports concerning antiviral activity of Kurokarin®, a crude extract of wild R. 
nigrum fruits commercially available in Japan: 
Knox et al. (2003) investigated the antiviral activity of Kurokarin against influenza virus IVA and 
IVB in vitro. The extract inhibited IVA and IVB with an IC50 of 3.2 µg/ml. Moreover, heat 
treatment at 121°C for 20 minutes did not affect antiviral activity of the extract. This is an 
important finding for the potential of R. nigrum in industrial processing applications. Suzutani 
et al. (2003) tested the same extract for in vitro anti-herpesvirus activity.  The extract inhibited 
HSV 1 attachment on the cell membrane completely at a 100fold dilution, as well as the 
plaque formation of HSV 1 and HSV 2, and varicella-zoster virus by 50% at a 400 fold dilution. 
The latter activity is due to the inhibition of protein synthesis in infected cells from the early 
stage of infection. 
 
6. EFFICACY 
Blackcurrant berries are rich in vitamin C.  The seeds contain high amounts of fatty oil; because 
of this high nutrient value blackcurrant pomace is often used in husbandry as a mast feed 
(Hänsel, 1994). No scientific data exist about the efficacy of blackcurrant fruits of leaves as a 
sensory and flavouring agent for animal feed production. 
In humans, the leaves are nowadays considered to be effective as an adjuvant in the treatment 
of rheumatic conditions (ESCOP, 2003). Because clinical studies are very rare, the efficacy for 
most traditional indications of blackcurrant fruits and berries is not yet documented. 
 
7. TOXICOLOGY 
7.1 SAFETY 
A lyophilized 14% ethanolic blackcurrant leaf extract, administered orally to rats at 2 g/kg/day 
for 21 days or 1.34 g/kg/day for 28 days, revealed no signs of toxicity and no gastric ulceration 
was observed. 
Rats treated orally for 28 days with a lyophilized blackcurrant leaf 15% ethanolic extracts had 
no gastric ulceration. No changes were apparent in food and fluid consumption or body weight, 
nor in results from blood analysis and histopathological evaluation of 14 different organs. In an 
acute toxicity study of the same lyophilizate in mice, the intraperitoneal LD50 was 1.90 g/kg. 
Oral doses of up to 3g/kg showed no overt toxicity. In another study, the LD0 and the LD50 of a 
blackcurrant leaf fluid extract in mice were equivalent to 22 and 49 g blackcurrant leaf/kg 
respectively (ESCOP, 2003). 
After feeding of dried blackcurrant fruit peel and pulp to mice (1000 and 2000 mg/kg orally for 
7 days), no toxic effects were observed (Hänsel, 1994). 
 
7.2 DOSAGE 
Adults: dried leaves as an infusion (20-50 g/litre), 250-500 ml daily; fluid extract (1:1), 5 ml 
twice daily, taken before meals (ESCOP, 2003). 
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ROSMARINUS OFFICINALIS 
  
Rosmarinus officinalis    
 
1. INTRODUCTION 
The genus and common name are derived from the Latin "ros marinus", meaning "dew of the 
sea" as the plant grows profusely near the Mediterranean sea coast and sea foam sprays upon 
it. Rosemary has long been considered a symbol of friendship and loyalty. The Ancients were 
well acquainted with the rosemary, which had a reputation for strengthening the memory. On 
this account, it became the emblem of fidelity for lovers. Not only was it used at weddings, but 
also for decking churches and banqueting halls at festivals, and incense in religious ceremonies 
and in magical spells. The Spaniards revere it as one of the bushes that gave shelter to the 
Virgin Mary in the flight into Egypt, and call it Romero, the Pilgrim's Flower. Both in Spain and 
Italy, it has been considered a safeguard from witches and evil influences generally (Grieve, 
1996).  
In early times Rosemary was freely cultivated in kitchen gardens. In addition to the well known 
culinary use, various medicinal properties are also associated with the herb. Documented 
antibacterial, antinflammatory and spasmolytic actions, which support the traditional use, are 
attributable to the essential oil (Barnes, 2002).  
The rosemary oil as reported by the European Pharmacopeia (Ph.Eur. 5, 2005) is obtained by 
steam distillation from the flowering tops. Nevertheless almost all the commercial oil is distilled 
from the stem and leaves of the plant before it is in flower.   
2. DESCRIPTION OF THE PLANT 
Rosmarinus officinalis L. is a small evergeen branched shrub, 50 to 150 cm high, with erect , 
climbing or occasionally decumbent brown branches. The leaves are sessile, thick aromatic, 
linear, coriaceous and entire-margined. The upper surface is dark green, glabrous and grainy, 
the lower surface is greyish-green and densely  tomentose, 15 to 40 mm by 1.2 to 3.5 mm, with 
recurved edges. The flowers grow on tomentose inflorescences in the leaf axils of the upper part 
of the branches. The calyx is 3 to 4 mm, green or reddish, initially tomentose, later 5 to 7 mm 
and glabrous. The corolla is 10 to 12 mm long, bluish, occasionally pinck or with. The nutlet is 
brown.  
 
2.1 SYSTEMATICS 
Rosmarinus officinalis belongs to the Family Lamiaceae being the only species of this genus.  
It has various vernacular synonyms: Folia Anthos, Folia Roris marini (Lat.), Sea Dew, Our Lady's 
Rose, Polar Plant, Compass Weed, Romero, and Rosemarine. 
Not to be confused with Ledum palustre, Andromeda polifolia, Teucrium montanum, Taxus 
baccata, Santolina rosmarifolia and S. chamaecyparissus. 
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2.2 OCCURRENCE 
It’s native in the Mediterranean region and Portugal and is cultivated there as well as on the 
Central Asia, India, Southeast Asia, South Africa, Australia and the U.S. 
 
2.3 PLANT PARTS AND PRODUCTS 
Rosemary is available as whole crude drug of the flowering dried twig tips, the dried leaves, the 
fresh leaves, the fresh aerial parts collected during flowering and the flowering branches. The 
second main product is rosemary essential oil. But also powder, infusion, dry extracts or other 
galenic preparations for internal (oral administration) and external (topical application) use are 
on the market. It is also available in composed preparations. 
The essential oil of rosemary distilled from the flowering tops, is superior to that obtained from 
the stems and leaves but nearly all the commercial oil is distilled from stems and leaves of the 
plant before it is in flower.  
The  essential oil is colourless or pale yellow with the characteristics of  rosemary and a warm 
camphoraceous taste. It is used in the perfume industry and as flavour agent. It is, however, 
known that variants of the same species can differ in their constituents essential oils. 
3. INGREDIENTS/CONSTITUENTS (CHEM. ANALYSIS, STANDARDIZATION) 
Rosmarini aetheroleum is the volatile oil  obtained by steam distillation from the aerial parts of 
Rosmarinus officinalis. Its composition may vary according to chemotype. Characteristic 
components of the oil are: 1,8-cineole (20-50%), alfa-pinene (15-26%), camphor (10-25%), 
bornyl acetate (1-5%), borneol (1-6%), camphene (5-10%) and alfa-terpineol (12-24%). 
Limonene, beta-pinene, beta-caryophyllene and myrcene are also present in the oil (ESCOP, 
2003). 
 
Flavonoids  
Include diosmetin, diosmin, genkwanin and derivatives, luteolin and derivatives, hispidulin, 
neptin, nepitrin and apigenin (ESCOP, 2003; PDR, 2004). 
 
Other charateristic constituents  
Phenols: caffeic, chlorogenic, labiatic, neochlorogenic. 
phenolic diterpenes suchs as carnosol (up to 4.6%), carnosolic acid, rosmanol, isorosmanol, 
epirosmanol,  rosmaridiphenol, rosmariquinone, hydroxycinnamic derivatives, e.g. rosmarinic 
acid (2-3%) (diterpenes);  triterpenoids such us oleanolic and ursolic acids, α- and β-amyrin, and 
rofficerone (ESCOP 2003).  
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Figure 1. Chem. structure of rosmanol (a), rosmarinic acid (b), carnosol (c) and carnosic acid (d). 
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3.1 CHEMICAL ANALYSIS: METHODS TO DETERMINE THE COMPOUNDS 
Rosemary oil 
The essential oil of rosemary is analysed by gas-chromatography / mass spectroscopy (GLC-MS) 
and gas- liquid chromatography / flame ionization detector (GLC-FID).     
The chemical identification test is performed by Thin-Layer Chromatography (Ph.Eur. 5, 2005). 
The chromatograms obtained in the test are examined for their fingerprint profile (Wagner and 
Bladt 1996). A yellowish-brown zone corresponds to bornyl acetate; a violet zone corresponds to 
cineole and a violet brown zone corresponds to borneol in the reference solution. 
 
Another chemical identification test refers to  the percentage content of total hydroxycinnamic 
derivatives expressed as rosmarinic acid by measuring the absorbance of the test solution. The 
specific absorbance of rosmarinic acid is 400 (Ph.Eur. 5, 2005). 
 
Peng et al. (2005) used a capillary electrophoresis  with electrochemical detection (CE-ED),  
method for the determination of rosemary active components The method was successfully 
used with relatively simple extraction procedures, and the assay results were satisfactory. The 
detection electrode was a 300 micro m carbon disc electrode at a working potential of +0.90 V 
(versus SCE). The analytes can be well separated with 25 min in a 75 cm length fused-silica 
capillary at a separation voltage of 16 kV in an 80 mmol/l borate buffer (pH 9.0). The current 
response was linear over about three orders of magnitude with detection limits (S/N=3) ranging 
from 2x10-7 to 1x10-6 g/ml for all the analytes.  
 
3.2 STANDARDIZATION, STABILITY 
According to Ph.Eur 5 (2005) Rosmarini folium (dried leaves of Rosmarinus officinalis) contain 
minimum 12 ml/kg of essential oil (anhydrous drug) and minimum 3% of total hydroxycinnamic 
derivatives expressed as rosmarinic acid. The powder  is greyish-green to yellowish –green and 
is examined under a microscope using chloral hydrate solution R. A measurable decrease of 
essential oil of rosemary leaves could be detected only after 18 months of storage. 
Rosmarini aetheroleum Ph.Eur.5 is tested on its identity by TLC, on its quantitative composition 
by GLC. The composition (main compounds: pinene, camphene, cineol, camphor and borneol) 
depends on the origin (Spain, North Africa).The most important adulterants of  Rosemary 
essential oils are turpentine and petroleum.  
The essential oil has to be stored in a well-filled, airtight container, protected from light, at a 
temperature not exceeding 25°C (Ph.Eur. 5, 2005).  
 
4. PHARMACOLOGY 
Rosemary has a long list of claims pertaining to its medicinal uses including antibacterial (Del 
Campo et al., 2000) and antioxidant properties (Ozcan, 2003). It is known to be an effective 
chemopreventive agent (Plouzek et al., 1999), an antimutagenic (Minnunni et al., 1992) and has 
been shown to be non-toxic in animal models (Lemonica et al., 1996). 
Rosmarinus officinalis is stated to act as a carminative, spasmolytic, anticonvulsant, sedative, 
diuretic, cholagogic, choleretic, antihepatotoxic, antioxidant, antimicrobial, antiviral, anti-
inflammatory, anti-ulcerogenic effects. Topically, rubefacient, mild analgesic, mild antiseptic, 
wound healing and parasiticide properties are documented (Grainger - Bisset, 1994).  
The German commission E approved internal use for: blood pressure problems, dyspeptic 
complaints, loss of appetite and rheumatism and external use as supporting therapy for 
rheumatic disease and circulatory problems. 
 
4.1 ANTIOXIDANT ACTIVITY 
Rosmarinus officinalis was found to contain several antioxidant compounds such as rosmarinic 
acid (Lamaison et al., 1990), diterpenoids like carnosic acid, carnosol, rosmanol and 
epirosmanol (Haraguchi et al., 1995), carotenoids and a-tocopherol (Munne-Bosch et al., 1999). 
A good correlation between the antioxidant  activities and total phenol content in the extracts 
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was found, although all rosemary extracts showed a high radical scavenging activity (Moreno et 
al., 2006). Furthermore, rosmanol is more effective than both R-tocopherol and BHT. The volatile 
oil of rosemary is an antioxidant with a thermal resistance that is stronger than that of BHA and 
BHT (Nakatani, 1994); the latter compounds volatize easily at high temperatures (Yaakob et al., 
2000). 
Carnosol, rosmanol, and epirosmanol had an inhibitory activity to lipid peroxidation and oxidized 
apo B formation in human bloods LDL.  The IC50 were 7-10 micromol/L.  The antioxidant 
mechanism was related to the scavenging activities to lipid free radical (Zeng et al., 2001).  
 
4.2 ANTICARCINOGENIC ACTIVITY 
Carnosol, a constant constituent of Rosmarinus officinalis extracts, is a phenolic diterpene 
shown to have antioxidant and anticarcinogenic properties.  Infact, carnosol inhibited the 
invasion of highly metastatic mouse melanoma B16/F10 cells in vitro (Huang et al., 2005).  
 
4.3 ANIMAL STUDIES 
 
4.3.1 HEPATOPROTECTIVE EFFECTS 
Rosemary extracts have been shown to have potent hepatoprotective effects against a variety of 
hepatotoxic agents including CCl4, t-BHP and cyclophosphamide. including CCl4 (Fahim et al., 
1999), tert-Butylhydroperoxide (t-BHP) (Joyeux et al., 1990) and cyclophosph-amide (Fahim et 
al., 1999). 
A water extract from this herb has a hepatoprotective effect against azathioprine-induced 
hepatoxicity. Animals pretreated with water extracts from rosemary extract under investigation 
not only failed to show necrosis of the liver after azathioprine administration, but also retained 
livers that, for the most part, were histologically normal. In addition, these herbs blocked the 
induced elevated levels of alanine aminotransferase and aspartate aminotranferase in serum. 
The extract of Carnosol, one of the main constituents of Rosmarinus, has been shown to have 
antioxidant and scavenging activities. The effectiveness of carnosol to normalize biochemical 
and histological parameters of CCl(4)-induced acute liver injury, was evaluated (Sotelo et al., 
2002).  Carnosol normalized bilirubin plasma levels, reduced malondialdehyde (MDA) content in 
the liver by 69%, reduced alanine aminotransferase (ALT) activity in plasma by 50%, and 
partially prevented the fall of liver glycogen content and distortion of the liver parenchyma. 
Carnosol prevents acute liver damage, possibly by improving the structural integrity of the 
hepatocytes.  To achieve this, carnosol could scavenge free radicals induced by CCl(4), 
consequently avoiding the propagation of lipid peroxides. 
Aqueous extracts of Rosmarinus officinalis young sprouts show a significant hepatoprotective 
effect on plasma GPT levels when given as pretreatment before carbon tetrachloride 
intoxication while the whole plant extract was inactive (Hoefler et al., 1987).  
The ability of rosemary to modulate cytochrome P450 (CYP) and detoxication enzymes in rat 
liver was evaluated by comparing the effects of rosmarinus extracts with different chemical 
compositions: essential oil (EO) containing monoterpenes, a dichloromethane extract (DCME) 
containing phenolic diterpenes and a water-soluble extract (WSE) containing phenolic 
compounds such as rosmarinic acid and flavonoids. Male Wistar rats received rosemary in their 
diet at 0.5% (w/w) for 2 weeks.   The study reports that essential oil selectively induced CYP, 
particularly CYP2B. Water-soluble estract enhanced both CYP and detoxication enzymes 
(Debersac et al., 2001).  
 
4.3.2 CHOLERETIC ACTIVITY 
Rosmarinus officinalis ethanol extracts prepared from young sprouts show a significant dose-
related choleretic activity and are more active than the total plant extract (Hoefler et al., 1987).   
 
4.3.3 ANTIULCEROGENIC ACTIVITY 
Rosmarinus officinalis L. crude hydroalcoholic (70%) extract was evaluated for antiulcerogenic 
activity employing different experimental models.  The crude hydroalcoholic extract (CHE) 
decreased the ulcerative lesion index produced by indomethacin, ethanol and reserpine in rats.   
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The pharmacological mechanism has no relationship with nitric oxide (NO) and has no 
relationship with prostaglandins. The crude hydroalcoholic extract of R. officinalis L. has active 
substances that increase the mucosal nonprotein sulfhydryl groups content (Dias et al., 2000).  
 
4.3.4 ANTISPASMODIC AND ANTICONVULSANT ACTIVITIES 
The volatile oil of Rosmarinus officinalis leaves inhibited the contractions of rabbit tracheal 
smooth muscle induced by acetylcholine stimulation and the contractions of guinea pig tracheal 
smooth muscle induced by histamine stimulation. Also, the volatile oil inhibited the contractions 
of rabbit and guinea pig tracheal smooth muscle induced by high potassium (K+) solution and 
the contraction induced by acetylcholine and histamine stimulation, respectively, in Ca(2+)-free 
solution.  These data suggest that the volatile oil of Rosmarinus officinalis leaves has a calcium 
antagonistic property (Aqel, 1991). 
Rosemary oil , 1-8 cineole and bornyl acetate have exerted a spasmolytic action  in both smooth 
muscle (guinea pig ileum) and cardiac muscle (guinea-pig atria prepration). In sooth muscle this 
spasmolytic effect  has been attributed to antagonism of acetylcholine.   
 
4.3.5 ANTICARCINOGEN ACTIVITY 
A methanol extract of the leaves of the plant Rosmarinus officinalis L. was evaluated for its 
effects on tumor initiation and promotion in mouse skin.  Application of rosemary to mouse skin 
inhibited the covalent binding of benzo(a)pyrene [B(a)P] to epidermal DNA and inhibited tumor 
initiation by B(a)P and 7,12-dimethylbenz[a]anthracene (DMBA).  Application of rosemary to 
mouse skin also inhibited TPA-induced ornithine decarboxylase activity, TPA-induced 
inflammation, arachidonic acid-induced inflammation, TPA-induced hyperplasia, and TPA-
induced tumor promotion. Topical application of carnosol or ursolic acid isolated from rosemary 
inhibited TPA-induced ear inflammation, ornithine decarboxylase activity, and tumor promotion 
(Huang Shiu-Chen et al., 2005).   
 
4.3.6 EFFECT ON METABOLISM OF ESTROGENS 
The effects of a methanol extract from the leaves of the plant Rosmarinus officinalis L. 
(rosemary) on the metabolism and action of estradiol and estrone were evaluated in female CD-
1 mice. Feeding female mice with a 2% rosemary diet for 3 weeks increased the liver 
microsomal oxidation and glucuronidation of estradiol and estrone and inhibited their 
uterotropic action (Zhu et al., 1998). 
 
4.3.7 OTHER ACTIVITIES 
The volatile oil of Rosmarinus officinalis has hyperglycemic and insulin release inhibitory effects 
in the rabbit. In normal rabbits, the intramuscular administration of the volatile oil (25 mg/kg) 
increases in plasma glucose levels following the administration of the intraperitoneal glucose 
test. The same treatment also resulted in a 30% decrease in serum insulin level (Al-Hader et al., 
1994).  
In alloxan diabetic rabbits, Rosmarinus officinalis volatile oil increased fasting plasma glucose 
levels. 
The aqueous and ethanol extracts of Rosmarinus officinalis aerial parts diminish morphine 
withdrawal syndrome in mice. Dependence was induced using subcutaneous injections of 
morphine daily for 3 days.  On day 4, morphine was injected 2 h prior to the intraperitoneal 
injection of naloxone.  The number of jumps during the 30 min period after naloxone injection 
was considered as a measure of the withdrawal syndrome.  The results indicated that the 
aqueous (1.68 g/kg and 2.4 g/kg, i.p.) and ethanol (0.96 g/kg, i.p.) extracts reduced the 
number of jumps (Hosseinzadeh et al., 2003).  
Rosemary showed significant antithrombotic activity in vitro and in vivo, in experimental models 
of thrombosis. The mechanism of the antithrombotic effect of rosemary may involve a direct 
inhibitory effect on platelets (Yamamoto et al., 2005). 
Essential oils of Zingiber officinale and Rosmarinus officinalis were found to be ovicidal and 
repellent, respectively,  towards three mosquito species (Prajapati et al., 2005). 
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4.4 HUMAN STUDIES 
Rosemary (Rosmarinus officinalis L.) extract enhanced the production of Nerve Growth Factor, a 
factor vital for the growth and functional maintenance of nerve tissue, in T98G human 
glioblastoma cells.  Furthermore, the results indicated that carnosic acid and carnosol, which 
are major components of the rosemary extract, were able to promote markedly enhanced 
synthesis of NGF (Kosaka et al., 2003). 
 
4.4.1 ANTI-INFLAMMATORY EFFECTS 
Rosmarinic acid is well absorbed from gastrointestinal tract and from the skin.  It increases the 
production of prostaglandin E2 and reduces the production of leukotriene B4 in human 
polymorphonuclear leukocytes, and inhibits the complement system. It is concluded that 
rosemary and its constituents especially  caffeic acid  such as rosmarinic acid have a 
therapeutic potential in treatment or prevention of inflammatory diseases (Al-Sereiti et al., 
1999). 
 
4.5 ADME 
The in vitro organic-matter digestibility of the  Rosmarinus officinalis  varies between 36-52%, 
the effective degradability of the crude proteins (CP) varies between 45-68%, and the 
concentration of undegraded dietary protein varies from 32-55 g/kg dry matter.   The availability 
of protein is 61% (RO), calculated protein digestibility of the undegraded dietary protein leaving 
the rumen at the degradability estimated was negative for Rosmarinus officinalis. The 
digestibility of the total carbohydrates and the efficiency of volatile fatty acid production were 
not affected by the supplementation.    
Rosmarinic acid is rapidly eliminated from the circulation t1/2=9 minutes following intravenous 
administration. 
Rosmarinic acid is well absorbed from gastrointestinal tract and from the skin. 
5. MICROBIOLOGY 
5.1 ANTIBACTERIAL ACTIVITY 
Several compounds found in Rosmarini aetheroleum have been reported to be inhibitory to 
micro-organism (Guenther, 1974). Although the essential oil of Rosmarinus officinalis from the 
Mediterranean region appears to be well studied, its composition, as well as its antimicrobial 
properties, could differ from those of the variants growing in South Africa because of the 
differences in the two environments (Janssen et al., 1987).  
Several components of essential oils have been reported to possess biological activities. 
Camphene, for instance was found to be effective against Staphylococcus aureus and 
Escherichia Coli.  α-Pinene significantly reduced growth of Erwinia amylovora while β-Pinene 
was inhibitory to bacteria, especially at higher bacterial population (Scortichini et al., 1991).  
The major components were assessed for their antibacterial activities against strains of 
Staphylococcus aureus possessing efflux mechanisms of resistance. Minimum inhibitory 
concentrations ranged from 16 to 64  µg/ml. Incorporation of carnosic acid and carnosol into 
the growth medium at 10 l µg/ml caused a 32- and 16-fold potentiation of the activity of 
erythromycin against an erythromycin effluxing strain, respectively (Oluwatuyi et al., 2004). 
Methanol extract containing 30% of carnosic acid, 16% of carnosol and 5% of rosmarinic acid 
was the most effective antimicrobial against Gram positive bacteria (minimal inhibition 
concentration, MIC, between 2 and 15 mug/ml), Gram negative bacteria (MIC between 2 and 60 
mug/ml) and yeast (MIC of 4 mug/ml). By contrast, water extract containing only 15% of 
rosmarinic acid showed a narrow activity. The antimicrobial rosemary extracts efficacy was 
associated with their specific phenolic composition. Carnosic acid and rosmarinic acid may be 
the main bioactive antimicrobial compounds present in rosemary extracts.  
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6. EFFICACY 
6.1 QUALITY OF THE ANIMAL PRODUCT 
The influence of rosemary (Rosmarinus officinalis) and vitamin E during  21 day of feeding  were 
evaluated in broilers on the growth and qualitative parameters of poultry meat. Broilers fed with 
rosemary achieved higher body weights, better feed conversion and lower feed consumption  
compared with the other groups. Sensory evaluation showed better sensory properties of poultry 
meat from chickens fed with rosemary. The most significant differences were in the taste and 
flavour of the meat. The meat from broilers fed rosemary extract had lower concentration of 
total cholesterol oxidation products and the value of TBARS of refrigerated meats were 
significantly lower (Marcincak et al., 2004). 
One experiment was conducted to evaluate the effect of supplementation of aromatic plants 
(dried rosemary leaves and stems, as well as oregano essential oil) in layers' diets, on the 
performance and egg traits. The results of this study showed that the addition of dried rosemary 
leaves and stems oil in layers diet did not significantly affect either the performance of laying 
hens or the egg traits. No distortion of the oviduct no any significant effects on the kidneys' 
condition were found (Mitsopoulos et al., 2005). 
A study was conducted to evaluate the effect of rosemary herbal supplementation in broiler 
diets on some prevalent species of gut microbes. There was no effect of treatment on the 
concentration of gastrointestinal bacteria compared to the control. (Lopez-Bote et al., 1998). 
Periparturient Saanen goats were fed a standard diet supplemented with 800 or 1600 mg/day 
Rosmarinus officinalis. Rosemary extract does not affect milk yield and milk and colostrum 
characteristics when given at 800 mg/day. 
Different antioxidants, either α-tocopheryl acetate, BHT, or a rosemary extract were tested in 
fish diet. The results showed that the use of antioxidants altered the fatty acids composition of 
fish fillet (Sant’Ana et al., 2000).  
In an other study  Rosemary extract was administered to New Zealand White male rabbits in 
order to evaluate its effect on lipid content and fatty acid composition of liver, Longissimus 
lumborum muscle and abdominal fat. More than 60% of the fatty acid composition was 
quantitatively different in liver; 40% in adipose tissue while only few differed in Longissimus 
lumborum muscle (Tava et al., 2002). 
7. TOXICOLOGY 
Rosmarinic acid exhibits low toxicity (LD50 in mice is stated as 561 mg/kg for intravenous 
administration) and is rapidly eliminated from the circulation. Acute LD50 values quoted include 
% ml/kg (rat, oral) and >10 ml/kg (rabbit, dermal).  Some  botanical compounds might be 
activated by P450 to short-lived electrophilic intermediates capable of alkylating cellular 
biomolecules or participating in redox cycling reactions and causing cellular damage.   
Pulsed ultrafiltration-mass spectrometry is a drug discovery technique invented for the affinity 
selection and mass spectrometric identification of small molecules that interact with a 
macromolecular receptor. This new assay provides a rapid in vitro toxicity screen to determine 
whether botanical dietary supplements should be tested for safety in animals and humans. 
Rosmarinus officinalis (rosemary) contains rosmarinic acid, carnosic acid, carnosol, and 
eugenol. Eugenol can be metabolized by P450 to a quinine methide and has been shown to be 
toxic to rat liver hepatocytes with an LC50 of 200-300 µM. As a food product, the leaves 
rosemary should pose no threat to human health if consumed in moderation, since small 
amounts of electrophilic quinones, if formed, could be deactivated by reaction with endogenous 
GSH.  However, certain extraction methods might concentrate compounds such as rosmarinic 
acid or eugenol and increase the risk of toxicity of dietary supplements containing rosemary. 
Since this data indicate that a methanol extract of rosemary contains compounds that may be 
activated metabolically to redox active compounds or electrophilic species (Johnson et al., 
2001). 
 
 
Rosmarinus 
----------------------------------------------------------------------------------------------------------------- 
 
 225
7.1 SAFETY  
 
7.1.1 ADMINISTRATION - DOSAGE 
Rosemary is available as whole, crude and powdered drug forms. The daily dosage is 4 to 6 g 
drug. Rosmarini aetheroleum is commonly used as flavouring agent in foods and was not 
considered necessary limited use in veterinary  medicine. No information on possible residues or 
residue depletion was considered necessary.  
Considering that Rosmarinus officinalis   is a normal component of human food and a normal 
component of the feed of food producing animals, the EMEA Committee on Veterinary 
Medicinals included it in Annex II of Council Regulation (EEC) No 2377/90 as a substance that 
does not need a MRL level (EMEA/MRL/290/97). 
 
7.1.2 SIDE EFFECTS/ ADVERSE REACTION /CONTRAINDICATIONS/ PRECAUTIONS 
Topical preparations containing rosemary oil should be used with caution by hypersensitive 
individuals. 
Rosemary preparations should not be to used during pregnancy. 
RO is a normal constituent of the animal diet in some Member State, and widely used a spice in 
the human diet.  No information on possible residues or residue depletion was considered 
necessary.  
 
7.1.3 INTERACTIONS WITH OTHER DRUGS 
In a laboratory study, rosemary extract increased the effectiveness of doxorubicin in treating 
human breast cancer cells. Human studies will be necessary to determine whether this is true in 
people. Meanwhile, those taking doxorubicin should consult with a healthcare practitioner 
before taking rosemary. 
The effects of  rosemary was studied on the permeability of some commonly used drugs. 
The permeabilities of verapamil, metoprolol, ketoprofen,, paracetamol, and furosemide were 
studied across Caco-2 cell monolayers. Mechanisms of interactions between drugs and herbs 
are similar to well known mechanisms of interactions between drugs and minerals (chelation, 
adsorption). Many herbal food supplements contain large amounts of flavonoids. These can 
interact with efflux proteins present in absorptive enterocytes, and there may be severe 
interactions with drugs administered contemporaneously (8–10) (Laitinen et al., 2004). 
Rosemary extracts, has been reported to enhance the oral and systemic availabilities of a 
variety of drugs. Effects on systemic availability were explained by acute inhibition of the MDR1 
efflux pump system that exists in various parts of the small intestine. Methanolic extracts of 
rosemary have been reported to inhibit P-gp efflux activity in breast-cancer cell cultures that 
over-expressed P-gp. The mechanism underlying the phenomenon is believed to be the ability of 
the rosemary extract to alter the activity of P-gp but not its expression (Castro et al., 1997). 
Furosemide permeability was strongly increased by the presence of 1 mg/ml rosemary extract, 
by opening of tight junctions between Caco-2 cells.  
_________________________________________________________________________________ 
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SALVIA OFFICINALIS 
   
Salvia officinalis L.  Salvia sclarea L. 
 
1. INTRODUCTION 
The name of the genus, Salvia, is derived from the Latin salvere, to save, in reference to the 
curative properties of the plant, which was in olden times celebrated as a medicinal herb. 
This species was used in ancient Egyptian, Greek, and Roman medicines. Ancient Egyptians 
used it as a fertility drug (Bown, 1995). In the first century C.E. Greek physician Dioscorides 
reported that the aqueous decoction of sage stopped bleeding of wounds and cleaned ulcers 
and sores. He also recommended sage juice in warm water for hoarseness and cough. Pliny the 
Elder (ca. 23–79 C.E.) reported that sage enhanced memory functions. He prescribed 
decoctions, boiled in water or wine, of sage, rosemary, honeysuckle, plantain, and honey for 
gargles to treat sore mouths and throats (Grieve, 1979). Its uses in traditional Greek medicine 
spread to India, where the dried leaf (Salbia-sefakuss in Hindi) and fluid extract are used in 
traditional Indian Ayurvedic, Siddha, and Unani medicines. Eight other related Indian species of 
Salvia (e.g., S. plebeia) are also listed in the Ayurvedic Pharmacopoeia and used interchangeably 
with the Mediterranean species. In India, its use is indicated for flatulent dyspepsia, pharyngitis, 
uvulitis, stomatitis, gingivitis, and glossitis (Karnick, 1994; Nadkarni, 1976). 
Hippokrates (5th c BC), Theophrastus (4th c BC) and Dioscorides (1st c AD) referred to them with 
the names "elelisfakon" and "sfakon". 
In modern Greece, three Salvia species, named "faskomilo" and "alisfakia", are used as spices 
or as ingredients of folk remedies: S. fruticosa, which is known in the international trade as 
"Greek sage", S. officinalis, the commercially known "Dalmatian or garden sage", and S. 
pomifera, the "Cretan sage". 
The essential oil of S. fruticosa is a folk remedy for toothaches and intestinal complaints 
(Fragaki 1969; Vokou et al., 1993; Rivera et al., 1994). Recent studies have revealed that a leaf 
infusion of S. fructicosa has a hypoglycemic effect (Perfumi et al., 1991); furthermore it has 
been shown that its essential oil exhibits antibacterial, cytotoxic and antiviral activities 
(Sivropoulou et al., 1997). 
Sage is an evergreen perennial subshrub, native to the Mediterranean rim, especially around the 
Adriatic Sea, now cultivated in Albania, Turkey, Greece, Italy, France, the United Kingdom, and 
the United States (Bruneton, 1995; Budavari, 1996; Leung and Foster, 1996; Wichtl and Bisset, 
1994). The material of commerce comes mainly from southeastern European countries, such as 
Albania and the former Yugoslavia (BHP, 1996; Wichtl and Bisset, 1994). Its cultivation in 
northern Europe dates back to medieval times, and it was introduced to North America during 
the seventeenth century (Bown, 1995). 
In Germany, sage is licensed as a standard medicinal tea to treat gastrointestinal catarrh and 
night sweats. The tea is also applied topically as a rinse or gargle for inflammations. Sage 
fluidextract, tincture, and essential oil are all used in prepared medicines for mouth and throat 
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and as gastrointestinal remedies in fluid (e.g., juice) and solid dosage forms (e.g., capsules, 
drageès) (Leung and Foster, 1996; Wichtl and Bisset, 1994). In the United States, sage is used 
as a component of dietary supplement products for similar conditions, usually in aqueous 
infusion or alcoholic tincture dosage forms. Sometimes the dry herb or dry extract is used in 
capsules and tablets. Sage was formerly official in the United States Pharmacopoeia from 1840 
to 1900 as a gargle in inflamed sore throat (Boyle, 1991). 
 
 
2. DESCRIPTION OF THE PLANT 
The genus Salvia, one of the largest Labiatae genera, includes c. 900 species and has almost 
cosmopolitan distribution. Southwest and central Asia is considered its major centre of origin 
(Hedge 1992). 
The sage plants of greece, the three sage species (S. fruticosa, S. officinalis, S. pomifera) are 
strongly aromatic, many branched shrubs and reach heights up to 1.60 m. S. fruticosa and S. 
officinalis, members of the Section Salvia, have actinomorphic calyces with 5 equal or subequal 
teeth or bilabiate calyces with a 3-toothed upper lip and a 2-toothed lower lip. S. pomifera 
belongs to the Section Hymenosphace Bentham and is clearly distinguished from the other two 
species by its membranous-reticulate, bilabiate calyces. The upper lip of these calyces is entire, 
sinuate or shortly three-mucronate, whereas the lobes of the lower lip are obtuse, emarginate or 
mucronate (cf. Hedge 1972, 1982). Glandular trichomes, where the essential oils are secreted 
and accumulated, appear in all aerial parts of the three Salvia species. Two types of glandular 
trichomes are found: (a) capitate glandular hairs consisting of a unicellular, bicellular or 
multicellular stalk and a unicellular or bicellular secretory head, and (b) peltate glandular hairs 
consisting of a unicellular stalk and a multicellular (up to 12-celled) head (Verzar -Petri and Then 
1975; Gupta and Bambie 1980; Bini Maleci et al., 1983; Venkatachalam et al., 1984; Werker et 
al., 1985; Corsi and Corsi 1988; Werker 1993; Länger 1997). Galls are frequently formed on the 
stems of S. fruticosa and S. pomifera. The three Salvia species have the same chromosome 
number, 2n=14 (Fedorov 1969; Bothmer 1970; Kuštrak et al., 1986). 
Salvia species of Africa, particularly southern Africa, have not been very well studied. With 
regard to taxonomy, a revision of Salvia in Africa was carried out by Hedge (1974). The 59 
species recognized were devided into 18 species-groups, of which the seven occur in southern 
Africa. Most of the species are restricted to Africa.  
Southern Africa is home to 30 species of the genus Salvia, for example S. sclarea (Clary sage), 
S. africana-lutea, S. chamelaeagnea, S. coccinea, S. reflexa S. tiliifolia and S. verbenaca. 
The ESCOP sage leaf monograph requires that the material comply with the European 
Pharmacopoeia (ESCOP, 1997).  
 
3. INGREDIENTS / CONSTITUENTS 
Sage leaf consists of the whole or cut dried leaves of Salvia officinalis L. The whole drug 
contains not less than 15 ml/kg of essential oil and the cut drug not less than 10 ml/kg of 
essential oil, both calculated with reference to the anhydrous drug. 
The ingredients of sage leaf (Salviae officinalis folium) are essential Oil, up to 2,5%, containing 
monoterpenes such as α- and β- thujone (up to 63% and 13% respectively), camphor and 1,8 - 
cineole. Other constituents are monoterpene glycosides and diterpenoids such as carnosic acid 
and its derivatives, e.g. carnosol and a quinone methide. Also triterpenoids including ursolic 
acid, oleanolic acid and their derivatives. Flavonoids, e.g. 5-methoxysalvigenin. Phenolic 
compounds, e.g. rosmarinic acid and derivatives, a caffeic acid trimer and flavonoid and 
phenolic glycosides are ingredients of sage leaf. [ESCOP] 
Sage leaf contains 3–8% condensed catechin-type tannins (salviatannin); phenolic acids 
(rosmarinic, caffeic, chlorogenic, ferulic, and gallic acids); 1–3% flavonoids (apigenin and 
luteolin derivatives); 1.5–2.8% volatile oil, mostly monoterpenoids of which 18–60% is a-
thujone, 3–10% b-thujone, 4.5–24.5% camphor, 5.5–13% cineole, 0–12% humulene, 1–6.5% 
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a-pinene, 1.5–7% camphene, 0.5–3% limonene, max. 1% linalool, and max. 2.5% bornyl 
acetate; diterpenoid bitter principles carnosol, carnosic acid, and rosmanol; triterpenoids 
oleanolic acid and ursolic acid; and resin (Bruneton, 1995; Budavari, 1996; ESCOP, 1997; Leung 
and Foster, 1996; Newall et al., 1996; Wichtl and Bisset, 1994).  
Pharmacopeial grade sage leaf must contain not less than 1.5% (v/m) thujone-rich volatile oil 
calculated with reference to the anhydrous drug as determined by DAB (German Pharacopoeia) 
method V.4.5.8 (DAB, 1997; ESCOP, 1997; AB, 1981; Ph.Helv.VII, 1987; Wichtl and Bisset, 
1994). It must contain not less than 16% water-soluble extractive, among other quantitative 
standards. Botanical identity requirements are carried out by thin-layer chromatography (TLC) as 
well as by examination of macroscopic and microscopic characteristics (BHP, 1996). 
Adulteration is determined with a TLC method that can be used to examine the volatile oil 
composition and flavonoids profile (DAB 1997; Wichtl and Bisset, 1994). The French 
Pharmacopoeia requires between 2–3% volatile oil (Bruneton, 1995; Ph.Fr.X., 1990). 
Pharmacopeial grade sage tincture (Salviae Tinctura) must contain not less than 0.1% thujone-
rich volatile oil. Its drug-to-extract ratio is 1:10 in ethanol 70% (v/v), manufactured by 
percolation according to the German Pharmacopoeia Tincture monograph. Botanical identity of 
the finished tincture is determined by DAB TLC method V.6.20.2 (DAB, 1997). 
 
3.1. S. OFFICINALIS AND S. FRUTICOSA 
S. officinalis is considered to have the highest essential oil yield among Salvia species, along 
with a higher total ketone content and a lower total alcohol content (Ivanic and Savin 1976, 
Newall et al., 1996). The major components of the essential oil of S. officinalis are α- and β- 
thujones (35-50%, mainly α). At least two chemotypes of S. officinalis exist, one with a low β- 
thujone content (4-8%) and another with a relatively high content (16-32%) (Boelens and 
Boelens 1997). 
 
3.2 S. SCLAREA 
The volatile fraction of the Greek S. sclarea differs from many Salvia species growing in the 
Mediterranean region, in regard to compounds, in the variety of its components and their 
relative quantity. While the oil of S. sclarea contains mainly monoterpenoid alcohols such as 
linalool, geraniol, terpineol, nerol, and linalyl acetate, geranyl acetate, neryl acetate, the 
essential oils from many Salvia species contain α- and β-pinenes, camphor, phelladrene, cineol 
and bornyl acetate as major constituents. 
 
 
4. PHARMACOLOGY 
The Commission E approved the internal use of sage leaf for dyspeptic symptoms and excessive 
perspiration, and external use for inflammations of the mucous membranes of nose and throat.  
ESCOP indicates its use for inflammations such as stomatitis, gingivitis and pharyngitis, and 
hyperhidrosis (ESCOP, 1997). The German Standard License for sage infusion indicates its use 
for inflammation of the gums and the mucous membranes of the mouth and throat; pressure 
spots caused by prostheses and in supportive treatment of gastrointestinal catarrh (Wichtl and 
Bisset, 1984).  
Sage leaves act appetising and digestive because of the bitter flavour (Reichling et al., 2005). 
 
4.1 ANIMAL AND IN VITRO TESTING 
When applied topically (5% in vehicle) to rhesus monkeys, rosmarinic acid significantly lowered 
both gingival and plaque indices in comparison with placebo. [ESCOP] 
 
4.2 HUMAN STUDIES 
A dialysate of an aequeous extract from fresh sage leaf showed antihyperhidrotic activity in 
humans. Excessive sweat production induced by pilocarpine was inhibited. 
 
Reduction of Sweat secretion: 
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One open study at an outpatient clinic investigated the equivalence of efficacy and compared 
tolerance between an aqueous dry extract product "Sweatosan" and sage tea. Eighty patients 
suffering from idiopathic hyperhidrosis were treated for four weeks. Forty patients were treated 
with 440 mg aqueous dry extract, corresponding to 2.6 g of dry leaf, and the other 40 with an 
aqueous infusion, 4.5 g leaf daily. The reduction of sweat secretion reported (less than 50%) 
was comparable for both treatment groups, though somewhat stronger in the aqueous dry 
extract group (ESCOP, 1997; Rˆsing, 1989). 
In an open study with 80 patients both an aqueous infusion and a dried aqueous extract 
comparably reduced sweat secretion (ESCOP, 1997). 
 
4.3 VETERINARY STUDIES 
 
4.3.1 RUMINANTS 
Positive effects on the rearing performance of calves with herbal mixtures including sage are 
reported (Kraszewski J, Wawrzynczak S, Wawrzynski M, 2002), but there is also a study wich did 
not show this effect (Stenzel R, Widenski K, Saba L.; 1998). 
The efficacy of feeding high-yielding cows with concentrates containing 2% herb supplements 
(sage included) on cow performance, modification of milk chemical composition, technological 
value of milk for processing and nutritive value for humans was determined (Kraszewski J, 
Grega T, Wawrzynski M.; 2004) Positive immunological effects (increasing IgG-levels) of mineral-
herbal mixtures as diet-supplements (containing sage) in growing calves were reported 
(Krukowski H, Nowakowicz DB, Saba L, Stenzel R.; 1998) 
 
4.3.2 PIGS 
It is reported that sage extracts improve the body weight gains and meat quality of pigs 
(Hanczakowska E, Wolski T, Urbanczyk J, Dobrowolska D, Lach H, Pilawski J; 2003; Wagner F., 
2003) 
Sage and its extract have an antioxidant capacity, which could be used as stabilisers of fat, in 
order to improve quality and shelf-life of meat and fat-containing food. On the one hand it 
seems possible to keep perishable fat-containing food longer by an addition of an extract of 
sage or oregano due to their antioxidative properties, on the other hand administration of feed 
additives of dried herbs (sage) to pigs had no effect on quality and shelf-life of fat obtained from 
these animals (Vichi S, Zitterl EK, Jugl M, Franz C.; 2001) (Bauer F, Siller D, Kleineisen S, Luf W, 
Pfannhauser W, Fenwick GR, Khokhar S.; 2001) 
 
 
5. MICROBIOLOGY 
The Commission E reported antibacterial, fungistatic, virustatic, astringent, secretion-promoting, 
and perspiration-inhibiting properties. 
 
Drug preparations act antimicrobial (against Staphylococcus aureus, Escherichia coli and 
others), antiviral (amongst others Influenza A2, Vacciniaviruses and Herpes-simplex-Virus), 
antihypertensive (a.o. in cats, rats), choleretic (for ex. aqueous infusion for rats), antisecretory 
(sweat), spasmolytic (for example at rats duodenum, guineapig-ileum) and antioxidative 
(Lipidperoxidation is limited because of rosmarinic acid). ( Reichling et al., 2005, 
Heilpflanzenkunde für Tierärzte). 
Antisecretory and antimicrobial acticity: 
The Merck Index reported its therapeutic category as antisecretory agent (Budavari, 1996). Its 
volatile oil has antimicrobial activity attributed to its thujone content. Its traditional uses may be 
explained by its volatile oil and tannin content (Jalsenjak et al., 1987; Newall et al., 1996).  
Bactericidal and fungicidal effects: 
In in vitro experiments sage oil exhibited bactericidal and fungicidal properties when tested on 
Gram-positive and Gram-negative bacteria, filamentous fungi and yeasts, e.g. Candida albicans. 
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An aequeous and a 50%- ethanolic extract of sage leaf exhibited strong inhibitory effects on the 
collagenolytic activity of Porphyromonas gingivalis. 
Aerial parts of sage contain diterpenes with antiviral activity against vesicular stomatitis virus. 
[ESCOP]. 
 
5.1 ANTIOXIDANT AND ANTIINFLAMMATORY ACTIVITY 
Two phenolic glycosides isolated from sage leaf, 6-O-caffeoyl-β-D-fructofuranosyl-α-D-
glucopyranoside and 1-O-caffeoyl-β-D-apiofuranosyl-β-D-glucopyranoside, were found to have 
moderate antioxidant activity in the DPPH and metmyoglobin tests. 
Rosmarinic acid has been shown to have antiinflammatory activity. 
Urosolic acid , the main component of the chloroform dry extract from sage leaf was found to be 
the major contributor to its anti-inflammatory activity in in vivo experiments. 
Oleanolic acid also showed anti-inflammatory activity in in vivo experiments but was less 
effective. 
 
6. EFFICACY 
 
6.1. STABILITY 
Sage -infusions shouldn´t be cooked, because of the volatility of the essential oil (Wagenauer 
and Wiesenauer, 2003) 
 
 
7. TOXICOLOGY 
In the case of overdose, there are no toxic effects reported. [ESCOP]. 
Epilepic cramps were reported because of the use of the essential oil in a high dosage (BRAUN, 
1994). 
 
7.1 SAFETY 
For internal use an infusion (1:10) out of sage leaves will be prepared. 
 
Internal Use of Sage leaves: 
Dosages 
recommended daily allowance: 
Cattle    30,0 - 80,0 g 
Horse    25,0 - 60,0 g 
Sheep    10,0 - 15,0 g 
Pig       5,0 -  10,0 g 
Dog      2,0 -   5,0 g 
Cat, Fowl      1,0 -   2,0 g 
(by Rabinovich 1981; Gachnian and Assenov 1986;; Lipnizkiji et al. 1987) 
 
Prescription: 
Rp.      Rp. 
Salviae fol.    2,5   Sage leaves    2,5 
Aqu. comm.  47,5   Drinking water  47,5 
M.f.infus.     make an infusion. 
 
D.S. Internal use 3 times daily a tablespoon of this infusion for a dog with diarroea [Gachnian 
and Assenov 1990] 
 
It is allowed to use Sage leaves (Salviae officinalis folium) as an active agent for foodstuff 
delievering animals in the EU. [VO (EWG) Nr. 2377/90]. [Reichling et al., 2005] 
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Calves suffering from diarrhoea get an infusion of 300 - 400ml over 3 - 5 days. This therapy 
normalises the function of the alimentary system, activates the appetite and enhance the 
general condition. 
 
Presently, there is no experience with sage leaves and pregnant or lactating animals. [Reichling 
et al., 2005] 
 
Caution is required with the use of alcoholic preparations because of the presence of thujone. 
Given the potential toxicity of some constituents of the essential oil, the use of sage leaf is not 
recommended during pregnancy or lactation. [ESCOP] 
Interactions with other drugs or undesirable effects are none known for sage leaves. [ESCOP] 
The pure essential oil and alcoholic extracts should not be used internally during pregnancy.    
It´s not recommended (McGuffin et al., 1997).  
Interactions with other drugs: 
None known 
Dosages for humans: 
Unless otherwise prescribed: 4–6 g per day of cut leaf for infusions, alcoholic extracts, and 
distillates for gargles, rinses and other topical applications, and for internal use. Also pressed 
juice of fresh plants. 
 
Internal: 
Dried leaf: 1–3 g, three times daily. 
Infusion: 1–3 g in 150 ml water, three times daily. 
Dry aqueous extract 5.5:1 (w/w): 0.18–0.36 g, three times daily. 
Fluidextract 1:1 (g/ml): 1–3 ml, three times daily. 
Fluidextract: 1.5–3 g (Erg.B.6). 
Tincture 1:10 (g/ml): 2.5–7.5 g (Erg.B.6). 
Essential oil: 0.1–0.3 ml. 
Succus: Pressed juice of fresh plant in 25% alcoholic preservation. 
 
External: 
Gargle or rinse: Use warm infusion: 2.5 g cut leaf in 100 ml water; or 2 to 3 drops of essential oil 
in 100 ml water; or use 5 ml of fluidextract diluted in 1 glass water, several times daily. 
Paint: Apply the undiluted alcoholic fluidextract to the affected area with a brush or swab. 
__________________________________________________________________________________
KBB 
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SILYBUM MARIANUM 
 
Silybum marianum   
 
1. INTRODUCTION 
Silybum marianum (L.) Gaertn. Synonyms: Carduus marianus (L.), Lady’s Thistle, Mediterranean 
Milk Thistle, St. Mary’s Thistle. It’s beloings to the Asteraceae family (Compositae). European 
colonists reportedly transported the herb to the New World from Britain and it has since become 
naturalized in the eastern United States, California and parts of Canada. Milk thistle also grows 
in India, China, South America, Mexico, Australia and Africa. In many regions, it’s a widespread 
wayside herb, often found in wastelands, along roadsides and on cultivated ground. Historically, 
grown in Europe as an vegetable, for edible peeled stalks; leaves salad green or pot herb; roots 
and flower receptacle eaten like artichoke; the food use as herb tea ingredient is reported.  
Traditionally, Milk Thistle fruits have been used for disorders of the liver, spleen and gallbladder; 
It is stated to posses hepatoprotective, antioxidant and choleretic properties. Current interest is 
focused on the hepatoprotective activity of Milk Thistle and its use in the prophylaxis and 
treatment of liver damage and disease (Herbal Medicines, 1996). 
Milk thistle seed extract are marketed in the European Union as dry extract, yellow brown 
powder (particle size: at least 95% must be less than 500 micron), to form capsules and tablet, 
and as a liquid extract used in infusion and tinctures.  
 
2. DESCRIPTION OF THE PLANT 
Milk thistle or Mary’s thistle (Silybum marianum) is a herbaceous annual or biennial plant, easily 
recognized by its stout thistle, reddish-purple flowers, large prickly leaves with milky white zones 
and tubular–shaped flowers that terminate in sharp pines. Silybum marianum has a stem 20-
150 cm high, rarely shorther, glabrous or slightly downy, erect and branched in the upper part. 
The leaves are alternate, large, white-veined, glabrous with strongly spiny margin.The 
inflorescences are large and round capitula, solitary at the apex of the stem or its branches, 
surrounded by thorny bracts. The florets are hermaphrodite, tubular in shape with corolla red-
purple.The fruits are hard-skinned achenes 6 to 8 mm long, shiny, generally brownish in colour 
with a white silk-like pappus at the apex (Botanical Medicines, 2002).  
 
2.1 SYSTEMATICS 
The Silybum genus belongs to the Asteraceae Family and contains two species: Silybum 
marianum (L.) Gaertner and Silybum eburneum. Both species are indigenous to the 
Mediterranean region, although Kashmir is considered the native home of Silybum marianum. 
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2.2 PLANT PARTS USED 
The fruits are harvested in July-August after blooming. 
The medicinal part of the plant are the fruits (often referred to as “seeds”).  
Other parts frequently used with different value: milk thistle herb, milk thistle (fatty) oil. 
 
3. INGREDIENTS / CONSTITUENTS: CHEMICAL STRUCTURE CONTENT OF VARIATION 
Milk thistle fruits contain: 
Silymarin, present only in the fruit (1.5-3%), is a mixture of flavonolignans, containing silybin, 
silychristin, silydianin, and isosilybin. Silymarin CAS number is 65666-07-1. Silymarin extract is 
standardized by silybin content, the major constituent. 
Flavonoids: apigenin, chrysoeriol, eriodictyol, naringenin, quercetin, taxifolin 
Lipids (20-30%): linoleic acid, oleic acid and palmitic acid.  
Sterol: cholesterol, campesterol and stigmasterol  
Other constituents: mucilages, sugars (arabinose, rhamnose, xylose, glucose) amine and 
saponins.   
Silymarin is a standardised ecxtract from the milk thistle fruit.  
Silymarin is the pharmacologically active component of Milk thistle fruit; silybin is the main 
component of silymarin. 
Silymarin usually contain 50-70% of flavonolignans (silybin, isosilybin, silydianin and silychristin) 
taxifolin and other minority compounds (Fig. 1). A residual fraction (30-50%) of silymarin, which 
has not yet been defined chemically in detail, contains polymerised polyphenolics.  
 
 
 
 
Figure 1. High performance liquid chromatogram of the silymarin mixture. 
 
 
Milk thistle herb contain: 
Flavonoids: apigenin, luteolin, kaempferol and their glycosides.  
Steroids: sterols, including beta-sitosterol, beta-sitosterol glucoside  
Organic acids: fumaric acid (3,3%) 
Milk thistle oil is rich in unsaturated fatty acids. 
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3.1 CHEMICAL ANALYSIS: METHODS TO DETERMINATE THE COMPOUND  
Separation and determination of Silybum marianum flavonoids (Silychristin, Silybin, Isosylibin 
and Silydianin) is achieved by HPLC as described in DAB 10 “Cardui mariae fructus extractum 
siccum” and in Pharmeuropa (2004), 1, 99 “Milk thistle dry extract, quantified and refined”. 
The method is suitable for the routine determination of the compounds of interest in S. 
marianum plant material and extracts in feed additive and in animal products. 
A thin-layer chromatography method is reported in European Pharmacopoeia  (01/2005:1860). 
 
3.2 STANDARDIZATION, STABILITY 
Silymarin is not soluble in water and is administered to the animals as a standard extract mixed 
in premixtures and feedingstuffs. 
Stable under normal conditions, stored in a dry and cool place, away from direct light. 
 
4. PHARMACOLOGY 
Silybum marianum is a medicinal plant widely used in traditional European medicine. 
In Europe, clinical use is widespread for toxic liver damage in supportive treatment of chronic 
inflammatory liver disorders and cirrhosis. In infusion therapy, silybin preparations is used for 
supportive treatment of Amanita mushroom poisoning and for acute liver toxicity induced by 
various toxic agents with different mechanism of action 
In Germany, milk thistle is approved for the treatment of toxic liver disorders and as a 
supportive treatment in chronic inflammatory liver disease and hepatic cirrhosis. The seeds are 
approved by Commission E for dyspeptic, liver and gallbladder complaints.   
In vitro studies using isolated hepatocytes have documented the protective activity of silymarin 
and several of its components against cell damage induced by various cytotoxic substances. 
Silymarin stimulates RNA polymerase A, enhancing ribosome protein synthesis and resulting in 
activating the regenerative capacity of the liver through cell development. Silybin increases the 
rate of synthesis of ribosomal ribonucleic acid through stimulation of nucleolar polymerase. This 
reinforces protein synthesis and accelerates cell-regeneration process. 
 
4.1 ANIMAL STUDIES  
 
4.1.1 ANTIOXIDANT ACTIVITY 
Due to its phenolic nature silymarin is considered to be an antioxidant able to react with 
numerous radicals in cell-free systems, including oxygen and hydroxylic radicals forming more 
stable and less reactive compounds (Mira et al., 1987).  
Another reported property of silybin and silymarin is its role as regulators of the content of GSH 
in various organs. In rats treated with silybin intravenously or silymarin intraperitoneally, a 
significant increase in the amount of GSH contained in the liver, intestine and stomach was 
found, whereas there were no changes in the lungs, spleen and kidneys (Valenzuela et al., 
1989). 
 
4.1.2 HEPATOPROTECTIVE PROPERTIES 
The hepatoprotective activity of the seed is from silymarin, in particular silychristin and 
silydianin. The compounds inhibits the entrance of toxins and block toxin binding sites through 
alteration of the liver cell’s outer membrane and hindering the uptake of toxins as 
demonstrated in rabbit liver microsomes and mononuclear lipid layers.   
It has been shown that silybin preserves the functional and structural integrity of hepatocytes 
membranes by preventing alterations of their phospholipid structure produced by carbon 
tetrachloride and by restoring alkaline phosphatase and GGT activities (Muriel and Mourelle, 
1990). Other authors have shown that silymarin affords hepatoprotection against specific injury 
induced by microcystin, paracetamol, halothane, alloxane, ethanol, in several experimental 
models.  
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Furthermore silymarin significantly lowers the levels of serum γ-glutamyl transpeptidase, 
alanine transaminase, and aspartate transaminase in rats with ethanol-induced liver damage. 
Silybin, a major constituent of silymarin, stimulates phosphatidylcholine synthesis and increases 
the activity of cholinephosphate cytidyltransferase in rat liver both in normal condition and after 
intoxication by galactosamine (Wang et al., 1996).  
The administration of silymarin reduces plasma level of cholesterol and low-density lipoprotein 
(LDL) cholesterol in hyperlipidaemic rats (Wagner et al., 1986). It has been reported that the 
polyphenolic fraction of silymarin positively modifies lipoprotein profile in plasma and reduces 
the development of fatty liver in rats (Skottova et al., 2003). 
Fibrotic transformation plays a key role in the pathogenesis of hepatic cirrhosis. The animals 
treated with silymarin had a 50% decrease in hepatic collagen content after 6 weeks. The dose 
dependence of the antifibrotic effect was also tested. A highly significant reduction in hepatic 
collagen accumulation was obtained with a dose of 50mg silybin/kg/day but not with 25 
mg/kg/day (Boigk  et al., 1997). 
 
4.1.2.1 ANTIHEPATOTOXIC 
Some authors reported that silymarin through a competitive inibition of α-amanitin uptake has 
hepatoprotective properties in experimental intoxication with Amanita phalloides. The efficacy 
of silymarin against phalloidin, hepatotoxiic chemicals, and alcohol is based on its tendency to 
bind to proteins and receptors on cell membranes, displacing toxic substances and preventing 
their entry into the cell. The antihepatotoxic properties of silymarin have been tested in dogs, 
rabbits, rats, mice. Histochemical and histoenzymological studies have shown that silymarin, 
administered 60 minutes before or no longer than 10 minutes after induction of acute 
intoxication with phalloidin, is able to neutralise the effects of the toxin and to modulate 
hepatocyte function (Desplaces et al., 1975, Choppin et al., 1978). Other authors studied the 
ability of silymarin to inhibit the hepatic cytochrome P450 detoxification system (Baer-
Dubowska et al., 1998). It has been reported that silymarin counteracted aflatoxin B1 (AFB1) 
induced changes in liver and serum in rats (Rastogi et al., 2000). In AFB1 experimentally 
intoxicated broiler chickens silymarin administration reduced hepatic histopathological damage, 
prevented the changes in serum ALT activity, and completely counteracted the effects of AFB1 
intoxication on growth performances (Tedesco et al., 2004b). 
 
4.1.3 ANTI-INFLAMMATORY EFFECTS 
In vitro studies have shown that silybin at a concentration of 100 µmol/L reduces the 
proliferation of stellate cells isolated from fresh liver of rats by about 75%, reduces the 
conversion of such cells into myofibroblasts, and down regulates gene expression of 
extracellular matrix components indispensable for fibrosis. In rats silymarin administered at a 
dosage of 50 mg/kg/day for six weeks is able to reduce fibrosis by 30 to 45% when compared 
with control (Fuchs et al., 1997) 
 
4.1.4 NEPHROPROTECTIVE PROPERTIES 
Silybin injected into rats prior to administration of cisplatin afforded protection of glomerular 
and proximal tubular function. 
 
4.1.5 ANTICANCER ACTIVITY 
Silymarin when applied to the skin of SENCAR mice, gave protection against the effects of the 
tumor promoters 12-O-tetradecanoylphorbol (TPA) and okaidic acid (OA). Topical application of 
silymarin prior to that of TPA and OA completely inhibited induction of tumor necrosis factor α 
(TNFα) mRNA expression in the epidermis. Substantial protection from photocarcinogenesis in 
mice treated with phorbol ester or 7,12-dimethylbenze(a)anthracene has been demonstrade. 
The antitumour effects is primarily 
At stage 1 tumour promotion and silymarin acts by inhibiting cyclooxygenase 2 (COX-2) and 
interleukin 1α (IL-1 α).  
 
4.1.6 GASTRIC ULCER PROTECTIVE EFFECTS  
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Oral administration of silymarin to rats prevented gastric ulceration induced by cold-restraint 
stress, reducing histamine concentration. It was suggested that the anti-ulcrogenic effect of 
silymarin may be related to inhibition of enzymic perossidation by the lipoxygenase pathway. 
 
4.2 HUMAN STUDIES 
In human medicine the bioactive extract from Silybum marianum (milk thistle), silymarin, a 
mixture of flavanolignans composed of silycristin, silydianin, silybin and isosilybin, are 
responsible for the pharmacological effects and has clinical applications in the treatment of 
liver diseases. 
Clinical trials with MilkThistle preparations have focused on their use in alcoholic liver disease, 
cirrhosis and acute viral and chronic hepatitis. However, several trials have included patients 
with liver disease of different aetiology, e.g. alcoholic and non alcoholic cirrhosis (Saller et al., 
2001). 
 
4.3 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
The pharmacokinetics and metabolism studies on silymarin and silybin are few. A plasma level 
of 500 µg/mL (as silybin) was found 90 min after oral administration in mice of 200 mg/kg of 
silybin. Silybin after oral administration showed peak time concentrations between 30 min and 
1 h after administration and a bioavailability of approximately 30% (Bulles et al., 1975). 
Approximately 20-50% of silymarin is absorbed following oral administration and approximately 
80% of the dose whether administered orally or intravenously is excreted in the bile; about 10% 
enters the enterohepatic circulation. A low renal excretion (1-2% of Silybin) is registered. 
Silymarin is excreted in bile as metabolites, which were identified, through hydrolysis with 
glucuronidase/arylsulfatase, as glucuronides and sulfates of silybin and dehydrosilybin (Bulles 
et al. , 1975). The ratio between dose and quantity excreted in bile was linear for oral doses up 
to 20 mg/kg and the minimum absorption percentage, evaluated on the basis of urinary and 
biliary excretion data, was 45%. The kinetics of the biliary excretion evidenced the maximum 
excretion 1 h after administration, which indicates a rapid absorption. After oral administration 
of 500-1000 mg/kg of silymarin in rats 75% was excreted in the faeces within three days 
(Meyer-Burg, 1972). 
After 8 h the intraperitoneal administration of 3H-silybin in rats, the following percent values of 
the administered radioactivity were found in the various organs and tissues: liver 5.1%, spleen 
0.3%, blood 2.1%, brain 0.1%. A similar trend was observed following the other way of 
administration. The 80% of the silybin found in the liver homogenate and in the cytosol fraction 
of the hepatic cells was the unconjugated form, while the remaining 20% was present as 
glucuronide or sulphate conjugated. In a pharmacokinetics study carried out in human healthy 
volunteers with oral administration of silymarin, the silybin metabolites other than glucuronides 
and sulphates were not found either in bile or urine (Flory et al., 1980). The biliary excretion of 
silybin after repeated oral administrations of silymarin reached the steady state at the latest on 
the second day of treatment and stopped within 72 h from the last administration 
(Sonnenbichler, 1980).  
A pharmacokinetic profile of silymarin following oral administration of 200 mg/kg (as silybin) in 
rats has been reported (Morazzoni et al., 1993) . Silybin reached peak plasmatic level 2 h after 
silymarin administration, with a Cmax of 0.06 µg/mL and 6,7 µg/mL for unconjugated and total 
drug respectively. Maximum total biliary concentration of silymarin (106 µg/ml) was reached 
within 2 h. 
After repeated oral administration of 10g/day of silymarin to dairy cows, no silybin residues 
were detected in milk samples (limit of detection 10 ppb) (Tedesco et al., 2004c). 
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5. MICROBIOLOGY 
No data in literature suggest an antimicrobial activity of silymarin. Inhibitory activity has been 
tested in milk samples from animal receiving silymarin exctract, and results were negative 
(Tedesco et al., 2002). 
 
6. EFFICACY 
6.1 QUALITY OF THE ANIMAL PRODUCT 
Data on the the safety and quality of food products after administration of silymarin have been 
provided in experimental studies on dairy ruminants. Concerning the residues in milk, no silybin 
residue was detected (detection limit =10 ppb) after 10 g/d administration for more than a 
week (Tedesco et al., 2004c). In dairy goats and cows treated with silymarin a higher milk 
production was found, without any variation in the milk composition, considering protein, fat 
and lactose content (Tedesco et al., 2004d). 
 
7. TOXICOLOGY 
The acute toxicity of silymarin and silybin were investigated after oral and intravenous 
administration in various animal species. Even in large doses silymarin is devoid of toxic effects. 
No mortality and signs of adverse effects were observed after oral administration of silymarin at 
the dose of 20 g/kg in mice and 1g/kg in dogs (Hahn et al., 1968). Long term oral 
administration of silymarin (100mg/Kg/day) to rats for 16 or 22 weeks did not reveal any 
adverse effect. The 50% lethal dose values (LD50) after intravenous infusion are 400 mg/kg in 
mice, 385 mg/kg in rats and 140 mg/kg in rabbits and dogs (Lecompte, 1975, Vogel et al., 
1975). These data demonstrate a low acute toxicity of silymarin. Similarly, the subacute and 
chronic toxicity of silymarin are low. The compound is also devoid of embryotoxic potential and 
has no harmful action on the embryo (Wagner et al., 1986). 
No adverse events were noted in a pharmacokinetic study involving healthy male volunteers 
following single oral doses of silymarin corresponding to up to 254 mg silybin. Some studies 
involving more than 3500 patients with various types of chronic liver disease treated with 
silymarin (560 mg/day) for eight weeks, have indicated that the frequency of adverse effects 
with silymarin is approximately 1%. Adverse effects are mainly transient, non serious, 
gastrointestinal complaints: in isolated cases, a mild laxative effect has been observed.  
 
7.1 SAFETY (INFORMATION ON THE DOSAGE) 
Silybum marianum seed extract is included in feed ration as a flavouring agent. The 
recommended usage range is 50 - 500 mg/kg. 
Most liver remedies were introduced into therapeutic use because they were found to have 
protective properties in certain animal species. The doses of silymarin products under the 
heading of liver remedies used in clinical trials, have ranged from 280 to 800 mg/day 
(equivalent to milk thistle extract 400 – 1140mg/day standardised to contain 70% silybin).  
No known contraindications and side effects are reported. 
In human clinical trial Silymarin has a good safety profile and only rare case reports of 
gastrointestinal disturbances and allergic skin rashes have been reported.  
Silymarin administration to dairy cows indicates a lack of transfer in milk, raising no concerns 
regarding the safety of the resulting milk and dairy products. Chemical and liver histological 
analysis did not provide any evidence for toxic effects in dairy cows and goats. The analysis of 
blood analytes did not show any differences between a group of animal treated with silymarin 
and a control group. Histological analysis carried out on hepatic biopsies is in agreement with a 
no harmful effect of silymarin extract (Tedesco et al., 2004a). 
Further information made available and estensive search of published literature did not provide 
any further evidence for pharmacological or toxicological properties of Silybum marianum 
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alerting to specific health risks which may result from residues in food producing animals 
following the intended use. 
Silybum marianum is included in the European Pharmacopoeia and is marketed in Europe 
under the trademark LEGALON®. Silybum marianum is included in Annex II of Council 
Regulation (EEC) N. 2377/90 for use in homeopathic veterinary medicinal products prepared 
according to homeopathic pharmacopoeias. 
Milk thistle is covered by a positive Commission E monograph and as the following applications:  
- Crude drug: dyspeptic disorders; 
- Preparations: for toxic liver damage; as supportive treatment in chronic inflammatory liver 
conditions and liver cirrhosis. 
Milk thistle became official in mid 1999 in the United States Pharmacopeia-National Formulary 
(USP23-NF18,1995-June 1999). It does not have GRAS status. However, it is freely available as 
a dietary supplement in the USA under DSHEA legislation (1994 Dietary supplement Health and 
Education Act.). 
Silymarin as other flavonoids has been shown to inhibit P-gp-mediated cellular efflux. The 
modulation of P-gp- activity may result in altered absorption and bioavailability of drugs that are 
P-gp- substrates.  
It has been reported that silymarin inhibit cytochrome P450 enzymes and consequently an 
interaction with drugs primarily metabolized by P450s cannot be excluded. 
Silymarin has an antagonistic effect with yohimbine and phentolamine when given 
simultaneously.  
DT/SG 
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THYMUS VULGARIS 
  
Thymus vulgaris  
 
1. INTRODUCTION 
The genus Thymus, in the family Lamiaceae, consists of more than 315 species. Thyme is 
perennial, with wide natural distribution extending from the Mediterranean to the coasts of 
Greenland, Canary Islands, North Africa, highlands of Ethiopia, the southwestern Arabian 
highlands, Sinai Peninsula, arid regions of West and East Asia, Himalayas, and Northern Europe 
extending to Siberia. Thyme species – such as T. serpyllum, T. vulgaris, T. pulegioides, T. 
cotroidora, and T. zygis – are known to thrive well upon introduction to new growing areas, such 
as South and North America (including Canada), South and West Africa, Australia, and New 
Zealand. 
Thyme is cultivated throughout the world for culinary, cosmetic, and medicinal purposes, the 
manufacture of perfume, and for red and white thyme oil. Common thyme (Thymus vulgaris) 
and Spanish thyme (T. zygis) are used interchangeably for medicinal purposes. Crude dried or 
fresh herb may be brewed as tea or extracted into an alcohol macerate. Common thyme 
contains 0.4–3.4% of the volatile oil; Spanish thyme contains 0.7–1.38%. The red or white 
thyme oil is manufactured commercially for use in cough drops, mouthwashes, liniment, 
toothpaste, detergent, and perfume. Because white thyme oil is a distilled red thyme oil product, 
red thyme oil is generally preferred (Leung and Foster, 1996). 
Thyme has an integral place in Western culture and folklore, and has been used since ancient 
times not only as a traditional medicine, but also as a tonic and libido enhancer. The essential 
oil or the alcohol extract from its leaves are used as natural preservatives in conventional food, 
beverage, cosmetic, and personal care products. Thyme oil and extracts are among the top 10 
natural products that have demonstrated antibacterial, antimycotic, antioxidative, and even 
some potentially anti-aging properties. Due to an increasing number of chemical studies, 
genetic improvement in the plant, and widening of the areas of its applications, thyme has been 
growing in international trade as a commodity of increased commercial importance. 
It has been used in traditional medicine to treat heartburn, gastritis, asthma, laryngitis, 
pertussis, and bronchitis (Newall et al., 1996). Extracts demonstrate in vitro anti-inflammatory 
effects on guinea pig tracheal smooth muscle tissue (Leung and Foster, 1996), and the volatile 
oil in the herb most likely exerts spasmolytic effects on bronchial tissues in humans (Tyler, 
1994). The herb is approved by ESCOP (2003) in the treatment of bronchitis, whooping cough, 
and upper respiratory inflammation. 
Like the herb's infusions and extracts, thyme oil is also carminative, expectorant, and possesses 
antimicrobial and anthelmintic properties, due to concentrated thymol and carvacrol content 
(Leung and Foster, 1996), but it is extremely toxic. As an ingredient in toothpaste, thyme oil has 
been blamed for cases of inflamed lips and tongue reported in the toothpaste users. Signs of 
toxicity escalate from nausea to respiratory arrest (Newall et al., 1996). For these reasons, the 
herb is preferred to the oil.  
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Thyme was known to classic Rome; it was added to cheeses and alcoholic beverages. In the 
seventeenth century, herbalist Nicholas Culpepper wrote that thyme teas and infusions were 
useful for whooping cough, shortness of breath, gout, and mild stomach pains. He suggested 
that a thyme ointment be used to eliminate abscesses and warts. Thyme oil was used as a 
rubefacient and counterirritant, and was part of an herbal cigarette that was smoked to relieve 
stomach upset, headache, and fatigue. Thyme essence was used in perfumes and embalming 
oils (Grieve, 1979). 
Thyme's common name may be derived from a Greek word meaning to fumigate, because the 
Greeks used thyme as an incense. It may also have come from the Greek word thumus, 
meaning courage. In medieval times, thyme was regarded as a plant that could impart courage 
and vigor, and women often embroidered a sprig of thyme on gifts for their favorite knight 
(Grieve, 1979).  
Indigenous to southern Europe. It is a pan – European species that is cultivated in Europe, the 
United Sates of America and other parts of the world. 
 
The aromatic plant of Coridothymus capitatus (L.) is a very common member of Labiatae family 
and it is distributed in the Mediterranean area, especially Turkey, Greece and Spain (Davis, 
1982; Kokkini and Vokou, 1989) and it’s known in trade as “Spanish Origanum”. Oregano 
species, Coridothymus, Satureja, Origanum, Thymus etc., have commercial importance in Turkey 
as well as in the world (8000 ton plants/year). These species are collected, their leaves are used 
as thyme and also essential oil of species exported (Satıl et al., 2002). Their essential oils are  
also important for the perfume, cosmetic, flavoring and pharmaceutical industries. They are 
used in folk medicine against cold, influenza and throat infection in Turkey (Baytop, 1962; 
Tabata et al., 1988). Insecticidal (Karpouhtsis et al., 1998), antioxidant (Demo et al., 1998; 
Lagouri et al., 1993), fungitoxic (Mullerriebau et al., 1995), nematicidal (Oka et al., 2000) 
activity studies and antibacterial effect of C. capitatus essential oil on potato storage (Vokou et 
al., 1993), were reported along with their chemical composition (Karpouhtsis et al., 1998; 
Fleisher and Fleisher, 2002; Ozek et al., 1995). The essential oil of the TurkishC. capitatus was 
reported for three different localities which are Marmara island, Marmaris and Eceabat region of 
Turkey (Ozek et al., 1995). 
 
1.1 HISTORY (WHO) 
Thyme extract has been used orally to treat dyspepsia and other gastrointestinal disturbances; 
coughs due to colds, bronchitis and pertussis; laryngitis and tonsillitis (as a gargle). Topical 
applications of thyme extract have been used in the treatment of minor wounds, the common 
cold, disorders of the oral cavity, and as an antibacterial agent in oral hygiene. Both the 
essential oil and thymol are ingredients of a number of proprietary drugs including antiseptic 
and healing ointments, syrups for the treatment of respiratory disorders, and preparations for 
inhalation. Another species in the genus, T. serpyllum L., is used for the same indications. 
Uses described in folk medicine, not supported by experimental or clinical data: 
As an emmenagogue, sedative, antiseptic, antipyretic, to control menstruation and cramps, and 
in the treatment of dermatitis. 
 
1.2 OTHER SPECIES COMMERCIALLY USED AS THYME 
Coridothymus capitatus, Origanum sp. and Satureja montana. 
 
 
2. DESCRIPTION OF THE PLANT 
An aromatic perennial sub-shrub, 20-30 cm in height, with ascending, quadrangular, greyish 
brown to purplish brown lignified and twisted stems bearing oblong – lanceolate to ovate – 
lanceolate greyish green leaves that are pubescent on the lower surface. The flowers have a 
pubescent calyx and a bilobate, pinkish or whitish, corolla and are borne in verticillasters. The 
fruit consists of 4 brown ovoid nutlets. 
Herba Thymi is the dried leaves and flowering tops of Thymus vulgaris L. or of Thymus zygis L. 
(Lamiaceae). 
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General appearance: 
-Thymus vulgaris: Leave 4-12 mm long and up to 3 mm wide; it is sessile or has a very short 
petiole. The lamina is tough, entire, lanceolate or ovate, covered on both surfaces by a grey to 
greenish grey indumentums; the edges are markedly rolled up towards the abaxial surface. The 
midrib is depressed on the adaxial surface and is very prominent on the abaxial surface. The 
calyx is green, often with violet spots, and is tubular; at the end are 2 lips of which the upper is 
bent back and has 3 lobes on it´s end; the lower is longer and has 2 hairy teeth. After flowering, 
the calyx tube is closed by a crown of long, stiff hairs. The corolla, about twice as long as the 
calyx, is usually brownish in the dry state and is slightly bilabiate. 
-Thymus zygis: Leaf 1.7-6.5 mm long and 0.4-1.2 mm wide; it is acicular to linear-lanceolate and 
the edges are markedly rolled toward the abaxial surface. Both surfaces of the lamina are green 
to greenish grey and the midrib is sometimes violet; the edges, in particular at the base, have 
long, white hairs. The dried flowers are very similar to those of Thymus vulgaris. 
Odour and taste aromatic. 
 
2.1 SYNONYMS 
Lamiaceae are also known as Labiatae. 
Selected vernacular names: Common Thyme, farigola, garden thyme, herba timi, herba thymi, 
mother of thyme, red thyme, rubbed thyme, ten, thick leave thyme, thym, Thymian, thyme, time, 
timi, tomillo, za´ater. 
 
2.2 PLANT MATERIAL OF INTEREST 
Dried leaves and flowering tops. 
 
 
3. INGREDIENTS / CONSTITUENTS 
Constituents include essential oil containing the phenols thymol and carvacrol; terpenoids; 
glycosides of phenolic monoterpenoids; eugenol and aliphatic alcohols; the flavonoids thymonin, 
cirsilineol, and 8-methoxycirsilineol; biphenyl compounds of monoterpenoid origin; caffeic and 
rosmarinic acids; and saponins (ESCOP 2003). Other constituents include tannins, labiatic acid, 
ursolic acid, and oleanolic acid (Leung and Foster, 1996). Thyme also contains apigenin, 
luteolin, and 6-hydroxyluteolin glycosides, as well as di-, tri-, and tetramethoxylated flavones, 
which are all substituted in the 6-position (5,4'-dihydroxy-6,7,3'-trimethoxyflavone and its 8-
methoxylated derivative, 5,6,4'-trihydroxy-7,8,3'-trimethoxyflavone, 5,4'-dihydroxy-6,7,8-
trimethoxyflavone, 5,4'-dihydroxy-6,7-dimethoxyflavone) (Bruneton, 1995). 
 
Herba Thymi contains about 2,5% but not less than 1% of volatile oil fluctuates depending on 
the chemotype under consideration. The principal components of Herba Thymi are thymol and 
carvacrol (up to 64% of oil), along with linalool, p-cymol, cymene, thymine, a-pinene, apigenin, 
luteolin, and 6-hydroxyluteolin glycosides, as well as di-, tri- and tetramethoxylated flavones, all 
substituent in the 6-position. 
ESCOP: Essential oil containing phenols, predominantly thymol and/or carvacrol, and 
terpenoids; glycosides of phenolic monoterpenoids, eugenol, aliphatic alcohols and 
acetophenones; flavonoids, among with thymonin, cirsilineol and 8- methoxycirsilineol are 
characteristic; biphenyl compounds of monoterpenoid origin; caffeic acid and rosmarinic acid; 
saponins; long-chain saturated hydrocarbons and aliphatic aldehydes; and an arabinogalactan. 
 
 
3.1. CHEMICAL ANALYSIS 
Herba Thymi contains not less than 1.0% volatile oil, and not less than 0,5% phenols. Volatile oil 
is quantitatively determined by water/steam distillation, and the percentage content of phenols 
expressed as thymol is determined by spectrophotometric analysis. Thin-layer chromatographic 
analysis is used for thymol, carvacrol, and linalool. 
3.2. STANDARDISATION 
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Thyme consists of the whole leaves and flowers separated from the previously dried stems of 
Thymus vulgaris L. or Thymus zygis Loefl. ex L. or a mixture of both species. It contains not less 
than 1.2 per cent (V/m) of essential oil and not less than 0.5 per cent of volatile phenols, 
expressed as thymol (C10H14O; Mr 150.2), both calculated with reference to the anhydrous 
drug. The material complies with the European Pharmacopoeia. Fresh material may also be 
used, provided that when dried it complies with the European Pharmacopoeia. 
Storage: 
Store in a well-closed container, protected from light and moisture. 
 
 
4. PHARMACOLOGY 
The Commission E approved thyme for the treatment of symptoms of bronchitis and whooping 
cough and catarrhs of the upper respiratory tracts. It has also been used as to improve digestion 
(Stecher, 1968) and to treat pertussis, stomatitis, and halitosis (Wichtl and Bisset, 1994; ESCOP 
2003). 
 
4.1 SPASMOLYTIC AND ANTITUSSIVE ACTIVITIES 
The spasmolytic and antitussive activity of thyme has been most often attributed to the phenolic 
constituents thymol and carvacrol, which make up a large percentage of the volatile oil (Reiter 
and Brandt, 1985). Although these compounds have been shown to prevent guinea pig ileum 
and trachea contractions induced by histamine, acetylcholine and other agents, the 
concentration of these phenolics in aqueous preparations of the drug is insufficient to account 
for this activity (Van den Broucke, 1980; Van den Broucke and Lemli, 1981). Experimental 
evidence suggests that the in-vitro spasmolytic activity of thyme preparations is due to the 
presence of polymethoxyflavones (Van den Broucke and Lemli, 1983). In-vitro studies have 
shown that flavones and thyme extracts inhibit responses to agonists of specific smooth muscle 
cells receptors, such as acetylcholine, histamine and L-norepinephrine, as well as to agents 
whose actions are not mediated by specific receptors, such as barium chloride (Van den 
Broucke and Lemli, 1983). The flavones of thyme were found to act as non-competetive and 
non-specific antagonists (Van den Broucke and Lemli, 1983); they were also shown to be Ca2+-
antagonists and musculotropic agents that act directly on smooth muscle (Van den Broucke and 
Lemli, 1983). 
 
4.2 EXPECTORANT AND SECRETOMOTORIC ACTIVITIES 
Experimental evidence suggests that thyme oil has secretomotoric activity (Gordonoff and Merz, 
1931). This activity has been associated with a saponin extract from T. vulgaris (Vollmer, 1932). 
Stimulation of ciliary movements in tha pharynx mucosa of frogs treated with diluted solutions 
of thyme oil, thymol or carvacrol has also been reported (Freytag, 1933). Furthermore an 
increase in mucus secretion of the bronchi after treatment with thyme extracts has been 
observed (Schilf, 1932). 
 
4.3 IN-VITRO/IN-VIVO STUDIES 
- In-vitro tests (guinea pig trachea): flavonoids and ethanol extract of thyme revealed 
spasmolytic effect 
- Antimicrobial effects: aqueous extract of thyme inhibited Helicobacter pylori 
- Acetone extract of thyme inhibited Mycobacterium tuberculosis 
- Fluid extract showed activity towards the pneumotropic bacteria Moraxella catarrhalis, 
Klebsiella pneumoniae and Diplococcus pneumoniae. 
- Thyme essential oil: antibacterial, antifungal (thymol, carvacrol), prostaglandin biosynthesis 
inhibition 
- Antiinflammatory effects: an ethanolic extract reduced the enzyme activity (rosmarinic acid)  
- Antioxidant: dry acetone extract, supercritical carbon dioxide extract (phenolic constituents) 
- In vivo-tests: fluid extract of thyme reduced carrageenan-induced rat paw oedema (comparable 
with phenylbutazone) 
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Intraperitoneal pretreatment of rats with essential oil protected against hepatotoxicity induced 
by carbon tetrachloride. 
- Clinical studies: thyme syrup was as effective as medicinal expectorants such as bromhexine 
(humans) 
- Acaricidal activity against Dermanyssus gallinae: thyme red and white oils (70 µg/cm2) 
provoked 100 % mortality of D. gallinae (Review of aromatic and medical plants 2004)  
 
In vitro and in vivo tests 
In vitro experiments found that the flavonoids thymonin, cirsilineol, and 8-methoxy-cirsilineol 
may be responsible for the bronchospasmolytic effect of thyme (ESCOP, 1997). In vivo, 
rosmarinic acid was shown to inhibit rat paw oedema induced by cobra venom factor but not the 
t-butyl hydroperoxide-induced paw oedema. Furthermore, it inhibited passive cutaneous 
anaphylaxis, and impaired activation by heat-killed Corynebacterium parvum of mouse 
macrophages. These observations demonstrate that its activity may be related to complement-
related processes, according to its inhibitory action on complement C-3 convertase in vitro 
(Englberger et al., 1988; ESCOP, 1997). 
 
4.4 TREATMENT OF MASTITIS 
Thymus vulgaris is used in a pharmaceutical preparation for the treatment of mastitis in 
animals and humans, which consists of a mixture of a decoction of 16 medicinal herbs and an 
ammonia solution infusion of the same plants (Deryabin AM; PCT International Patent 
Application 1990; -13305). 
 
4.5 VETERINARY STUDIES 
 
4.5.1 HORSE 
The effects of an oral preparation containing an extract of thyme and primula (Bronchipret; 
Bionorica) on the lung function of five horses suffering from heaves were determined in a 
longitudinal study (Austria). The horses accepted the product well. The plasma concentrations of 
the marker substance, thymol, indicated that at least one of the substances in the extract had 
been absorbed from the gastrointestinal tract. The compliance, pulmonary pressure and airway 
resistance of the horses' lungs were all significantly improved after one month of treatment. 
However, the severity of their clinical signs and their arterial oxygen partial pressure had not 
improved significantly (Hoven R. et al., 2003). 
 
4.5.2 FOWL 
The aim of the studies was to test performance, results of dissection, blood and selected meat 
and colour traits of chicken skin. The experiment involved 900 day-old cockerels allotted to 6 
groups. Except that of the control group, diets contained 1.5% dried herbs (onion, caraway, 
camomile, thyme and dandelion) throughout the 51-day experiment. The addition of herbs had 
no effect on final body weight and feed conversion. Carcasses of chickens given herbal feeds 
contained less abdominal fat than control chickens. Organoleptic traits of meat were regarded 
as satisfactory in all the groups. The skin of chickens given herbs was redder, while the presence 
of yellow colour, its tone and intensity were most noticeable in controls (P<0.05) (Schleicher A. 
et al., 1998). 
Diets were studied on gain and feed:gain ratio of broilers over 6 weeks. Studies were arranged 
in a factorial design with mashed feed compared with pellets with or without 10% virginiamycin 
Dried thyme (100 mg) improved feed:gain ratio by 3.2±1.5g/kg gain, but effect of virginiamycin 
was substantially greater. Spice supplements did not affect taste of broiler meat (Vogt H. et al., 
1989). 
On the other hand there is a study where groups of male, 1-day-old Lohmann broilers were given 
maize-soyabean meal diets, with oils extracted from thyme, mace and caraway or coriander, 
garlic and onion (0, 20, 40 and 80 mg/kg) for 6 weeks. Average daily gain and feed conversion 
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were not different between the broilers fed with the different oils; meat was not tainted with 
flavour or smell of the oils (Vogt H and Rauch HW., 1991). 
4.5.3 PIG 
4.5.3.1 PREVENTION AND TREATMENT OF DIARRHOEA 
The Yugoslav product Fito-diaro-stop, prepared from thyme (Thymus vulgaris), was given orally 
as a 5 or 10% emulsion to 200 piglets at 3 and 10 days of age for prevention and treatment of 
diarrhoea and also used as a feed additive (1-2 kg/ton) for weaned pigs from 1 to about 3 
months of age. In comparison with controls the treated animals showed higher daily weight 
gains, lower mortality, and lower drug expenses for their breeding (Teodorovic M. et al., 1990). 
4.5.3.2 HERB MIXTURE AS AN ANTIBIOTIC SUBSTITUTE 
In an experiment, 24 gilts and 24 crossbred barrows (Landrace x PLW x Duroc x Pietrain) were 
used to evaluate the efficiency of a multi-component herb mixture used as a substitute for 
fodder antibiotic in pig feeding. The herb mixture was composed of Melissa officinalis, Mentha x 
piperita, Urtica dioica, Thymus vulgaris, Agropyron repens [Elymus repens], Allium, Capsicum 
annuum, Origanum majorana, Coriandrum sativum, Taraxacum vulgare, and Silybum 
marianum. The gilts and barrows were assigned to 3 groups: 1. receiving feed mixture without 
any additives;2. receiving feed mixture with 0.5 % supplement of herbs; and 3. receiving feed 
mixture and 20 mg/kg of Flavomycine. Pigs fed the herb mixture supplement obtained the best 
average body weight gains (825 g) over the entire fattening period. The herbs added to the pig 
feed decreased backfat thickness by 8.4% and improved loin eye area (15.1%) and meat 
content in the carcass (6.7%). Animals receiving this mixture had the lightest thyroid glands, 
livers, and kidneys. There were no significant differences between the experimental groups in 
meat quality (colour, acidity, or water holding capacity). The cooked meat of the longissimus 
dorsi of pigs obtaining the herb supplement was more tender and juicier compared to the other 
fatteners. The obtained results confirmed the possibility of using the herb mixture as an 
antibiotic substitute in pig feed (Urbanczyk J. et al., 2002). 
In another study, pigs were fed with a herbal mixture (30 g herb mixture per 1 kg diet), 
containing leaves of Urtica dioica and Plantago lanceolata, Rosmarinus officinalis, Thymus 
vulgaris and Thymus serpyllum and fruits of Juniperus communis. The experiment lasted 40 
days. The herb supplements to the diets allowed for the attainment of even better production 
gains than in case of the antibiotic additive of the control group (Grela ER. et al., 2003). 
In this study, 200 growing-finishing pigs were randomly divided into 5 feeding groups. Pigs in 
Group 1 (control group) were fed with a basal diet, whereas those in Group 2 were fed a basal 
diet plus an antibiotic (Tylosin, 25 mg/kg). Pigs in the remaining three groups were fed with a 
basal diet plus essential oils (at 25 mg/kg) of oregano (Group 3), thyme (Group 4) and garlic 
(Group 5). The inclusion of essential oil of spices in the pigs' diet significantly improved the 
average daily weight gain and feed conversion ratio of the pigs in Groups 3, 4 and 5, as 
compared to Groups 1 and 2 (P < 0.01). Furthermore, pigs fed the essential oils had higher 
carcass weight (P < 0.01), dressing percentage (P < 0.01), and carcass length (P < 0.01) than 
those fed the basal and antibiotic-supplemented diet. In Groups 3, 4 and 5, back fat thickness 
was significantly lower than those in Groups 1 and 2. Moreover, lean meat and ham portions 
from pigs in Groups 3, 4 and 5 were significantly higher than those from pigs in Groups 1 and 2. 
In conclusion, the use of essential oils as feed additives improves the growth of pigs and has 
greater positive effects on carcass composition than antibiotics (Onibala et al., 2001). 
4.5.3.3 PERFORMANCE 
Piglets fed rations containing sage, coriander, yarrow and thyme had significantly higher daily 
gain (by 7%) and feed conversion efficiency (by 3%) than controls (Wagner F., 2003). 
Diet supplemented with 0.3% and 0.5% of a herbal mixture (couch grass rhizome, coriander 
seed, caraway seed, savory, camomile, thyme, mint, milk thistle endosperm) showed positive 
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effects on growing-finishing pigs. Pigs fed with 0.5% herbal supplementation showed best 
results in daily gain, the consumption of feed/kg gain, dressing percentage, right half-carcass 
weight, loin weight and ham weight. Backfat thickness was lower than in the control group (with 
no herbal supplementation) (Paschma J., 2000). 
 
4.5.4 CATTLE 
4.5.4.1 PERFORMANCE 
Two groups of calves were fed with 0.5% or 1.0% herbs (Mentha piperita, Thymus vulgaris, 
Salvia officinalis, Viola tricolor, Chamomilla recutita and Urtica dioica) to their ration. Compared 
to a control group (fed with no herbal supplementation), they showed a tendency for higher 
intake of concentrates (which contained herbs) and forage. They had significantly higher final 
body weights at 120 days of age and higher mean daily weight gains. These groups also 
improved the conversion of ration nutrients per kg of body weight gain. The best rearing 
performance of calves was obtained in the group given 1% herbs in concentrate (Wawrzynczak 
S. et al., 2000). 
The effect of feeding diets containing different proportions of herb mixtures (Mentha piperita, 
Urtica dioica, Matricaria chamomilla [Chamomilla recutita] Thymus vulgaris, Salvia officinalis, 
Foeniculum vulgare, Viola tricolor, and Trigonella foenum-graceum) on calves was investigated. 
Feeding concentrates with 1.0 and 2.0% herbs increased the intake of all solid feeds in the 
rations, ensured significantly higher body weights and daily gains in the experimental rearing 
periods, and improved the utilization of nutrients from the rations with respect to control 
animals fed without herb mixture. Best effects were obtained when heifer and bull calves were 
fed the 2.0% herb mixture concentrate (Kraszewski et al., 2002). 
4.6 COMMERCIAL PRODUCTS FOR ANIMALS 
Very often thymus vulgaris is used in commercial products for animals against diseases of the 
upper respiratory tract. 
 
4.7 ADME / PHARMACOKINETICS 
Data about pharmacokinetics of essential oils are scarcely available, although some 
information are reported for the phenolic terpenes, thymol and carvacrol. In an early publication 
Schröder and Vollmer (1932) described thymol and carvacrol to redistribute rapidly to the blood 
and kidneys following oral administration. The metabolism of carvacrol and thymol has been 
studied in rats. It was found that the urinary excretion of metabolites was rapid and only very 
small amounts were excreted after 24h. Although large qhantities of carvacrol and, especially, 
thymol were excreted unchanged (or as their glucuronide and sulphate conjugates), extensive 
oxidation of the methyl and isopropyl groups occured. This resulted in the formation of 
derivatives of benzyl alcohol and 2-phenylpropanol and their corresponding carboxylic acids. In 
contrast, ring hydroxylation of the two phenols was a minor reaction (Austgulen et al., 1987). 
Takada et al. (1979) investigated the metabolism of thymol in rabbits and humans. Thymol 
glucuronide featering an intact aglycone was isolated from the urine of thymol-medicated 
rabbits and identified as an acetyl derivate of methyl glucuronate. The hydroxylated product of 
thymol, thymohydroquinone, was detected in small amounts in the urines of thymol-medicated 
humans. It was presumed that thymolhydroquinone is excreted as an ethereal sulfuric acid 
conjugate. 
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5. MICROBIOLOGY 
 
 
Thyme in its crude herb form is carminative, antibiotic, anthelmintic, astringent, expectorant, 
and antitussive (Leung and Foster, 1996; Newall et al., 1996). 
The Commission E reported bronchoantispasmodic, expectorant, and antibacterial activity. 
 
5.1 ANTIFUNGAL AND ANTIBACTERIAL ACTIVITY 
In vitro studies have shown that both thyme essential oil and thymol have antifungal activity 
against a number of fungi, including Cryptococcus neoformans, Aspergillus, Saprolegnia and 
Zygorhynchus species (Tantaoui-Elaraki and Errifi, 1994; Vollon and Chaumont, 1994; Perrucci 
et al., 1995; Paster et al., 1995). Both the essential oil and thymol posses antibacterial activity 
against Salmonella typhimurium, Staphylococcus aureus, Escherichia coli and a number of 
other bacterial species (Janssen et al., 1987; Juven et al., 1994; Dorman and Deans, 2000). As 
an antibiotic, thymol is 25 times as effective as phenol, but less toxic (Czygan, 1989). 
 
6. EFFICACY 
In the ESCOP monographs (2003) the application of thyme and thyme preparations is only 
recommended for the treatment of some clearly-defined diseases as follows: 
External use: bath additive as a supporting cure of acute and chronical diseases of the upper 
respiratory tract; in addition against pruritus of dermatosis. 
Internal use: thyme preparations can be administered against symptoms of bronchitis and 
whooping cough, and catarrhs of the upper respiratory tract. 
 
7. TOXICOLOGY 
Toxic effects of the vegetable parts of thyme, T. vulgaris, have not been published, but it is 
important to mention that a certain level of toxicity can be found for the essential oil of thyme 
(LD50=4,7g/Kg after oral administration in rats). This toxicity has been attributed by some 
authors to thymol and carvacrol (Dilaser, 1979), their acute oral LD50 in rats being 0,88-
1,8g/Kg and 0,1-0,18g/Kg, respectively. Furthermore, these phenols cause skin irritations and 
especially irritations of the mucosa, which precludes patients with gastroduodenal ulcers from 
the use of the essential oil. Thus undiluted thyme oil was found to be severely irritating to both 
mouse and rabbit skin, however it produced no irritation on human subjects when tested at the 
concentration of 12 % (Tisserand and Balacs, 1995). Hypersensitivity reactions have also been 
reported for thyme herb after contact with the skin, inhalation or ingestion (Tisserand and 
Balacs, 1995; Benito et al., 1996; Lemiere et al., 1996); therefore it is strongly recommended to 
perform a tolerance test prior to attempting its use. Various essential oils from Thymus contain 
considerable quantities of camphor and other terpenic ketones, which are known to produce 
convulsions and neurotoxic crises (Dupeyron et al., 1976; Steinmetz et al., 1980). Limonene, 
which is a common component of thyme oil, is capable of diminishing the incidence of tumors 
in experimental animals treated with tumor-inducing agents (Tisserand and Balacs, 1995). This 
carcinogenic effect as well as other renal damages observed in male rats are species and 
gender specific: consequently they are not predictable for human toxic effects (Meek et al., 
2003). Therefore it is important to use fresh, non-oxidized essential oil of thyme in phytotherapy 
and aromatherapy. 
Due to the toxic effects, the use of the essential oil during pregnancy and lactation is 
contraindicated (Peris et al., 1995). 
Thymus vulgaris leaves fed to rats at 2% or 10% of standard diet for 6 weeks did not induce 
signs of toxicity (Haroun et al., 2002). 
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7.1 SAFETY 
 
7.1.1 PREGNANCY AND LACTATION 
The safety of Herba Thymi preparations during pregnancy and lactation has not been 
established. As a precautionary measure, the drug should not be used during pregnancy or 
lactation except on medical advice. 
 
7.1.2 ADVERSE REACTIONS 
Contact dermatitis has been reported. Patients sensitive to birch pollen or celery may have a 
cross-sensitivity to thyme. 
 
 
7.1.3 INTERNAL USE OF HERBA THYMI/ MODE OF ADMINISTRATION 
Cut herb, powder, liquid extract or dry extract for infusions and other galenic preparations. Liquid 
and solid medicinal forms for internal and external application. Note: Combinations with other 
herbs that have expectorant action could be appropriate. 
 
Dosages 
recommended daily allowance: 
Cattle    25,0 - 50,0 g 
Horse      6,0 - 15,0 g 
Small ruminants, Pig      2,0 - 10,0 g 
Dog      0,5 -   1,0 g 
Cat, Fowl     0,01 - 0,3 g 
(by Gachnian and Assenov, 1990] 
 
Presently it is not allowed to use Thyme herb (Thymi herba) as an active agent for foodstuff 
delivering animals in the EU, but it is allowed to use Thyme-oil (Thymi aetheroleum) as an active 
agent for foodstuff delivering animals in the EU. [VO (EWG) Nr. 2377/90]. [Reichling et al., 
2005] 
 
Internal: 
Infusion: 1–2 g of herb for 1 cup of tea, several times daily as needed. 
Fluidextract 1:1 (g/ml): 1–2 ml, one to three times daily.  
External: 
Compress: 5% infusion for compresses. 
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UNCARIA TOMENTOSA 
 
 
 
 
Uncaria tomentosa  
 
 
1. INTRODUCTION 
 
The use of Uncaria tomentosa and U. guianensis by indigenous healers of tropical South 
America has not been traced to any particular time in history, but extends for untold past 
generations as part of an oral tradition of healing. In the region of the eastern incline of the 
Peruvian Andes to the Amazon rainforest, indigenous healers prepare a decoction of the bark of 
U. tomentosa or U. guianensis for internal use to treat gastric ulcers. They regard the 
preparations as antitumor, anti-inflammatory, antirheumatic and contraceptive. In central Peru, 
indigenous people primarily use the bark of U. tomentosa to relieve inflammations, including 
those associated with rheumatism, arthritis, urinary tract inflammations and gastric ulcers. 
Other central Peruvian indigenous uses of cat´s claw bark include the relief of side effects from 
antibiotics and chemotherapy, and other treatments of cancer, weakness, bone pain, and deep 
wounds. It is also used to cleanse the kidneys, and for recovery from childbirth. External 
application of the bark decoction or tea is applied to wounds using the preparation as a wash 
twice daily. 
The Asháninka Indians of central Peru are noted to use the root bark in the treatment of cancer. 
The highest order of Asháninka shaman priests use the root bark of U. tomentosa-PC, known to 
them as savéntaro or powerful plant, to remove the main cause of disease in the Asháninka 
medico-religious system of healing: a disturbance between the spirit and the body, or an 
"anxiety". Accordingly, U. tomentosa -PC is used by Asháninka shamans in the treatment of 
psychological disorders, and is regarded as being inhabited by "good spirits". Other uses of , U. 
tomentosa by the Indians of Peru include the treatment of skin "impurities", "blood purification", 
"bone pains", fevers, asthma (sap with water), disease prevention, hemorrhages, menstrual 
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irregularity, recovery from childbirth, contraception, "loose" stomach, fevers, and for a 
normalizing effect on the body. The main stem (stalk) holds potable water which is obtained by 
cutting it open. 
Traditional uses of U. guianensis in Peru are similar to U. tomentosa and include treatment of 
arthritis, rheumatism, gastric ulcers, gastritis, female contraception, female genitourinary tract 
cancers, tumors, cirrhosis, and diabetes. In Brazil, the Yanomami drink an infusion of the stem 
to treat diarrhea and stomachache which is also treated by wrapping the crushed stem around 
the waist. Indians of Columbia use the vine to treat gonorrhea and dysentery. 
Compared to U. tomentosa, this species remains scarcely studied. The chemical composition of 
the plant shows similarities to U. tomentosa, yet, whereas U. guianensis is reported to contain 
nearly only tetracyclic oxindole alkaloids, U. tomentosa contains largely pentacyclic oxindole 
alkaloids or both forms. 
Around the mid-1970s, the Austrian Klaus Keplinger began his comprehensive studies of the 
traditional medicine system and medicinal plants used by the Asháninka Indians of Peru. At that 
time Uncaria tomentosa (Willd.) DC was still completely unknown to Western medicine.  
The convincingly positive research findings finally led to the development of patented extracts 
from the root of this plant, tested for the absence of TOA and with a standardised POA content, 
and to the regulatory approval of a medicinal drug as an adjunctive to basic therapy, and if 
required to pain therapy, in patients with rheumatoid arthritis (active agent: Extractum radicis 
Uncariae tomentosae (Willd.) DC mod. pent. titratum).  
 
 
 
2. DESCRIPTION OF THE PLANT 
Uncaria tomentosa is a massive climbing vine with curved, sharp, highly pungent, protruding 
spines on the braches. The main stam (stalk) can reach over 27 meters in length with a 
diameter of close to 15 cm for most of its length, although 20 cm and larger diameters are 
known.The roots are porous, bitter-tasting, and adstringent. They usually measure several 
meters in length and as much as 7 cm in diameter. The leaves, measuring 10 cm in length, are 
opposite, ovate oblong, with either to ten pairs of lateral veins; the underside of the leaves 
shows minute hairs, hence the term tomentosa. The flowers are fragrant, five-lobed, yellowish-
white and tiny, occurring in globose heads at the end of the vine. Uncaria tomentosa is native to 
tropical South America and occurs in Colombia, Ecuador, Venezuela, Costa Rica, Guatemala, 
Panama and Peru. 
The only other tropical American species, Uncaria guianensis(Aubl.) Gmel., also known as "uńa 
de gato", can be readily distinguished from U. tomentosa by its alternating, recurving to 
spiralling spines, rather than the slightly curved, opposite spines of the former. The leaves are 
glabrous whereas those of U. tomentosa are hairy and generally less elongated. The 
inflorescence of U. guianensis is reddish-orange, spherical, three-lobed, and 2 to 4 cm in 
diameter, whereas those of U. tomentosa are yellowish-white, five-lobed, and 1,5 to 2,5 cm in 
diameter. 
Two chemotypes were identified for Peruvian U. tomentosa: a tetracyclic oxindole alkaloid type 
and a pentacyclic oxindole alkaloid type. The pentacyclic chemotype (PC) contains isomeric 
pentacyclic oxindole alkaloids and the precursor indole alkaloids in small amounts. These 
differences were confirmed in analyses of progeny sprouted from the seeds of the two 
chemotypes. 
 
 
3. INGREDIENTS / CONSTITUENTS 
The ingredients of Uncaria are carbohydrates (Glycosides), nitrogenous compounds (alkaloids), 
phenolic compounds (tannins and polyphenolics) and terpenoid compounds (triterpenes and 
steroids). 
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Carbohydrates: 
Glycosides 
Major active constituents of U. tomentosa are various quinovic acid glycosides, which have been 
identified by Cerri et al. (1998) and Aquino at al. (1989, 1991, 1997) in the barks of U. 
tomentosa and U. guianensis by Yepes et al. (1991). Due to manufacturing procedures (e.g., 
aqueous-acid), quinovic acid derivates are not extracted without undergoing chemical 
modification (Keplinger, 1999). 
 
Nitrogenous Compounds: 
Alkaloides 
The main active constituents of the root and stalk bark are thought to be oxindole alkaloids 
(Wagner, Kreutzkamp et al., 1985; Reinhard, 1999; Wurm et al., 1998). The major pentacyclic 
oxindole alkaloids (POAs) identified in the root and stalk bark of Peruvian Uncaria tomentosa 
are pteropodine (uncarine C), isopteropodine (uncarine E), speciophylline (uncarine D), uncarine 
F (methyl-2-oxo-formosanan-16-carboxylic acid-methyl ester), mitraphylline, and 
isomitraphylline. The tetracyclic oxindole alkaloids (TOAs) rynchophylline and isorynchophylline 
also occur in the root. The TOAs occur in small amounts in U. tomentosa-PC and in relatively 
large amounts in U. tomentosa-TC. The main alkaloids in the stalk of U. tomentosa-PC are POAs  
(0,5%) (Keplinger et al., 1996). The POA content of the roots (U. tomentosa-PC) ranges from 0,5-
3% (Laus and Keplinger, 1997). The leaves, stalk and root barks of U. guianensis contain 
predominantly tetracyclic oxindole alkaloids (TOAs), the major one being rynchophylline. Most 
cat´s claw products contain varying mixtures of TOAs and POAs (Keplinger et al., 1999), and 
possibly mixtures of two species of Uncaria indigenous to Peru: U. tomentosa and U. guianensis 
 
Phenolic Compounds: 
Tannins 
The stalk bark of U. tomentosa contains a high amount (20%) of tannins (De Ugaz, 1995). 
Polyphenolics 
The root bark of U. tomentosa contains proanthocyanidins 1b, 2b, 3b, 4b and 1a and (-)-
epicatechin (Montenegro de Matta et al., 1976; Wirth and Wagner, 1997). 
 
Terpenoid Compounds: 
Triterpenes 
The root bark of U. tomentosa contains triterpenes (Aquino et al., 1990, 1991, 1997), including 
ursolic acid, oleanolic acid (Aquino et al., 1991), and hydroxylated ursenes (Aquino et al., 1991). 
Four hydroxyursolic acid-type triterpenes were identified in the stem bark (Kitajima, Hashimoto, 
Yokoya, Takayama, and Aimi, 2000). 
Steroids 
Stigmasterol and campesterol were identified in the bark of U. tomentosa and β-sitosterol was 
found to comprise 60% of the total sterolic fraction (Senatore et al., 1989). 
 
Other Constituents: 
The inner bark of the stalk contains β-sitosteryl glucoside and 7-deoxyl-organic acid, the C-8-(S)-
isomer of 7-deoxyloganic acid, a newly reported natural productstructurally similar to 
deoxyloganic acid isomers found in Nepeta cataria (Muhammad et al., 2001). 
 
 
3.1. CHEMICAL ANALYSIS 
 
Two chemotypes were identified for Peruvian U. tomentosa: a tetracyclic oxindole alkaloid type 
and a pentacyclic oxindole alkaloid type. Researchers have noted that the pentacyclic oxindole 
alkaloid type is named savéntaro (powerful plant) by shamans of the Asháninka tribe of Peru. 
The pentocyclic chemotype (PC) contains isomeric pentacyclic oxindole alkaloids and their 
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precursor indole alkaloids in small amounts. These differences were confirmed in analyses of 
progeny sprouted from the seeds of the two chemotypes. 
 
 
3.2. STANDARDISATION 
No offici(n)al standardisation known 
 
4. PHARMACOLOGY 
In vitro tests: 
Cytoprotective effects: 
The decoction of Uncaria guianensis stalk bark was shown to limit gastric and intestinal 
epithelial cells death in response to oxidant stress, an effect that could have significant 
therapeutic potential against gastritis and enteritis, such as those induced by Helicobacter pylori 
or by non steroidal anti-inflammatory drugs intake (Miller et al., 2001). The cytoprotective effect 
could depend from the inhibition of transcription factors associated with apoptosis and 
inflammation, such as NF-kappaB, which is inhibited by Uncaria extracts (Sandoval-Chacón et 
al., 1998; Miller et al., 1999 and 2001). 
 
Endocrine and Hormonal Functions: 
An aqueous extract of dried U. tomentosa bark from Peru was tested for the specific interaction 
with the estrogen receptor of ductal carcinoma cells, in comparison with tamoxifen. The extract 
significantly and concentration-dependently inhibited [3H] estradiol binding to the cell receptor 
of the estrogen-dependent tumor cytosol after 1 h incubation. The results of these tests suggest 
that constituents of the cat´s claw bark extract can interact with "distinct binding sites" on the 
estrogen receptor which undergoes "different conformational modifications" that may be 
related to the biological response (Salazar and Jayme, 1998). 
Rodriguez and colleagues found out, that cat´s claw has the potential to selectively alter ovarian 
hormone production and therefore should be used with care. 
Clinical studies: 
 
Rheumatoid arthritis: 
A randomized double blind clinical trial of a dry extract from the pentacyclic alkaloid-chemotype 
of  Uncaria tomentosa was investigated for the treatment of rheumatoid arthritis. Forty patients 
with active rheumatoid arthritis undergoing sulfasalazine or hydroxychloroquine treatment were 
included in a randomized 52-week 2-phase-study to evaluate safety and clinical efficacy of U. 
tomentosa extract (60 mg/day, orally). During the first phase (24 weeks, double blind, placebo 
controlled), patients were treated with the extract or placebo. In the second phase (28 weeks) all 
patients received the plant extract. 24 weeks of treatment with the extract resulted in a 
reduction of the number of painful joints compared to placebo. Patients receiving the extract 
only during the second phase demonstrated a reduction in the number of painful and swollen 
joints and the articular index for the assessment of joint tenderness (Ritchie Index) compared to 
the values after 24 weeks of placebo. Only minor side effects were observed (Mur et al., 2002). 
A study on the efficacy of a dried aqueous extract of U. guianensis bark in the treatment of 
osteoarthritis of the knee was carried out on forty-five patients: 30 patients were treated with 
the extract (100 mg/day, orally) and 15 with placebo, for four weeks. The results showed that U. 
guianensis extract reduced pain associated with activity, with benefits occurring within the first 
week of therapy, even though knee pain at rest or at night, and knee circumference were not 
significantly reduced during the trial (Piscoya et al., 2001). 
 
Cancer: 
Chemotherapy adjunct treatments. An open-label trial of a proprietary extract of cat´s claw root 
bark (Immodal Pharmaka, GmbH,Austria, Krallendorn a.k.a. Savéntaro) (Uncaria tomentosa-PC, 
20-60 mg orally daily) as an adjuvant with conventional treatments was reported over a period 
of nine years in 53 patients with tumors. All patients were reported to have less side effects 
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from radiation and chemotherapy and increased mobility and vitality. Those with early-stage 
tumors remained in remission ten years later, while those with advanced tumors showed, in 
some cases, arrested cancer growth for several months. Preliminary results indicated promise 
for the adjuvant in acute myeloid leukemia, brain stem glioma, adenocarcinoma of the colon, 
testicular teratoma, cervical carcinoma stage IVA, relapsing melanoma, and medulloblastoma 
(Immodal Pharmaka, 1996). 
A 12-month open-label trial therapy of the same extract at 60 mg/day as an adjuvant with 
conventional cancer treatments in 78 cases of brain tumors was conducted by the University of 
Innsbruck, Austria. The best results appeared in patients who remained in remission after 
treatment for some types of brain tumors (e.g. ependymoblastoma WHO II and II, astrocytoma 
WHO II) more than others (e.g., glioblastoma multiforme WHO IV, malignant meningioma) 
(Immodal Pharmaka, 1996). 
 
Immune Disorders: 
In Europe, physicians using cat´s claw in the form of 4:1 standardized, hydrochloric acid extract 
of the root bark (Immodal Pharmaka, GmbH, Austria, Krallendorn a.k.a Savéntaro) (Uncaria 
tomentosa-PC) have reported benefits in their patients with viral infections of HIV (Keplinger, 
1992, 1993), herpes simplex, and h. zoster (Immodal Pharmaka, 1996). 
13 HIV patients, who refused all other treatments, took voluntarily the same standardized 
powder extract (total POA content, 12 mg/g) for five months (20 mg/day orally). The extract 
appeared to decrease the levels of neutrophils in people with high levels of these cells (>9000 
cells/µL), while in people with low levels of these  cells (<4000 cells/µL) neutrophil levels rose 
to normal.  There were no significant changes in T4/T8 cells ratios. However, absolute and 
relative lymphocyte counts showed a significant increase. (Keplinger et al., 1999). 
 
Immune Modulation: 
Lamm et al. (2001) conducted a study on the potential of a stalk bark extract of U. tomentosa 
(C-Med-100) to enhance the persistence of antibody responses to a 23 valent pneumococcal 
vaccine (Pneumovax). Male volunteers (n=23) ages 40-60 who had not received previous 
pneumococcal vaccines and had no chronic disease or were taking nutritional supplements or 
medications were randomly assigned to two groups: one group received the cat´s claw extract 
for 60 days at the oral dosage of 350 mg, twice daily and the other group did not receive the 
extract. After two months the cat´s claw treated group showed a significant enhancement in the 
ratio of lymphocytes to neutrophils, but no changes in other blood cells. No significant difference 
in antibody titers between the two groups were observed. Nevertheless, at five months, the 
cat´s claw-treated group showed no drop in antibody titer responses to pneumococcal 
vaccination whereas the other group had significantly decreased pneumococcal antibody titers. 
No reports of side effects attributable to the cat´s claw extract were reported.  
  
 
5. MICROBIOLOGY 
Anti-inflammatory activity: 
In vivo studies showed that U. tomentosa possesses anti-inflammatory properties. Aguilar et al. 
(2002) assessed the anti-inflammatory activity of U. tomentosa bark, comparing the effect of a 
hydroalcoholic extract to that of an aqueous extract after daily oral administration to mice, for 8 
days. The anti-inflammatory activity of the hydroalcoholic extract, evaluated as inhibition of the 
carrageenan paw oedema, was higher than that of the aqueous extract. The extracts inhibited 
also the transcription factor NF-kappaB, the hydroalcoholic one being the most active.  
Aqueous extracts of U. tomentosa and U. guianensis bark, were shown to possess antioxidant 
activity and to inhibit TNF-α production in RAW 264.7 cells. Despite its higher oxindole and 
pentacyclic alkaloids content, U. tomentosa was significantly less active than U. guianensis, 
suggesting that the effect is independent from the alkaloid content. Moreover, administration of 
each extract to rats for 3 days in drinking water (5 mg/ml), reduced the gastric lesions induced 
by indomethacin, and prevented TNF-α mRNA expression and apoptosis (Sandoval et al., 2002). 
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Among U. tomentosa constituents, a quinovic acid glycoside was shown to possess anti-
inflammatory properties (Aquino et al., 1991). 
 
Antiviral activity: 
Six quinovic acid glycosides from U. tomentosa were shown to inhibit vesicular stomatitis virus 
infections in CER cells, whereas a  quinovic acid glycoside [(28)-β-D-glucopyranosyl ester] was 
reported to exhibit activity against rhinovirus type 1B infection in HeLa cells (Aquino et al., 
1989). The procyanidins cinchonain Ia and cinchonain Ib, and (-)-epicatechin, isolated from the 
bark of U. tomentosa, are considered responsible for both antiinflammatory and antiviral activity 
(Aquino et al., 1989). These studies support the suggestion that both forms of bioactivity in U. 
tomentosa (anti-inflammatory and antiviral) are due to a combination of active compounds. 
 
Antibacterial properties: 
Although the Uncaria genus is not used extensively to treat infections in traditional medicine, 
some reports evaluating antibacterial activity have appeared as early as 1965. An extract of U. 
glabrata was observed to inhibit the growth of Streptococcus aureus and Escherichia coli as 
evaluated by the disk diffusion method (Arret et al., 1971). 
As part of an antimutagenicity study of U. tomentosa, toxicity against Salmonella typhimurium 
TA 98 and TA 100 strains was evaluated. Results indicated toxicity only at the highest 
concentrations (1000 μg/plate) (Wurm et al., 1998). Toxicity of U. tomentosa towards 
Photobacterium phosphoreum was evaluated using a Microtox assay which showed no toxicity 
of aqueous extracts at concentrations up to 100 μg/ml (Sandoval et al., 2002). 
Kloucek et al. (2005) showed an antibacterial activity for an ethanol extract of U. tomentosa 
bark against the Gram + Bacillus cereus, B. subtilis, Enterococcus faecalis, Staphylococcus 
aureus and S. epidermidis, as well as against the Gram – Escherichia coli. 
 
 
6. EFFICACY 
The principal action of the extract from the pentacyclic chemotype of Uncaria tomentosa (Willd.) 
DC is on the immune system.  
Pentacyclic oxindole alkaloids of U. tomentosa stimulate the phagocytotic activity of the 
macrophages(Wagner et al., 1985).. and RES cells. Under the influence of pentacyclic oxindole 
alkaloids, human endothelial cells secrete a protein that regulates the proliferation of 
lymphocytes: while the proliferation rate of resting or weakly activated lymphocytes is 
significantly increased, this protein inhibits the clonal expansion of lymphoblasts and lymphoid 
cells lines (Keplinger et al., 1999). The pentacyclic oxindole alkaloids increase or reduce the 
reactivity of the immune system, depending on the initial status. These chemical constituents 
can thus stimulate a weak immune system and suppress an over-reactive immune system 
(www.uncaria.at).  
This immunological action of preparations of Uncaria tomentosa (Willd.) DC is corroborated by 
its use in folk medicine as well as by recent scientific studies. The efficacy of Uncaria tomentosa 
(Willd.) DC in the treatment of rheumatoid arthritis and osteoarthritis has been clinically proven 
(Piscoya et al., 2001; Mur et al., 2002).  This immunological action of preparations of Uncaria 
tomentosa (Willd.) DC is corroborated by its use in folk medicine as well as by recent scientific 
studies. The efficacy of Uncaria tomentosa (Willd.) DC in the treatment of rheumatoid arthritis 
has been clinically proven.  
Efficacy recommended in Phytokodex: antiphlogistic, antiviral, immun-stimulant, immun-
modulating, enhancement of the number of leucocytes and enhancement of phagocytosis 
(Kubelka,W.,Länger,R,2001). 
 
No scientific studies of the efficacy of cat´s claw as birth control or for menstrual difficulties 
exist, though hormonal effects in animals indicate potential efficacy. 
Uncaria 
----------------------------------------------------------------------------------------------------------------- 
 
 265
 
 
7. TOXICOLOGY 
In vitro Toxicity: An aqueous extract of U. tomentosa bark, evaluated for cytotoxicity against 
Chinese hamster ovary cells and bacterial cells (Photobacterium phosphoreum) at 
concentrations ranging from 10 to 100 mg/ml, did not induce toxic effects detectable at neutral 
red assay, total protein content, tetrazolium assay and Microtox test (Santa Maria et al., 1997). 
U. tomentosa root bark extracts and fractions did not show mutagenicity in different strains of 
Salmonella typhimurium with and without metabolic activation (Rizzi et al., 1993).  
The acute median lethal dose (LD50) in mice of the freeze-dried aqueous extract of the root (U. 
tomentosa-PC) administered as 40% suspension in tragacanth gruel (0,5 %) by oral route was 
shown to be is greater than 16 g/kg (Reinhard, 1999; Keplinger et al., 1999).  
After single oral administration to rats, a hydroalcoholic extract of U. tomentosa, containing 4 % 
alkaloids, showed LD50 and maximum tolerated dose levels greater than 8 g/kg. The same 
extract, daily administered to rats at oral doses of 10-80 mg/kg for 8 weeks, or 160 mg/kg for 
4 weeks, did not induce acute or chronic toxicity signs observable symptomatically. In addition, 
no body weight, food consumption, organ weight and kidney, liver, spleen, and heart 
pathological changes were found to be associated with the extract treatment (Sheng et al., 
2000). 
Further studies revealed that oral administration of an aqueous extract of U. tomentosa in mice 
at the dose of 16 mg/kg was lethal for two of ten animals and that the LD50 of the extract was 
higher than 16 mg/kg. Moreover, an aqueous extract administered to rats for 28 days (1000 
mg/kg/day), did not provoke mortality of animals, but it caused a slight increase in percentage 
of lymphocytes, a reduction in percentage of neutrophil granulocytes, and an increase of the 
relative weight of the kidney (Keplinger et al., 1999).  
A commercial cat´s claw extract obtained in the United States (water/ethanol extract containing 
4 % alkaloids) showed a maximum tolerated dose level of 2,5-5 g/kg, with diarrhea and 
sedation as toxic signs (Sheng et al., 2000). 
 
7.1. SAFETY 
 
Recommended dosage for humans 
recommended daily allowence: 60 mg extract (standardised on pentacyclic Oxindole-alcaloids, 
free from tetracyclic Oxindole-alcaloids. 
 
Contraindications: 
In Europe, use of root (U. tomentosa-PC) and preparations thereof is not advised for infants 
under three years of age because of a lack of clinical data.Other contraindicated patients are 
those waiting to undergo bone marrow or any other organ transplants (Immodal Pharmaka, 
1995). 
 
Drug interactions: 
In Europe, patients are advised to avoid the root (U. tomentosa-PC) or extract preparations 
thereof if receiving or about to receive treatment with any of the following medical interventions: 
any treatment using immunosuppressant agents: hyperimmunoglobulin therapy (intravenously: 
i.v.); thymic extracts (i.v.); hormone treatments with animal peptide or protein hormones, such 
as insulin derived from pigs or cattle: cryoprecipitates or fresh plasma (in hemophiliacs) 
although standardized factor presents no problem; and passive vaccines made from animal 
sera which present a risk of serum reaction, although active vaccinations present no risk except 
for the possibility of a more severe postvaccinational reaction which may be attended with fever 
(Immodal Pharmaka: Kemper, 1995). 
Keplinger et al. (1999) analyzed approximately fifty products of U. tomentosa from United 
States, Central America and Peru and found varying mixtures of pentacyclic and tetracyclic (up 
to 80 % of total) alkaloids. Two chemotypes of Uncaria tomentosa with different alkaloids 
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patterns occur in nature: one contain pentacyclic oxindoles and the other contains tetracyclic 
oxindoles. This difference should be considered when the plant has to be used for medicinal 
purposes as tetracyclic oxindole alkaloids act on the central nervous system, whereas 
pentacyclikic oxindole alkaloids affect the cellular immune system. Moreover, tetracyclic 
alkaloids exert antagonistic effects on the action of pentacyclic alkaloids (Reinhard, 1999). The 
pentacyclic oxindole alkaloids of U. tomentosa were shown to stimulate human endothelial cells 
to release a factor which increases the production of B and T lymphocytes and that the secretion 
of this factor was antagonized by tetracyclic oxindole alkaloids (Wurm et al., 1998; Keplinger et 
al., 1999). For these reasons, mixtures of the two types of drugs are unsuitable for medicinal 
uses (Reinhard, 1999).  
 
Pregnancy and Lactation: 
Use of cat´s claw root (U.tomentosa-PC) and extract preparations is contraindicated for 
pregnant or lactating women and in children less than three years old (Kemper, 1999). However, 
the considerations for pregnancy and lactating differ. 
A number of studies have demonstrated hormonal effects of U. tomentosa extract that may 
interfere with fertility as well as caus miscarriage during pregnancy. Mice administered with an 
aqueous extract of cat´s claw root (U. tomentosa) in their drinking water (6,25mg/kg and 25 
mg/kg) showed no signs of toxicity. However, when caged with male mice, the female mice 
produced no offspring. Cat´s claw stalk bark (U. tomentosa) has shown in in-vitro anti-estrogenic 
activity. Amounts equivalent to dietary doses caused a dose-dependent (100 pg/mL to 10 
μg/mL) and statistically significant inhibition of progesterone production in vitro. In sexually 
mature female rats, cat´s claw bark (2mg/day or 20 mg/kg orally: p.o) reduced serum 
progesterone (P4) and estradiol (E2) levels by 68% and 71%, respectively. Low progesterone 
states are known to reduce fertility, trigger miscarriage, and contribute to menstrual difficulties. 
No studies of cat´s claw in lactating animals exist. No cases of adverse reactions of infants 
exposed to cat´s claw are known. 
 
The root bark decoction may, in some patients, result in temporary constipation during the first 
course of ingestion (Reinhard, 1999). 
 
In patients infected with HIV and in cancer patients, however, rarely, an increase in uric acid 
may result from an increased lysis of tumor and virally-infected cells. In patients with tumors 
taking the same extract, a resultant lytic fever may persist for  as long as two weeks. In patients 
with autoimmune diseases or tumors, intermittent constipation and/or diarrhea may occur as a 
result of additive lactose, both of which are readily treatable with available agents. 
 
Interaction with chemotherapies: 
Patients receiving large doses of chemotherapy and taking a standardized liquid extract of the 
root (U.tomentosa-PC, p.o.) have sometimes shown a dramatic fall in erythrocytes, which may be 
the result of increased elimination of damaged cells. The effect can be avoided by taking the 
extract up to two days prior to and every two to six days following chemotherapy (Immodal 
Pharmaka, 1995). 
 
KBB 
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URTICA SP 
  
Herba/folium Urticae  
 
1. INTRODUCTION 
Nettles have been used for more than 2000 years in various ways including fiber production, 
the use as a nutrient and animal fodder, as a dye for fabrics and as a vegetarian rennet for 
cheese making.  For medical purposes, in Europe mainly U. dioica L. and U. urens L. are used.  
The main medicinal uses of nettles historically were internally as a tonic and highly nutrient 
food and for the treatment of anemia, rheumatism, and arthritis, eczema, asthma, urinary 
gravel, stomach complaints, skin infections and as an anti-haemorrhagic.  Externally they have 
traditionally been used as a hair tonic/shampoo, as a styptic for nose bleeds and haemorrhoids 
and for stinging treatment (urtication) in arthritis and rheumatism (Randall, 2003a). Some of 
these traditional indications could be proven by pharmacological testings and clinical studies, 
but in many cases the compounds responsible for the effects attributed to nettle remain 
unknown.  
The plant parts used for medical purposes nowadays are the leaves, the herbs, the roots and 
the fruits (Frank et al. 1998).  
Nettle leaf and herb are used internally and externally for the adjuvant therapy of rheumatic 
diseases, as a mild diuretic in disorders of the urinary tract and for the prevention and therapy 
of renal gravel (Wichtl, 2002, Randall, 2003b). They are used as fresh plant, tea preparation,  
pressed juice, tincture, fluid and dried extract (Blaschek et al, 1998; Wichtl, 2002). There is also 
some evidence that nettle fruit extracts are effective in the adjuvant therapy of rheumatic 
diseases. Nettle roots are used as tea or extracts for the treatment of benign prostatic 
hypertrophy (Randall, 2003b). The present monograph will focus on nettle herbs and leaves.   
 
 
2. DESCRIPTION OF THE PLANT 
The genus Urtica L. belongs to the family Urticaceae, under the division Spermatophyta, 
subdivision of Angiospermae, class Dicotyledonae, group Apetalae, order Urticales. The 
members of the genus are annual or perennial herbs, in some cases shrubs or small trees, 
furnished with stinging hairs. The genus comprises about 100 species, distributed in temperate 
and tropical regions throughout the world. Some Urtica species are grown for food and nutrition 
purposes (Kalvali, 2003). 
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2.1 SYSTEMATICS 
 U. dioica is a perennious plant reaching a height of 30-150 cm; the stems are tetragonal and 
bear stinging hairs; the leaves are greygreen, opposite, ovate-oblong, tapering, with serrate leaf 
edges, cordiform at the leaf base and on both sides covered with stinging hairs. The plant is 
usually dioecious. In contrast, U. urens is annual, monoecious and smaller than U. dioica (10-60 
cm), also the leaves are smaller, more roundish and incised more deeply than in U. dioica. 
(Frank et al., 1998; Schomakers et al., 1995). U. dioica is indigenous to Africa and western 
Asia, but is nowadays found in all temperate regions of the world. Due to the difficulty in 
botanical differentiation between U. dioica and U. urens in the wild, they are often harvested 
together. Altough both species have a similar distribution, U. urens has become less widely 
distributed due to the reduction of its habitat (WHO, 2002). 
 
2.2 PLANT PARTS USED 
Nettle leaves consist of the whole or cut dried leaves of U. dioica, U. urens or a mixture of the 2 
species. The material complies with the monograph of the European Pharmacopoea (EAB, 
2005).  
 
3. CHEMICAL CONSTITUENTS  
 The chemical constituents of the upper plant parts of U. dioica and U. urens are rather similar 
with exception of the caffeic acid derivatives: U. dioica contains up to 1.6%  caffeoylmalic acid, 
which is absent in U. urens; besides, up to 0.5% chlorogenic acid and small amounts of several 
other organic acids are present in both species (WHO, 2002; Frank et al., 1998). The EAB 
specifies at minimum 0.3% for the sum of caffeoylmalic acid and chlorogenic acid, expressed 
as chlorogenic acid (dried drug) (EAB, 2005). 
Apart from that, in both species flavonoids, coumarins (mainly scopoletin) and steroids (β-
sitosterol and β-sitosterolglucoside) can be found (Frank et al., 1998). A TLC method with 
scopoletin and chlorogenic acid as reference compounds is used for examination of identity 
according to EAB. The quantification of chlorogenic and caffeoylmalic acid can be performed by 
HPLC (EAB, 2005).  
The aerial parts are rich in inorganic minerals (about 18% expressed as ash) including 
potassium (1.8-2%) and silica (0.9-1.8%). (ESCOP, 2003). The plant accumulates nitrate 
dependent on the nitrogen content of the soil. Marketed drugs contain on the average 1.5% 
nitrate, but high variation is possible. The leaves are rich in vitamins, especially vitamin C and 
α-tocopherol. 
As 100 g of fresh herb contain 3.82 g protein, the yield in protein per hectare is higher than in 
most of the traditional fodder plants. Its biological quality is similar to that of yeast or oilseed 
protein (Frank et al., 1998). 
The stinging hairs contain acetylcholine, histamine, serotonine, choline and small amounts of 
leukotrienes (ESCOP, 2003). These compounds are responsible for the typical skin reactions. 
 
4. PHARMACOLOGY 
4.1 IN VITRO AND ANIMAL TESTING 
 
4.1.1 ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY 
A U. dioica leaf hydroethanolic extract and its main phenolic constituent, caffeoylmalic acid, 
were tested for inhibitory potential on the biosynthesis of arachidonic acid metabolites in RBL-1 
cells. Both showed inhibitory activity against 5-lipoxygenase dependent synthesis of LTB4 and 
COX-derived prostaglandin synthesis. The same extract was shown to reduce the LPS 
stimulated release of two proinflammatory cytokines in human whole blood. An aqueous nettle 
leaf extract significantly modulated the cytokine production of human Th1 and Th2 T helper 
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cells which indicates that the extract may inhibit the inflammatory cascade in autoimmune 
diseases such as rheumatoid arthritis (ESCOP, 2003). 
Inflammatory joint diseases are characterized by enhanced extracellular matrix degradation, 
which is predominatly mediated by cytokine stimulated upregulation of matrix 
metalloproteinase (MMP) expression. Besides TNF-α, IL-1β produced by articuar chondrocytes 
and synovial macrophages is the most important cytokine stimulating MMP expression. A 95% 
isopropanolic extract from nettle leaf and 13-hydroxyoctadecatrienoic acid which is present in  
the extract significantly suppressed IL-1β induced expression of MMP proteins on cultured 
human chondrocytes at a concentration of 10 µg/ml (Schulze-Tanzil et al., 2002). 
The analgesic activity of aqueous and ethanolic nettle extracts has been investigated in vivo in 
rats and mice with inconsistent results. Local application of a nettle herb aqueous extract to the 
rat tail led to a local anaesthetic effect in the tail flick test comparable to that of lidocaine 
(ESCOP, 2003). 
 
4.1.2 DIURETIC AND HYPOTENSIVE EFFECTS 
Continuous intravenous perfusion of isotonic solutions of an aqueous nettle herb extract led to 
a significant diuretic and natriuretic effect which was in the higher dose comparable to that of 
furosemide. This effect was accompanied by a dose dependent hypotensive effect which was 
reversible within about 1 hour at the lower dose but persistent after the higher dose of nettle 
extract indicating a possible toxic effect at this dose level. 
Other authors did not find diuretic effects of nettle herb extracts in rats. Due to these 
contradictory results, the efficacy of nettle herbs as a diuretic is not yet fully documented 
(ESCOP, 2003, Wichtl, 2002). 
 
4.1.3 INFLUENCE ON THE LEVEL OF BLOOD SUGAR 
An 80% ethanolic extract and an aqueous decoction of nettle herb produced hyperglycaemic 
effects in an oral glucose tolerance test in mice (Neef et al., 1995). Roman et al. (1992), who 
tested the antidiabetic effect of an U. dioica decoction in rabbits, also found a slight increase in 
glycemia.  In contrary to that, Bnouham et al. (2003) found a strong blood glucose lowering 
effect in rats for an aqueous nettle herb extract which was administered 30 minutes prior to 
glucose loading. According to the authors this effect may be caused in part by the reduction of 
intestinal glucose absorption.  
 
4.2 VETERINARY STUDIES 
The number of studies concerning the effect of nettle herbs and leaves on productive livestock 
is very small and mainly concerning herbal mixtures that contain Urtica among other plants. 
Grela et al. (2003) investigated the influence of dietary supplementation with two different 
herbal mixtures, both containing U. dioica leaves, on the general performance and blood 
parameters of piglets. After 40 days, they compared the results to a control group receiving 
standard feed and a positive control receiving 20 mg avilamycin/kg diet. The group fed the 
mixture containing U. dioica leaves, Plantago lanceolata herbs, lyophilized Allium sativum 
bulbs, Pimpinella anisum seeds and Echinacea purpurea fruits had the best daily gains, feed 
utilization and blood indices; the production gains were even better than with the antibiotic 
additive. 
Urbańczyk et al. (2002) studied the efficacy of a different multi-component herb mixture as an 
antibiotic substitute in pig feeding: A mixture consisting of Melissa officinalis, Mentha piperita, 
U. dioica, Thymus vulgaris, Agropyron repens, Allium sativum, Capsicum annuum, Origanum 
majorana, Coriandrum sativum, Taraxacum vulgare and Silybum marianum was compared to a 
control group fed standard feed and a positive control receiving 20 mg/kg flavomycin. Also in 
this study pigs fed the herb mixture obtained the best average body weight gains. There were 
no statistical differences between the experimental groups in meat quality (colour, acidity, 
water holding capacity). 
Due to the complexity of the mixtures used in these studies it is impossible to estimate the 
contribution of U. dioica to the observed effects. 
Dügenci and coauthors (2003) studied the immunostimulant effect of a nettle leave hot water 
extract in fish (rainbow trout, Onchorhynchus mykiss). General growth performance and non 
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specific defense mechanisms (respiratory burst activities of blood leukocytes inside and 
outside the cells production, phagocytosis of blood leukocytes, total plasma protein level) were 
determined at the end of a feeding period of three weeks. The nettle extract only showed 
moderate activity. 
Pohorecka (2004) performed a study on the effect of standardized plant herb extracts on the 
general condition of the honeybee (Apis mellifera L.) and found that the administration of a 
syrup preparation containing 5% of a standardized nettle extract significantly alleviated the 
impact of adverse caging conditions. The worker bees of the nettle group showed better 
condition than on the sampling day and than bees fed syrup containing other herbal 
supplements or syrup alone.  
 
4.3 HUMAN STUDIES 
 
4.3.1 ADJUVANT TREATMENT OF ARTHRITIS, ARTHROSES AND/OR RHEUMATIC CONDITIONS  
Five open, multicentric, post marketing surveillance studies have been performed on patients 
with arthritic or rheumatic complaints using a preparation containing a dry hydroethanolic 
extract of nettle leaf (6.4-8:1) at a daily dosage of 2x670 mg. In each study a proportion of the 
patients also continued other therapies such as non steroidal anti-inflammatory drugs, while 
others only received the nettle extract. Assessments were carried out through patient 
questionnaires and consultations with physicians. Overall, 80-95% of the patients rated the 
efficacy, and 93-95% rated the tolerability of the extract as good or very good. 
In an open, randomized 14-day study, patients with acute arthritis received daily either 2x100 
mg of diclofenac or 50 mg of diclofenac and 50 g of nettle leaf puree (caffeoylmalic acid 
content 20 mg). The elevated serum levels of C-reactive protein, which was the main criterion 
of the study, decreased by about 70% in both groups. Assessment of physical impairment, 
subjective pain and stiffness showed improvements in the range 52-77%, with no significant 
differences between the groups (ESCOP, 2003). 
The efficacy of the external application of fresh nettle leaves was studied in a randomized, 
double-blind, crossover study involving 27 patients with persistent oseoarthritic pain at the base 
of the thumb or index finger. As a placebo Lamium album was used. Treatments were applied 
for 1 week each, interrupted by a 5-week washout period. Compared to placebo, significantly 
greater reductions in scores were observed with nettle leaf on a visual analogue scale for pain. 
No serious side effects were reported (Randall et al., 2000). 
 
4.3.2 DIURETIC EFFECTS (ESCOP,2003) 
In an open 2-week study, 32 patients suffering from myocardial or chronic venous insufficiency 
were treated daily with 3x15 ml nettle herb pressed juice. A significant increase in the daily 
volume of urine was observed throughout the treatment. Minor decreases in body weights and 
systolic blood pressure were also observed.  
 
4.3.3 EFFECT AGAINST ALLERGIC RHINITIS 
A randomized, double blind, placebo-controlled trial assessed the effects of a freeze dried 
nettle herb preparation in subjects with allergic rhinitis. At the onset of symptoms, 600 mg of 
the preparation or placebo were ingested daily for 1 week. Nettle herb was rated higher than 
placebo in the global assessment, but rated less high on the basis of data from the symptom 
diaries (Barnes et al., 2002). 
 
4.4 ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
 
No data available 
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5. MICROBIOLOGY 
Steenkamp et al. (2004) found no antibacterial activity for U. urens aqueous and methanolic 
extracts against Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli and 
Pseudomonas aeruginosa. 
Gülçin et al. (2004) found antimicrobial activity for an U. dioica aqueous extract (250 µg per 
disc) against nine microorganisms (Pseudomonas aeruginosa, Eschericia coli, Proteus 
mirabilis, Citrobacter koseri, Staphylococcus aureus, Streptococcus pneumoniae, Enterobacter 
aerogenes, Micrococcus luteus, Staphylococcus epidermidis and Candida albicans), but no 
MICs were determined. 
Keleş and coauthors (2001) tested an 80% ethanolic U. dioica herb extract against several 
pathogens of veterinary importance, namely Staphylococcus aureus, Streptococcus agalactiae, 
Straptococcus dysgalactiae, Salmonella gallinarum, Escherichia coli and Klebsiella 
pneumoniae, using the agar diffusion and dilution method. They only found activity against E. 
coli, S. aureus and S. agalactiae, with rather high MIC´s (4 mg/ml). 
 
6. EFFICACY 
The leaves of Urtica species are excellent sources of some important minerals and vitamins. 
Moreover they have a higher level and a better quality of protein compared with many other 
green leafy vegetables and fodder plants. Because of their high nutritional value they are used 
in husbandry as a fodder for pigs and poultry (Frank et al. 1998; Wetherilt, 2003). About the 
efficacy of nettle as sensory and flavouring agent for animal feed no data are available. 
Concerning the use in humans, nettle leaves and herbs is listed by the Council of Europe as a 
natural source of food flavouring in category 1 (no restrictions for use proposed; not considered 
as a health risk in the quantities used). Nettle is used as a food in soups or herbal teas. In the 
USA, the plant is listed by the FDA as Herb of Undefined Safety (Barnes et al., 2002). 
Concerning the medical efficacy in humans, U. dioica and U. urens herb and leaf preparations 
are considered to be effective in the internal and external adjuvant therapy of rheumatic 
diseases and as diuretics in the therapy of inflammatory diseases of the urinary tract and for 
the prevention and therapy of renal gravel (Wichtl, 2002). 
 
7. TOXICOLOGY 
7.1 SAFETY 
 
7.1.1 PRECLINICAL SAFETY DATA 
The intraperitoneal LD50 of an aqueous U. dioica herb extract has been determined in mice as 
3.625 g/kg b.w (ESCOP, 2003) and 3,5 g/kg b.w. respectively (Bnouham et al., 2003), 
suggesting a low toxicity of the water extract. 
An ethanolic U. dioica herb extract showed low toxicity in rats and mice after oral and 
intraperitoneal administration at the equivalent of up to 2 g of dried drug per kg body weight 
(ESCOP, 2003). 
 
7.1.2 CLINICAL SAFETY DATA 
No serious adverse effects were reported from 5 clinical studies in which a total of 10,368 
patients took 2x 670 mg of a dry hydroethanolic nettle leaf extract (6.4-8:1) daily  for periods of 
3 weeks up to 12 months; the incidence of minor adverse effects (mainly gastrointestinal 
upsets or allergic reactions) was 1.2-2.7%. In a study where 19 patients received 50 g of a 
stewed nettle leaf puree daily for 14 days, 3 patients reported meteorism (ESCOP, 2003) 
. 
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For productive livestock, no safety data are available. 
 
 
 
 
 
 
7.2 DOSAGE 
 
7.2.1 INTERNAL USE 
Adults: hydroalcoholic extracts corresponding to 8-12 g of nettle leaf daily, divided into 2-3 
doses; 3-5 g drug as an infusion up to 3 times daily; tincture 1:5 (25% ethanol) 2-6 ml 3 times 
daily; 15 ml of fresh juice up to 3 times daily (Frank et al., 1998; ESCOP, 2003). 
External use: 
Adults: fresh nettle leaf applied to the skin in the area of pain for 30 seconds once daily 
(ESCOP, 2003). 
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VALERIANA OFFICINALIS 
 
 
 
 
 
 
Valeriana officinalis 
 
 
1.  INTRODUCTION 
The use of valerian species has a very long tradition in many parts of the world. The original use 
as a perfume or as a source of food was totally different to its modern application as a sedative 
and calming agent. The most important commercial Valeriana species are V. officinalis, V. 
wallichii, V. fauriei and V. edulis (Dweck, 1997). The present monograph will focus on Valeriana 
officinalis L., the species commonly used in northern European medicine. 
Valerian is stated to possess sedative, mild anodyne, hypnotic, antispasmodic, carminative and 
hypotensive properties. Traditionally, it has been used for hysterical states, excitability, 
insomnia, hypochondriasis, migraine, cramp, intestinal colic, rheumatic pains, dysmenorrhoea 
and specifically for conditions presenting nervous excitability. Modern interest in valerian is 
focused on its use as a sedative and tranquillizing agent. In a draft Community Herbal 
Monograph on valerian root, the European Medicines Evaluation Agency Commitee on Herbal 
Medicinal Products (EMEA HMPC) designates the use of aqueous or aqueous/ethanolic valerian 
root preparations for the relief of mild nervous tension and difficulty in falling asleep to be well-
established (EMEA, 2005).  The plant is also used as a sedative for animals in herbal veterinary 
medicine (Bentz et al., 1989). However, for some animals such as cats or rats, it is an 
attractant and has an excitatory effect (Dweck, 1997) 
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Despite intensive efforts it is not possible so far to attribute the quite well documented sedative 
activity of the drug to a single compound or a class of compounds; current thinking is that the 
activity of valerian is based on a synergistic effect of the active classes of compounds and not 
caused by a single substance (Wichtl, 2002). 
 
2. DESCRIPTION OF THE PLANT 
Valeriana officinalis is a tall perennial herb whose underground portion consists of a vertical 
rhizome bearing numerous rootlets and one or more stolons. The aerial portion consists of a 
cylindrical hollow, channeled stem attaining 2 m in height, branched in the terminal region, 
bearing opposite exstipulate, pinnatisect, cauline leaves with clasping petioles. The 
inflorescence consists of racemes of cymes whose flowers are small, white or pink. The fruits 
are oblong-ovate, 4-ridged, single-seeded achenes (WHO, 1999). The morphology can vary in 
detail depending on the subtype (Reichling et al., 1994).  
 
2.1  SYSTEMATICS 
 
Valeriana is the major genus of the Valerianaceae, a family represented in all the temperate 
and subtropical areas in the world (Dweck, 1997). The genus Valeriana is extremely rich in 
species, it comprises more than 250 species. 
V. officinalis L. s.l.  is a very diverse composite species occurring all over the temperate regions 
of Eurasia, which is split up in several ecotypes and geographic races. Additionally, differences 
exist concerning the number of chromosomes, ranging from diploid to octaploid races. They are 
partly restricted to certain regions, partly they are spread over wide areas. Nowadays, in middle 
and southern Europe they are grouped in 4 base types depending on morphology: exaltata, 
collina, procurrens and sambucifolia (Reichling et al., 1994). 
 
Other Valeriana species used: Valeriana celtica, celtic valerian, Speick (for fragrance); 
V. wallichii, Indian or Himalayan valerian; V. edulis ssp. procera, Mexican valerian 
 
2.2  PLANT PARTS USED 
For medical purposes, the underground parts of the plant are used. Valerian root (Valerianae 
radix) consists of the gently dried (not > 40°C), whole or cut underground parts of V.officinalis L. 
s.l., including the rhizome surrounded by the roots and stolons. The material complies with the 
monograph of the European Pharmacopoea (EAB, 2005, WHO, 1999). The drug has a 
characteristic smell like isovaleric acid and camphor. The taste is sweetish at the beginning, 
later aromatic and weekly bitter (Reichling et al., 1994). 
The drug is prepared as a tea or processed to tinctures, fluid and dry extracts or pressed juices 
and other galenic preparations for internal use. The extracts and/or the essential oil of valerian 
root can also be used externally as bath essence (Reichling et al., 1994; Wichtl, 2002). 
According to the EMEA HMPC draft monograph (EMEA, 2005), the use of aqueous and 
hydroethanolic extracts and tinctures is well-established, whereas the use of dried valerian root, 
fresh plant juice and valerian root oil is based on tradition. 
As the drug nowadays is mostly derived from cultures, adulterations and confusions are rare 
(Reichling et al., 1994). 
 
3. CHEMICAL CONSTITUENTS 
Due to the many subtypes and varieties of V. officinalis  L. s.l., the spectrum and amount of 
constituents can vary considerably depending on  geographic origin and subtype (Reichling et 
al., 1994). The classes of compounds the sedative activity of valerian root is nowadays mainly 
attributed to are the volatile oil and the valepotriates and their degradation products, but 
latterly also a contribution of lignans and flavonoids is discussed.  
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Current thinking is that these classes of compounds contribute to the overall activity of the drug 
by different mechanisms of action. Therefore, the quality of valerian preparations will depend 
on the presence and concentrations of several classes of compounds (Barnes et al.2002). 
The volatile oil consists of monoterpenes mainly present as esters, sesquiterpens and the 
sesquiterpene acids acetoxyvalerenic acid, hydroxyvalerenic acid and valerenic acid. 
Acetoxyvalerenic acid and valerenic acid are characteristic compounds for V. officinalis and do 
not occur in non European Valeriana species, so they are used for the identification of the drug 
(Barnes et al., 2002, Reichling et al., 1994). The European Pharmacopoea specifies a minimum 
volatile oil content of 5 ml/kg for the whole drug and 3 ml/kg for the cut drug. The content of 
sesquiterpene acids has to be at least 0.17%, calculated as valerenic acid. The volatile oil 
content is determined by steam distillation, and the sesquiterpene acids are quantified by 
HPLC (Ph. Eur. 5, 2005). 
The dried crude drug contains about 0.5 to 2% valepotriates (iridoids) with valtrate as the main 
compound. Those compounds are unstable and decompose by high drying temperature, long 
storage and processing.  Valepotriates are not present in significant amounts in aqueous or 
dilute alcoholic extracts after a few days. They are also metabolized in the gastrointestinal 
tract. The main degradation products are baldrinal and homobaldrinal. There is evidence that 
these compounds are partly responsible for the sedative activity of the drug (Reichling et al., 
1994, Houghton, 1997). 
Additionally the drug contains organic acids such as chlorogenic acid, caffeic acid and 1-2% 
isoferulic acid, which serves as a marker compound for aqueous extracts, because it is only 
present in V. officinalis root. Recently several lignans have been isolated, and some of them 
have also shown effects in radioligand binding assays on several CNS-receptors (Schumacher et 
al., 2002; Bodesheim and Hölzl, 1997). Small amounts of alkaloids are present, and the 
concentration of amino acids is quite high in the drug. Especially γ-aminobutyric acid (GABA) is 
present in quite high quantities and could therefore also contribute to the sedative effect of the 
drug (Reichling et al.1994, Houghton, 1997). 
 
4. PHARMACOLOGY 
4.1   IN VITRO TESTING 
Sedative effects 
The sedative activity of V. officinalis has been demonstrated both in vitro and in vivo and has 
been attributed to the volatile oil and the valepotriate fractions (Barnes et al., 2002). Recent 
studies also revealed effects of other compounds in several in vitro and animal models. 
Many potential mechanisms for the sedative activity of valerian have been proposed, including 
agonistic activities on the GABA, adenosine, benzodiazepine and barbiturate receptors (Barnes 
et al., 2002). However, in some older reports the concentrations used in these investigations 
were very high, and more recent reports put some of these data into question (Dietz et al., 
2005). So, the discussion about the mechanism of sedative action is still going on. 
Aqueous and hydroalcoholic extracts were found to show affinity to the GABAA receptors; also 
an inhibition of the uptake and a stimulation of the release of radiolabelled GABA in 
synaptosomes isolated from rat brain cortex was shown. This effect was attributed to GABA 
itself, which was present in the extract in high concentrations. Additionally, valerenic acid was 
shown to inhibit the enzyme system responsible for the central catabolism of GABA (Barnes et 
al., 2002).  
Wasowski et al.(2002) found that 6-methylapigenin, a flavone present in valerian, is a ligand 
for the benzodiazepine binding site of the GABAA receptor. Recently, Granger et al. (2005) 
found, that the essential oil compounds (+)-and (-)-borneol are positive modulators of GABA 
action at human recombinant α1β2γ2L GABAA receptors, enhancing the action of low GABA 
concentrations by more than 1000%. The enhancing effect was independent to flumenazil, 
indicating that the compounds do not act at classical benzodiazepine sites. 
Schumacher et al. (2002) performed radioligand binding assays at various receptors of the 
central nervous system (CNS) and found that an olivil derivative acts as a partial agonist at 
adenosine A1 receptors exhibiting A1 affinity and activity in low micromolar concentrations. 
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Another lignan, namely 8´-hydroxypinoresinol, was shown to exhbit affinity to serotonin 5-HT1A 
receptors (Bodesheim and Hölzl, 1997). Dietz and coauthors (2005) tested valerian root 
extracts of different polarities in radioligand binding studies for 8 serotonin receptor subtypes  
and some other CNS receptors and showed that lipophilic valerian root extracts and valerenic 
acid act as partial agonists of the 5-HT1A receptor. This serotonin receptor is believed to be 
involved in circadian (sleep-wake) rhythms, anxiety and explorative behavior. 
 
Spasmolytic activity 
The spasmolytic activity of the valepotriates is principally due to valtrate or dihydrovaltrate. 
These agents can act on centres of the CNS and through direct relaxation of smooth muscle, 
apparently by modulating Ca2+ entry into the cells or by binding to smooth muscle (WHO, 1999; 
Barnes et al., 2002). The antispasmodic activity of valerian oil was shown on isolated guinea 
pig uterine muscle, but could not be confirmed in vivo (Barnes et al., 2002). 
 
4.2  ANIMAL STUDIES 
 
Also many animal studies were performed to prove the sedative activity of valerian root: 
A screening of the volatile oil components for sedative activity concluded valerenal and 
valerenic acid to be the most active compounds, causing ataxia in mice at a dose of 50 mg/kg 
(i.p.). Valerenic acid also acts as a general CNS depressant at high doses (100 mg/kg i.p.); a 
dose of 400 mg/kg however resulted in muscle spasms, convulsions and death. Valerenic acid 
was also reported to prolong pentobarbitone induced sleep in mice, resulting in a hangover 
effect (Barnes et al., 2002). 
CNS-depressant activities in mice have also been documented for the valepotriates and for 
their degradation products, the activity being higher after i.p. than after p.o. administration. A 
specific valepotriate fraction has been documented to exhibit tranquillizing, central 
myorelaxant, anticonvulsant, coronary-dilating and anti-arrhythmic actions in mice, rabbits and 
cats (Barnes et al., 2002). 
The central depressant activity of a valerian root extract was assessed in vivo using an 
autoradiographic tracer method to measure glucose transformations in more than 30 areas of 
the rat brain after i.p. injection of test substances, as a measure of neuronal activity. A 
dichloromethane extract and a particular fraction from it were demonstrated to be active at 50 
and 10 mg/kg respectively, but no activity was found for the essential oil, pure valerenic acid, 
valeranone, valtrate, didrovaltrate and homobaldrinal (ESCOP, 2003). 
Recently, some flavonoids present in valerian were shown to exhibit CNS-activity in mice and 
rats:  2S(-) hesperidin showed sedative and sleep enhancing properties, and 6-methylapigenin 
was found to have anxiolytic properties and to potentiate the sleep enhancing activities of  2S(-) 
hesperidin (Marder et al., 2003). The flavone glycoside linarin also showed sedative and sleep –
enhancing properties that were potentiated by simultaneous administration of valerenic acid 
(Fernandez et al., 2004). 
To summarize, several mechanisms of action possibly contributing to the clinical effect have 
been identified for diverse valerian root constituents (sesquiterpenoids, lignans, flavonoids) and 
include interactions with the GABA-system, agonism at the A1 adenosine receptor and binding 
at the 5-HT1A receptor (EMEA, 2005). 
 
4.3 HUMAN STUDIES 
 
Numerous studies have explored the effects of valerian preparations on subjective and/or 
objective sleep parameters. Collectively, the findings of these studies are difficult to evaluate, 
as different studies have assessed different valerian preparations at different dosages, and 
some have involved healthy volunteers whereas others have involved patients with diagnosed 
sleep disorders. In addition, some studies have been performed in sleep laboratories and 
others with test persons sleeping at home. Overall, several, but not all studies have 
documented a sleep enhancing effect of valerian preparations with regard to subjective 
measures of sleep quality, and some have documented effects on objective measures of sleep 
structure (Barnes et al., 2002).  
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Stevinson and Ernst (2000) included randomized, placebo controlled double blind clinical trials 
that had measured the effect of valerian monopreparations on sleep in human participants in a  
systematic review. From the evaluation of 9 studies that met the inclusion criteria, the authors 
conclude that the evidence of the efficacy of valerian for improving sleep is promising, but not 
fully conclusive. The results of some trials suggest that valerian may have both acute and 
cumulative effects on sleep, but not all studies have produced positive findings. These 
discrepancies may be a result of inconsistencies between trials in experimental design. 
In a recent trial, Diaper and Hindmarch (2004) compared the acute effects of two doses of 
valerian (single dose 300 and 600 mg of the commercial valerian extract Sedonium™, with a 
washout period of 6 days after each dose) in 16 elderly patients with mild sleep disorders. Tests 
were performed in a sleep laboratory, and the sleep EEG was recorded form 23 to7 h each 
night. Psychometric tests and mood scales were performed after the test nights. No significant 
differences were observed between placebo and verum. The authors conclude that valerian at 
these doses is ineffective as an acute remedy for sleep disorders. Also Glass et al. (2003) found 
no acute sedative effect for a commercial valerian extract (400 or 800 mg), which was ingested 
to elderly healthy volunteers. Effects were assessed 0.5, 1, 2, 3, 4, 6 and 8 hours after 
medication using validated measures of subjective sedation, mood and psychomotor 
performance. No sedation and no impairment of psychomotor performance were observed at 
any time studied. A study involving healthy young volunteers provided similar results (Guiterrez 
et al., 2004). 
 
4.4  ABSORPTION, DISTRIBUTION, METABOLISM, EXCRETION 
 
There are some pharmacokinetic data available concerning valtrate and valerenic acid 
derivatives: 
The in vivo distribution and metabolism of 14C-valtrate after p.o. and i.v. administration was 
investigated in NMRI-mice. The results of p.o. administration indicate that the stomach is the 
most important resorption area for valepotriates. The relative specific activity in blood and 
different organs was rather low with the highest activity in the liver. Intact valtrate could only be 
found in very low concentrations, the major part of radioactivity was found in metabolites. 
After i.v. application, the highest relative activity was found in the liver, followed by lung and 
spleen (Reichling et al., 1994). 
 In order to study the pharmacokinetics of valerenic acid, 6 healthy volunteers received a single 
600 mg oral dose of valerian (SedoniumTM, Lichtwer Pharma), and blood samples were 
collected at particular times after administration. Valerenic acid was quantified in the serum 
using derivatization of valerenic acid followed by LC-MS determination. The maximum serum 
concentration for 5 of the 6 subjects occurred between 1 and 2 hours after administration. 
Valerenic acid was detectable in serum for at least 5 hours after intake. The elimination half 
life for valerenic acid was 1.1±0.6 hours (Anderson et al., 2005). 
To investigate the occurrence and the effect of metabolic changes of valerian constituents in 
the liver in vitro, a valerian 50% methanolic extract was incubated with freshly prepared rat 
hepatocytes and subsequently analyzed phytochemically by HPLC and pharmacologically by 
testing for the binding affinity of the extract to the benzodiazepine and picrotoxin binding sites 
of the GABAA receptor. HPLC analysis revealed considerable metabolic changes concerning the 
sesquiterpenes and the valepotriates: The amount of acetoxyvalerenic acid decreased 9-fold, 
while the hydroxyvalerenic acid content increased 9-fold due to deacetylation. The valepotriates 
didrovaltrate, isovaltrate and valtate decreased 2-, 18-, and 16-fold respectively. However, the 
binding affinity to the GABAA receptor remained unchanged, indicating that other or multiple 
compounds are responsible for this action (Simmen et al., 2005). 
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5. MICROBIOLOGY 
Valerian oil is generally regarded as lacking in antimicrobial activity. However, one study exists 
that showed mild antimicrobial activities of certain valerian cultivars against some 
microorganisms such as Aspergillus niger, Escherichia coli, Pseudomonas aeruginosa, 
Staphylococcus aureus and Saccharomyces cerevisiae. The authors demonstrate that the 
antimicrobial activity of the essential oil may depend on its biological origin (cultivar) and on 
the developmental stage of the plant, both factors causing variations in the amount and 
composition of the essential oil (Letchamo et al., 2004). 
 
6. EFFICACY 
Concerning its medical indications, valerian root is stated to be effective for the relief of 
temporary nervous tension and difficulties in falling asleep (Blumenthal, 1998, EMEA, 2005). 
The efficacy in these indications is quite well documented in comparison to other herbal drugs, 
however the active compounds could not yet be fully identified and also the exact mechanisms 
of action remain to be investigated.  
Because of its gradual onset of efficacy, the drug is obviously not suitable for acute 
interventional treatment of stress symptoms or reactive sleep disturbances, so a continued use 
over 2 to 4 weeks is recommended to achieve an optimal effect (EMEA, 2005). 
As far as the use as flavouring agent is concerned, the legal status depends on the country. It is 
listed by the Council of Europe as a natural source of food flavouring with some restrictions 
(root: category 5, products for which additional toxicological and/or chemical information is 
required. These could temporarly be acceptable provided that any limits set for the active 
principles or the other chemical components are not exceeded). In the USA, valerian is 
permitted for use in food (Barnes et al., 2002). 
 
 
 
 6.1 VETERINARY  USE 
 
The transport of pigs can cause stress, thereby raising the issue of animal welfare. The use of 
pharmacological (synthetic) sedatives before transport is forbidden in the European Union to 
avoid risky food residues. 
The effect of a herbal preparation containing V. officinalis L. and Passiflora incarnata L. 
(Sedafit™) on responses of pigs during a transport simulation was investigated. Sedafit 
supplementation (2.5 g/l drinking water for 2 days) resulted in smaller increases of the 
investigated heart variables (minimum heart rate, ventricular ectopic beats, ST elevation) 
during and after stress evocation compared with the control group, suggesting sedative and 
antianxiety effects (Peeters et al., 2004).  
 
The use as a sedative in herbal veterinary medicine for horses and small animals has also been 
described (Bentz et al., 1989), but it is not yet sufficiently documented by studies. 
 
7. TOXICOLOGY 
7.1  SAFETY 
 
Preclinical safety data: 
A low order of toxicity was reported for an ethanolic valerian root extract (LD50 after i.p. 
injection in mice 3.3 g/kg b.w.). The same extract was administered daily to rats for 45 days in 
doses ranging from 400- 600 mg/kg b.w. i.p. daily, no significant changes in weight, blood or 
urine were observed in comparison with control animals. A similar result was obtained in a 30 
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day study in rats when growth, arterial pressure, weight of key organs, haematological and 
biochemical parameters were compared (daily administration of 300 or 600 mg/kg/day 
ethanolic valerian root extract). The LD50 of valerian essential oil was determined as 15 g/kg 
b.w. in rats. In acute oral toxicity tests the LD50 of valeranone was greater than 3 g/kg b.w. in 
rats and mice. 
Valerenic acid caused reduction of spontaneous motility at a dose of 50 mg/kg b.w. i.p. in 
mice, at a dose of 100 mg/kg it caused ataxia, 150-200 mg caused muscle spasms and 400 
mg/kg led to heavy convulsions resulting in the death of 6 out of 7 mice within 24 hours 
(ESCOP, 2003). 
In vitro cytotoxicity (inhibition of DNA and protein synthesis and potent alkylating activity) has 
been reported for the valepotriates, with valtrate stated to be the most toxic compound.  
However, the valepotriates are known to be unstable in both acidic and alkaline media and it 
has been suggested that their in vivo toxicity is limited due to poor absorption and distribution. 
Due to their low stability it is also unlikely that they are present at significant concentrations in 
finished products (Barnes et al.2002, Reichling et al., 1994).  
Baldrinal and homobaldrinal, decomposition products of the valepotriates, have exhibited 
direct mutagenic activity in vitro in the Ames test and the SOS-Chromotest. Their in vitro 
cytotoxicity was lower than that of the valepotriates (Barnes et al.2002, Reichling et al., 1994). 
Due to the poor resorption of the valepotriates and the high first pass effect and the rapid 
metabolism of the baldrinals, the systemic distribution of these compounds is very low. Thus, 
the mucosa of the gastrointestinal tract and to a lower extent the liver might be the target 
organs for a potential mutagenic, genotoxic and cytotoxic risk of the valepotriates and their 
decomposition products (Reichling et al., 1994). 
In vivo, the following LD50 values were determined for valepotriates and baldrinals in mice:  
For i.p. injection 62 mg/kg for valtrate, 150 mg/kg for acevaltrate, 125 mg/kg for didrovaltrate 
and 460 mg/kg for baldrinal. For p.o. administration, 4600 mg/kg for valtrate, acevaltrate and 
didrovaltrate (Reichling et al., 1994). 
 
 
 
Clinical safety data 
Only few controlled clinical trials of valerian preparations have provided detailed information on 
safety. Where adverse event data were provided, randomised, placebo-controlled trials 
involving healthy volunteers or patients with diagnosed insomnia reported that they were mild 
and transient and that the types and frequency were similar to those for placebo (Barnes et al., 
2002, Stevinson and Ernst, 2000).  Slight or no physical or cognitive impairment was reported 
after single or repeated administration of valerian, and serious hang over effects obviously do 
not occur. There have been case reports about hepatotoxic reactions in individuals taking 
herbal products containing valerian, and a report of cardiac complication and delirium following 
sudden valerian withdrawal. At high doses, valerian has been associated with cardiac function 
disturbance and depression of the central nervous system, making potentiation of other central 
nervous depressants a possibility. Addiction to valerian preparations has not been reported. For 
evaluation of the safety of long term use, more studies would be necessary (Stevinson and 
Ernst, 2000).  About the safety of valerian intake during pregnancy and lactation, no data exist. 
For this reason, the use is not recommended (EMEA, 2005). 
 
Interactions 
Investigating valerian´s potential for herb-drug interactions, Defevbre et al.(2004) studied the 
potential of 9 commercially available valerian preparations to inhibit a major human drug 
metabolism enzyme and transport protein, namely cytochrome P450 3A4 and P-glycoprotein,  
in vitro. Most of the extracts tested exhibited a moderate to high inhibitory activity that was not 
correlated with the valerenic acid content. 
A clinical study dealing with this problem focused on the activity of the two P450 isoforms 
CYP3A4 and CYP2D6. Together, these isoforms are involved in the metabolism of an estimated 
of 70% of prescription and non-prescription medications. Probe drugs dexometorphan (CYP2D6 
activity) and alprazolam (CYP3A4 activity) were administered to 12 healthy volunteers at 
baseline and after supplementation with tablets containing 1000 mg valerian root extract 
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(containing 11.2 mg valerenic acid) nightly for 14 days. Dexometorphan and alprazolam 
metabolic rates were determined at baseline and after treatment. The results indicate that 
although a modest increase was observed in cmax of alprazolam, typical doses of valerian are 
unlikely to produce clinically significant effects on the disposition of medications dependent on 
the CYP2D6 or CYP3A4 pathways (Donovan et al., 2004).  
Gurley and coworkers (2005) performed a study evaluating the ability of valerian and 3 other 
herbal medications to modulate CYP activity in 12 health volunteers. Each supplementation 
period was 28 days, followed by a washout period of 30 days. The study was randomized for 
supplementation sequence. Concerning valerian, capsules containing 125 mg valerian root 
extract were administered 3 times daily. The activity of CYP phenotypes CYP1A2, CYP2D6, 
CYP2E1 and CYP3A4/5 was assessed before and at the end of each supplementation phase by 
determination of the metabolic rates for caffeine, midazolam, chlorzoxazon and debrisoquin. 
No significant changes in phenotypic ratios were observed during valerian supplementation. 
The authors conclude that valerian is not very likely to produce CYP-mediated herb-drug 
interactions, but as the valerenic acid content of the used valerian preparation was below the 
limit of detection, the authors admit that this result may not be representative of products 
containing greater amounts of valerenic acid.  
For general conclusions, more data from larger studies would be necessary. 
 
7.2  DOSAGE 
 
Humans 
Adolescents over 12 years of age, adults elderly: tinctures (1:5), aqueous or hydroethanolic 
extracts equivalent to 2-3 g of the drug for nervous tension up to 3 times daily; as an aid to 
sleep, a single dose ½ to 1 hour before bedtime, with an earlier dose during the evening if 
necessary.  
0.3 to 1 g dried valerian root (powdered or as a herbal tea), 15 ml of fresh plant juice, 14 mg of 
valerian root oil up to 3 times daily (based on traditional use). 
Because there is no experience available, the use of the product is not recommended in 
children below the age of 12 years (EMEA, 2005). 
 
Animals 
Valerian root p.o.: horse 20-50 g, cattle 30-100 g, small ruminants 5-15 g, pigs 5-10 g 
Valerian tincture p.o.: pig 2-5 g, dog 0,5-3 g (Bentz et al., 1989). 
Scientific studies to confirm the safety and efficacy of these doses are missing. 
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CONCLUSIONS 
Taking into account the large number of herbs and herbal products (“botanicals”) widely 
available for animal nutrition through several distribution channels and marketed actually for a 
variety of uses, several issues have arised mainly relating to the quality assurance and safety: 
 
1. Identification of the starting material 
2. Natural variation of the plant material 
a. biodiversity and genetic variation 
b. ontogenetic variation (development stage) 
c. morphogenetic variation (plant parts) 
3. Agricultural and harvesting practices 
4. Contaminations 
a. agrochemicals (plant protection products) 
b. microbiological contamination 
5. Identification of the “active substance(s)” 
6. Product consistency and stability 
7. Hazard identification and characterisation 
8. Risk characterisation 
 
AD 1. IDENTIFICATION OF THE STARTING MATERIAL 
One of the problems when dealing with herbs and herbal products is the correct identification of 
the species and chemotype. Quite often, narrowly related species are used with different 
chemical outfit, as e.g. yarrow (Achillea millefolium aggr.) or oregano (Origanum sp.) consisting 
of a number of small and/or subspecies of different ploidy level and with distinct chemical 
composition. Sometimes also chemotypes occur within a species of which only one is 
appropriately effective. This is problematic, especially if the chemical variation results in adverse 
effects. For example, bitter substances vary considerably within Labiatae and the acceptance by 
animals (espec. chicken) might not be given causing minor uptake and losses. 
 
Exotic herbs are often known under different common/vernacular names and the correct 
botanical source is sometimes unclear. Consequently mixtures with poisonous plants might and 
do occur. A specific problem in this respect is related to wild collected herbs. To avoid confusion 
a clear description to ensure the authenticity is therefore an indispensable prerequisite. 
AD  2. NATURAL VARIATION OF THE PLANT MATERIAL 
It is of common knowledge that crops vary from year to year. Prerequisite for a batch to batch 
conformity is therefore a uniform plant material. Special attention has to be paid in first line to 
the correct (chemo)variety since many plants, especially essential oil bearing species, show not 
only a high inter-specific phytochemical diversity but also an intra-specific chemical variation. 
Moreover, the respective phytochemicals are not equally distributed in the plant but can be 
concentrated in specific plant parts, organs and tissues. A clear description and specification of 
the plant part used is therefore necessary. For example, milk thistle (Silybum marianum) 
contains the effective flavonolignans in the fruit husk, thistle oil and thistle herb being totally 
different products. 
 
Another typical characteristic of secondary plant products is their phase dependence. They are 
rarely quantitatively or qualitatively present uniformly over the life cycle of the plant but depend 
on the development stage, the latter being influenced by the environment, especially day length, 
temperature, water and nutrition. As a result, the quality of the product depends on the harvest 
date and the ecological influences at the production site. 
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AD  3. AGRICULTURAL PRACTICES AND HARVESTING  
Since the above problematic of batch to bach conformity is well recognized for medicinal and 
aromatic plants, the European Herb Growers Association (EUROPAM/EHGA) elaborated, already 
in the 1990ies, ‘Guidelines for Good Agricultural Practice’ and ‘Guidelines for Good Wild 
Collection Practice of Medicinal and Aromatic Plants’ (GAP/GCP-Guidelines, ), adopted 
meanwhile by EMEA and WHO The respective guidelines refer to the following items (which 
must not all be dealt with in detail in the present context): 
 
- seeds and propagation material 
- Cultivation, including soil and fertilisation, irrigation, crop maintenance and plant 
protection (products) 
- Wild collection 
- Harvest 
- Primary processing and packaging 
- Storage and distribution   
 
and also to: 
- Quality assurance 
- Personnel and education 
- Building and facilities 
- Equipment 
- Documentation 
 
Therefore the principles stated on these guidelines should also be applied at plants/herbs used 
as additives in animal nutrition. 
 
AD  4. CONTAMINATIONS 
A rather crucial problem represent the different possible contaminations which might occur  
independent if the plants are cultivated or wild collected. They can be divided into the following 
main groups: 
 
- admixtures with undesired plant material  
- insects and microbiological load 
- residues of plant protection products 
- toxic heavy metals and radioactive isotopes 
 
Admixtures with wrong plant material are caused on one side by lacking knowledge or 
performance of the plant collector, on the other side by deficiencies in crop maintenance, 
harvest and post-harvest processing. In field crops, weed control is done manually, mechanically 
or by application of herbicides causing probably respective residues.  Impurities with wrong 
plant material will not only reduce the quality of the product, but may also result in severe 
problems if toxic plants/plant parts  are concerned. 
 
Pest and disease infected material is in general of lower quality but could also be hazardous if 
toxic substances are produced by one of the organisms. Apart from crop management special 
attention has to be paid to storage conditions to avoid insect and microorganism proliferation. 
Insect (and rodent) control is possible by gazing with CO2 or liquid N2 at low temperatures and 
/or high pressure. A certain reduction of the microbial load can be obtained through steam 
disinfection or irradiation with ionizing rays, fumigants as e.g. ethylenoxide or methylbromide 
are prohibited in Europe but respective residues might be found in imported material from 
outside  the EU. Although indicating the tidiness of the production process, not the total number 
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of germs is decisive but the absence of pathogens and a low load with aflatoxine/ochratoxine 
producers. 
 
In systematic plant production and in storehouses plant protection products are used to avoid 
phytosanitary problems. There are no specifically developed products for herbs on the market, 
but herbicides, insecticides and fungicides commonly used in agriculture can be applied  in 
specific cases according to European and national legislations. Residues of plant protection 
products have not to exceed the respective maximum residue levels: for herbs in general 
according the food legislation, for medicinal plants according to the European Pharmacopoea 
(Ph Eur 5). In organic production, special attention has to be paid to the EU Directive 2092/91. 
Critical points for the users are herbs and products from outside Europe contaminated with HCH 
or DDT as well as herbal mixtures, extracts and essential oils with uncontrolled residues. 
 
Contaminations with heavy metals originate from the soil, from overloaded fertilizers or from 
immissions. There are limits for heavy metal contaminations in food as well as pharmaceutical 
legislation, but some of the species as e.g. linseed (Linum usitatissimum) or St. Johns wort 
(Hypericum perforatum) exceed quite often the general limits. Contaminations with 
radionuclides are rare and problematic only at herbs of certain regional origin. 
 
In general, residues of (agro)chemicals and contaminations with abiotic and biotic toxicants 
have to be controlled also at herbs and herbal products not to exceed the limits to avoid a carry 
over into the food chain. 
 
AD 5. IDENTIFICATION OF THE ‘ACTIVE’ SUBSTANCES 
Botanicals used for health purposes or as sensory food ingredients are in general well identified 
and characterised with regard to their major compounds. Sometimes, however, the active 
principle is not definitely identified yet, as in the case e.g. of valerian, or some of the compounds 
acting as pro-drug (for example salicin from willow bark being metabolised first to active 
salicylic acid derivatives). In addition, in several cases, marker substances, without direct 
relation to the activity but characteristic for the species, are used for product identification. In 
plant preparations, quite often, not only a single compound is active, but the interaction of a 
number of substances is evident, and additive or adverse effects may occur, complicating the 
situation even more. According to the European Pharmacopoeia standardized extracts based on 
a level of several active constituents are therefore regarded as the ‘active principle’, and 
especially constituents with known adverse effects should be included as standardisation 
criteria. In cases where neither appropriate marker compounds nor active constituents are 
known, a chemical fingerprint will be required with limits on its variability. 
 
As methods for quality assessment, chromatographic techniques are normally used to 
adequately characterise the material. In a first approach TLC (thin layer chromatography) will be 
the appropriate analytical method for confirming authenticity and to detect adulterations. But 
for more detailed information, including determination of residues, a battery of analytical micro- 
(and nano-)  techniques may be useful (IR, UV, GLC, HPLC and coupled with MS.). 
For identification of herbal compounds in feed mixtures, new approaches are available based on 
molecular biological methods as e.g. PCR. 
AD 6. PRODUCT CONSISTENCY AND STABILITY 
Consistent quality for products of herbal origin can only be assured if the starting materials are 
adequately defined (as already mentioned under 1. – 4.). In particular, the specific botanical and 
phytochemical identification of the plant material used should be defined. Critical elements are 
the reproducibility of the batches, when originating from different sources (environments, 
varieties, etc.), and the inconsistency, if different plant parts are present in the product (herb 
consisting of more or less leaves/stems, flowers with/without vegetation).  
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Product stability depends on the degree of comminution (cutting, crushing and milling), the 
storage conditions and the type of active substances. No herbal product should be stored above 
room temperature and the humidity of the product has not to exceed 14% moisture to avoid 
microbial growth. Essential oils, as volatile compounds, will be reduced during the storage this 
being more relevant for herbs and flowers than fruits/seeds and roots. The more the product is 
processed/comminuted and the smaller the particle size is, the higher are the losses of 
volatiles. Used as additives in industrially processed animal feed, essential oils and extracts 
should be micro-encapsulated, otherwise a short term use (consumption) is recommended. Non-
volatile compounds (flavonoids, glycosides, alkaloids) show in general a better stability, but 
oxidation processes might also alter the quality. 
 
AD 7. HAZARD IDENTIFICATION AND CHARACTERIZATION 
Identification of the inherent biological activity of the material and assessment of relevance to 
animals and humans are necessary before the exposure depending risk can be characterised. Of 
most of the herbs in question, human safety data are available and cited in the respective 
chapters. But much less information is known on the activity and metabolism in target animals 
and especially on the carry over of single compounds in the food chain. ADME (absorption, 
distribution, metabolism and excretion) of herbal products in food producing animals is scarce 
and will be of significance only if possibly hazardous substances are contained in the starting 
material. Especially, matrix effects will play an important role in the safety assessment of herbs 
and herbal preparations used in animal nutrition. The herbs themselves consist of a complex 
mixture of components of macro- and micro-molecules of nutritive value, flavour compounds 
and other secondary metabolites being responsible for beneficial and/or adverse effects. 
Interactions due to the complex matrix will result in only partly comparable data to results from 
ADME studies performed on individual active substances. Therefore, the extent of the necessary 
experimental investigations depends on the adequacy of the use history and on the product 
comparability to traditional food/feed ingredients. 
A special problem might be the safety in handling herbs and herbal products due to their 
allergenic potential. Since this is well documented for herbs of human use, the respective 
precautions should be taken also with herbal feed additives. 
 
AD 8. RISK CHARACTERISATION 
Any risk characterisation has to be considered predominantly from the poin of view of safety for 
the target animal and the consumer of food of animal origin. Although a couple of data may 
exist on pharmacological effects in laboratory animals, toxicology on target animals is seldom to 
be found. There is obviously a wide range of knowledge on the activity and safety of herbs and 
herbal products to the target animals from ‘traditional use’ (from field experience to 
experimental data up to well documented scientific results). But most of published data sets are 
presumably reduced to zootechical parameters (i.e. weight gain and feed conversion) not to risk 
further use or future authorisation by demonstrating metabolic, microbial or even 
pharmacological effects. 
Regarding the consumer, safety data of herbs and herbal preparations used in food or food 
supplements may be used. A decision tree designed as guidance tool for the safety evaluation 
of functional plant products (Schilter et al., 2003) might also be useful in the present context 
(Scheme 1). Depending on the history of use, different levels of information could be requested 
to decide on the risk : benefit of a herbal product. 
In conclusion, results and information on herbs and herbal products for human use – either as 
food, food supplement or herbal medicinal product – can also be applied for decisions and 
regulations of herbs in animal nutrition. In addition to the existing guidelines on feed additives, a 
specific guidance for the application/assessment of herbs and herbal products used as 
additives in animal nutrition is needed. 
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Scheme 1. Decision tree to assist in determining the information that needs to be 
                   considered for the safety evaluation of a botanical ingredient or product. 
                   (Schilter et al. 2003) 
 
(for explanation see next page) 
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Information required on a herbal product as indicated by exit point of the decision tree:  
A – I, II, III, IV;  
B – I, II, III, IV, VI, VII, VIII, (IX); 
C – I, II, III, IV, V;  
D – I, II, III, IV, V, VI, VII, VIII (IX);  
E – I, II, III, IV, V, VI, VII, VIII, IX  
F – I, II, III, IV, V, VI, VII, VIII, IX;  
G – The product needs to be characterised before a specification can be produced and  
       a safety assessment made for its use  
H – Do not add to food/feed or use in supplements at intakes comparable to medicinal use 
       without a comprehensive risk: benefit analysis. 
  
Summary of information required to demonstrate safety of botanical food supplements:  
I – Specification of the ingredient or product;  
II – Details of the source organism (Genus, species, portion of the plant consumed);  
III – Evidence from previous human exposure through food and/or other sources;  
IV – Extent of use and estimated intake;  
V – Technical details of any processing and stability in formulation;  
VI – Nutritional assessment (including assessment of any effects of the active principles on the 
       bioavailability of other dietary components);  
VII – Toxicological assessment (including assessment of any effects of other dietary 
         components on the bioavailability of the active components 
VIII – Human clinical data including variability of response, adverse effect reports and  
         contraindications; 
IX – Ancillary data (mode of action of beneficial effect to allow consideration of special studies) 
 
 
 
 
 
References 
----------------------------------------------------------------------------------------------------------------- 
 
 293
REFERENCES 
 
 
Boothe, D.M. 1997: Nutraceuticals in veterinary medicine I: definitions and regulations. Comp 
Cont Ed Pract Vet 19 (11). 
 
Caygill, J.C., I. Mueller-Harvey, 1999: Secondary Plant Products –Antinutritional and beneficial 
actions in animal feeding. Nottingham University Press, Nottingham/UK, 129 pp. 
 
Council of Europe, 2005: Guidelines on the safety of plant based food supplements and 
consumer interest in those supplements. 15th March 2005 
 
Database “Functional plant products in veterinary medicine”: 
http://i104srv1.vu-wien.ac.at/rmwp 
 
EFSA/SC/26 FINAL, 2004: Botanicals and botanical preparations widely used as food 
supplements and related products; coherent and comprehensive risk assessment and consumer 
information approaches 
 
EFSA/SC, 2004: Proposed Mandate for the Scientific Committee on Botanicals and Botanical 
Preparations, Opinion under development 
 
EFSA Botanical Forum: Report and Conclusion from the Botanical Forum Workshop, 30.11.-
01.12.2005, Brussels 
 
EHGA/EUROPAM, GAP/GWP-Subcommittee 2005: Guidelines for Good Agricultural Practice 
(GAP) and Guidelines for Good Wild Crafting Practice (GWP) for Medicinal and Aromatic Plants 
 
EMEA, 1998: Note for guidance on quality of herbal medicinal products 
 
EMEA, 1999: Note for guidance and specifications: test procedures and acceptance criteria for 
herbal drugs, hebal drug preparations and herbal medicinal products 
 
EMEA/HMPWP/344/03: Points to consider on the biopharmaceutical characterisation of herbal 
medicinal products 
 
EMEA/CVMP/814/00 Rev1: Guideline on Quality of herbal medicinal products/traditional 
herbal medicinal products 
 
EMEA/CVMP/815/ßß Rev1: Guideline on specifications: test procedures and acceptance criteria 
for herbal substances, herbal preparations and HMP’s/ traditional HMP’s 
 
EMEA/HPMC/246816/2005: Guideline on Good Agricultural and Collection Practice (GACP) for 
Starting Materials of Herbal Origin 
 
EMEA/EC Enterprise and Industry DG, 16/03/2006 EU Guidelines to Good Manufacturing 
Practice, Medicinal Products for Human and Veterinary Use, Annex 7: Manufacture of Herbal 
Medicinal Products 
 
ESCOP (European Scientific Cooperative on Phytotherapy) 2003. Monographs. Thieme Stuttgart 
 
French Food Safety Agency, 2004: Framework for the evaluation of the safety, the effect and 
the claims of foodstuff made from plants for the human diet 
 
References 
----------------------------------------------------------------------------------------------------------------- 
 
 294
Gollnisch, K., I. Halle, G. Flachowsky 2001: The use of herbs and essential oils in animal 
nutrition. Proceedings DGQ conference Herbs and Spices, Jena 20. 03. 2001, p.249-258. DGQ 
Freising-Weihenstephan  
 
Hess, M. 2002: Phytopharmaka beim Geflügel. Sympos. Bioact.Plant Subst. in Vet.Med., Vienna.  
CD-ROM Vet.-med. Univ. Vienna 
 
Jensen, B.B. 1998: The impact of feed additives on the microbial ecology of the gut in young 
pigs. J. Anim. Feed Sci. 7, 45-64. 
 
Kamel, C. 2001: Plant extracts in an integrated approach. Feed Mix 9 (6) 1-14. 
 
Leung, A.Y., Foster, S. 1996. Encyclopedia of common natural ingredients used in food, drugs, 
and cosmetics. Wiley New York 
 
Pharmacopoeia Europaea 5, 2005. EDQM Strasbourg 
 
Schilter, B., C. Andersson, R. Anton, A. Constable, J. Kleiner, J. O’Brien, A.G. Renwick, O. Korver, 
F. Smit, R. Walker. 2003. Guidance for the safety assessment of botanicals and botanical 
preparations for use in food and food supplements. Food and Chem. Toxicol. 41, 1625-1649 
 
WHO 2003: Guidelines on good agricultural and collection practices (GACP) for medicinal plants 
. WHO Geneva 
 
Zabielski, R., W. Barej, V. Lesniewska, S.G. Pierzynowski 1999: Pancreas and upper gut 
dysfunctions around weaning in pigs and calves, in Th. Wensing (Ed.): 10th International 
Conference on Production Diseases in Farm Animals, p. 134-144. Wageningen Press, 
Wageningen/NL 
 
 
 
Acronyms 
----------------------------------------------------------------------------------------------------------------- 
 
 295
 
LIST OF ACRONYMS 
 
 
 
ACSO     alkenyl-L-cysteine sulphoxides 
ADME     Adsorption Distribution Metabolism Excretion 
AE     anethole epoxide 
All   allyl-  
AUC     area under curve 
BCO     blackcurrant seed oil  
CADs     caffeic acid derivatives  
CHE     chelerythrine  
CNS     Central Nervous System 
COX     cyclooxygenase 
CRP     C-reactive protein  
DAB     German Pharmacopoeia 
DHSA     dihydroxystearic acid 
DMBA     dimethylbenzanthraeene 
EAB     European Pharmacopoeia 
EMEA     European Medicines Agency 
ESCOP     European Scientific Cooperative on Phytotherapy 
EUROPAM/EHGA   European Herb Growers Association 
FA     fagaronine  
FEMA     Flavour and Extract Manufacturer Association 
FeSO4     ferrous  sulphate 
GABA     y-aminobutyric acid 
GRAS     Generally Recognized As Safe 
GSH     intracellular glutathione 
HMPC     Committee on Herbal Medicinal Products 
IgG, IgA and CRP   Immunglobuline G, Immunglobuline A, and C- 
                                                                 reaktives Protein 
LC/NMR and LC/APCI-MS (/MS) Liquid chromatography/nuclear magnetic resonance 
spectrometer and Liquid chromatography/atmospheric 
pressure chemical ionization 
LD50     lethal dose (50%) 
LDH     lactate dehydrogenase  
MAO     mitochondrial monoamine oxidase 
MBC values    minimum bactericidal concentration 
Acronyms 
----------------------------------------------------------------------------------------------------------------- 
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Me      methyl- 
MIC values    minimum inhibitory concentration 
MMP     Matrix metalloproteinase  
MRT     Magnetic Resonance Tomography 
NF-kappaB    nuclear factor-kappa B 
Ph Eur 5    European Pharmacopoeia, 5th Edition 
PKC     protein kinase C 
Pr     propyl- 
RBL-1     retinoblastoma- like 1 
SA     sanguinarine 
SCOP     structural classifications of proteins 
SERM     selective estrogen receptor modulator 
slgA     secretory immunoglobuline A 
TNF     tumour necrosis factor  
WHHL     Watanabe heritable hyperlipidemic 
WHO     World Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
Authors 
 297
 
INDEX OF AUTHORS 
 
 
Prof. Dr. Chlodwig Franz (Editor-in-Chief), Prof. Dr.  Karin Zitterl-Eglseer (KZE),  Dr. Karen Barker-
Benfield (KBB) 
Institute for Applied Botany, University of Veterinary Medicine, Veterinärplatz 1, A-1210 Wien  
 
Prof. Dr. Rudolf Bauer, Dr. Eva Maria Wenzig (EMW)  
Institute for Pharmacognosy, Karl-Franzens-Universität Graz, Universitätsplatz4/1, A-8010 Graz 
 
Prof. Dr. Reinhold Carle, DI Karin Schütz (KS), DI Ute Schweiggert (US) 
Institute of Food Technology, Section Plant Foodstuff Technology, Hohenheim University, 
Garbenstr. 25, D-70599 Stuttgart  
 
Prof. Dr. Doriana Tedesco, Dr. Sara Galletti, (SA), Dr. Laura Garavaglia, (LG), Dr. Aldo Tava 
Department of Veterinary Science and Technologies for Food Safety, University of Milan, 
Via Festa del Perdono , I-720133 Milano 
 
Prof. Dr. Aurelia Tubaro, 
Institute of Pharmacognosy, University of Triest, Via A. Valerio 6, I-34127 Trieste 
 
